UNIVERSITYOF BIRMINGHAM University of Birmingham Research at Birmingham

2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS

Kirchhof, Paulus; Benussi, Stefano; Kotecha, Dipak; Ahlsson, Anders; Atar, Dan; Casadei, Barbara; Castella, Manuel; Diener, Hans-Christoph; Heidbuchel, Hein; Hendriks, Jeroen; Hindricks, Gerhard; Manolis, Antonis S.; Oldgren, Jonas; Popescu, Bogdan Alexandru; Schotten, Ulrich; Van Putte, Bart; Vardas, Panagiotis; Agewall, Stefan; Camm, John; Baron Esquivias, Gonzalo

DOI: 10.1093/europace/euw295

License: None: All rights reserved

Document Version Peer reviewed version

Citation for published version (Harvard):

Kirchhof, P, Benussi, S, Kotecha, D, Ahlsson, A, Atar, D, Casadei, B, Castella, M, Diener, H-C, Heidbuchel, H, Hendriks, J, Hindricks, G, Manolis, AS, Oldgren, J, Popescu, BA, Schotten, U, Van Putte, B, Vardas, P, Agewall, S, Camm, J, Baron Esquivias, G, Budts, W, Carerj, S, Casselman, F, Coca, A, De Caterina, R, Deftereos, S, Dobrev, D, Ferro, JM, Filippatos, G, Fitzsimons, D, Gorenek, B, Guenoun, M, Hohnloser, SH, Kolh, P, Lip, GYH, Manolis, A, McMurray, J, Ponikowski, P, Rosenhek, R, Ruschitzka, F, Savelieva, I, Sharma, S, Suwalski, P, Tamargo, JL, Taylor, CJ, Van Gelder, IC, Voors, AA, Windecker, S, Zamorano, JL & Zeppenfeld, K 2016, '2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS', Europace, vol. 18, no. 11, pp. 1609-1678. https://doi.org/10.1093/europace/euw295

Link to publication on Research at Birmingham portal

Publisher Rights Statement:

For internal use only; end product is available OA on ESC website

General rights

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

•Users may freely distribute the URL that is used to identify this publication.

•Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.

•User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?) •Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

Take down policy

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to the work immediately and investigate.

UNIVERSITY^{OF} BIRMINGHAM

The University of Birmingham Research at Birmingham

2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS

Kirchhof, Paulus; Benussi, Stefano; Kotecha, Dipak; Ahlsson, Anders; Atar, Dan; Casadei, Barbara; Castella, Manuel; Diener, Hans-Christoph; Heidbuchel, Hein; Hendriks, Jeroen; Hindricks, Gerhard; Manolis, Antonis S; Oldgren, Jonas; Popescu, Bogdan Alexandru; Schotten, Ulrich; Van Putte, Bart; Vardas, Panagiotis; Authors/Task Force Members *DOI*:

10.1093/europace/euw295

Document Version Peer reviewed version

Citation for published version (Harvard):

Kirchhof, P, Benussi, S, Kotecha, D, Ahlsson, A, Atar, D, Casadei, B, Castella, M, Diener, H-C, Heidbuchel, H, Hendriks, J, Hindricks, G, Manolis, AS, Oldgren, J, Popescu, BA, Schotten, U, Van Putte, B, Vardas, P & Authors/Task Force Members 2016, '2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS: The Task Force for the management of atrial fibrillation of the European Society of Cardiology (ESC)Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESCEndorsed by the European Stroke Organisation (ESO)' Europace. DOI: 10.1093/europace/euw295

Link to publication on Research at Birmingham portal

Publisher Rights Statement:

For internal use only; end product is available OA on ESC website

General rights

When referring to this publication, please cite the published version. Copyright and associated moral rights for publications accessible in the public portal are retained by the authors and/or other copyright owners. It is a condition of accessing this publication that users abide by the legal requirements associated with these rights.

• You may freely distribute the URL that is used to identify this publication.

• Users may download and print one copy of the publication from the public portal for the purpose of private study or non-commercial research.

• If a Creative Commons licence is associated with this publication, please consult the terms and conditions cited therein.

• Unless otherwise stated, you may not further distribute the material nor use it for the purposes of commercial gain.

Take down policy

If you believe that this document infringes copyright please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to the work immediately and investigate.



2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS

The Task Force for the management of atrial fibrillation of the European Society of Cardiology (ESC)

Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC

Endorsed by the European Stroke Organisation (ESO)

Authors/Task Force Members: Paulus Kirchhof* (Chairperson) (UK/Germany), Stefano Benussi^{*1} (Co-Chairperson) (Switzerland), Dipak Kotecha (UK), Anders Ahlsson¹ (Sweden), Dan Atar (Norway), Barbara Casadei (UK), Manuel Castella Pericas¹ (Spain), Hans-Christoph Diener² (Germany), Hein Heidbuchel (Belgium), Jeroen Hendriks (The Netherlands), Gerhard Hindricks (Germany), Antonis S. Manolis (Greece), Jonas Oldgren (Sweden), Bogdan Alexandru Popescu (Romania), Ulrich Schotten (The Netherlands), Bart Van Putte¹ (The Netherlands), Panagiotis Vardas (Greece)

Document Reviewers: Stefan Agewall (CPG Review Coordinator) (Norway), John Camm (CPG Review Coordinator) (UK), Gonzalo Baron Esquivias (Spain), Werner Budts (Belgium), Scipione Carerj (Italy), Filip Casselman (Belgium), Antonio Coca (Spain), Raffaele De Caterina (Italy), Spiridon Deftereos (Greece), Dobromir Dobrev (Germany), José M. Ferro (Portugal), Gerasimos Filippatos (Greece), Donna Fitzsimons (UK), Bulent Gorenek (Turkey), Maxine Guenoun (France), Stefan H. Hohnloser (Germany), Philippe Kolh (Belgium), Gregory Y. H. Lip (UK), Athanasios Manolis (Greece), John Mc Murray (UK), Piotr Ponikowski (Poland), Raphael Rosenhek (Austria), Frank Ruschitzka (Switzerland), Irina Savelieva (UK), Sanjay Sharma (UK), Piotr Suwalski (Poland), Juan Luis Tamargo (Spain), Clare J. Taylor (UK), Isabelle C. Van Gelder (The Netherlands), Adriaan A. Voors (The Netherlands), Stephan Windecker (Switzerland), Jose Luis Zamorano (Spain), Katja Zeppenfeld (The Netherlands)

ESC Committee for Practice Guidelines (CPG) and National Cardiac Society Reviewers can be found in the Appendix

The disclosure forms of all experts involved in the development of these guidelines are available on the ESC website <u>www.escardio.org/guidelines</u>

37 Keywords:

- 38 Guidelines Atrial fibrillation Anticoagulation Vitamin K antagonists Non vitamin-K-antagonist oral
- 39 anticoagulants Left atrial appendage occlusion Rate control Cardioversion Rhythm control -
- 40 Antiarrhythmic drugs Upstream therapy Catheter ablation AF surgery Valve repair Pulmonary vein 41 isolation - Left atrial ablation
- 42

Stefano Benussi, Department of Cardiovascular Surgery, University Hospital Zurich, Rämistrasse 100, 8091 Zürich, Switzerland Tel: +41(0)788933835, E-mail: <u>stefano.benussi@usz.ch</u>

¹Representing the European Association for Cardio-Thoracic Surgery (EACTS); ²Representing the

^{*} Corresponding authors: Paulus Kirchhof, Institute of Cardiovascular Sciences, University of Birmingham, SWBH and UHB NHS trusts, IBR, Room 136, Wolfson Drive, Birmingham B152TT, United Kingdom. Tel: +44 121 4147042, E-mail: <u>p.kirchhof@bham.ac.uk</u>

European Stroke Association (ESO)

ESC entities having participated in the development of this document:

Associations: European Association of Cardiovascular Imaging (EACVI), European Heart Rhythm Association (EHRA), Heart Failure Association (HFA).

Councils: Council on Cardiovascular Nursing and Allied Professions

Working Groups: Cardiac Cellular Electrophysiology, Cardiovascular Pharmacotherapy

The content of these European Society of Cardiology (ESC) Guidelines has been published for personal and educational use only. No commercial use is authorized. No part of the ESC Guidelines may be translated or reproduced in any form without written permission from the ESC. Permission can be obtained upon submission of a written request to Oxford University Press, the publisher of the European Heart Journal and the party authorized to handle such permissions on behalf of the ESC (journals.permissions@oxfordjournals.org).

Disclaimer. The ESC Guidelines represent the views of the ESC and were produced after careful consideration of the scientific and medical knowledge and the evidence available at the time of their publication. The ESC is not responsible in the event of any contradiction, discrepancy and/or ambiguity between the ESC Guidelines and any other official recommendations or guidelines issued by the relevant public health authorities, in particular in relation to good use of healthcare or therapeutic strategies. Health professionals are encouraged to take the ESC Guidelines fully into account when exercising their clinical judgment, as well as in the determination and the implementation of preventive, diagnostic or therapeutic medical strategies; however, the ESC Guidelines do not override, in any way whatsoever, the individual responsibility of health professionals to make appropriate and accurate decisions in consideration of each patient's caregiver. Nor do the ESC Guidelines exempt health professionals from taking into full and careful consideration the relevant official updated recommendations or guidelines issued by the competent public health authorities, in order to manage each patient's case in light of the scientifically accepted data pursuant to their respective ethical and professional obligations. It is also the health professional's responsibility to verify the applicable rules and regulations relating to drugs and medical devices at the time of prescription.

© The European Society of Cardiology 2016. All rights reserved. For permissions please email: journals.permissions@oxfordjournals.org.

1 2	Ta 1		Contents nble	10
3	2		duction	
4	3		emiology and impact for patients	
5		3.1.	Incidence and prevalence of atrial fibrillation	
6		3.2.	Morbidity, mortality, and healthcare burden of atrial fibrillation	
7		3.3.	Impact of evidence-based management on outcomes in atrial fibrillation patients	
8		3.4.	Gender	
9	4	Patho	physiological and genetic aspects that guide management	14
10		4.1.	Genetic predisposition	14
11		4.2.	Mechanisms leading to atrial fibrillation	14
12		4.2	1. Remodelling of atrial structure and ion channel function	14
13		3.2	1. Electrophysiological mechanisms of atrial fibrillation	16
14	5	Diag	nosis and timely detection of atrial fibrillation	17
15		5.1.	Overt and silent atrial fibrillation	17
16		5.2.	Screening for silent atrial fibrillation	17
17		5.2	1. Screening for atrial fibrillation by electrocardiogram in the community	17
18		5.2	2. Prolonged monitoring for paroxysmal atrial fibrillation	17
19		5.2	3. Patients with pacemakers and implanted devices	17
20		5.2	4. Detection of atrial fibrillation in stroke survivors	18
21		5.3.	Electrocardiogram detection of atrial flutter	19
22	6	Class	sification of atrial fibrillation	
23		6.1.	Atrial fibrillation pattern	19
24		6.2.	Atrial fibrillation types reflecting different causes of the arrhythmia	
25		6.3.	Symptom burden in atrial fibrillation	
26	7	Dete	ction and management of risk factors and concomitant cardiovascular diseases	21
27		7.1.	Heart failure	
28		7.1	1. Patients with atrial fibrillation and heart failure with reduced ejection fraction	23
29		7.1	2. Atrial fibrillation patients with heart failure with preserved ejection fraction	
30		7.1		
31		7.1		
32		7.2.	Hypertension	
33		7.2		
34		7.2	1 1	
35		7.3.	Valvular heart disease	
36		7.4.	Diabetes mellitus	
37		7.5.	Obesity and weight loss	
38		7.5		
39 40		7.5		
40 41		7.5	•	
41		7.6.	Chronic obstructive pulmonary disease, sleep apnoea, and other respiratory diseases	
42		7.7.	Chronic kidney disease	27

43	8	Integrated	management of patients with atrial fibrillation	
44		8.1. Evi	dence supporting integrated atrial fibrillation care	
45		8.2. Con	mponents of integrated atrial fibrillation care	
46		8.2.1.	Patient involvement	
47		8.2.2.	Multidisciplinary atrial fibrillation teams	31
48		8.2.3.	Role of non-specialists	31
49		8.2.4.	Technology use to support atrial fibrillation care	31
50		8.3. Dia	gnostic workup of atrial fibrillation patients	31
51		8.3.1.	Recommended evaluation in all atrial fibrillation patients	31
52		8.3.2.	Additional investigations in selected patients with atrial fibrillation	
53		8.4. Stru	actured follow-up	
54		8.5. Def	Fining goals of atrial fibrillation management	
55	9	Stroke pre	vention therapy in atrial fibrillation patients	
56		9.1. Pre	diction of stroke and bleeding risk	
57		9.1.1.	Clinical risk scores for stroke and systemic embolism	
58		9.1.2.	Anticoagulation in patients with a CHA2DS2-VASc score of 1 in men and 2 in women.	
59		9.1.3.	Clinical risk scores for bleeding	
60		9.2. Stro	oke prevention	
61		9.2.1.	Vitamin K antagonists	
62		9.2.2.	Non-vitamin K antagonist oral anticoagulants	
63		9.2.3.	Non-vitamin K antagonist oral anticoagulants or vitamin K antagonists	40
64		9.2.4.	Oral anticoagulation in atrial fibrillation patients with chronic kidney disease	40
65		9.2.5.	Oral anticoagulation in atrial fibrillation patients on dialysis	41
66		9.2.6.	Patients with atrial fibrillation requiring kidney transplantation	41
67		9.2.7.	Antiplatelet therapy as an alternative to oral anticoagulants	41
68		9.3. Lef	t atrial appendage occlusion and exclusion	42
69		9.3.1.	Left atrial appendage occlusion devices	42
70		9.3.2.	Surgical left atrial appendage occlusion or exclusion	42
71		9.4. Sec	ondary stroke prevention	43
72		9.4.1.	Treatment of acute ischaemic stroke	43
73		9.4.2.	Initiation of anticoagulation after transient ischaemic attack or ischaemic stroke	43
74		9.4.3.	Initiation of anticoagulation after intracranial haemorrhage	44
75		9.5. Stra	ategies to minimize bleeding on anticoagulant therapy	46
76		9.5.1.	Uncontrolled hypertension	46
77		9.5.2.	Previous bleeding event	46
78 79		9.5.3. dosing	Labile international normalized ratio and adequate non-vitamin K antagonist oral antico 46	oagulant
80		9.5.4.	Alcohol abuse	46
81		9.5.5.	Falls and dementia	46
82		9.5.6.	Genetic testing	46
83		9.5.7.	Bridging periods off oral anticoagulation	47
84		9.6. Ma	nagement of bleeding events in anticoagulated patients with atrial fibrillation	47

85	9.6.1.	Management of minor, moderate, and severe bleeding	47
86	9.6.2.	Oral anticoagulation in atrial fibrillation patients at risk of or having a bleeding event	48
87	9.7. Co	mbination therapy with oral anticoagulants and antiplatelets	49
88 89	9.7.1. in patien	Antithrombotic therapy after acute coronary syndromes and percutaneous coronary inter ts requiring oral anticoagulation	
90	10 Rate contr	ol therapy in AF	52
91	10.1. Acu	ite rate control	52
92	10.2. Lor	ng-term pharmacological rate control	53
93	10.2.1.	Beta-blockers	53
94	10.2.2.	Non-dihydropyridine calcium channel blockers	53
95	10.2.3.	Digitalis	53
96	10.2.4.	Amiodarone	54
97	10.3. Hea	art rate targets in atrial fibrillation	54
98	10.4. Atr	ioventricular node ablation and pacing	55
99	11 Rhythm c	ontrol therapy in atrial fibrillation	57
100	11.1. Acu	ute restoration of sinus rhythm	57
101	11.1.1.	Antiarrhythmic drugs for acute restoration of sinus rhythm ('pharmacological cardiovers	sion')57
102	11.1.2.	'Pill in the pocket' cardioversion performed by patients	58
103	11.1.3.	Electrical cardioversion	59
104	11.1.4.	Anticoagulation in patients undergoing cardioversion	59
105	11.2. Lor	ng-term antiarrhythmic drug therapy	59
106	11.2.1.	Selection of antiarrhythmic drugs for long-term therapy: Safety first!	60
107	11.2.2.	Twelve-lead electrocardiogram as a tool to identify patients at risk of proarrhythmia	61
108	11.2.3.	New antiarrhythmic drugs	63
109	11.2.4.	Antiarrhythmic effects of non-antiarrhythmic drugs	63
110	11.3. Cat	heter ablation	65
111	11.3.1.	Indications	66
112	11.3.2.	Techniques and technologies	66
113	11.3.3.	Outcome and complications	66
114	11.3.4.	Anticoagulation – before, during, and after ablation	67
115	11.3.5.	Ablation of atrial fibrillation in heart failure patients	68
116	11.3.6.	Follow-up after catheter ablation	68
117	11.4. Atr	ial fibrillation surgery	68
118	11.4.1.	Concomitant atrial fibrillation surgery	68
119	11.4.2.	Stand-alone rhythm control surgery	70
120	11.5. Cho	pice of rhythm control following treatment failure	71
121	11.6. The	e atrial fibrillation Heart Team	71
122	12 Hybrid rh	ythm control therapy	73
123	12.1. Cor	mbining antiarrhythmic drugs and catheter ablation	73
124	12.2. Con	mbining antiarrhythmic drugs and pacemakers	73
125	13 Specific s	ituations	73
126	13.1. Fra	il and 'elderly' patients	73

127	13.2.	Inherited cardiomyopathies, channelopathies, and accessory pathways	74
128	13.2	.1. Wolff–Parkinson–White syndrome	74
129	13.2	.2. Hypertrophic cardiomyopathy	74
130	13.2		75
131	13.3.	Sports and atrial fibrillation	76
132	13.4.	Pregnancy	76
133	13.4	.1. Rate control	76
134	13.4	.2. Rhythm control	76
135	13.4	.3. Anticoagulation	77
136	13.5.	Postoperative atrial fibrillation	77
137	13.5	.1. Prevention of postoperative atrial fibrillation	77
138	13.5	.2. Anticoagulation	
139	13.5	.3. Rhythm control therapy in postoperative atrial fibrillation	
140	13.6.	Atrial arrhythmias in grown-up patients with congenital heart disease	
141	13.6		
142	13.6	2. Atrial tachyarrhythmias and atrial septal defects	79
143	13.6	5.3. Atrial tachyarrhythmias after Fontan operation	
144	13.6		
145	13.7.	Management of atrial flutter	
146	14 Patier	t involvement, education and self-management	
147	14.1.	Patient-centred care	
148	14.2.	Integrated patient education	
149	14.3.	Self-management and shared decision-making	
150	-	in evidence	
151	15.1.	Major health modifiers causing atrial fibrillation	
152	15.2.	How much atrial fibrillation constitutes a mandate for therapy?	
153	15.3.	Atrial high-rate episodes and need for anticoagulation	
154	15.4.	Stroke risk in specific populations	
155	15.5.	Anticoagulation in patients with severe chronic kidney disease	
156	15.6.	Left atrial appendage occlusion for stroke prevention	
157	15.7.	Anticoagulation in atrial fibrillation patients after a bleeding or stroke event	
158	15.8.	Anticoagulation and optimal timing of non-acute cardioversion	
159	15.9.	Competing causes of stroke or transient ischaemic attack in atrial fibrillation patients	
160 161	15.10. implan	Anticoagulation in patients with biological heart valves (including transcatheter aortic valv tation) and non-rheumatic valve disease	
162	15.11.	Anticoagulation after 'successful' catheter ablation	
163	15.12.	Comparison of rate control agents	
164	15.13.	Catheter ablation in persistent and long-standing persistent AF	
165	15.14.	Optimal technique for repeat catheter ablation	
166	15.15.	Combination therapy for maintenance of sinus rhythm	
167	15.16.	Can rhythm control therapy convey a prognostic benefit in atrial fibrillation patients?	
168	15.17.	Thoracoscopic 'stand-alone' atrial fibrillation surgery	

169	15.18.	Surgical exclusion of the left atrial appendage	
170	15.19.	Concomitant atrial fibrillation surgery	
171	16 To do a	nd not to do messages from the Guidelines	85
172	17 A short	summary of the management of AF patients	
173	18 Web Ad	Idenda	
174	19 Append	ix	
175	20 Referen	ces	90
176 177 178			

100	A h h	d
180		s and acronyms
181	ABC	age, biomarkers, clinical history
182	ACE	angiotensin-converting enzyme
183	ACS	acute coronary syndromes
184	AF	atrial fibrillation
185	AFFIRM	Atrial Fibrillation Follow-up Investigation of Rhythm Management
186	AFNET	German Competence NETwork on Atrial Fibrillation
187	AHRE	atrial high rate episodes
188	ARB	angiotensin receptor blocker
189	ARISTOTLE	Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation
190	ARNI	angiotensin receptor neprilysin inhibition
191	ATRIA	AnTicoagulation and Risk factors In Atrial fibrillation
192	AXAFA	Anticoagulation using the direct factor Xa inhibitor apixaban during Atrial Fibrillation
193		catheter Ablation: Comparison to vitamin K antagonist therapy
194	BAFTA	Birmingham Atrial Fibrillation Treatment of the Aged Study
195	BMI	body mass index
196	bpm	beats per minute
197	CABANA	Catheter Ablation versus Antiarrhythmic Drug Therapy for Atrial Fibrillation Trial
198	CAD	coronary artery disease
199	CHA ₂ DS ₂ -VASc	Congestive Heart failure, hypertension, Age \geq 75 (doubled), Diabetes, Stroke (doubled),
200		Vascular disease, Age 65–74, and Sex (female)
201	$CHADS_2$	Cardiac failure, Hypertension, Age, Diabetes, Stroke (Doubled)
202	CI	confidence interval
203	CKD	chronic kidney disease
204	CrCl	creatinine clearance
205	CT	computed tomography
206	DIG	Digitalis Investigation Group
207	EACTS	European Association for Cardio-Thoracic Surgery
208	EAST	Early treatment of Atrial fibrillation for Stroke prevention Trial
209	ECG	electrocardiogram/electrocardiography
210	EHRA	European Heart Rhythm Association
211	ENGAGE AF-TIM	
212		Thrombolysis in Myocardial Infarction 48
213	EORP	EURObservational Research Programme
214	FAST	Atrial Fibrillation Catheter Ablation vs Surgical Ablation Treatment
215	FEV1	forced expiratory volume in 1 second
216	GDF-15	growth differentiation factor 15
217	GFR	glomerular filtration rate
218	GFR	glomerular filtration rate
219	GUCH	grown up congenital heart disease
220	HARMONY	A Study to Evaluate the Effect of Ranolazine and Dronedarone When Given Alone and in
$\frac{1}{221}$		Combination in Patients With Paroxysmal Atrial Fibrillation
222	HAS-BLED	hypertension, abnormal renal/liver function (1 point each), stroke, bleeding history or
$\frac{1}{223}$		predisposition, labile INR, elderly (>65 years), drugs/alcohol concomitantly (1 point each)
224	HFmrEF	heart failure with mid-range ejection fraction
225	HFpEF	heart failure with preserved ejection fraction
226	HFrEF	heart failure with reduced ejection fraction
227	HR	hazard ratio
228	INR	international normalized ratio
229	LA	left atrium/atrial
230	LAA	left atrial appendage
231	LAAOS	Left Atrial Appendage Occlusion Study
232	LV	left ventricular
232	LVEF	left ventricular ejection fraction
233	LVH	left ventricular hypertrophy
235	MANTRA-PAF	Medical ANtiarrhythmic Treatment or Radiofrequency Ablation in Paroxysmal Atrial
235	1111 11 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	Fibrillation
230	MERLIN	Metabolic Efficiency With Ranolazine for Less Ischemia in Non ST-Elevation Acute
237		Coronary Syndrome
238	MRI	magnetic resonance imaging
	171111	

240	NOAC	non-vitamin K antagonist oral anticoagulant
241	NYHA	New York Heart Association
242	OAC	oral anticoagulation/oral anticoagulant
243	OR	odds ratio
244	ORBIT	Outcomes Registry for Better Informed Treatment of Atrial Fibrillation
245	PCI	percutaneous coronary intervention
246	PREVAIL	Prospective Randomized Evaluation of the Watchman LAA Closure Device In Patients
247		with AF Versus Long Term Warfarin Therapy trial
248	PROTECT AF	Watchman Left Atrial Appendage System for Embolic Protection in Patients With AF trial
249	PVI	pulmonary vein isolation
250	RACE	Rate Control Efficacy in Permanent Atrial Fibrillation
251	RATE-AF	Rate Control Therapy Evaluation in Permanent Atrial Fibrillation
252	RCT	randomized controlled trial
253	RE-CIRCUIT	Randomized Evaluation of dabigatran etexilate Compared to warfarin in pulmonaRy vein
254		ablation: assessment of different peri-proCedUral anticoagulation sTrategies
255	RE-LY	Randomized Evaluation of Long-Term Anticoagulation Therapy
256	ROCKET-AF	Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K
257		Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation
258	RR	risk ratio
259	SD	standard deviation
260	SPAF	Stroke Prevention in Atrial Fibrillation
261	TIA	transient ischaemic attack
262	TIMI	Thrombolysis In Myocardial Infarction
263	TOE	transoesophageal echocardiography
264	TTR	time in therapeutic range
265	UFH	unfractionated heparin
266	US	United States
267	VKA	vitamin K antagonist
268	WOEST	What is the Optimal antiplatElet and anticoagulant therapy in patients with oral
269		anticoagulation and coronary StenTing
270	WPW	Wolff-Parkinson-White syndrome
271		
272		

Preamble 1 273

274 Guidelines summarize and evaluate all available evidence on a particular issue at the time of the writing process, 275 with the aim of assisting health professionals in selecting the best management strategies for an individual 276 patient with a given condition, taking into account the impact on outcome, as well as the risk-benefit ratio of 277 particular diagnostic or therapeutic means. Guidelines and recommendations should help health professionals to 278 make decisions in their daily practice. However, the final decisions concerning an individual patient must be 279 made by the responsible health professional(s) in consultation with the patient and caregiver as appropriate.

280 A great number of Guidelines have been issued in recent years by the European Society of Cardiology (ESC) 281 and by the European Association for Cardio-Thoracic Surgery (EACTS), as well as by other societies and 282 organisations. Because of the impact on clinical practice, quality criteria for the development of guidelines have 283 been established in order to make all decisions transparent to the user. The recommendations for formulating 284 and issuing ESC Guidelines can be found on the ESC website (http://www.escardio.org/Guidelines-&-285 Education/Clinical-Practice-Guidelines/Guidelines-development/Writing-ESC-Guidelines). ESC Guidelines 286 represent the official position of the ESC on a given topic and are regularly updated.

287 Members of this Task Force were selected by the ESC, including representation from the European Heart 288 Rhythm Association (EHRA), and EACTS as well as by the European Stroke Organisation (ESO) to represent 289 professionals involved with the medical care of patients with this pathology. Selected experts in the field 290 undertook a comprehensive review of the published evidence for management (including diagnosis, treatment, 291 prevention and rehabilitation) of a given condition according to ESC Committee for Practice Guidelines (CPG) 292 policy and approved by the EACTS and ESO. A critical evaluation of diagnostic and therapeutic procedures was 293 performed, including assessment of the risk-benefit ratio. Estimates of expected health outcomes for larger 294 populations were included, where data exist. The level of evidence and the strength of the recommendation of 295 particular management options were weighed and graded according to predefined scales, as outlined in Tables 1 296 and 2.

297 The experts of the writing and reviewing panels provided declaration of interest forms for all relationships that

298 might be perceived as real or potential sources of conflicts of interest. These forms were compiled into one file

299 and can be found on the ESC website (http://www.escardio.org/guidelines). Any changes in declarations of

300 interest that arise during the writing period must be notified to the ESC and EACTS and updated. The Task 301 Force received its entire financial support from the ESC and EACTS without any involvement from the

302 healthcare industry.

303 The ESC CPG supervises and coordinates the preparation of new Guidelines produced by task forces, expert 304 groups or consensus panels. The Committee is also responsible for the endorsement process of these Guidelines. 305 The ESC Guidelines undergo extensive review by the CPG and external experts, and in this case by EACTS and 306 ESO-appointed experts. After appropriate revisions the Guidelines are approved by all the experts involved in 307 the Task Force. The finalized document is approved by the CPG, EACTS and ESO for publication in the 308 European Heart Journal, Europace, and in the European Journal of Cardio-Thoracic Surgery as well as in the 309 International Journal of Stroke (TBC). The Guidelines were developed after careful consideration of the 310 scientific and medical knowledge and the evidence available at the time of their dating.

311 The task of developing ESC and EACTS Guidelines covers not only integration of the most recent research, but 312 also the creation of educational tools and implementation programmes for the recommendations. To implement 313

the guidelines, condensed pocket guideline versions, summary slides, booklets with essential messages,

314 summary cards for non-specialists and an electronic version for digital applications (smartphones, etc.) are 315

produced. These versions are abridged and thus, if needed, one should always refer to the full text version, 316 which is freely available on the ESC website. The National Societies of the ESC are encouraged to endorse,

317

translate and implement all ESC Guidelines. Implementation programmes are needed because it has been shown 318 that the outcome of disease may be favourably influenced by the thorough application of clinical

319 recommendations.

320 Surveys and registries are needed to verify that real-life daily practice is in keeping with what is recommended 321 in the guidelines, thus completing the loop between clinical research, writing of guidelines, disseminating them 322 and implementing them into clinical practice.

323 Health professionals are encouraged to take the ESC and EACTS Guidelines fully into account when exercising 324 their clinical judgment, as well as in the determination and the implementation of preventive, diagnostic or

325 therapeutic medical strategies. However, the ESC and EACTS Guidelines do not override in any way

326 whatsoever the individual responsibility of health professionals to make appropriate and accurate decisions in 327 consideration of each patient's health condition and in consultation with that patient and the patient's caregiver

328 where appropriate and/or necessary. It is also the health professional's responsibility to verify the rules and 329 regulations applicable to drugs and devices at the time of prescription.

330

331 332

333 **Table 1 Classes of recommendations**

Table 1: Classes of Recommendations						
Classes of Recommendations	Definition	Suggested wording to use				
Class I	Evidence and/or general agreement that a given treatment or procedure is beneficial, useful, effective.	ls recommended/is indicated				
Class II	Conflicting evidence and/or a divergence of opinion about the usefulness/efficacy of the given treatment or procedure.					
Class lla	Weight of evidence/opinion is in favour of usefulness/efficacy.	Should be considered				
Class Ilb	Usefulness/efficacy is less well established by evidence/opinion.	May be considered				
Class III	Evidence or general agreement that the given treatment or procedure is not useful/effective, and in some cases may be harmful.	Is not recommended				

Table 2 Levels of evidence

Level of Evidence A	Data derived from multiple randomized clinical trials or meta-analyses.	
Level of Evidence B	Data derived from a single randomized clinical trial or large non-randomized studies.	
Level of Evidence C	Consensus of opinion of the experts and/or small studies, retrospective studies, registries.	

337 338 339

361

340 **2 Introduction**

Despite good progress in the management of patients with atrial fibrillation (AF), this arrhythmia remains one of the major causes of stroke, heart failure, sudden death, and cardiovascular morbidity in the world. Furthermore, the number of patients with AF is predicted to rise steeply in the coming years. To meet the growing demand for effective care of patients with AF, new information is continually generated and published, and the last few years have seen substantial progress. It therefore seems timely to publish this 2nd edition of the ESC guidelines on AF.

Reflecting the multidisciplinary input into the management of patients with AF, the Task Force includes cardiologists with varying subspecialty expertise, cardiac surgeons, stroke neurologists, and specialist nurses amongst its members. Supplementing the evidence review as outlined in the preamble, this task force identified three PICOT questions on relevant topics for the guideline. The ESC commissioned external systematic reviews to answer these three questions. These reviews informed specific recommendations.

Further to adhering to the standards for generating recommendations that is common to all ESC guidelines (see preamble), this task force discussed each draft recommendation during web-based conference calls dedicated to specific chapters, followed by consensus modifications and an online vote on each recommendation. Only recommendations that were supported by at least 75% of the task force members were included in the guideline.

We hope that this guideline will help to deliver good care to all patients with AF based on the current state-ofthe-art evidence in 2016.

362 **3 Epidemiology and impact for patients**

363 3.1. Incidence and prevalence of atrial fibrillation

364 In 2010, the estimated numbers of men and women with atrial fibrillation (AF) worldwide were 20.9 million and 12.6 million, respectively, with higher incidence and prevalence rates in developed countries.^{1, 2} One in four 365 middle-aged adults in Europe and the United States (US) will develop AF.³⁻⁵ By 2030, 14–17 million AF 366 patients are anticipated in the European Union, with 120,000-215,000 newly diagnosed patients per year.^{2, 6, 7} 367 368 Estimates suggest an AF prevalence of approximately 3% in adults age 20 years or older.^{8,9} with more AF in elderly persons¹ and in patients with conditions such as hypertension, heart failure, coronary artery disease (CAD), valvular heart disease, diabetes mellitus, and chronic kidney disease (CKD).^{7, 10-15} The increase in AF 369 370 prevalence can be attributed to better detection of silent AF^{16-18} and increasing age and conditions predisposing 371 372 to AF.¹⁹

373

374 3.2. Morbidity, mortality, and healthcare burden of atrial fibrillation

AF is independently associated with a twofold increased risk of all-cause mortality in women and a 1.5-fold increase in men²⁰⁻²² (*Table 3*). Death due to stroke can largely be mitigated by anticoagulation, while other cardiovascular deaths, for example due to heart failure and sudden death, remain common even in AF patients treated according to the current evidence-base.²³ AF is also associated with increased morbidity, such as heart failure and stroke.^{21, 24, 25} Contemporary studies show that 20–30% of patients with an ischaemic stroke have AF diagnosed before, during, or after the initial event.^{17, 26, 27} White matter lesions in the brain, cognitive impairment,²⁸⁻³⁰ decreased quality of life,^{31, 32} and depressed mood³³ are common in AF patients, and between 10% and 40% of AF patients are hospitalized each year.^{23, 34, 35}

The direct costs of AF already amount to approximately 1% of total healthcare spending in the UK, and between \$6.0 and \$26.0 billion in the US for 2008,^{36,37} driven by AF-related complications (e.g. stroke) and AF-

between \$6.0 and \$26.0 billion in the US for 2008,^{36,37} driven by AF-related complications (e.g. stroke) and AFrelated treatment costs (e.g. hospitalizations). These costs will increase dramatically unless AF is prevented and treated in a timely and effective manner.

387 388

Event	Association with AF		
Death	Increased mortality, especially cardiovascular mortality due to sudden death, heart		
	failure, or stroke		
Stroke	20–30% of all strokes are due to AF. A growing number of patients with stroke are		
	diagnosed with 'silent', paroxysmal AF		
Hospitalizations	10-40% of AF patients are hospitalized every year		
Quality of life	Quality of life is impaired in AF patients independent of other cardiovascular		
	conditions		
LV dysfunction and	LV dysfunction is found in 20-30% of all AF patients. AF causes or aggravates LV		
heart failure	dysfunction in many AF patients, while others have completely preserved LV		
	function despite long-standing AF		
Cognitive decline and	Cognitive decline and vascular dementia increase even in anticoagulated patients.		
vascular dementia	Brain white matter lesions are more common in AF patients than in patients without		
	AF		

389

AF = atrial fibrillation; LV = left ventricular.

390

391 3.3. Impact of evidence-based management on outcomes in atrial fibrillation 392 patients

Figure 1 depicts the major milestones in the management of AF. Despite these advances, substantial morbidity
 remains. Oral anticoagulation (OAC) with vitamin K antagonists (VKAs) or non-VKA oral anticoagulants

395 (NOACs) markedly reduces stroke and mortality in AF patients.^{38, 39} Other interventions such as rhythm control

and rate control improve AF-related symptoms and may preserve cardiac function, but have not demonstrated a $\frac{40}{41}$

397 reduction in long-term morbidity or mortality.^{40, 41}

First maze surgery for 000 AF treatment VKA superior to aspirin published for stroke prevention in ΔF PVI can suppress AF ACEi/ARBs prevent RF based maze AF in heart failure maintains SR after Rate control not inferior to rhythm control cardiovascular VKA reduces stroke in AF surgerv by 2/3 ARBs prevent AF in **PVI** maintains SR hypertension & LVH better than 2005 Ximelagatran as effective antiarrhythmic drugs as VKA Amiodarone not superior to rate ARBs do not prevent Dronedarone improves Dabigatran at least as control in heart outcomes in non-AF or adverse effective as VKA in AF failure outcomes in patients permanent AF without hypertension Lenient rate control AF ablation acceptable improves QoL Rixaroxaban and PUFA do not Apixaban at least as prevent AF Dronedarone harms effective as VKA in AF in permanent AF First-line PVI MRA prevent AF in Bipolar RF more maintains SR better HFrEF patients pre-Edoxaban at least as than antiarrhythmic effective than treated with ACEi/ conventional RF for effective as VKA in AF drugs beta-blockers stand-alone AF ACEi/ARBs prevent surgerv AF in hypertension Meta-analysis and healthcare PVI alone as Beta-blockers without effective as databases: NOACs safer and prognostic benefit in Beta-blockers complex ablation in Concomitant maze slightly more effective AF patients with prevent AF in HFrEF persistent AF surgery maintains SR 2015 compared to VKA HFrEF patients pre-treated but increases risk of Cryoenergy as with ACEi permanent pacemaker effective as RF for PVI

398 399 400 401 402 403 404 405

Figure 1 Timeline of major landmarks in AF management, including treatment of concomitant conditions and prevention (green), anticoagulation (blue), rate and rhythm control (orange and red), and surgical therapy (purple).
ACEi = angiotensin-converting enzyme inhibitor; AF = atrial fibrillation; ARB = angiotensin receptor blocker;

HF = heart failure; HFrEF = heart failure with reduced ejection fraction; LVH = left ventricular hypertrophy;
NOAC = non-vitamin K antagonist oral anticoagulant; PUFA = polyunsaturated fatty acid; PVI = pulmonary
vein isolation; QoL = quality of life; RACE = Rate Control Efficacy in Permanent Atrial Fibrillation; RF =
radiofrequency; SR = sinus rhythm; VKA = vitamin K antagonist.

In contemporary, well-controlled, randomized clinical trials in AF, the average annual stroke rate is about 1.5%
and the annualized death rate is around 3%.⁴⁰ In real life, the annual mortality can be different (both higher and lower).⁴² A minority of these deaths are related to stroke, while sudden cardiac death and death from progressive heart failure are more frequent, emphasizing the need for interventions beyond anticoagulation.^{43, 44}
Furthermore, AF is also associated with high rates of hospitalization, commonly for AF management, but often

414 also for heart failure, myocardial infarction, and treatment-associated bleeding.^{34, 45}

415

416 **3.4.** Gender

417 In both developed and developing countries, the age-adjusted incidence and prevalence of AF are lower in women, while the risk of death in women with AF is similar to or higher than that in men with AF.^{1, 46, 47} Female 418 419 AF patients who have additional stroke risk factors (particularly older age) are also at greater risk than men of having a stroke, 48,49 even those anticoagulated with warfarin⁵⁰ (see Chapter 8 for details). Women with 420 diagnosed AF can be more symptomatic than men and are typically older with more comorbidities.^{51, 52} Bleeding risk on anticoagulation is similar in both sexes,^{49, 50, 53} but women appear less likely to receive 421 422 specialist care and rhythm control therapy,⁵⁴ while the outcomes of catheter ablation or AF surgery are comparable to those in men.^{55, 56} These observations highlight the need to offer effective diagnostic tools and 423 424 425 therapeutic management equally in women and men. 426

427 **Recommendations relating to gender**

Recommendations	Class ^a	Level ^b	Refs ^c
AF clinicians must offer effective diagnostic tools and therapeutic management to women and men equally to prevent stroke and death	I	A	39, 46, 57
Catheter or surgical ablation techniques should be regarded as equally effective in women and men	lla	В	55, 56

428 AF = atrial fibrillation 429

^aClass of recommendation.

430 ^bLevel of evidence. ^cReference(s) supporting recommendations.

431 432

433 Pathophysiological and genetic aspects that guide management 4

434 4.1. Genetic predisposition

435 AF, especially early-onset AF, has a strong heritable component, independent of concomitant cardiovascular 436 conditions.^{58, 59} A few young AF patients suffer from inherited cardiomyopathies or channelopathies mediated 437 by disease-causing mutations. These monogenic diseases also convey a risk for sudden death (see Chapter 5). 438 Up to one-third of AF patients carry common genetic variants that predispose to AF, albeit with a relatively low 439 added risk. At least 14 of these common variants, often single nucleotide polymorphisms, are known to increase the risk of prevalent AF in populations.⁶⁰⁻⁶² The most important variants are located close to the paired-like 440 homeodomain transcription factor 2 gene on chromosome 4q25.^{63, 64} These variants modify the risk of AF up to 441 442 sevenfold.⁶⁴ Several of the AF risk variants are also associated with cardioembolic or ischaemic stroke, possibly due to silent AF (see section 4.1).^{62, 65, 66} Changes in atrial action potential characteristics,⁶⁷⁻⁷⁰ atrial remodelling, 443 444 and modified penetration of rare gene defects⁶¹ have been suggested as potential mechanisms mediating increased AF risk in carriers of common gene variants. Genetic variants could in the future become useful for patient selection of rhythm control strategies,⁷¹⁻⁷³ but it is currently unknown whether common gene variants 445 446 447 differentially affect the efficacy of antiarrhythmic drugs or rate control medication.⁷⁴ While genomic analysis may provide an opportunity to improve diagnosis and management of AF in the future,^{75, 76} routine genetic 448 449 testing for common gene variants associated with AF cannot be recommended at present.⁷⁷

450

451 4.2. Mechanisms leading to atrial fibrillation

452 4.2.1. Remodelling of atrial structure and ion channel function

453 External stressors such as structural heart disease, hypertension, possibly diabetes, but also AF itself induce a 454 slow but progressive process of structural remodelling in the atria (Figure 2). Activation of fibroblasts, 455 enhanced connective tissue deposition, and fibrosis are the hallmarks of this process.⁷⁸⁻⁸⁰ In addition, atrial fatty infiltration, inflammatory infiltrates, myocyte hypertrophy, necrosis, and amyloidosis are found in AF patients with concomitant conditions predisposing to AF.⁸¹⁻⁸⁴ Structural remodelling results in electrical dissociation 456 457 between muscle bundles and local conduction heterogeneities,⁸⁵ favouring reentry and perpetuation of the 458 459 arrhythmia.⁸⁶ In many patients, the structural remodelling process occurs before the onset of AF.⁷⁸ As some of 460 the structural remodelling will be irreversible, early initiation of treatment seems desirable.⁸⁷ Table 4 gives an 461 overview of the most relevant pathophysiological alterations in atrial tissue associated with AF, and lists 462 corresponding clinical conditions that can contribute to these changes.

463 The functional and structural changes in atrial myocardium and stasis of blood, especially in the left 464 atrial appendage (LAA), generate a prothrombotic milieu. Furthermore, even short episodes of AF lead to 465 myocardial damage and expression of prothrombotic factors on the atrial endothelial surface, and activation of platelets and inflammatory cells, and contribute to a generalized prothrombotic state.^{88, 89} The atrial and 466 467 systemic activation of the coagulation system can partially explain why short episodes of AF convey a long-468 term stroke risk.




Figure 2 Major mechanisms causing AF that can be considered when guiding therapy. The various aetiological factors (left) cause a complex array of pathophysiological changes in the atria, including stretch-induced atrial fibrosis, hypocontractility, fatty infiltration, inflammation, vascular remodelling, ischaemia, ion channel dysfunction, and Ca²⁺-instability. These changes enhance both ectopy and conduction disturbances, increasing the propensity of the atria to develop or maintain AF. At the same time, some of these alterations are involved in the occurrence of the hypercoagulable state associated with AF. For example, hypocontractility reduces local endothelial shear stress, which increases PAI-1 expression, and ischaemia-induced inflammation enhances the expression of endothelial adhesion molecules or promotes shedding of endothelial cells, resulting in tissue factor exposure to the blood stream. These changes contribute to the thrombogenic milieu in the atria of AF patients. AF in itself can aggravate many of the mechanisms shown, which may explain the progressive nature of the arrhythmia. AngII = angiotensin II; TF = tissue factor; FXII = factor XII; IL-6 = interleukin 6; PAI-1 = plasminogen

activator inhibitor 1; VCAM-1 = vascular cell adhesion molecule 1.

Table 4 Pathophysiological alterations in atrial tissue associated with AF and clinical conditions that could contribute to such alterations

Pathophysiological alteration	Clinical conditions contributing to the alteration	Proarrhythmic mechanism/ functional consequence	References
Changes of the extract	ellular matrix, fibroblast function, an	d fat cells	
Interstitial and replacement fibrosis	AF (especially forms with a high AF burden), hypertension, heart failure, valvular heart disease (via pressure and volume overload)	Electrical dissociation, conduction block, enhanced AF complexity	78, 79, 90, 91
Inflammatory infiltration		Profibrotic responses, enhanced AF complexity	81
Fatty infiltration	Obesity (fatty infiltration)	Profibrotic/proinflammatory responses, localized conduction	82, 92

Amyloid deposition	Ageing, heart failure, CAD (via atrial scarring), genetic factors	block Conduction disturbances	83, 93
Ion channel alterations			
Ion channel remodelling	AF (especially forms with a high AF burden), genetic predisposition to AF	AF cycle shortening (if due to atrial tachycardia), AF cycle length prolongation (if due to heart failure), enhanced heterogeneity of atrial repolarization	94-96
Ca ²⁺ handling instability	AF (especially forms with a high AF burden), possibly heart failure and hypertension (possibly through increased sympathetic activation)	Enhanced propensity to ectopy	97, 98
Gap-junction redistribution	AF	Conduction disturbances	99
Myocyte alterations			
Apoptosis and necrosis	CAD, heart failure (through cardiomyocyte death and atrial scarring)	May induce replacement fibrosis	100
Myocyte hypertrophy	Atrial dilatation, AF	Aggravates conduction disturbances	84, 101
Endothelial and vascul	ar alterations		
Microvascular changes	Atherosclerosis, CAD and peripheral artery disease, possibly	Aggravation of atrial ischaemia, heterogeneity of electrical	102
Endocardial remodelling	AF	function, structural remodelling Enhanced risk for thrombus formation	103, 104
Changes of the autonor	nic nervous system		
Sympathetic hyperinnervation	Heart failure, hypertension	Enhanced propensity to ectopy	80, 105

488 AF = atrial fibrillation; CAD = coronary artery disease.

489

490 3.2.1. Electrophysiological mechanisms of atrial fibrillation

491 AF provokes a shortening of the atrial refractory period and AF cycle length during the first days of the 492 arrhythmia, largely due to downregulation of the Ca²⁺-inward current and upregulation of inward rectifier K⁺ 493 currents.^{94, 95} Structural heart disease, in contrast, tends to prolong the atrial refractory period, illustrating the heterogeneous nature of mechanisms that cause AF in different patients.⁹⁶ Hyperphosphorylation of various 494 Ca^{2+} handling proteins may contribute to enhanced spontaneous Ca^{2+} release events and triggered activity, ^{97,98} 495 thus causing ectopy and promoting AF. Although the concept of Ca^{2+} handling instability has been challenged 496 recently, ^{106, 107} it may mediate AF in structurally remodelled atria and explain how altered autonomic tone can generate AF.^{80, 105} 497 498

499

500 Focal initiation and maintenance of AF: The seminal observation by Haissaguerre et al¹⁰⁸ was that a focal 501 source in the pulmonary veins can trigger AF, and ablation of this source can extinguish the arrhythmia. The mechanism of focal activity might involve both triggered activity and localized reentry.^{109, 110} Hierarchic 502 organization of AF with rapidly activated areas driving the arrhythmia has been documented in patients with 503 paroxysmal AF,^{111, 112} but is more challenging in patients with persistent AF.¹¹³ 504 505

506 The multiple wavelet hypothesis and rotors as sources of AF: Moe and Abildskov¹¹⁴ proposed that AF can be 507 perpetuated by continuous conduction of several independent wavelets propagating through the atrial 508 musculature in a seemingly chaotic manner. As long as the number of wavefronts does not decline below a 509 critical level, they will be capable of sustaining the arrhythmia. Numerous experimental and clinical

observations can be reconciled with the multiple wavelet hypothesis.¹¹⁵ All localized sources of AF (ectopic 510

foci, rotors, or other stable reentry circuits) cause fibrillatory conduction remote from the source, which is
 difficult to distinguish from propagation sustaining AF by multiple wavelets, and either of these phenomena
 may generate 'rotors' picked up by intracardiac^{116, 117} or body surface¹¹⁷ recordings.

514 515

516 **5 Diagnosis and timely detection of atrial fibrillation**

517 5.1. Overt and silent atrial fibrillation

The diagnosis of AF requires rhythm documentation using an electrocardiogram (ECG), with the typical pattern
of AF. ECG-documented AF was the entry criterion in trials forming the evidence for these guidelines. By
accepted convention, an episode lasting at least 30 seconds is diagnostic. Individuals with AF may be
symptomatic or asymptomatic ('silent AF'). Many AF patients have both symptomatic and asymptomatic
episodes of AF.¹¹⁸⁻¹²¹

523 Silent, undetected AF is common,^{120, 122} with severe consequences such as stroke and death.¹²³⁻¹²⁵ 524 Prompt recording of an ECG is an effective and cost-effective method to document chronic forms of AF.¹²⁶ The 525 technology to detect paroxysmal, self-terminating AF episodes is rapidly evolving (see Chapter 5 for a 526 definition of AF patterns). There is good evidence that prolonged ECG monitoring enhances the detection of 527 undiagnosed AF, for 72 hours after a stroke,^{27, 127} for even longer periods,^{18, 128} or by daily short-term ECG 528 recording in patients over 75 years of age¹²⁹ (*Web Addenda Figure 1*). Ongoing studies will determine whether 529 such early detection alters management (e.g. initiation of anticoagulation) and improves outcomes.

Once the ECG diagnosis of AF has been established, further ECG monitoring can inform management
in the context of: (1) a change in symptoms or new symptoms; (2) suspected progression of AF; (3) monitoring
of drug effects on ventricular rate; and (4) ECG monitoring of antiarrhythmic drug effects or catheter ablation
for rhythm control.

535 **5.2.** Screening for silent atrial fibrillation

536 5.2.1. Screening for atrial fibrillation by electrocardiogram in the community

537 Undiagnosed AF is common, especially in older populations and in patients with heart failure.¹³⁰ Opportunistic screening for silent AF seems cost-effective in elderly populations (e.g. > 65 years),¹³¹ and similar effects have been reported using single-lead ECG screening in other at-risk populations.^{132, 133} Screening of elderly 538 539 540 populations (mean age 64 years) yielded a prevalence of 2.3% for chronic forms of AF in 122,571 participants 541 using either short-term ECG or pulse palpation (followed by ECG in those with an irregular pulse).¹³⁴ 542 Previously undiagnosed AF was found in 1.4% of those aged > 65 years, suggesting a number needed to screen 543 of 70. These findings encourage the further evaluation of systematic AF screening programmes in at-risk 544 populations. 545


546 **5.2.2.** Prolonged monitoring for paroxysmal atrial fibrillation

Paroxysmal AF is often missed.¹²⁰ Repeated daily ECG recordings increased the detection of silent,
asymptomatic paroxysmal AF in an unselected Swedish population aged > 75 years.^{120, 135} Several patientoperated devices^{136, 137} and extended continuous ECG monitoring using skin patch recorders¹³⁸ have been
validated for detection of paroxysmal AF.¹³⁹ The detection rate of asymptomatic AF by new technologies such
as smartphone cases with ECG electrodes, smart watches, and blood pressure machines with AF detection
algorithms, has not yet been formally evaluated against an established arrhythmia detection method.¹⁴⁰

553554 5.2.3. Patients with pacemakers and implanted devices

555 Implanted pacemakers or defibrillators with an atrial lead allow continuous monitoring of atrial rhythm. Using 556 this technology, patients with atrial high rate episodes (AHRE) can be identified. Depending on the risk profile of the population studied, such AHRE are detected in 10–15% of pacemaker patients.¹⁴¹ AHRE are associated 557 558 with an increased risk of overt AF (hazard ratio [HR] 5.56; 95% confidence interval [CI] 3.78–8.17; P < 0.001) 559 and ischaemic stroke or systemic embolism (HR 2.49; 95% CI 1.28–4.85; P = 0.007). The stroke risk in AHRE patients seems lower than the stroke risk in patients with diagnosed AF, and not all AHRE represent AF.¹⁴² 560 Strokes often occur without AHRE detected within 30 days before the event.¹⁴³⁻¹⁴⁷ Consequently, it is unclear 561 whether AHRE imply the same therapeutic requirements as overt AF,¹⁴⁸ and the benefit of OAC in patients with 562 563 AHRE is being evaluation in ongoing clinical trials (e.g. ARTESiA [NCT01938248] and NOAH 564 [NCT02618577]). At present, pacemakers and implanted devices should be interrogated on a regular basis for 565 AHRE, and patients with AHRE should undergo further assessment of stroke risk factors and for overt AF,

566 including ECG monitoring (*Figure 3*).¹⁴⁹



5.2.4. Detection of atrial fibrillation in stroke survivors

Sequential stratified ECG monitoring detected AF in 24% (95% CI 17-31) of stroke survivors,¹⁵¹ and in 11.5% (95% CI 8.9%–14.3%) in another meta-analysis,¹⁷ with large variations depending on the timing, duration, and method of monitoring. AF detection is not uncommon in unselected stroke patients (6.2%, 95% CI 4.4-8.3),¹²⁸ but is more likely in patients with cryptogenic stroke implanted with loop recorders or who have had ECG monitors for several weeks.^{18, 128, 152} Cryptogenic stroke is defined as a stroke in which the cause could not be identified after extensive investigations.¹⁵³ A broader definition is embolic stroke of undetermined source.¹⁵⁴ Several studies have also found AF in patients in whom another competing cause for stroke has been identified clinically (e.g. hypertension or carotid artery stenosis).^{27, 127} Hence, prolonged ECG monitoring seems reasonable in all survivors of an ischaemic stroke without an established diagnosis of AF.

Recommendations for screening for AF

Recommendations	Class ^a	Level ^b	Ref s ^c
Opportunistic screening for AF is recommended by pulse taking or ECG rhythm strip in patients > 65 years of age	I	В	130, 134, 155
In patients with TIA or ischaemic stroke, screening for AF is recommended by short-term ECG recording followed by continuous ECG monitoring for at least 72 hours	I	В	27, 127

It is recommended to interrogate pacemakers and ICDs on a regular basis for atrial high rate episodes (AHRE). Patients with AHRE should undergo further ECG monitoring to document AF before initiating AF therapy	I	В	141, 156
In stroke patients, additional ECG monitoring by long-term non- invasive ECG monitors or implanted loop recorders should be considered to document silent AF	lla	В	18, 128
Systematic ECG screening may be considered to detect AF in patients aged > 75 years, or those at high stroke risk	llb	В	130, 135, 157

- 587 AF = atrial fibrillation; AHRE = atrial high rate episodes; ECG = electrocardiogram; ICD = implantable
- 588 cardioverter defibrillator; TIA = transient ischaemic attack.
- 589 ^aClass of recommendation.
- 590 ^bLevel of evidence.
- 591 ^cReference(s) supporting recommendations.
- 592

593 5.3. Electrocardiogram detection of atrial flutter

Right atrial isthmus-dependent flutter has a typical ECG pattern and ventricular rate.¹⁵⁸ The prevalence of atrial flutter is less than one-tenth of the prevalence of AF.¹⁵⁹ Atrial flutter often coexists with or precedes AF.¹⁶⁰ In typical, isthmus-dependent flutter, P waves will often show a 'saw tooth' morphology, especially in the inferior leads (II, III, aVF). The ventricular rate can be variable (usual ratio of atrial to ventricular contraction 4:1 to 2:1, in rare cases 1:1) and macro-reentrant tachycardias may be missed in stable 2:1 conduction. Vagal stimulation or intravenous adenosine may be helpful to unmask atrial flutter. The management of atrial flutter is discussed in Section 12.7. Left or right atrial macro-reentrant tachycardia is usually confined to patients after catheter ablation for AF, AF surgery, or after open heart surgery.¹⁵⁸

602

603 6 Classification of atrial fibrillation

604 6.1. Atrial fibrillation pattern

In many patients, AF progresses from short, infrequent episodes to longer and more frequent attacks. Over time,
 many patients will develop sustained forms of AF. In a small proportion of patients, AF will remain paroxysmal
 over several decades (2–3% of AF patients).¹⁶¹ The distribution of paroxysmal AF recurrences is not random,
 but clustered.¹⁶² AF may also regress from persistent to paroxysmal AF. Furthermore, asymptomatic recurrences
 of AF are common in patients with symptomatic AF.¹²⁰

610

611Based on presentation, duration, and spontaneous termination of AF episodes, five types of AF are612traditionally distinguished: first diagnosed, paroxysmal, persistent, long-standing persistent, and permanent AF613(*Table 5*). If patients suffer from both paroxysmal and persistent AF episodes, the more common type should be614used for classification. Clinically determined AF patterns do not correspond well to the AF burden measured by615long-term ECG monitoring. ¹⁶³ Even less is known about the response to therapy in patients with long-standing616persistent AF or long-standing paroxysmal AF. Despite these inaccuracies, the distinction between paroxysmal617and persistent AF has been used in many trials and therefore still forms the basis of some recommendations.618There is some evidence suggesting that AF burden may influence stroke risk^{44, 124, 164} and could modify

 $\begin{array}{ccc} 618 \\ 619 \\ 619 \\ 620 \end{array}$ There is some evidence suggesting that AF burden may influence stroke risk^{44, 124, 164} and could modify the response to rhythm control therapy.^{76, 165} The evidence for this is weak. Therefore, AF burden should not be a major factor in deciding on the usefulness of an intervention that is deemed suitable for other reasons.

- 621 622
- Table 5 Patterns of AF

AF pattern	Definition
First diagnosed AF	AF that has not been diagnosed before, irrespective of the duration of the arrhythmia or the presence and severity of AF-related symptoms.
Paroxysmal AF	Self-terminating, in most cases within 48 hours. Some AF paroxysms may continue for up to 7 days. ^a Most AF episodes that are cardioverted within 24-48 hours should be considered paroxysmal. ^a
Persistent AF	AF that lasts longer than 7 days, including episodes that are terminated by cardioversion, either with drugs or by direct current cardioversion, after 7 days or more.
Long-standing persistent AF	Continuous AF lasting for \geq 1 year when it is decided to adopt a rhythm control strategy.
Permanent AF	AF is accepted by the patient (and physician). Hence, rhythm control

interventions are, by definition, not pursued in patients with permanent AF. Should a rhythm control strategy be adopted, the arrhythmia would be re-classified as 'long-standing persistent AF'.

623 AF = atrial fibrillation.

^aThe distinction between paroxysmal and persistent AF is often not made correctly without access to long-term
 monitoring.¹⁶³ Hence, this classification alone is often insufficient to select specific therapies. If both persistent
 and paroxysmal episodes are present, the predominant pattern should guide the classification.

627

628 6.2. Atrial fibrillation types reflecting different causes of the arrhythmia

The risk of developing AF is increased in a variety of physiological and disease states, and the historic term 'lone AF' is probably misleading and should be avoided.¹⁶⁶ Although the pattern of AF may be the same, the mechanisms underpinning AF vary substantially between patients¹⁶⁷ (*Table 6*). This suggests that stratifying AF patients by underlying drivers of AF could inform management, for example, considering cardiac and systemic comorbidity (e.g. diabetes and obesity¹⁶⁸), lifestyle factors (e.g. activity level, smoking, alcohol intake^{169, 170}), markers of cardiac structural remodelling (e.g. fibrosis¹⁷¹⁻¹⁷³ or electrocardiographic parameters of AF complexity¹⁷⁴), or genetic background. *Table 6* provides such a taxonomy, informed by expert consensus,^{76, 120, 175} but without much evidence to underpin its clinical use.¹⁷⁶ Systematic research defining the major drivers of AF is clearly needed to better define different types of AF.¹⁷⁶

638 639

Table 6 Clinical types of AF (modified from the report on the 4 th AFNET/EHRA consensus conference ⁷⁶) ^a					
AF type	Clinical presentation	Possible pathophysiology			
AF secondary to structural heart disease	AF in patients with LV systolic or diastolic dysfunction, long-standing hypertension with LVH, and/or other structural heart diseases. The onset of AF in these patients is a common cause of hospitalization and a predictor of poor outcome	Increased atrial pressure and atrial structural remodelling, together with activation of the sympathetic and renin– angiotensin system			
Focal AF	Patients with repetitive atrial runs and frequent, short episodes of paroxysmal AF. Often highly symptomatic, younger patients with distinguishable atrial waves (coarse AF), atrial ectopy, and/or atrial tachycardia deteriorating in AF	Localized triggers, in most cases originating from the pulmonary veins, initiate AF. AF due to one or a few reentrant drivers is also considered to be part of this type of AF			
Polygenic AF	AF in carriers of common gene variants that have been associated with early onset AF	Currently under study. The presence of some gene variants may also influence treatment outcomes			
Postoperative AF	New onset of AF (usually self-terminating) after major (typically cardiac) surgery in patients who were in sinus rhythm before surgery and had no history of AF	Acute factors: inflammation, atrial oxidative stress, high sympathetic tone, electrolyte changes, and volume overload, possibly interacting with a pre-existing substrate			
AF in patients with mitral stenosis or prosthetic heart valves	AF in patients with mitral stenosis, after mitral valve surgery and in some cases other valvular disease	Left atrial pressure (stenosis) and volume (regurgitation) load are the main drivers of atrial enlargement and structural atrial remodelling in these patients			
AF in athletes	Usually paroxysmal, related to duration and intensity of training	Increased vagal tone and atrial volume			
Monogenic AF	AF in patients with inherited cardiomyopathies, including channelopathies	The arrhythmogenic mechanisms responsible for sudden death are likely to contribute to the occurrence of AF in these patients			

640 AF = atrial fibrillation; LV = left ventricular; LVH = left ventricular hypertrophy.

⁶41 ^aIt is recognized that these types of AF will overlap in clinical practice, and that their impact for management

642 needs to be evaluated systematically.

643

644 6.3. Symptom burden in atrial fibrillation

645 Patients with AF have significantly poorer quality of life than healthy controls, experiencing a variety of 646 symptoms including lethargy, palpitations, dyspnoea, chest tightness, sleeping difficulties, and psychosocial 647 distress.^{32, 177-180} Improved quality of life has been noted with both pharmacological and interventional therapies,¹⁸¹⁻¹⁸⁵ but there are limited data to compare the benefit of different treatments.^{32, 186} Assessment of 648 649 quality of life is further constrained by a lack of cross-validation of the several AF-specific quality-of-life tools.¹⁸⁷⁻¹⁹¹ With regard to symptom assessment, the European Heart Rhythm Association (EHRA) suggested the EHRA symptom scale (*Table 7*) to describe symptom severity in AF patients.¹⁹² A similar scale (the 650 651 Canadian Cardiovascular Society Severity of Atrial Fibrillation Scale) is used in Canada.¹⁹³ The EHRA scale has been used and validated.¹⁹⁴⁻¹⁹⁹ A modification was proposed in 2014, subdividing EHRA class 2 into mild 652 653 654 (2a) or moderate (2b) impact.¹⁹⁹ As symptoms in class 2b ('troubling' symptoms) identified patients with a 655 health utility benefit of rhythm control in that study, this modification may provide a threshold for potential treatment decisions, but this remains to be tested. While some AF patients had no or minimal symptoms (25-656 40%), many (15–30%) reported severe or disabling symptoms.^{194, 196} The EHRA scale should be used to guide 657 symptom-orientated treatment decisions and for longitudinal patient profiling. 658

659 660

Table 7 Modified EHRA symptom scale (modified from Wynn et al¹⁹⁹)

Modified EH	RA Symptoms	Description
score		
1	None	AF does not cause any symptoms
2a	Mild	Normal daily activity not affected by symptoms related to AF ^a
2b	Moderate	Normal daily activity not affected ^a
3	Severe	Normal daily activity affected
4	Disabling	Normal daily activity discontinued

661 AF = atrial fibrillation; EHRA = European Heart Rhythm Association.

^aEHRA class 2a and 2b can be differentiated by evaluating whether patients are functionally affected by their

AF symptoms. AF-related symptoms are most commonly fatigue/tiredness and exertional shortness of breath, or
 less frequently palpitations and chest pain.^{42, 194, 200-202}

665 666

Recommendation on use of the modified EHRA symptom scale

Recommendation	Class ^a	Level ^b	Refs ^c
Use of the modified EHRA symptom scale is recommended in clinical practice and research studies to quantify AF-related symptoms	I	С	192, 199

667 AF = atrial fibrillation; EHRA = European Heart Rhythm Association.

^aClass of recommendation.

669 ^bLevel of evidence.

670 ^cReference(s) supporting recommendations.

672 **7** Detection and management of risk factors and concomitant

673 cardiovascular diseases

Many cardiovascular diseases and concomitant conditions increase the risk of developing AF (*Table 8*),
 recurrent AF, and AF-associated complications. Identification of such conditions, their prevention and treatment
 is an important leverage to prevent AF and its disease burden. Knowledge of these factors and their management

677 is hence important for optimal management of AF patients.^{203, 204}

678 679

671

Table 8 Cardiovascular and other conditions independently associated with AF

Characteristic/comorbidity	Association with AF
Genetic predisposition (based on multiple common gene variants associated with AF) ⁶⁴	HR range 0.4–3.2

19	
Older age ¹⁹	HR:
50–59 years	1.00 (reference)
60–69 years	4.98 (95% CI 3.49–7.10)
70–79 years	7.35 (95% CI 5.28–10.2)
80–89 years	9.33 (95% CI 6.68–13.0)
Hypertension (treated) vs. none ¹⁹	HR 1.32 (95% CI 1.08–1.60)
Heart failure vs. none ¹⁹	HR 1.43 (95% CI 0.85–2.40)
Valvular heart disease vs. none ²⁰⁵	RR 2.42 (95% CI 1.62–3.60)
Myocardial infarction vs. none ¹⁹	HR 1.46 (95% CI 1.07–1.98)
Thyroid dysfunction ^{206, 207}	(reference: euthyroid)
hypothyroidism	HR 1.23 (95% CI 0.77-1.97)
subclinical hyperthyroidism	RR 1.31 (95% CI 1.19–1.44)
overt hyperthyroidism	RR 1.42 (95% CI 1.22–1.63)
Obesity ^{19, 208}	HR:
none (BMI $< 25 \text{ kg/m}^2$)	1.00 (reference)
overweight (BMI 25–30 kg/m ²)	1.13 (95% CI 0.87–1.46)
obese (BMI \ge 31 kg/m ²)	1.37 (95% CI 1.05–1.78)
Diabetes mellitus vs. none ¹⁹	HR 1.25 (95% CI 0.98–1.60)
Chronic obstructive pulmonary disease ²⁰⁹	RR:
FEV1	
$\geq 80\%$	1.00 (reference)
60-80%	1.28 (95% CI 0.79–2.06)
< 60%	2.53 (95% CI 1.45–4.42)
Obstructive sleep apnoea vs. none ²¹⁰	HR 2.18 (95% CI 1.34–3.54)
Chronic kidney disease ²¹¹	OR:
none	1.00 (reference)
stage 1 or 2	2.67 (95% CI 2.04-3.48)
stage 3	1.68 (95% CI 1.26–2.24)
stage 4 or 5	3.52 (95% CI 1.73–7.15)
Smoking ²¹²	HR:
never	1.00 (reference)
former	1.32 (95% CI 1.10–1.57)
current	2.05 (95% CI 1.71–2.47)
Alcohol consumption ²¹³	RR:
None	1.00 (reference)
1–6 drinks/week	1.01 (95% CI 0.94–1.09)
7–14 drinks/week	1.07 (95% CI 0.98–1.17)
15–21 drinks/week	1.14 (95% CI 1.01–1.28)
> 21 drinks/week	1.39 (95% CI 1.22–1.58)
Habitual vigorous exercise ²¹⁴	RR:
Non-exercisers	1.00 (reference)
<1 day/week	0.90 (95% CI 0.68-1.20)
1-2 days/week	1.09 (95% CI 0.95–1.26)
3–4 days/week	1.04 (95% CI 0.91–1.19)
5–7 days/week	1.20 (95% CI 1.02-1.41)
AF = atrial fibrillation; BMI = body mass index; CI = confid	

AF = atrial fibrillation; BMI = body mass index; CI = confidence interval; FEV1 = forced expiratory volume in 681 1 second; HR = hazard ratio; OR = odds ratio; RR = risk ratio

682

683 7.1. **Heart failure**

Heart failure and AF coincide in many patients.²¹⁵⁻²¹⁷ They are linked by similar risk factors and share a 684 common pathophysiology.²¹⁸ Heart failure and AF can cause and exacerbate each other through mechanisms 685 686 such as structural cardiac remodelling, activation of neurohormonal mechanisms, and rate-related impairment of left ventricular (LV) function. Patients with AF and concomitant heart failure, both with preserved ejection fraction (LV ejection fraction [LVEF] \geq 50%) and reduced ejection fraction (LVEF < 40%),^{219, 220} suffer from a worse prognosis, including increased mortality.^{16, 221} The recent ESC Guidelines on heart failure²²² have also 687 688 689 690 introduced a new category of heart failure with mid-range ejection fraction (HFmrEF; LVEF 40-49%), although 691 data on AF patients in this group are currently limited. Prevention of adverse outcomes and maintenance of a

692 good quality of life are the aims of management in all patients with AF and concomitant heart failure, regardless of LVEF.²²³ The general approach to AF management does not differ between heart failure patients and others,
 but a few considerations are worthwhile to consider. Of note, the only therapy with proven prognostic value in
 these patients is anticoagulation, and appropriate OAC should be prescribed in all patients at risk of stroke (see
 Chapter 8).

697

6987.1.1.Patients with atrial fibrillation and heart failure with reduced ejection

699 fraction

In addition to OAC, standard heart-failure therapy should be used in patients with heart failure with reduced
 ejection fraction (HFrEF), as detailed in the ESC Guidelines.²²² This includes angiotensin-converting enzyme
 (ACE) inhibitors or angiotensin receptor blockers (ARBs), mineralocorticoid antagonists, defibrillators and
 cardiac resynchronization therapy,²¹⁸ in addition to combined angiotensin receptor neprilysin inhibition (ARNI)
 in patients able to tolerate an ACE inhibitor or ARB with ongoing symptoms.²²⁴

705 Rate control of AF is discussed in detail in Chapter 9. In brief, only beta-blockers and digoxin are 706 suitable in HFrEF because of the negative inotropic potential of verapamil and diltiazem. Beta-blockers are 707 usually the first-line option in patients with clinically stable HFrEF, although a meta-analysis using individual 708 patient data from randomized controlled trials (RCTs) found no reduction in mortality from beta-blockers versus placebo in those with AF at baseline (HR 0.97, 95% CI 0.83–1.14).²³ Digoxin is commonly prescribed in 709 710 clinical practice but no head-to-head RCTs in AF patients have been performed. In a meta-analysis of 711 observational studies, digoxin had a neutral effect on mortality in patients with AF and concomitant heart failure 712 (adjusted observational studies HR 0.90, 95% CI 0.70-1.16; propensity-matched observational studies RR 1.08, 713 95% CI 0.93–1.26).²²⁵ Initial and combination rate-control therapy for AF in HFrEF should therefore take 714 account of individual patient characteristics and symptoms; beta-blocker initiation should be delayed in patients 715 with acute decompensated heart failure, and digoxin has more adverse effects in patients with renal impairment 716 (see Chapter 9).

Patients with AF and HFrEF who present with severe symptoms may require rhythm control therapy in addition to rate control therapy. For patients who develop HFrEF as a result of rapid AF (tachycardiomyopathy), a rhythm control strategy is preferred, based on several relatively small patient cohorts and trials reporting improved LV function after restoration of sinus rhythm.^{185, 226-228} The diagnosis of tachycardiomyopathy can be challenging, and at times requires restoration of sinus rhythm.²²⁹ Catheter ablation may be a useful method to restore LV function and quality of life in AF patients with HFrEF,^{185, 226-228} but further data are needed. *Figure 4* summarizes the approach to patients with AF and heart failure.

Management of patients presenting acutely with AF and heart failure




Figure 4 Initial management of newly diagnosed with AF and heart failure. Adapted from Kotecha and Piccini.²¹⁸

ACE = angiotensin-converting enzyme; AF = atrial fibrillation; ARB = angiotensin receptor blocker; ARNI = angiotensin receptor neprilysin inhibition; bpm = beats per minute; HF = heart failure.

^aIn patients with heart failure and reduced ejection fraction; also consider combined ARNI in patients able to tolerate an ACE inhibitor or ARB with ongoing symptoms.

731732 **7.1.2.** Atrial fibrillation patients with heart failure with preserved ejection fraction

733 The diagnosis of heart failure with preserved ejection fraction (HFpEF) in patients with AF is problematic 734 because of the difficulty in separating symptoms that are due to HF from those due to AF. Although diagnostic 735 differentiation can be achieved by cardioversion and clinical reassessment, this option is often not appropriate in 736 this group, particularly as a specific therapy that improves prognosis in HFpEF is currently lacking. 737 Echocardiography can support detection of HFpEF in patients with symptomatic AF by providing evidence of 738 relevant structural heart disease (e.g. LV hypertrophy [LVH]) and/or measurement of diastolic dysfunction. 739 Reduced early diastolic myocardial velocity e' by tissue Doppler reflects impaired LV relaxation, while the ratio of E/e' has demonstrated a significant correlation with invasive measurement of LV filling pressures.²³⁰⁻²³⁴ 740 741 Natriuretic peptide levels are part of the diagnostic assessment of HFpEF,²²² although natriuretic peptide levels are elevated in AF patients and the optimum diagnostic cut-off is still unknown.²³⁵ The management of patients 742 743 with AF and concomitant HFpEF should focus on control of fluid balance and concomitant conditions such as 744 hypertension and ischaemia.

745

746 **7.1.3.** Atrial fibrillation patients with heart failure with mid-range ejection

747 fraction

HFmrEF is a recently defined entity, describing patients with symptoms and signs of heart failure, LVEF 40–
49%, elevated levels of natriuretic peptides, and either LV hypertrophy, left atrial (LA) enlargement, or
evidence of diastolic dysfunction.²²² However, diagnosis is more difficult in patients with AF, as natriuretic

- 751 peptides are elevated in AF and LA dilatation is common, regardless of concomitant heart failure. LVEF is also
- variable and difficult to assess in AF patients because of AF-induced reduction in systolic LV function and

variable cardiac cycle length. Further study of this group is required before particular treatment strategies in AF
 patients with HFmrEF can be recommended.

755756 **7.1.4.** Prevention of atrial fibrillation in heart failure

Retrospective analyses from large randomized trials have reported a lower incidence of new-onset AF in patients treated with ACE inhibitors/ARBs compared with placebo.²³⁶⁻²³⁸ The reduced incidence of AF with 757 758 ACE inhibitors/ARBs is less evident in patients with HFpEF²³⁹ and is lost in patients without heart failure.²⁴⁰⁻²⁴² 759 Neprilysin inhibition does not seem to add to this effect.²²⁴ Beta-blocker therapy was associated with a 33% 760 761 reduction in the adjusted odds of incident AF in HFrEF patients pretreated with ACE inhibitors/ARBs, 762 reinforcing the importance of beta-blocker therapy in HFrEF patients in sinus rhythm.²³ Eplerenone, a 763 mineralocorticoid receptor antagonist, also reduced the risk of new-onset AF in patients with LVEF \leq 35%, 764 New York Heart Association (NYHA) Class II, and pretreatment with ACE inhibitors/ARBs and betablockers.243 765

766

767 7.2. Hypertension

768 **7.2.1.** Treatment of hypertension to prevent incident atrial fibrillation

Inhibition of the renin–angiotensin–aldosterone system can prevent structural remodelling and recurrent AF.²³⁶
 ²⁴⁴ A recent analysis of the Danish healthcare database with long-term monitoring of the effect of different antihypertensive agents on the occurrence of overt AF suggests a beneficial effect of ACE inhibitors or ARBs.²⁴⁵ Secondary analyses of ACE inhibitors or ARBs in patients with heart failure or LVH show a lower

incidence of new-onset AF.^{238, 246}

775 **7.2.2.** Blood pressure control in patients with atrial fibrillation

Hypertension is a stroke risk factor in AF, and uncontrolled high blood pressure enhances the risk of stroke and
bleeding events and may lead to recurrent AF. Good blood-pressure control should therefore form an integral
part of the management of AF patients.²⁴⁷ In patients with established AF, but without LV dysfunction or heart
failure, ARBs do not prevent recurrent AF better than placebo.^{240, 241} ACE inhibitors or ARBs may reduce
recurrent AF after cardioversion when coadministered with antiarrhythmic drug therapy compared with an
antiarrhythmic drug alone.^{248, 249} Meta-analyses driven by these studies suggested a lower risk of recurrent
AF, ^{236-238, 250} but at least one controlled trial failed to demonstrate benefit.^{240, 251}

784 7.3. Valvular heart disease

Valvular heart disease is independently associated with incident AF.²⁵² Approximately 30% of patients with AF
have some form of valvular heart disease, often detected only by echocardiography.^{201, 253-255} AF worsens
prognosis in patients with severe valvular heart disease,²⁵⁶ including those undergoing surgery or transcatheter
interventions for aortic or mitral valve disease.²⁵⁷⁻²⁶² Valvular heart disease can be associated with an increased
thromboembolic risk, which probably also adds to the stroke risk in AF patients.²⁶³ Similar to heart failure,
valvular disease and AF interact and sustain each other through volume and pressure overload,

valvular disease and AF interact and sustain each other through volume and pressure overload,
 tachycardiomyopathy, and neurohumoral factors.²⁶⁴⁻²⁷⁰ When valve dysfunction is severe, AF can be regarded as
 a marker for progressive disease, thus favouring valve repair or replacement.²⁷¹

Traditionally, patients with AF have been dichotomized into 'valvular' and 'non-valvular' AF.²⁷² Although slightly different definitions have been used, valvular AF mainly refers to AF patients that have either rheumatic valvular disease (predominantly mitral stenosis) or mechanical heart valves. In fact, while AF implies an incremental risk for thromboembolism in patients with mitral valve stenosis,^{263, 273, 274} there is no clear evidence that other valvular diseases, including mitral regurgitation or aortic valve disease, need to be considered when choosing an anticoagulant or indeed to estimate stroke risk.²⁷⁵ We have therefore decided to

- replace the historic term 'non-valvular' AF with reference to the specific underlying conditions.
- 800 801

Recommendations for patients with valvular heart disease and AF

Recommendations	Class ^a	Level ^D	Refs ^c
Early mitral valve surgery should be considered in severe mitral regurgitation, preserved LV function, and new-onset AF, even in the absence of symptoms, particularly when valve repair is feasible	lla	С	276

	Mitral valvotomy should be considered for asymptomatic patients with severe mitral stenosis and suitable valve anatomy who have new-onset AF	lla	С	
2	AF = atrial fibrillation; LV = left ventricular.			
	^a Class of recommendation.			

- 803 804 ^bLevel of evidence.
- 805 ^cReference(s) supporting recommendations.
- 806
- 807

808 7.4. **Diabetes mellitus**

Diabetes and AF frequently coexist because of associations with other risk factors.²⁷⁷⁻²⁸³ Diabetes is a risk factor 809 for stroke and other complications in AF.²⁸⁴ In patients with AF, a longer duration of diabetes appears to confer 810 811 a higher risk of thromboembolism, albeit without greater risk of OAC-related bleeding.²⁸⁵ Unfortunately, 812 intensive glycaemic control does not affect the rate of new-onset AF,²⁸⁴ while treatment with metformin seems 813 to be associated with a decreased long-term risk of AF in diabetic patients²⁸⁶ and may even lower long-term 814 stroke risk.¹³ Diabetic retinopathy, a measure of disease severity, does not increase the risk of ocular bleeding in anticoagulated patients.28 815

816

817 7.5. **Obesity and weight loss**

818 7.5.1. Obesity as a risk factor

Obesity increases the risk for AF (risk ratio 1.5–1.8),²⁸⁸⁻²⁹¹ with a progressive increase according to body mass 819 index.^{288, 290-292} Obese patients may have more LV diastolic dysfunction, increased sympathetic activity and inflammation, and increased fatty infiltration of the atria.²⁹³⁻²⁹⁵ Obesity may also be a risk factor for ischaemic 820 821 822 stroke, thromboembolism, and death in AF patients.²⁹² 823

824 Weight reduction in obese patients with atrial fibrillation 7.5.2.

825 Intensive weight-reduction management in addition to management of other cardiovascular risk factors (in the range of 10–15 kg weight loss achieved) led to fewer AF recurrences and symptoms compared with an approach based on general advice in obese patients with AF.^{203, 204, 296} Improved cardiorespiratory fitness can further decrease AF burden in obese patients with AF.²⁹⁷ Although the findings in these studies have to be confirmed, 826 827 828 829 they underpin the positive effect of weight reduction in obese patients. 830

831 7.5.3. Catheter ablation in obese patients

Obesity may increase the rate of AF recurrence after catheter ablation,²⁹⁸⁻³⁰¹ with obstructive sleep apnoea as an 832 833 important potential confounder. Obesity has also been linked to a higher radiation dose and complication rate during AF ablation.^{302, 303} Notably, the symptomatic improvement after catheter ablation of AF in obese patients 834 seems comparable to the improvement in normal-weight patients.²⁹⁸ In view of the potential to reduce AF 835 836 episodes by weight reduction (see Section 6.5.2.), AF ablation should be offered to obese patients in conjunction 837 with lifestyle modifications that lead to weight reduction. 838

839 Recommendation for obese patients with AF

AF = atrial fibrillation

841	AF = atrial fibrillation.			
	Recommendation	Class ^a	Level ^b	Refs ^c
	In obese patients with AF, weight loss together with management of	IIa	В	204, 288, 296
	other risk factors should be considered to reduce AF burden and			
	symptoms			
017				

842 843

840

^a Class of recommendation

^b Level of evidence 844

845 ^cReference(s) supporting recommendation(s) 846

847 7.6. Chronic obstructive pulmonary disease, sleep apnoea, and other respiratory 848 diseases

AF has been associated with obstructive sleep apnoea.^{304, 305} Multiple pathophysiological mechanisms can 849 850 contribute to AF in obstructive sleep apnoea, including autonomic dysfunction, hypoxia, hypercapnia, and inflammation.^{96, 304-307} Obstructive sleep apnoea exaggerates intrathoracic pressure changes, which in itself and 851 852 via vagal activation can provoke shortening of the atrial action potential and induce AF. Risk factor reduction and continuous positive airway pressure ventilation can reduce AF recurrence.³⁰⁸⁻³¹² It seems reasonable to 853 854 consider obstructive sleep apnoea screening in AF patients with risk factors. Obstructive sleep apnoea treatment 855 should be optimized to improve AF treatment results in appropriate patients. Servo-controlled pressure support 856 therapy should not be used in HFrEF patients with predominantly central sleep apnoea (of which 25% had 857 concomitant AF).³¹³

Patients with chronic obstructive pulmonary disease often suffer from atrial tachycardias, which need
to be differentiated from AF by ECG. Agents used to relieve bronchospasm, notably theophyllines and betaadrenergic agonists, may precipitate AF and make control of the ventricular response rate difficult. Nonselective beta-blockers, sotalol, propafenone, and adenosine should be used with caution in patients with
significant bronchospasm, while they can safely be used in patients with chronic obstructive pulmonary disease.
Beta-1 selective blockers (e.g. bisoprolol, metoprolol, and nebivolol), diltiazem, and verapamil are often

tolerated and effective (see Chapter 9).

865

866 Recommendations for patients with AF and respiratory diseases

Recommendations	Class ^a	Level ^b	Ref s ^c
Correction of hypoxaemia and acidosis should be considered as initial management for patients who develop AF during an acute pulmonary illness or exacerbation of chronic pulmonary disease	IIa	С	
Interrogation for clinical signs of obstructive sleep apnoea in all AF patients should be considered	IIa	В	304, 305, 314, 315
Obstructive sleep apnoea treatment should be optimized to reduce AF recurrences and improve AF treatment results	IIa	В	307-311

- 867 AF = atrial fibrillation.
- 868 ^aClass of recommendation.
- 869 ^bLevel of evidence.
- 870 ^cReference(s) supporting recommendations.
- 871

872 7.7. Chronic kidney disease

AF is present in 15–20% of patients with CKD.³¹⁶ The definition of CKD in most AF trials is relatively strict.
Although an estimated creatinine clearance (CrCl) rate of < 60 mL/min is indicative of CKD, a number of trials
in AF patients have used CrCl < 50 mL/min to adapt NOAC dosage, usually estimated using the Cockroft–Gault
formula. CrCl in AF patients can deteriorate over time.³¹⁷ The management of OAC in patients with CKD is
discussed in Section 8.2.4.

878

879 Recommendations for patients with kidney disease and AF880

Recommendations	Class ^a	Level ^b	Refs ^c
The assessment of kidney function by serum creatinine or creatinine clearance is recommended in all AF patients to detect kidney disease and to support correct dosing of AF therapy	I	A	316, 318-321
All AF patients treated with oral anticoagulation should be considered for at least yearly renal function evaluation to detect kidney disease	lla	В	


AF = atrial fibrillation.

- ^aClass of recommendation.
- 883 ^bLevel of evidence.
- 884 ^cReference(s) supporting recommendations.

8 Integrated management of patients with atrial fibrillation 886


887 Most patients access the healthcare system initially through pharmacists, community health workers, or primary 888 care physicians. As AF is often asymptomatic, these healthcare professionals are important stakeholders to 889 enable adequate detection of AF and to ensure consistent management. The initial assessment should be 890 performed at the point of first contact with the healthcare system, and is feasible in most healthcare settings 891 (when an ECG is available). We propose to consider five domains in the initial assessment of patients presenting 892 with newly diagnosed AF (Figure 5). These domains are:

- 893 1. Haemodynamic instability or limiting, severe symptoms
- 894 Presence of precipitating factors (e.g. thyrotoxicosis, sepsis, or postoperative AF) and 2. 895 underlying cardiovascular conditions
- Stroke risk and need for anticoagulation 896 3.
- 897 Heart rate and need for rate control 4.
- 898 5. Symptom assessment and decision for rhythm control



899	
900	Figure 5 Acute and chronic management of AF patients, desired cardiovascular outcomes, and patient benefits.
901	Adapted from the report on the 4th AFNET/EHRA consensus conference. ⁷⁶
902	AF = atrial fibrillation; AFNET = German Competence NETwork on Atrial Fibrillation; EHRA = European
903	Heart Rhythm Association.
904	
905	An integrated, structured approach to AF care, as applied successfully to other domains of medicine, ³²²⁻³²⁴ will
906	facilitate consistent, guideline-adherent AF management for all patients ³²⁵ (Figure 6), with the potential to
907	improve outcomes. ^{42, 326, 327} Such approaches are consistent with the Innovative Care for Chronic Conditions
908	Framework proposal put forward by the World Health Organization. ³²⁸ Review by an AF service, or at least
909	referral to a cardiologist, will usually be required after the initial assessment to fully evaluate the effect of AF on
910	cardiovascular health. ³²⁹ There may also be reasons for early or urgent referral (<i>Table 9</i>). Integrated care of all
911	patients with newly diagnosed AF should help to overcome the current shortcomings of AF management, such
912	as underuse of anticoagulation, access to rate and rhythm control therapy, and inconsistent approaches to
913	cardiovascular risk reduction. Integrated AF care requires the cooperation of primary care physicians,
914	cardiologists, cardiac surgeons, AF specialists, stroke specialists, allied health practitioners and patients,

915 encompassing lifestyle interventions, treatment of underlying cardiovascular diseases and AF-specific therapy 916 (Figure 7).



917 918 Figure 6 Achieving optimal management of AF patients.

919 AF = atrial fibrillation.

920 ^aOn-site or through institutionalized cooperation.

921 ^bSafety outcomes should be collected in published and monitored central databases.

Integrated AF management

- Central role in care process
- Patient education
- Encouragement and empowerment for selfmanagement
- · Advice and education on lifestyle and risk factor
- management Shared decision Making
- Informed, involved, empowered patient

- Physicians (general physicians, cardiology and stroke AF specialists, surgeons) and allied health professionals work in a collaborative practice model
- Efficient mix of communication skills. education, and experience
- Working together in a multidisciplinary chronic AF care team

Technology tools

- Information on AF Clinical decision support
- Checklist and communication tool
- Used by healthcare professionals and patients
- Monitoring of therapy adherence and

effectiveness

 Navigation system to support decision making in treatment team

- Structured support for lifestyle changes
- Anticoagulation
- Rate control
- Antiarrhythmic drugs
- Catheter and surgical interventions (ablation, LAA occluder, AF surgery, etc)
- Complex management decisions underpinned by an AF Heart Team

922 923

Figure 7 Fundamentals of integrated care in AF patients. 924 AF = atrial fibrillation; LAA = left atrial appendage. 925 926 Table 9 Clinical signs calling for urgent involvement of a specialized AF service.^a Haemodynamic instability Uncontrollable rate Symptomatic bradycardia not amenable to reduced dosing of rate control agents Severe angina or worsening left ventricular function Transient ischemic attack or stroke

927 AF = atrial fibrillation

928 ^aAnticoagulation should be initiated early in all suitable patients and will not routinely require specialist input.

929

930 8.1. **Evidence supporting integrated atrial fibrillation care**

931 Several structured approaches to AF care have been developed. Some evidence underpins their use, while more 932 research is needed into the best way of delivering integrated AF care. Integrated AF management in an RCT 933 increased the use of evidence-base care and reduced by approximately one-third the composite outcome of 934 cardiovascular hospitalization and cardiovascular death over a mean follow-up of 22 months (14.3% vs. 20.8%, 935 HR 0.65; 95% CI 0.45–0.93; P = 0.017) compared with usual care in a large tertiary care centre.³³⁰ Integrated AF management appeared cost-effective in that study.³³¹ However, an Australian RCT showed only a marginal 936 effect on unplanned admissions and death using integrated AF care limited to the initial care period, possibly 937 emphasizing the need for sustained integration of AF care.³³² Two observational studies of integrated AF care found fewer hospitalizations,^{333, 334} one study showed fewer cases of stroke,³³³ and a further non-randomized 938 939 940 study identified a trend for a lower rate of the composite outcome of death, cardiovascular hospitalization, and 941 AF-related emergency visits.³³⁵ More research is needed, and integrated AF care is likely to require different 942 designs in different healthcare settings. 943

944 **Components of integrated atrial fibrillation care** 8.2.

945 8.2.1. Patient involvement

946 Patients should have a central role in the care process. As treatment of AF requires patients to change their 947 lifestyles and adhere to chronic therapy, at times without an immediately tangible benefit, they need to 948 understand their responsibilities in the care process. Physicians and healthcare professionals are responsible for 949 providing access to evidence-based therapy, but adherence to therapy is ultimately the responsibility of informed and autonomous patients, best described as 'shared accountability'.³³⁶ Hence, information and 950 education of patients and often of their partners and relatives is indispensable to encourage a self-management 951 role and to empower patients to participate in shared decision-making, ^{326, 328} and to support their understanding 952 953 of the disease and the suggested treatments.³³⁷

955 8.2.2. Multidisciplinary atrial fibrillation teams

956 Delegation of tasks from specialists to general physicians and from physicians to allied health professionals is a 957 fundamental concept of integrated care models. A multidisciplinary AF team approach includes an efficient mix 958 of interpersonal and communication skills, education and expertise in AF management, as well as the use of 959 dedicated technology. This approach underlines the importance of redesigning daily practice in a way that 960 encourages non-specialists and allied professionals to have an important role in educating patients and 961 coordinating care, while the specialist remains medically responsible. Cultural and regional differences will 962 determine the composition of AF teams.

964 8.2.3. Role of non-specialists

AF patients often initially present to general practitioners or pharmacists. Some physicians in primary care have
 extensive expertise in stroke prevention and initial management of AF patients. Others may seek training to
 acquire such knowledge. Other components of AF management (e.g. assessment of concomitant cardiovascular
 conditions, antiarrhythmic drug therapy, or interventional treatment) often require specialist input. Integrated
 AF care structures should support treatment initiation by non-specialists where appropriate, and provide ready
 access to specialist knowledge to optimize AF care.

972 8.2.4. Technology use to support atrial fibrillation care

973 Technology, such as decision support software, has the potential to enhance the implementation of evidence974 based care and improve outcomes, when used to enhance expert advice.³³⁸ Electronic tools can also ensure
975 coherent communication within the AF team. With a view to support the wider use of such technology, this
976 Task Force is providing tools free of charge, in the form of smartphone apps, to AF healthcare professionals and

977 to AF patients. 978

954

963

979 Recommendations for an integrated approach to care

Recommendations	Class ^a	Level ^b	Ref s ^c
An integrated approach with structured organization of care and follow- up should be considered in all patients with AF, aiming to improve guideline adherence and reduce hospitalization and mortality	IIa	В	330-332
Placing patients in a central role in the decision-making should be considered in order to tailor management to patient preferences and improve adherence to chronic therapy	IIa	С	330, 332, 334

980 AF = atrial fibrillation

- 981 ^aClass of recommendation.
- 982 ^bLevel of evidence.
- 983 ^cReference(s) supporting recommendations.
- 984

985 8.3. Diagnostic workup of atrial fibrillation patients

AF is often found in patients with other, at times undiagnosed, cardiovascular conditions. Thus, all AF patients
 will benefit from a comprehensive cardiovascular assessment.³³⁹

989 **8.3.1.** Recommended evaluation in all atrial fibrillation patients

990 A complete medical history should be taken and all patients should undergo clinical evaluation that includes

- thorough assessment for concomitant conditions, establishing the AF pattern, estimation of stroke risk and AFrelated symptoms, and assessment of arrhythmia-related complications such as thromboembolism or LV
- related symptoms, and assessment of arrhythmia-related complications such as thromboembolism or LV
- 993 dysfunction. A 12-lead ECG is recommended to establish a suspected diagnosis of AF, to determine rate in AF,

994 and to screen for conduction defects, ischaemia, and signs of structural heart disease. Initial blood tests should 995 evaluate thyroid and kidney function as well as serum electrolytes and full blood count. Transthoracic

evaluate thyroid and kidney function as well as serum electrolytes and full blood count. Transthoracic
 echocardiography is recommended in all AF patients to guide treatment decisions. Transthoracic

997 echocardiography is recommended in an Air patients to guide deathent decisions. Transmonate 997 echocardiography should be used to identify structural disease (e.g. valvular disease) and assess LV size and

998 function (systolic and diastolic), atrial size, and right heart function.^{339, 340} Although biomarkers such as

999 natriuretic peptides are elevated in AF patients, there is insufficient data to suggest that blood-based parameters are independent markers for AF.³⁴¹⁻³⁴³

1001Additional investigations in selected patients with atrial fibrillation8.3.2.Additional investigations in selected patients with atrial fibrillation

Ambulatory ECG monitoring in AF patients can assess the adequacy of rate control, relate symptoms with AF recurrences, and detect focal induction of bouts of paroxysmal AF. Transoesophageal echocardiography (TOE) is useful to further assess valvular heart disease and to exclude intracardiac thrombi, especially in the LAA, to facilitate early cardioversion or catheter ablation.³⁴⁴ Patients with symptoms or signs of myocardial ischaemia should undergo coronary angiography or stress testing as appropriate. In patients with AF and signs of cerebral ischaemia or stroke, computed tomography (CT) or magnetic resonance imaging (MRI) of the brain is

1009 recommended to detect stroke and support decisions regarding acute management and long-term

anticoagulation. Delayed-enhancement MRI of the left atrium using gadolinium contrast,³⁴⁵⁻³⁴⁷ T1 mapping
 using cardiac MRI,³⁴⁷ and intracardiac echo³⁴⁸ may help to guide treatment decisions in AF, but require external
 validation in multicentre studies.

1012

1014 8.4. Structured follow-up

1015 Most AF patients need regular follow-up to ensure continued optimal management. Follow-up may be

1016 undertaken in primary care, by specially trained nurses, by cardiologists, or by AF specialists.^{325, 330} A specialist

1017 should coordinate care and follow-up. Follow-up should ensure implementation of the management plan,

1018 continued engagement of the patient, and therapy adaptation where needed.

1019

1020 **Recommendations for diagnostic workup of AF patients**

Recommendations	Class ^a	Level ^b	Refs ^c
ECG documentation is required to establish the diagnosis of AF	I	В	349
A full cardiovascular evaluation, including an accurate history, careful clinical examination, and assessment of concomitant conditions, is recommended in all AF patients	I	С	
Transthoracic echocardiography is recommended in all AF patients to guide management	I	С	339
Long-term ECG monitoring should be considered in selected patients to assess the adequacy of rate control in symptomatic patients and to relate symptoms with AF episodes	lla	С	

1021 AF = atrial fibrillation; ECG = electrocardiogram.

1022 ^aClass of recommendation.

- 1023 ^bLevel of evidence.
- 1024 ^cReference(s) supporting recommendations.
- 1025

1026 8.5. Defining goals of atrial fibrillation management

1027AF management comprises therapies with prognostic impact (anticoagulation and treatment of cardiovascular1028conditions) and therapies predominantly providing symptomatic benefit (rate control, rhythm control, *Table 10*).1029Therapies with prognostic benefit need careful explanation to patients when their benefits are not directly felt.1030Rhythm control therapy can be successful if symptoms are controlled, even when AF recurs. Explaining the1031expected benefits to each patient at the start of AF management will prevent unfounded expectations and has the1032potential to optimize quality of life.

1033

1034 **Table 10** Goal-based follow-up

Category

Intervention

Follow-up aspects


Prognostic	Comorbidity control	Obesity	Weight loss
	(relevant examples	Arterial hypertension	Blood pressure control
	given)	Heart failure	Heart failure therapy
		Coronary artery disease	Statin and antiplatelet therapy
			Revascularization
		Diabetes	Glycaemic control
		Valvular Heart Disease	Valve repair or replacement
Prognostic	Anticoagulation	Indication (risk profile; timing,	Stroke
		e.g. post-cardioversion);	Bleeding
		Adherence (NOAC or VKA)	Mortality
		and INR (if VKA);	
		NOAC dosing (co-	
		medications, age, weight, renal	
		function)	
Mainly symptomatic	Rate control	Symptoms	EHRA score
Partly prognostic		Average resting heart rate	Heart failure status
		< 110 bpm	LV function
			Exercise capacity
Symptomatic at present	Rhythm control	Symptoms vs. side-effects	Hospitalization
		Exclusion of proarrhythmia	Therapy complications
		(PR; QRS; QTc interval)	
Relevant for	Patient education and	Knowledge (about disease;	Adherence to therapy
implementation of and	self-care capabilities	about treatment; about	Directed evaluation, preferably
adherence to therapy		management goals)	based on systematic checklists
		Capabilities (what to do if)	
Relevant for chronic	Caregiver	Who? (spouse; GP; home	Directed evaluation of task
care management	involvement	nurse; pharmacist)	performance (e.g. via patient
		Clearly spelling out	card)
		participation roles	Dispensed medication
		Knowledge and capabilities	GP log of follow-up visits

1035 bpm = beats per minute; EHRA = European Heart Rhythm Association; GP = general practitioner; INR = 1036 international normalized ratio; LV = left ventricular; NOAC = non-vitamin K antagonist oral anticoagulant; 1037 VKA = vitamin K antagonist. 1038

9 Stroke prevention therapy in atrial fibrillation patients

1039 OAC therapy can prevent the majority of ischaemic strokes in AF patients and can prolong life.^{38, 39, 42, 194, 201, 329,} 1040 ³⁵⁰⁻³⁵² It is superior to no treatment or aspirin in patients with different profiles for stroke risk. ^{353, 354} The net 1041 1042 clinical benefit is almost universal, with the exception of patients at very low stroke risk, and OAC should 1043 therefore be used in most patients with AF (Figure 8). Despite this evidence, underuse or premature termination 1044 of OAC therapy is still common. Bleeding events, both severe and nuisance bleeds, a perceived 'high risk of bleeding' on anticoagulation, and the efforts required to monitor and dose-adjust VKA therapy are among the most common reasons for withholding or ending OAC.^{352, 355-359} However, the considerable stroke risk without 1045 1046 OAC often exceeds the bleeding risk on OAC, even in the elderly, in patients with cognitive dysfunction, or in patients with frequent falls or frailty.^{360, 361} The bleeding risk on aspirin is not different to the bleeding risk on VKA³⁶² or NOAC therapy,^{354, 363} while VKA and NOACs, but not aspirin, effectively prevent strokes in AF 1047 1048 1049 patients. 38, 354, 362, 363 1050

1051



1004	
1053	Figure 8 Stroke prevention in AF.
1054	AF = atrial fibrillation; CHA_2DS_2 -VASc = Congestive Heart failure, hypertension, Age \geq 75 (doubled),
1055	Diabetes, Stroke (doubled), Vascular disease, Age 65–74, and Sex (female); LAA = left atrial appendage;
1056	NOAC = non-vitamin K antagonist oral anticoagulant; OAC = oral anticoagulation; VKA = vitamin K
1057	antagonist.
1058	^a Congestive heart failure, hypertension, age \geq 75 years (2 points), diabetes, prior stroke/TIA/embolus (2 points),
1059	vascular disease, age 65–74, female sex.
1060	^b Includes women without other stroke risk factors.
1061	^c IIaB for women with only one additional stroke risk factor,
1062	^d IB for patients with mechanical heart valves or mitral stenosis
1063	

1064 9.1. Prediction of stroke and bleeding risk

1065 9.1.1. Clinical risk scores for stroke and systemic embolism

Simple, clinically applicable stroke risk-stratification schemes in AF patients were developed in the late 1990s in small cohort studies and have later been refined and validated in larger populations.³⁶⁴⁻³⁶⁸ The introduction of the CHA₂DS₂-VASc score (*Table 11*) has clearly simplified the initial decision for OAC in AF patients. Since its first incorporation in the ESC guidelines in 2010,³⁶⁹ it has been widely used.³⁷⁰ We recommend estimating stroke risk in AF patients based on the CHA₂DS₂-VASc score.³⁶⁸ In general, patients without clinical stroke risk factors do not need antithrombotic therapy, while patients with stroke risk factors (i.e. CHA₂DS₂-VASc score of 1 or more for men, and 2 or more for women) are likely to benefit from OAC.

1074Table 11 Clinical risk factors for stroke, transient ischemic attack, and systemic embolism in the1075CHA2DS2-VASc score.

CHA ₂ DS ₂ -VASc risk factor	Points
Congestive heart failure	+1
Signs/symptoms of heart failure or objective evidence of reduced left-ventricular ejection fraction	

Hypertension	+1
Resting blood pressure > 140/90 mmHg on at least two occasions or current antihypertensive	
treatment	
Age 75 years or older	+2
Diabetes mellitus	+1
Fasting glucose > 125 mg/dL or treatment with oral hypoglycaemic agent and/or insulin	
Previous stroke, transient ischemic attack, or thromboembolism	+2
Vascular disease	+1
Previous myocardial infarction, peripheral artery disease, or aortic plaque	
Age 65 to 74 years	+1
Sex category (female)	+1

 CHA_2DS_2 -VASc = Congestive Heart failure, hypertension, Age >75 (doubled), Diabetes, Stroke (doubled), Vascular disease, Age 65–74, and Sex (female).

1077 1078

1076

1079 Other, less established risk factors for stroke include unstable international normalized ratio (INR) and low time 1080 in therapeutic range (TTR) in patients treated with VKAs; previous bleed or anaemia; alcohol excess and other 1081 markers for decreased therapy adherence; CKD; elevated high-sensitivity troponin T; and elevated N-terminal 1082 pro-B-type natriuretic peptide.

1083

1085

1104

1084 9.1.2. Anticoagulation in patients with a CHA₂DS₂-VASc score of 1 in men and 2

in women

Controlled trials studying OAC in AF patients have been enriched for patients at high risk of stroke,^{38, 39, 42, 194, 201, 329, 351, 352} and hence there is strong evidence that patients with a CHA₂DS₂-VASc risk score of 2 or more in 1086 1087 1088 men, and 3 or more in women benefit from OAC. Fortunately, we now have a growing evidence-base regarding 1089 stroke risk in patients with one clinical risk factor (i.e. CHA2DS2-VASc score of 1 for men, and 2 for women), although this relies largely on observed stroke rates in patients not receiving OAC. In many of these patients, anticoagulation seems to provide a clinical benefit.³⁷¹⁻³⁷⁵ The rates of stroke and thromboembolism vary 1090 1091 considerably in patients with CHA_2DS_2 -VASc scores of 1 or 2 due to differences in outcomes, populations, and anticoagulation status (*Web Addenda Table 1*).^{371, 376, 377, 1041} OAC should be considered for men with a 1092 1093 1094 CHA_2DS_2 -VASc score of 1 and women with a score of 2, balancing the expected stroke reduction, bleeding risk, and patient preference. Importantly, age (65 years and older) conveys a relatively high and continuously 1095 1096 increasing stroke risk that also potentiates other risk factors (such as heart failure and sex). Hence, an 1097 individualized weighing of risk, as well as patient preferences, should inform the decision to anticoagulate 1098 patients with only one CHA2DS2-VASc risk factor, apart from female sex. Female sex does not appear to increase stroke risk in the absence of other stroke risk factors (Web Addenda Table 1).^{378, 379} 1099

Measurement of cardiac troponin (high-sensitivity troponin T or I) and N-terminal pro-B-type natriuretic peptide may provide additional prognostic information in selected AF patients.³⁸⁰⁻³⁸² Biomarker-1100 1101 1102 based risk scores may in the future prove helpful to better stratify patients (e.g. those at a truly low risk of stroke).75, 382 1103

1105 9.1.3. Clinical risk scores for bleeding

1106 Several bleeding risk scores have been developed, mainly in patients on VKAs. These include HAS-BLED 1107 (hypertension, abnormal renal/liver function [1 point each], stroke, bleeding history or predisposition, labile 1108 INR, elderly [>65 years], drugs/alcohol concomitantly [1 point each]), ORBIT (Outcomes Registry for Better Informed Treatment of Atrial Fibrillation), and more recently, the ABC (age, biomarkers, clinical history) bleeding score, which also makes use of selected biomarkers.³⁸³⁻³⁸⁵ Stroke and bleeding risk factors overlap 1109 1110 (compare *Table 11* and *Table 12*). For example, older age is one of the most important predictors of both ischaemic stroke and bleeding in AF patients.^{386, 387} A high bleeding risk score should generally not result in 1111 1112 1113 withholding OAC. Rather, bleeding risk factors should be identified and treatable factors corrected (see Section 1114 8.5). Table 12 provides details of modifiable bleeding risk factors. 1115

1116 Table 12 Modifiable and non-modifiable risk factors for bleeding in anticoagulated patients based on 1117 bleeding risk scores.

Modifiable bleeding risk factors Hypertension (especially when systolic blood pressure is $> 160 \text{ mmHg})^{a,b,c}$

Medication pre	disposing to bleeding, such as antiplatelet drugs and non-steroidal anti-inflammatory drugs ^{a,}
	$(\geq 8 \text{ drinks/week})^{a,b}$
Potentially mo	difiable bleeding risk factors
Anaemia ^{b,c,d}	
Impaired renal	
Impaired liver	
	et count or function ^b
Non-modifiab	le bleeding risk factors
Age ^e (> 65 yea	$rs)^a (\geq 75 years)^{b,c,d}$
	or bleeding ^{a,b,c,d}
Previous stroke	ab
	dent CKD or renal transplant ^{a,c}
Cirrhotic liver	disease ^a
Malignancy ^b	
Genetic factors	b
Biomarker-ba	sed bleeding risk factors
High-sensitivit	y troponin T ^e
Growth differe	ntiation factor-15 ^e
Serum creatini	ne/estimated CrCL ^e

- 1118 ABC = age, biomarkers, clinical history; ATRIA = AnTicoagulation and Risk factors In Atrial fibrillation; CKD
- 1119 = chronic kidney disease; CrCl = creatinine clearance; HAS-BLED = hypertension, abnormal renal/liver
- 1120 function (1 point each), stroke, bleeding history or predisposition, labile INR, elderly (>65 years), drugs/alcohol
- 1121 concomitantly (1 point each); INR = international normalized ratio; ORBIT = Outcomes Registry for Better 1122 Informed Treatment of Atrial Fibrillation; TTR = time in therapeutic range; VKA = vitamin K antagonist.
- 1123 ^aDerived from the HAS-BLED score.³⁸⁴
- ^bDerived from the HEMORR₂HAGES score.³⁸³ 1124
- 1125 ^cDerived from the ATRIA score.^{38:}
- ^dDerived from the ORBIT score.³⁸⁸ 1126
- 1127 ^eDerived from the ABC bleeding score.³⁸⁷
- 1128

1129 Recommendations for prediction of stroke and bleeding risk

Recommendations	Class ^a	Level ^b	Refs ^c
The CHA ₂ DS ₂ -VASc score is recommended for stroke risk prediction in patients with AF	I	A	368, 371, 386
Bleeding risk scores should be considered in AF patients on oral anticoagulation to identify modifiable factors for major bleeding	lla	В	384, 386, 387, 389-392
Biomarkers such as high-sensitivity troponin and N-terminal pro- B-type natriuretic peptide may be considered to further refine stroke and bleeding risk in AF patients	llb	В	380-382, 387, 393

- 1130 AF = atrial fibrillation; CHA_2DS_2 -VASc = Congestive Heart failure, hypertension, Age \geq 75 (doubled),
- 1131 Diabetes, Stroke (doubled), Vascular disease, Age 65–74, and Sex (female); OAC = oral anticoagulation.
- 1132 ^aClass of recommendation.
- 1133 ^bLevel of evidence.
- 1134 ^cReference(s) supporting recommendations. 1135

1136 9.2. **Stroke prevention**

1137 9.2.1. Vitamin K antagonists

1138 Warfarin and other VKAs were the first anticoagulants used in AF patients. VKA therapy reduces risk of stroke 1139

- by two-thirds and mortality by one-quarter compared with control (aspirin or no therapy).³⁸ VKAs have been used in many patients throughout the world with good outcomes,³⁹⁴⁻³⁹⁶ and this is reflected in the warfarin arms 1140
- 1141 of the NOAC trials (see Section 8.2.2.). The use of VKAs is limited by the narrow therapeutic interval,
- 1142 necessitating frequent monitoring and dose adjustments, but VKAs, when delivered with adequate TTR, are

1143 effective for stroke prevention in AF patients. Clinical parameters can help to identify patients who are likely to 1144 achieve a decent TTR on VKA therapy.³⁹⁷ These have been summarized in the SAMe-TT₂R₂ score. Patients who 1145 fare well on this score, when treated with a VKA, have on average a higher TTR than patients who do not fare well on the score.^{398, 399} VKAs are currently the only treatment with established safety in AF patients with 1146 1147 rheumatic mitral valve disease and/or a mechanical heart valve prosthesis.⁴⁰⁰

1148 1149 9.2.2. Non-vitamin K antagonist oral anticoagulants

1150 NOACs, including the direct thrombin inhibitor dabigatran and the factor Xa inhibitors apixaban, edoxaban, and 1151 rivaroxaban, are suitable alternatives to VKAs for stroke prevention in AF (Table 13). Their use in clinical 1152 practice is increasing rapidly.⁴⁰¹ All NOACs have a predictable effect (onset and offset) without need for regular 1153 anticoagulation monitoring. The phase III trials have been conducted with carefully selected doses of the 1154 NOACs, including clear rules for dose reduction that should be followed in clinical practice (Table 13).

1155 1156 Apixaban

1157 In the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial 1158 Fibrillation) trial,³¹⁹ apixaban reduced stroke or systemic embolism by 21% compared with warfarin, combined 1159 with a 31% reduction in major bleeding and an 11% reduction in all-cause mortality (all statistically significant). 1160 Rates of haemorrhagic stroke and intracranial haemorrhage, but not of ischaemic stroke, were lower on apixaban. Rates of gastrointestinal bleeding were similar between the two treatment arms.⁴⁰² 1161

1162 Apixaban is the only NOAC that has been compared with aspirin in AF patients: apixaban significantly 1163 reduced stroke or systemic embolism by 55% compared with aspirin, with no significant difference in rates of 1164 major bleeding or intracranial haemorrhage.^{354, 403} 1165

1166 Dabigatran

1167 In the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) study,^{318, 404} dabigatran 150 mg 1168 twice daily reduced stroke and systemic embolism by 35% compared with warfarin without a significant 1169 difference in major bleeding events. Dabigatran 110 mg twice daily was non-inferior to warfarin for prevention 1170 of stroke and systemic embolism, with 20% fewer major bleeding events. Both dabigatran doses significantly 1171 reduced haemorrhagic stroke and intracranial haemorrhage. Dabigatran 150 mg twice daily significantly 1172 reduced ischaemic stroke by 24% and vascular mortality by 12%, while gastrointestinal bleeding was 1173

significantly increased by 50%. There was a non-significant numerical increase in the rate of myocardial infarction with both dabigatran doses,^{318, 404} which has not been replicated in large post-authorization

1174

1175 analyses.³⁹⁶ These data have also replicated the benefit of dabigatran over VKAs found in the RE-LY trial in 1176 patients enriched for the higher dabigatran dose (150 mg twice daily).³⁹⁶

1177 1178 Edoxaban

In the ENGAGE AF-TIMI 48 (Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation– Thrombolysis in Myocardial Infarction 48) trial,³²¹ edoxaban 60 mg once daily and edoxaban 30 mg once daily 1179 1180 (with dose reductions in certain patients according to *Table 13*), were compared with adjusted-dose warfarin.⁴⁰⁵ 1181 1182 Edoxaban 60 mg once daily was non-inferior to warfarin (primary outcome, HR 0.87; 97.5% CI 0.73–1.04; P = 1183 0.08). In an on-treatment analysis, edoxaban 60 mg once daily significantly reduced stroke or systemic 1184 embolism by 21% and significantly reduced major bleeding events by 20% compared with warfarin, while 1185 edoxaban 30 mg once daily was non-inferior to warfarin for prevention of stroke and systemic embolism but 1186 significantly reduced major bleeding events by 53%. Cardiovascular death was reduced in patients randomized 1187 to edoxaban 60 mg once daily or edoxaban 30 mg once daily compared with warfarin. Only the higher dose

- 1188 regimen has been approved for stroke prevention in AF.
- 1189 1190 Rivaroxaban

1191 In the ROCKET-AF (Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K 1192 Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) trial,³²⁰ patients were 1193 randomized to rivaroxaban 20 mg once daily or VKA, with a dose adjustment to 15 mg daily for those with

1194 estimated CrCl 30-49 mL/min by the Cockroft-Gault formula. Rivaroxaban was non-inferior to warfarin for the

1195 prevention of stroke and systemic embolism in the intent-to-treat analysis, while the per-protocol on-treatment

1196 analysis achieved statistical superiority with a 21% reduction in stroke or systemic embolism compared with

1197 warfarin. Rivaroxaban did not reduce the rates of mortality, ischaemic stroke, or major bleeding events

- 1198 compared to VKA. There was an increase in gastrointestinal bleeding events, but a significant reduction in
- 1199 haemorrhagic stroke and intracranial haemorrhage with rivaroxaban compared with warfarin. Comparable event
- 1200 rates have been reported in post-authorization analyses, which are part of the post-approval risk-management
- process.406,407 1201

1202 **Table 13 NOACs compared with warfarin in controlled trials**

	Dabigatran (RE-LY)	Rivaroxaban (ROCKET-AF)	Apixaban (ARISTOTLE)	Edoxaban (ENGAGE AF-TIMI 48)
Mechanism	Oral direct thrombin inhibitor	Oral direct factor Xa inhibitor	Oral direct factor Xa inhibitor	Oral direct factor Xa inhibitor
Bioavailability, %	6	66 fasting, 80–100 with food	50	62
Time to peak levels, h	3	2-4	3	1–2
Half-life, h	12–17	5–13	9–14	10–14
Excretion	80% renal	66% liver, 33% renal	27% renal	50% renal
Dose	150 mg or 110 mg twice daily	20 mg once daily	5 mg twice daily	60 mg or 30 mg once daily
Dose reduction in selected patients		Rivaroxaban 15 mg once daily if CrCl 30–49 mL/min	Apixaban 2.5 mg twice daily if at least 2 of age \geq 80 years, body weight \leq 60 kg or serum creatinine level \geq 1.5 mg/dL (133 µmol/L)	Edoxaban 60 mg reduced to 30 mg once daily, and edoxaban 30 mg reduced to 15 mg once daily, if any of the following: CrCl 30– 50 mL/min, body weight \leq 60 kg, concomitant use of verapamil or quinidine or dronedarone
Study design	Randomized, open-label	Randomized, double-blind	Randomized, double-blind	Randomized, double-blind
Number of patients	18,113	14,264	18,201	21,105
Follow-up period, years	2	1.9	1.8	2.8
Randomized groups	Dose-adjusted warfarin vs. blinded doses of dabigatran (150 mg twice daily or 110 mg twice daily)	Dose-adjusted warfarin vs. rivaroxaban 20 mg once daily	Dose-adjusted warfarin vs. apixaban 5 mg twice daily	Dose-adjusted warfarin vs. edoxaban (60 mg once daily or 30 mg once daily)
Age, years	Mean ± SD 71.5 ± 8.7	Median 73; IQR 65–78	Median 70; IQR 63–76	Median 72; IQR 64–78
Men, %	63.6	60.3	64.5	61.9
CHADS ₂ score (mean)	2.1	3.5	2.1	2.8

1203

	Warfarin	Dabigatran 150	Dabigatran 110	Warfarin	Rivaroxaban	Warfarin	Apixaban	Warfarin	Edoxaban 60	Edoxaban 30
	<i>n</i> = 6022	<i>n</i> = 6076	<i>n</i> = 6015	<i>n</i> = 7133	<i>n</i> = 7131	<i>n</i> = 9081	<i>n</i> = 9120	<i>n</i> = 7036	<i>n</i> = 7035	<i>n</i> = 7034
	Event rate, %/year	Event rate, %/year (RR vs. warfarin)	Event rate, %/year (RR vs. warfarin)	Event rate, %/year	Event rate, %/year (HR vs. warfarin)	Event rate, %/year	Event rate, %/year (HR vs. warfarin)	Event rate, %/year	Event rate, %/year (HR vs. warfarin)	Event rate, %/year (HR vs. warfarin)
Stroke/systemic embolism	1.72	1.12 (0.65, 0.52–0.81; <i>P</i> for non- inferiority and superiority < 0.001)	1.54 (0.89, 0.73–1.09; <i>P</i> for non- inferiority < 0.001)	2.42	2.12 (0.88, 0.75–1.03; <i>P</i> for non-inferiority < 0.001, <i>P</i> for superiority = 0.12)	1.60	1.27 (0.79, 0.66–0.95; P < 0.001 for non- inferiority, P = 0.01 for superiority)	1.80	1.57 (0.87, 0.73– 1.04; <i>P</i> < 0.001 for non-inferiority, <i>P</i> = 0.08 for superiority)	2.04 (1.13, 0.96–1.34; P = 0.005 for non- inferiority, $P = 0.10$ for superiority)
Ischaemic stroke	1.22	$\begin{array}{l} 0.93 \ (0.76, \\ 0.59 - 0.97; \\ P = 0.03) \end{array}$	$\begin{array}{l} 1.34 \ (1.10, \\ 0.88 - 1.37; \\ P = 0.42) \end{array}$	1.42	$\begin{array}{l} 1.34 \ (0.94; \ 0.75-1.17; \\ P = 0.581) \end{array}$	1.05	$\begin{array}{l} 0.97 \ (0.92, \ 0.74 - 1.13; \\ P = 0.42) \end{array}$	1.25	1.25 (1.00, 0.83– 1.19; P = 0.97)	$\begin{array}{c} 1.77 \ (1.41, \\ 1.19 - 1.67; \\ P < 0.001) \end{array}$
Haemorrhagic stroke	0.38	0.10 (0.26, 0.14–0.49; <i>P</i> < 0.001)	0.12 (0.31, 0.17–0.56; <i>P</i> < 0.001)	0.44	0.26 (0.59; 0.37-0.93; P = 0.024)	0.47	$\begin{array}{c} 0.24 \ (0.51, \ 0.35 - 0.75; \\ P < 0.001) \end{array}$	0.47	0.26 (0.54, 0.38– 0.77; <i>P</i> < 0.001)	0.16 (0.33, 0.22–0.50; <i>P</i> < 0.001)
Major bleeding	3.61	3.40 (0.94, 0.82-1.08; P = 0.41)	2.92 (0.80, 0.70-0.93; P = 0.003)	3.45	3.60 (1.04; 0.90-2.30; P = 0.58)	3.09	2.13 (0.69, 0.60–0.80; <i>P</i> < 0.001)	3.43	2.75 (0.80, 0.71– 0.91; <i>P</i> < 0.001)	1.61 (0.47, 0.41–0.55; <i>P</i> < 0.001)
Intracranial bleeding	0.77	0.32 (0.42, 0.29–0.61; <i>P</i> < 0.001)	0.23 (0.29 0.19–0.45; <i>P</i> < 0.001)	0.74	0.49 (0.67; 0.47-0.93; P = 0.02)	0.80	0.33 (0.42, 0.30–0.58; <i>P</i> < 0.001)	0.85	0.39 (0.47, 0.34– 0.63; <i>P</i> < 0.001)	0.26 (0.30, 0.21–0.43; <i>P</i> < 0.001)
Gastrointestinal major bleeding	1.09	1.60 (1.48, 1.19–1.86; <i>P</i> < 0.001)	1.13 (1.04, 0.82–1.33; P = 0.74)	1.24	2.00 (1.61; 1.30-1.99; <i>P</i> < 0.001)	0.86	0.76 (0.89, 0.70–1.15; <i>P</i> = 0.37)	1.23	1.51 (1.23, 1.02 - 1.50; P = 0.03)	0.82 (0.67, 0.53–0.83; <i>P</i> < 0.001)
Myocardial infarction	0.64	$\begin{array}{l} 0.81 \ (1.27, \\ 0.94 \text{-} 1.71; \\ P = 0.12) \end{array}$	0.82 (1.29, 0.96-1.75; P = 0.09)	1.12	0.91 (0.81; 0.63–1.06; P = 0.12)	0.61	0.53 (0.88, 0.66–1.17; P = 0.37)	0.75	0.70 (0.94, 0.74– 1.19; P = 0.60)	0.89 (1.19, 0.95–1.49; P = 0.13)
Death from any cause	4.13	3.64 (0.88, 0.77-1.00; P = 0.051)	$\begin{array}{c} 3.75 \ (0.91, \\ 0.80 - 1.03; \\ P = 0.13) \end{array}$	2.21	1.87 (0.85; 0.70–1.02; P = 0.07)	3.94	3.52 (0.89, 0.80-0.99; P = 0.047)	4.35	3.99 (0.92, 0.83– 1.01; <i>P</i> = 0.08)	3.80 (0.87, 0.79–0.96; P = 0.006)

1204 $AF = atrial fibrillation; CHADS_2 = Cardiac failure, Hypertension, Age, Diabetes, Stroke (Doubled); CrCl = creatinine clearance; HR = hazard ratio; IQR = interquartile range (25th to 1205 75th quartiles); RR = risk ratio; SD = standard deviation.$

1206 RRs and HRs compared to warfarin therapy are presented with 95% confidence intervals and *P*-values.

1207

1208 9.2.3. Non-vitamin K antagonist oral anticoagulants or vitamin K antagonists

1209 Both VKAs and NOACs are effective for the prevention of stroke in AF. A meta-analysis³⁹ based on the high-1210 dose treatment groups of the pivotal studies of warfarin versus NOACs included 42,411 patients receiving a 1211 NOAC and 29,272 receiving warfarin. NOACs in these dosages significantly reduced stroke or systemic 1212 embolic events by 19% compared with warfarin (RR 0.81; 95% CI 0.73–0.91; P < 0.0001), mainly driven by a 1213 reduction in haemorrhagic stroke (RR 0.49; 95% CI 0.38–0.64; P < 0.0001). Mortality was 10% lower in 1214 patients randomized to NOAC therapy (RR 0.90; 95% CI 0.85–0.95; P = 0.0003) and intracranial haemorrhage 1215 was halved (RR 0.48; 95% CI 0.39–0.59; P < 0.0001), while gastrointestinal bleeding events were more 1216 frequent (RR 1.25; 95% CI 1.01–1.55; P = 0.04).³⁹ The stroke reduction with NOACs was consistent in all 1217 evaluated subgroups, while there was a suggestion of greater relative reduction in bleeding with NOACs at 1218 centres with poor INR control (interaction P = 0.022). Notably, the substantial reduction in intracranial 1219 haemorrhage by NOACs compared with warfarin seems unrelated to poor or good INR control.^{408,405} 1220 1221 Oral anticoagulation in atrial fibrillation patients with chronic kidney 9.2.4.

1222 disease

CKD is associated with stroke and bleeding in large data sets.^{410, 411} Anticoagulation can be safely used in AF 1223 1224 patients with moderate or moderate-to-severe CKD (glomerular filtration rate [GFR] \geq 15 mL/min): the SPAF 1225 (Stroke Prevention in Atrial Fibrillation) III trial randomized 805/1936 participants with stage 3 CKD (estimated $GFR < 59 \text{ mL/min/1.73 m}^2$), and reported good outcomes on warfarin (INR 2–3).⁴¹² This finding is supported by 1226 1227 a large Swedish database, in which stroke risk was lower in CKD patients with AF treated with warfarin 1228 (adjusted HR 0.76; 95% CI 0.72–0.80),⁴¹³ while bleeding was also slightly increased, especially during therapy 1229 initiation.⁴¹⁴ In a meta-analysis of the major NOAC trials, patients with mild or moderate CKD suffered fewer 1230 strokes, systemic emboli, or major bleeding events on NOACs than on warfarin.⁴¹⁵ Kidney function should be 1231 regularly monitored in AF patients on OAC to allow dose adaptation for those on NOACs (Table 14) and to refine risk estimation.416 1232 1233

Table 14 Inclusion criteria, dose adjustments, and outcomes in patients with chronic kidney disease in the
 four major randomized trials comparing NOACs with warfarin in patients with AF. Adapted from Hart
 *et al.*³¹⁶

<i>ei ui</i> .				
	Dabigatran (RE-LY) ^{318, 425}	Rivaroxaban (ROCKET-AF) 320, 426	Apixaban (ARISTOTLE) ^{319, 427}	Edoxaban (ENGAGE AF- TIMI 48) ³²¹
Renal clearance	80%	35%	25%	50%
Number of patients	18,113	14,264	18,201	21,105
Dose	150 mg or 110 mg twice daily	20 mg once daily	5 mg twice daily	60 mg or 30 mg once daily
Exclusion criteria for CKD	CrCl < 30 mL/min	CrCl < 30 mL/min	Serum creatinine > 2.5 mg/dL or CrCl < 25 mL/min	CrCl < 30 mL/min
Dose adjustment with CKD	None	15 mg once daily if CrCl < 30–49 mL/min	2.5 mg twice daily if serum creatinine ≥ 1.5 mg/dL plus age ≥ 80 years or weight ≤ 60 kg	30 mg or 15 mg once daily if CrCl < 50 mL/min
Per cent of patients with CKD	20% with CrCl 30–49 mL/min	21% with CrCl 30–49 mL/min	15% with CrCl 30–50 mL/dL	19% with CrCl < 50 mL/min
Reduction of stroke and systemic embolism	No interaction with CKD status	No interaction with CKD status	No interaction with CKD status	NA
Reduction of major haemorrhages compared with warfarin	Reduction in major haemorrhage with dabigatran was greater in patients with	Major haemorrhage similar	Reduction in major haemorrhage with apixaban	NA

	estimated GFR		
	> 80 mL/min		
	with either dose		

1237 AF = atrial fibrillation; CKD = chronic kidney disease; CrCl = creatinine clearance; GFR = glomerular filtration 1238 rate; NA = not available; NOAC = non-vitamin K antagonist oral anticoagulant.

1240 **9.2.5**. Oral anticoagulation in atrial fibrillation patients on dialysis

1241 Approximately one in eight dialysis patient suffers from AF, with an incidence rate of 2.7/100 patient-years.⁴¹⁷

AF is associated with increased mortality in patients on dialysis.⁴¹⁷ There are no randomized trials assessing 1242

OAC in haemodialysis patients,⁴¹⁸ and no controlled trials of NOACs in patients with severe CKD (CrCl < 25-30 mL/min).³¹⁸⁻³²¹ Warfarin use was associated either with a neutral or increased risk of stroke in database 1243

1244 1245

analyses of patients on dialysis, ⁴¹⁹⁻⁴²¹ including a population-based analysis in Canada (adjusted HR for stroke 1.14; 95% CI 0.78–1.67, adjusted HR for bleeding 1.44; 95% CI 1.13–1.85).⁴²² In contrast, data from Denmark 1246

suggest a benefit of OAC in patients on renal replacement therapy.⁴²³ Hence, controlled studies of 1247

anticoagulants (both VKAs and NOACs) in AF patients on dialysis are needed.⁴²⁴ 1248

1249

1239

1250 **9.2.6**. Patients with atrial fibrillation requiring kidney transplantation

1251 There are no randomized trials assessing OAC in patients after kidney transplantation. The prescription of

1252 NOAC therapy should be guided by the estimated GFR of the transplanted kidney. Potential pharmacokinetic

1253 interactions of OAC with immunosuppressive agents should be considered.

1254

1255

1256 9.2.7. Antiplatelet therapy as an alternative to oral anticoagulants

The evidence supporting antiplatelet monotherapy for stroke prevention in AF is very limited.^{38, 428-430} VKA 1257 1258 therapy prevents stroke, non-central nervous system embolus, myocardial infarction, and vascular death better 1259 than single or dual antiplatelet therapy with aspirin and clopidogrel (annual risk of 5.6% for aspirin and 1260 clopidogrel vs. 3.9% with VKA therapy).⁴³¹ Even greater benefits were seen in VKA-treated patients with a high TTR.⁴³² Antiplatelet therapy increases bleeding risk, especially dual antiplatelet therapy (2.0% vs. 1.3% with 1261 antiplatelet monotherapy; P < 0.001),⁴³³ with bleeding rates that are similar to those on OAC.^{354, 362, 431, 434} Thus, 1262 antiplatelet therapy cannot be recommended for stroke prevention in AF patients. 1263 1264

1265 Recommendations for stroke prevention in patients with AF

Recommendations	Class ^a	Level ^b	Refs ^c
Oral anticoagulation therapy to prevent thromboembolism is recommended for all male AF patients with a CHA ₂ DS ₂ -VASc score of 2 or more	I	A	38, 318-321, 354, 404
Oral anticoagulation therapy to prevent thromboembolism is recommended in all female AF patients with a CHA ₂ DS ₂ -VASc score of 3 or more	I	A	38, 318-321, 354, 404
Oral anticoagulation therapy to prevent thromboembolism should be considered in male AF patients with a CHA ₂ DS ₂ - VASc score of 1, considering individual characteristics and patient preferences	lla	В	371, 375-377
Oral anticoagulation therapy to prevent thromboembolism should be considered in female AF patients with a CHA ₂ DS ₂ - VASc score of 2, considering individual characteristics and patient preferences	lla	В	371, 376, 377
Vitamin K antagonist therapy (INR 2.0–3.0 or higher) is recommended for stroke prevention in AF patients with moderate-to-severe mitral stenosis or mechanical heart valves	I	В	274, 435-440
When oral anticoagulation is initiated in a patient with AF who is eligible for a NOAC (apixaban, dabigatran, edoxaban, or rivaroxaban), a NOAC is recommended in preference to a Vitamin K antagonist	Ι	A	39, 318-321, 404
When patients are treated with a vitamin K antagonist, time	I	A	395, 432, 441-444

in therapeutic range (TTR) should be kept as high as possible and closely monitored			
AF patients already on treatment with a vitamin K antagonist may be considered for NOAC treatment if TTR is not well controlled despite good adherence, or if patient preference without contraindication (e.g. prosthetic valve)	llb	A	39, 318, 319, 404, 408
Combinations of oral anticoagulants and platelet inhibitors increase bleeding risk and should be avoided in AF patients without another indication for platelet inhibition	III (harm)	В	429, 445
In male or female AF patients without additional stroke risk factors, anticoagulant or antiplatelet therapy is not recommended for stroke prevention	III (harm)	В	368, 371, 376, 377
Antiplatelet monotherapy is not recommended for stroke prevention in AF patients, regardless of stroke risk	III (harm)	A	38, 429, 430
NOACs (apixaban, dabigatran, edoxaban, and rivaroxaban) are not recommended in patients with mechanical heart valves (Level of evidence B) or moderate-to-severe mitral stenosis (Level of evidence C)	III (harm)	B/C	318-321, 400, 404

- 1266 AF = atrial fibrillation; CHA₂DS₂-VASc = Congestive Heart failure, hypertension, Age \geq 75 (doubled),
- 1267 Diabetes, Stroke (doubled), Vascular disease, Age 65–74, and Sex (female); INR = international normalized
- 1268 ratio; NOAC = non-vitamin K antagonist oral anticoagulant; OAC = oral anticoagulation; TTR = time in
- 1269 therapeutic range; VKA = vitamin K antagonist.
- 1270 ^aClass of recommendation.
- 1271 ^bLevel of evidence.
- 1272 ^cReference(s) supporting recommendations.
- 1273

1274 **9.3**. Left atrial appendage occlusion and exclusion

1275 Left atrial appendage occlusion devices 9.3.1.

Interventional LAA occlusion, 446-449 and limited experience with percutaneous LAA ligation, has mainly been 1276 1277 reported in observational studies and registries. Only one device (Watchman®) has been compared with VKA 1278 therapy in randomized trials (PROTECT AF [Watchman Left Atrial Appendage System for Embolic Protection 1279 in Patients With AF trial], see Web Addenda Table 2; and PREVAIL [Prospective Randomized Evaluation of 1280 the Watchman LAA Closure Device In Patients with AF Versus Long Term Warfarin Therapy trial]).⁴⁴⁹⁻⁴⁵¹ In these data sets, LAA occlusion was non-inferior to VKA treatment for the prevention of stroke in AF patients with moderate stroke risk, with a possibility of lower bleeding rates in the patients who continued follow-up.⁴⁵², 1281 1282 ⁴⁵³ These data were confirmed in a patient-level meta-analysis of the two trials and their associated registries.⁴⁵³ 1283 LAA occlusion may also reduce stroke risk in patients with contraindications to OAC.^{454, 455} The implantation procedure can cause serious complications,^{446, 456-458} with high event rates reported in analyses from insurance 1284 1285 databases and systematic reviews, possibly identifying a certain degree of reporting bias.^{446, 456} A large recent 1286 European registry reported a high rate of implantation success (98%), with an acceptable procedure-related complication rate of 4% at 30 days.⁴⁵⁹ Most patients who historically would be considered unsuitable for OAC therapy seem to do relatively well on contemporarily managed OAC.^{396, 407, 460} Adequately powered controlled 1287 1288 1289 1290 trials are urgently needed to inform the best use of these devices, including LAA occluders in patients who are 1291 truly unsuitable for OAC or in patients who suffer a stroke on OAC, randomized comparisons of LAA occluders 1292 with NOACs, and assessment of the minimal antiplatelet therapy acceptable after LAA occlusion. 1293

1294 9.3.2. Surgical left atrial appendage occlusion or exclusion

1295 Surgical LAA occlusion or exclusion concomitant to cardiac surgery has been performed for many decades and 1296 with various techniques. Multiple observational studies indicate the feasibility and safety of surgical LAA 1297 occlusion/exclusion, but only limited controlled trial data are available.⁴⁶¹⁻⁴⁶⁴ Residual LAA flow or incomplete 1298 LAA exclusion can increase stroke risk.⁴⁶⁵ In most studies, LAA occlusion/exclusion was performed during other open heart surgery, and more recently in combination with surgical ablation of AF⁴⁶³ or as a stand-alone 1299 1300 thoracoscopic procedure. One randomized trial evaluating the role of concomitant AF surgery and LAA occlusion reported in 2015, without a clear benefit of LAA exclusion for stroke prevention in the subgroup 1301 undergoing AF surgery.⁴⁶⁶ A large randomized trial is currently underway.⁴⁶⁷

- 1302
- 1303

1304 Recommendations for occlusion or exclusion of the LAA

Recommendations	Class ^a	Level ^b	Refs ^c
After surgical occlusion or exclusion of the LAA, it is recommended to continue anticoagulation in at-risk patients with AF for stroke prevention	Ι	В	461, 462
LAA occlusion may be considered for stroke prevention in patients with AF and contraindications for long-term anticoagulant treatment (e.g. those with a previous life-threatening bleed without a reversible cause)	IIb	В	449, 453, 454
Surgical occlusion or exclusion of the LAA may be considered for stroke prevention in patients with AF undergoing cardiac surgery	IIb	В	463
Surgical occlusion or exclusion of the LAA may be considered for stroke prevention in patients undergoing thoracoscopic ablation surgery	IIb	В	468

- 1305 AF = atrial fibrillation; LAA = left atrial appendage.
- 1306 ^aClass of recommendation.
- 1307 ^bLevel of evidence.
- 1308 ^cReference(s) supporting recommendations.
- 1309

1310 **9.4**. **Secondary stroke prevention**

1311 The most important risk factors for stroke in patients with AF are advanced age and previous cardioembolic stroke or TIA,³⁸² emphasizing the need for OAC in these patients. The highest risk of recurrent stroke is in the

- 1312 early phase after a first stroke or TIA.469,470 1313
- 1314

1315 9.4.1. Treatment of acute ischaemic stroke

1316 Systemic thrombolysis with recombinant tissue plasminogen activator (rtPA) is an effective and approved

1317 medical treatment for acute ischaemic stroke in patients presenting within 4.5 hours of symptom onset.⁴⁷¹

Systemic thrombolysis is contraindicated in patients on therapeutic OAC.^{472, 473} Recombinant tissue 1318

plasminogen activator can be given in patients treated with a VKA if the INR is below 1.7,⁴⁷⁴ or in dabigatran-1319

treated patients with a normal activated partial thromboplastin time and last intake of drug > 48 hours previously (based on expert consensus).⁴⁷² Whether specific NOAC antidotes⁴⁷⁵ could be used followed by systemic 1320

1321

thrombolysis needs to be investigated. Thrombectomy can be performed in anticoagulated patients with distal 1322 1323 occlusion of the internal carotid artery or middle cerebral artery in a 6-hour window.⁴⁷⁶

1324

1325 9.4.2. Initiation of anticoagulation after transient ischaemic attack or ischaemic

1326 stroke

1327 Data on the optimal use of anticoagulants (heparin, low-molecular-weight heparin, heparinoid, VKA, NOAC) in

1328 the first days after a stroke are scarce. Parenteral anticoagulants seem to be associated with a non-significant

1329 reduction in recurrent ischaemic stroke when administered 7 to 14 days after the acute stroke (odds ratio [OR]

1330 0.68; 95% CI 0.44-1.06), with a significant increase in symptomatic intracranial bleeding (OR 2.89; 95% CI

1.19–7.01), and a similar rate of death or disability at final follow-up.⁴⁷⁷ It seems likely that the bleeding risk on 1331


1332 parenteral anticoagulation exceeds the stroke prevention benefit in the first days after a large stroke, whereas 1333 patients with a TIA or a small stroke may benefit from early (immediate) initiation or continuation of

1334 anticoagulation. Therefore, we propose to initiate anticoagulation in AF patients between 1 and 12 days after an

- ischaemic stroke, depending on its severity (*Figure 9*).⁴⁷⁸ We suggest repeat brain imaging to determine the 1335
- optimal initiation of anticoagulation in patients with a large stroke at risk for haemorrhagic transformation. Long-term OAC with a VKA^{363, 479-481} or NOAC⁴⁸² conveys benefits in AF patients who survived a stroke. 1336
- 1337


1338 NOACs seem to convey slightly better outcomes, mainly driven by fewer intracranial haemorrhages and

- haemorrhagic strokes (OR 0.44, 95% CI 0.32-0.62).⁴⁸² Detailed data for edoxaban have not yet been 1339
- 1340 published.³²¹ If a patient suffers a stroke or TIA whilst taking an anticoagulant, switching to another
- 1341 anticoagulant should be considered.
- 1342



1352 No prospective studies have investigated the benefit or risk of the initiation of OAC after intracranial haemorrhage,⁴⁸³ and patients with a history of intracranial bleeding were excluded from the randomized trials 1353 1354 comparing NOACs with VKAs. The available evidence indicates that anticoagulation in patients with AF can be 1355 reinitiated after 4-8 weeks, especially when the cause of bleeding or the relevant risk factor (e.g. uncontrolled hypertension) has been treated, and that such treatment leads to fewer recurrent (ischaemic) strokes and lower mortality.^{460, 484} If anticoagulation is resumed, it seems reasonable to consider anticoagulants with a low 1356 1357 bleeding risk.³⁹ Figure 10 depicts a consensus opinion on the initiation or resumption of OAC after an 1358 1359 intracranial haemorrhage. We recommend a multidisciplinary decision with input from stroke 1360

physicians/neurologists, cardiologists, neuroradiologists, and neurosurgeons.



1366 OAC = oral anticoagulation; PCI = percutaneous coronary intervention; VKA = vitamin K antagonist.

1367

1368 Recommendations for secondary stroke prevention

Recommendations	Class ^a	Level ^b	Refs ^c
Anticoagulation with heparin or low-molecular-weight heparin immediately after ischaemic stroke is not recommended in AF patients	III (harm)	A	477
In patients who suffer a transient ischemic attack or stroke while on anticoagulation, adherence to therapy should be assessed and optimized	lla	С	
In patients who suffer a moderate-to-severe ischaemic stroke while on anticoagulation, anticoagulation should be interrupted for 3–12 days based on a multidisciplinary assessment of acute stroke and bleeding risk	lla	С	
In AF patients who suffer a stroke, aspirin should be considered for prevention of secondary stroke until the initiation or resumption of oral anticoagulation.	lla	В	485
Systemic thrombolysis with a recombinant tissue plasminogen activator is not recommended if the INR is above 1.7 (or, for patients on dabigatran, if activated partial thromboplastin time is outside the normal range)	III (harm)	С	472, 474
NOACs are recommended in preference to VKAs or aspirin in AF patients with a previous stroke	I	В	363, 482
After TIA or stroke, combination therapy of OAC and an	III (harm)	В	486

antiplatelet is not recommended			
After intracranial haemorrhage, oral anticoagulation in patients with AF may be reinitiated after 4–8 weeks provided the cause of	llb	В	483, 484, 487
bleeding or the relevant risk factor has been treated or controlled			

1369

- 1370
- 1371 AF = atrial fibrillation; INR = international normalized ratio; NOAC = non-vitamin K antagonist oral
- 1372 anticoagulant; OAC = oral anticoagulation; TIA = transient ischaemic attack; VKA = vitamin K antagonist.
- 1373 ^aClass of recommendation.
- 1374 ^bLevel of evidence.
- 1375 ^cReference(s) supporting recommendations.
- 1376

1377 **9.5**. Strategies to minimize bleeding on anticoagulant therapy

1378 In a meta-analysis of 47 studies, the overall incidence of major bleeding with VKAs was 2.1 (range 0.9–3.4) per 1379 100 patient-years in controlled trials and 2.0 (range 0.2-7.6) per 100 patient-years for observational data sets.

1380 Minimizing treatable bleeding risk factors (see Table 12) seems paramount to reduce the bleeding rate on 1381 anticoagulants.

1382

1383 9.5.1. **Uncontrolled hypertension**

Uncontrolled blood pressure increases the risk of bleeding on OAC.⁵³ Hence, keeping systolic blood pressure 1384

well controlled is of particular relevance in anticoagulated patients with AF. Treatment according to current 1385 guidelines is recommended in patients with known hypertension.489

1386 1387

1388 9.5.2. **Previous bleeding event**

1389 History of bleeding events and the presence of anaemia are important parts of the assessment of all patients

1390

receiving OAC. The majority of bleeding events are gastrointestinal. Compared with warfarin, the risk of gastrointestinal bleeds was increased for dabigatran 150 mg twice daily,^{396, 490} rivaroxaban 20 mg once daily,⁴⁹¹ and edoxaban 60 mg once daily.³²¹ The risk of gastrointestinal bleeds was comparable to warfarin on dabigatran 110 mg twice daily⁴⁹⁰ and on apixaban 5 mg twice daily³¹⁹ Recent observational analyses do not replicate these findings, suggesting a smaller effect.^{396, 492, 493} In patients in whom the source of bleeding has been identified and 1391

1392

1393 1394

1395 corrected, OAC can be reinitiated. This also appears true for patients who have had an intracranial haemorrhage,

1396 once modifiable bleeding risk factors (e.g. uncontrolled hypertension) have been corrected.^{460, 484}

1397

1398 9.5.3. Labile international normalized ratio and adequate non-vitamin K

1399 antagonist oral anticoagulant dosing

1400 TTR on VKA therapy is an important predictor of major haemorrhage.^{432, 441, 494} Therefore we recommend

targeting the INR between 2.0 and 3.0 in patients on VKAs, maintaining a high TTR (e.g. $\geq 70\%^{494}$), and to 1401

1402 consider switching to a NOAC when a high TTR cannot be sustained.⁴⁴⁴ NOAC dosing should follow the dose-

1403 reduction criteria evaluated in the clinical trials, considering renal function, age, and weight. Patient information

1404 and empowerment, best delivered through integrated AF management, seem paramount to achieve this goal.

1405

1406 **9.5.4**. Alcohol abuse

Alcohol excess is a risk factor for bleeding in anticoagulated patients,³⁸⁴ mediated by poor adherence, liver 1407 1408 disease, variceal bleeding, and risk of major trauma. Severe alcohol abuse and binge drinking habits should be

1409 corrected in patients eligible for OAC.

1410 1411 **9.5.5**. Falls and dementia

1412 Falls and dementia are associated with increased mortality in AF patients,⁴⁹⁵ without evidence that these 1413 conditions markedly increase the risk of intracranial haemorrhage.^{495,496} Hence, anticoagulation should only be

1414 withheld from patients with severe uncontrolled falls (e.g. epilepsy or advanced multisystem atrophy with

1415 backwards falls), or in selected patients with dementia where compliance and adherence cannot be ensured by a 1416 caregiver.

1417

1418 **9.5.6**. **Genetic testing**

1419 In addition to food and drug interactions, multiple genetic variations affect the metabolism of VKAs.⁴⁹⁷ The 1420 systematic use of genetic information for adjustment of VKA dosage has been evaluated in several controlled

1421 clinical studies.⁴⁹⁸⁻⁵⁰⁰ Genetic testing has little effect on TTR or bleeding risk on warfarin, and is not

1422 recommended for clinical use at present.⁵⁰¹ 1423

1424 **9.5.7.** Bridging periods off oral anticoagulation

1425 Most cardiovascular interventions (e.g. percutaneous coronary intervention or pacemaker implantation) can be

1426 performed safely on continued OAC. When interruption of OAC is required, bridging does not seem to be 1427 beneficial, except in patients with mechanical heart valves. In a randomized trial of 1884 patients with AF,

1428 interruption of anticoagulation was non-inferior to heparin administration for the outcome of arterial

1429 thromboembolism (incidence of 0.4% and 0.3%, respectively) and resulted in a lower risk of major bleeding

1430 (1.3% and 3.2%, respectively).⁵⁰² A short interruption or continued OAC should be considered in patients at

- 1431 highest risk of stroke.
- 1432

1433 9.6. Management of bleeding events in anticoagulated patients with atrial fibrillation 1434 9.6.1. Management of minor, moderate, and severe bleeding


1435 General assessment of an anticoagulated patient with AF experiencing a bleeding event should include 1436 assessment of bleeding site, onset, and severity of the bleeding, the time-point of last intake of OAC and other 1437 antithrombotic drugs, and other factors influencing bleeding risk such as CKD, alcohol abuse, and concurrent 1438 medications. Laboratory tests should include haemoglobin, haematocrit, platelet count, renal function, and for 1439 VKA patients, prothrombin time, activated partial thromboplastin time, and INR. Coagulation tests do not 1440 provide much information in patients on NOACs, except for activated partial thromboplastin time in the case of 1441 dabigatran. More specific coagulation tests do exist, including diluted thrombin time (HEMOCLOT) for dabigatran and calibrated quantitative anti-factor Xa assays for factor Xa inhibitors.⁵ not always readily available and are often unnecessary for bleeding management.⁵⁰⁴ ⁰³ However, these tests are 1442 1443 1444 We propose a simple scheme to manage bleeding events in patients on OAC (Figure 11). Minor 1445 bleeding events should be treated with supportive measures such as mechanical compression or minor surgery to 1446 achieve haemostasis. In patients receiving VKAs, the next dose of VKA can be postponed. NOACs have a short 1447 plasma half-life of approximately 12 hours and improved haemostasis is expected within 12-24 hours after a 1448 delayed or omitted dose. Treatment of moderate bleeding events may require blood transfusions and fluid 1449 replacement. Specific diagnostic and treatment interventions directed against the cause of the bleeding (e.g. 1450 gastroscopy) should be performed promptly. If the intake of NOAC was recent (< 2-4 h), charcoal 1451 administration and/or gastric lavage will reduce further exposure. Dialysis clears dabigatran but is not effective 1452 for the other NOACs. 1453 Immediate reversal of the antithrombotic effect is indicated in severe or life-threatening bleeding 1454 events. An agreed, the institutional procedure for the management of life-threatening bleeds should be 1455 documented and accessible at all times to ensure adequate initial management. For VKAs, administration of 1456 fresh frozen plasma restores coagulation more rapidly than vitamin K, and prothrombin complex concentrates achieve even faster blood coagulation.⁵⁰⁵ Registry data suggest that the combination of plasma and prothrombin 1457 1458 complex concentrates is associated with the lowest case fatality following intracranial haemorrhage on VKA treatment with an INR ≥ 1.3 .⁵⁰⁶ In a multicentre randomized trial of 188 patients, four-factor prothrombin 1459 1460 complex concentrates achieved more rapid INR reversal and effective haemostasis than plasma in patients undergoing urgent surgical or invasive procedures.⁵⁰⁷ Administration of prothrombin complex concentrates may 1461 1462 also be considered for severe bleeding on NOAC treatment if specific antidotes are not available. 1463 Several antidotes to NOACs are under development. Idarucizumab (approved in 2015 by the US Food 1464 and Drug Administration and the European Medicines Agency) is a clinically available humanized antibody


fragment that binds dabigatran and rapidly and dose-dependently reverses the effects without over-correction or thrombin generation.⁴⁷⁵ Andexanet alpha, a modified recombinant human factor Xa that lacks enzymatic activity, reverses the anticoagulant activity of apixaban and rivaroxaban in healthy probands within minutes after administration and for the duration of infusion, with a transient increase in markers of coagulation activity of uncertain clinical relevance.⁵⁰⁸ Another agent under development is ciraparantag (PER977), an antidote

1470 targeted to reverse both direct thrombin and factor Xa inhibitors as well as the indirect inhibitor enoxaparin.⁵⁰⁹

1471 The clinical usefulness of these specific antidotes needs further evaluation.

1472





vitamin K antagonist.

1477 1478

1479 **9.6.2**. Oral anticoagulation in atrial fibrillation patients at risk of or having a

1480 bleeding event

1481 While anticoagulation therapy should be paused to control active bleeding, absolute contraindications to long-1482 term OAC after a bleeding episode are rare. When nuisance bleeds are the reason to stop OAC, a change from 1483 one anticoagulant to another seems reasonable. Many causes or triggers of major bleeding events can be treated and/or eliminated, including uncontrolled hypertension, gastrointestinal ulcers, and intracranial aneurysms. Reinitiation of anticoagulation after a bleeding event is often clinically justified.^{460, 510} Difficult decisions, 1484 1485 1486 including the discontinuation and recommencement of OAC, should be taken by a multidisciplinary team, 1487 balancing estimated risk of recurrent stroke and bleeding, and considering the bleeding risk of different stroke 1488 prevention therapies. LAA exclusion or occlusion might be an alternative in selected patients.

1489

1490 **Recommendations for management of bleeding**

Recommendations	Class ^a	Level ^b	Refs ^c
Blood pressure control in anticoagulated patients with hypertension should be considered to reduce the risk of bleeding	lla	В	511
When dabigatran is used, a reduced dose of dabigatran (110 mg twice daily) may be considered in patients > 75 years to reduce the risk of bleeding	llb	В	490
In patients at high risk of gastrointestinal bleeding, a VKA or another NOAC should be preferred over dabigatran 150 mg twice daily, rivaroxaban 20 mg once daily, or edoxaban 60 mg once daily	lla	В	321, 396, 402, 405, 490, 492, 493, 512

Advice and treatment to avoid alcohol excess should be considered in all AF patients considered for OAC	lla	С	
Genetic testing before the initiation of VKA therapy is not recommended.	III (no benefit)	В	497
Reinitiation of OAC after a bleeding event should be considered in all eligible patients by a multidisciplinary AF team, considering different anticoagulants and stroke-prevention interventions, improved management of factors that contributed to bleeding, and stroke risk	lla	В	460
In AF patients with severe active bleeding events, it is recommended to interrupt OAC therapy until the underlying cause is resolved	I	С	

1491 AF = atrial fibrillation; NOAC = non-vitamin K antagonist oral anticoagulant; OAC = oral anticoagulation;

1492 VKA = vitamin K antagonist

1493 ^aClass of recommendation.


¹⁴⁹⁴ ^bLevel of evidence.

1495 ^cReference(s) supporting recommendations.

1496

1497 9.7. Combination therapy with oral anticoagulants and antiplatelets

1498 Approximately 15% of AF patients in contemporary trials⁵¹³ and registries⁵¹⁴⁻⁵¹⁶ have a history of myocardial infarction. Between 5% and 15% of AF patients will require stenting at some point in their lives. This scenario 1499 requires careful consideration of antithrombotic therapy, balancing bleeding risk, stroke risk, and risk of acute 1500 coronary syndromes (ACS).⁵¹⁶ Co-prescription of OAC with antiplatelet therapy, in particular triple therapy, increases the absolute risk of major haemorrhage.^{445, 517, 518} A recent meta-analysis involving 30,866 patients 1501 1502 with a recent ACS evaluated the effects of adding NOAC therapy to single (4135 patients) or dual (26,731 1503 patients) antiplatelet therapy.⁵¹⁹ The addition of a NOAC increased the bleeding risk by 79–134%, while 1504 1505 reducing recurrent ischaemic events only marginally in patients without AF. OAC monotherapy, and not 1506 combination therapy with antiplatelets, is recommended in AF patients with stable CAD but without an ACS 1507 and/or coronary intervention in the previous 12 months. In patients treated for ACS and in those receiving a 1508 coronary stent, short-term triple combination therapy of OAC, clopidogrel, and aspirin seems warranted (Figure 1509 12).



1510

1511 Figure 12 Antithrombotic therapy after an ACS in AF patients requiring anticoagulation. 1512 ACS = acute coronary syndrome; AF = atrial fibrillation; OAC = oral anticoagulation (using vitamin K)1513 antagonists or non-vitamin K antagonist oral anticoagulants); PCI = percutaneous coronary intervention. 1514 ^aDual therapy with OAC and aspirin or clopidogrel may be considered in selected patients, especially those not 1515 receiving a stent or patients at a longer time from the index event. 1516 ^bOAC plus single antiplatelet. 1517 ^cDual therapy with OAC and an antiplatelet agent (aspirin or clopidogrel) may be considered in patients at high 1518 risk of coronary events. 1519 1520 1521 **9.7.1**. Antithrombotic therapy after acute coronary syndromes and percutaneous 1522 coronary intervention in patients requiring oral anticoagulation 1523 The optimal combination antithrombotic therapy or duration of combination therapy for AF patients undergoing 1524 percutaneous coronary intervention is not known, but the continued bleeding risk suggests a short duration. 1525 Expert consensus,⁵²⁰ reviewed and reconsidered by this Task Force, suggests the following principles: AF 1526 patients at risk for stroke, patients with mechanical valves, and patients with recent or recurrent deep vein 1527 thrombosis or pulmonary embolism should continue OAC during and after stenting. In general, a short period of

1528 triple therapy (OAC, aspirin, clopidogrel) is recommended, followed by a period of dual therapy (OAC plus a 1529 single antiplatelet) (Figure 13). When a NOAC is used, the consensus recommendation is that the lowest dose

1530 effective for stroke prevention in AF should be considered. Dose reduction beyond the dosing regimens tested in 1531 the phase III trials is not currently recommended, and awaits assessment in ongoing controlled trials. The 1532 combination of aspirin, clopidogrel, and low-dose rivaroxaban (2.5 mg twice daily) is not recommended for

1533 stroke prevention in AF.⁵²¹

1534 The use of prasugrel or ticagrelor as part of triple therapy should be avoided unless there is a clear need for these agents (e.g. stent thrombosis on aspirin plus clopidogrel), given the lack of evidence and the greater risk of major bleeding compared with clopidogrel.^{522, 523} Ongoing trials will inform about such combination 1535 1536 1537 therapies in the future.

1538 The omission of aspirin while maintaining clopidogrel and OAC has been evaluated in the WOEST 1539 (What is the Optimal antiplatElet and anticoagulant therapy in patients with oral anticoagulation and coronary 1540 StenTing) trial, in which 573 anticoagulated patients undergoing percutaneous coronary intervention (70% with

1541 AF) were randomized to either dual therapy with OAC and clopidogrel (75 mg once daily) or to triple therapy


1542 with OAC, clopidogrel, and aspirin.⁵²⁴ Bleeding was lower in the dual versus triple therapy arm, driven by fewer

1543 minor bleeding events. The rates of myocardial infarction, stroke, target vessel revascularization, and stent

thrombosis did not differ (albeit with low event numbers), but all-cause mortality was lower in the dual therapy group at 1 year (2.5% vs. triple 6.4%). Although the trial was too small to assess ischaemic outcomes, dual

1546 therapy with OAC and clopidogrel may emerge in the future as an alternative to triple therapy in patients with

1547 AF and ACS and/or coronary intervention.⁵²⁵



1548

15-0	
1549	Figure 13 Antithrombotic therapy after percutaneous intervention in AF patients requiring anticoagulation.
1550	ACS = acute coronary syndrome; AF = atrial fibrillation; OAC = oral anticoagulation (using vitamin K
1551	antagonists or non-vitamin K antagonist oral anticoagulants); PCI = percutaneous coronary intervention.
1552	^a Dual therapy with OAC and aspirin or clopidogrel may be considered in selected patients.
1553	^b OAC plus single antiplatelet.
1554	^c Dual therapy with OAC and an antiplatelet agent (aspirin or clopidogrel) may be considered in patients at high
1555	risk of coronary events.
1556	
1557	Recommendations for combination therapy with oral anticoagulants and antiplatelets

1558

Recommendations	Class ^a	Level ^b	Refs ^c
After elective coronary stenting for stable coronary artery disease in AF patients at risk of stroke, combination triple therapy with aspirin, clopidogrel and an oral anticoagulant should be considered for 1 month to prevent recurrent coronary and cerebral ischaemic events	Па	В	522, 524
After an ACS with stent implantation in AF patients at risk of stroke, combination triple therapy with aspirin, clopidogrel, and an oral anticoagulant should be considered for 1–6 months to prevent recurrent coronary and cerebral ischaemic events	Па	С	520

After an ACS without stent implantation in AF patients at risk of stroke, dual therapy with an oral anticoagulant and aspirin or clopidogrel should be considered for up to 12 months to prevent recurrent coronary and cerebral ischaemic events	IIa	С	
The duration of combination antithrombotic therapy, especially triple therapy, should be kept to a limited period, balancing the estimated risk of recurrent coronary events and bleeding	IIa	В	520
Dual therapy with any oral anticoagulant plus clopidogrel 75 mg/day may be considered as an alternative to initial triple therapy with aspirin in selected patients.	IIb	С	524, 525

1559 ACS = acute coronary syndromes; AF = atrial fibrillation

- 1560 ^aClass of recommendation.
- 1561 ^bLevel of evidence.

1562 ^cReference(s) supporting recommendations.

1563

10 Rate control therapy in AF 1564

1565 Rate control is an integral part of the management of AF patients, and is often sufficient to improve AF-related

1566 symptoms. Compared with stroke prevention and rhythm control, very little robust evidence exists to inform the

1567 best type and intensity of rate control treatment, with the majority of data derived from short-term crossover trials and observational studies.^{41, 526-528} Pharmacological rate control can be achieved for acute or long-term rate

- 1568 1569
- control with beta-blockers, digoxin, the calcium channel blockers diltiazem and verapamil, or combination 1570
- therapy (Table 15). A number of antiarrhythmic drugs also have rate-limiting properties (amiodarone,
- 1571 dronedarone, sotalol, and to some extent propafenone), but they should only be used in patients needing rhythm 1572 control therapy (see Chapter 10).
- 1573

1574 10.1. Acute rate control

1575 In the setting of acute new-onset AF, patients are often in need of heart rate control. Physicians should evaluate

1576 underlying causes of elevated heart rate, such as infection, endocrine imbalance, anaemia, and pulmonary

1577 embolism. For acute rate control, beta-blockers and diltiazem/verapamil are preferred over digoxin because of

their rapid onset of action and effectiveness at high sympathetic tone.⁵²⁸⁻⁵³² The choice of drug (*Table 15*) and 1578 1579

target heart rate will depend on patient characteristics, symptoms, LVEF and haemodynamics, but a lenient 1580


initial approach to heart rate seems acceptable. Combination therapy may be required (Figure 14). In patients with evidence of HFrEF, beta-blockers, digitalis (digoxin or digitoxin), or their combination should be used,²¹⁸,

1581 ⁵³³ as diltiazem and verapamil can have negative inotropic effects in patients with LVEF < 40%.^{222, 534, 535} In 1582

1583 critically ill patients and those with severely impaired LV systolic function, intravenous amiodarone can be used

where excess heart rate is leading to haemodynamic instability.⁵³⁶⁻⁵³⁸ Urgent cardioversion should be considered 1584

1585 in unstable patients (see Chapter 10.2).



1586

1590

1587 Figure 14 Acute heart rate control of AF.

1588 See *Table 15* for medication dosage. Digitoxin is a suitable alternative to digoxin, where available.

1589 AF = atrial fibrillation; bpm = beats per minute; LVEF = left ventricular ejection fraction.

1591 **10.2**. Long-term pharmacological rate control

1592 10.2.1. **Beta-blockers**

1593 Beta-adrenoreceptor blocker monotherapy is often the first-line rate-controlling agent, ⁵³⁹ largely based on 1594 observations of better acute heart rate control than digoxin. Interestingly, the prognostic benefit of beta-blockers 1595 seen in HFrEF patients with sinus rhythm is lost in those with AF. In an individual patient-level meta-analysis 1596 of RCTs, beta-blockers did not reduce all-cause mortality compared to placebo in those with AF at baseline (HR 1597 0.97; 95% CI 0.83–1.14; P = 0.73), whereas there was a clear benefit in patients with sinus rhythm (HR 0.73; 1598 95% CI 0.67–0.80; P < 0.001).²³ The study, which included 3066 participants with HFrEF and AF, showed 1599 consistency across all subgroups and outcomes, with no heterogeneity between the 10 RCTs included ($I^2 = 0\%$). 1600 Despite this lack of prognostic benefit in HFrEF, this Task Force still considers beta-blockers as a useful first-1601 line rate control agent across all AF patients, based on the potential for symptomatic and cardiac function improvement as a result of rate control, the lack of harm from published studies, and the good tolerability profile 1602 across all ages in sinus rhythm and in AF.^{23, 540} 1603

1604

Non-dihydropyridine calcium channel blockers 1605 10.2.2.

Verapamil or diltiazem provides reasonable rate control in AF patients.⁵⁴¹ They should be avoided in patients with HFrEF because of their negative inotropic effects.^{222, 534, 535} Verapamil or diltiazem can improve 1606 1607 arrhythmia-related symptoms, ⁵²⁶ in comparison with beta-blockers, which reduced exercise capacity and 1608 1609 increased B-type natriuretic peptide in one small trial of low-risk patients with preserved LVEF.⁵⁴²

1610 1611 10.2.3. Digitalis

Cardiac glycosides such as digoxin and digitoxin have been in use for over two centuries, although prescriptions have been declining steadily over the past 15 years.⁵⁴³ In the randomized Digitalis Investigation Group (DIG) 1612

- 1613
- 1614 trial, digoxin had no effect on mortality compared to placebo in HFrEF patients in sinus rhythm (RR 0.99; 95%

- 1615 CI 0.91–1.07), but reduced hospital admissions (RR 0.72; 95% CI 0.66–0.79).^{544, 545} There have been no head-
- to-head RCTs of digoxin in AF patients.⁵⁴⁶ Observational studies have associated digoxin use with excess mortality in AF patients,⁵⁴⁷⁻⁵⁴⁹ but this association is likely due to selection and prescription biases rather than harm caused by digoxin,⁵⁵⁰⁻⁵⁵³ particularly as digoxin is commonly prescribed to sicker patients.²²⁵ In a 1616 1617
- 1618
- 1619 crossover mechanistic trial of 47 patients with HFrEF and AF, there were no differences in heart rate, blood
- 1620 pressure, walking distance, or LVEF between carvedilol and digoxin, although beta-blockers did result in higher
- 1621 B-type natriuretic peptide levels, combination carvedilol/digoxin improved LVEF, and digoxin withdrawal
- 1622 reduced LVEF.⁵⁵⁴ Comparisons with other rate control therapies are based on small, short-duration studies that
- 1623 identify no or marginal differences in exercise capacity, quality of life, or LVEF compared to digoxin. 526, 554-550
- 1624 Lower doses of digoxin ($\leq 250 \mu g$ once daily), corresponding to serum digoxin levels of 0.5–0.9 ng/mL, may be
- 1625 associated with better prognosis.
- 1626


1627 10.2.4. Amiodarone

1628 Amiodarone can be useful for rate control as a last resort. The wide array of extracardiac adverse effects

1629 associated with amiodarone renders it a reserve agent in patients whose heart rate cannot be controlled with

1630 combination therapy (e.g. beta-blocker or verapamil/diltiazem combined with digoxin).

- 1631
- 1632 In summary, there is equipoise for the use of different rate control agents in AF. The choice of beta-blocker.
- 1633 diltiazem/verapamil, digoxin, or combination therapy should be made on an individual basis, after consideration
- 1634 of patient characteristics and patient preference. All available therapies have the potential for adverse effects and 1635
- patients should initially be treated with a low dose and uptitrated to achieve symptom improvement. In practice, 1636 achieving a heart rate < 110 bpm will often require combination therapy (*Figure 15*). The benefit of different
- rate control strategies on symptoms, quality of life, and other intermediate outcomes is under investigation.⁵⁵⁹ 1637



1638

- 1639 Figure 15 Long-term heart rate control of AF.
- 1640 See *Table 15* for medication dosage. Digitoxin is a suitable alternative to digoxin, where available.
- AF = atrial fibrillation; bpm = beats per minute; LVEF = left ventricular ejection fraction. 1641
- 1642

Heart rate targets in atrial fibrillation 1643 **10.3**.

1644 The optimal heart rate target in AF patients is unclear. The RACE (Rate Control Efficacy in Permanent Atrial

- 1645 Fibrillation) II study randomized 614 patients with permanent AF to either a target heart rate < 80 bpm at rest 1646 and < 110 bpm during moderate exercise, or to a lenient heart rate target of < 110 bpm. There was no difference
- in a composite of clinical events (14.9% in the strict rate control group, 12.9% in the lenient group),⁵⁶⁰ NYHA 1647
- class, or hospitalizations.^{560, 561} Similar results were found in a pooled analysis of the AFFIRM (Atrial 1648
- Fibrillation Follow-up Investigation of Rhythm Management) and RACE trials (1091 participants), albeit with 1649
- 1650 smaller heart rate differences and without randomization.⁵⁶² It is worthwhile to note that many 'adequately rate-
- 1651 controlled' patients (resting heart rate 60-100 bpm) are severely symptomatic, calling for additional
- 1652 management.¹⁹⁴ Nonetheless, lenient rate control is an acceptable initial approach, regardless of heart failure
- 1653 status, unless symptoms call for stricter rate control.
- 1654

Atrioventricular node ablation and pacing 1655 10.4.

1656 Ablation of the atrioventricular node/His bundle and implantation of a VVI pacemaker can control ventricular rate when medications fail to control rate and symptoms. It is a relatively simple procedure with a low complication rate and low long-term mortality risk,^{563,564} especially when the pacemaker is implanted a few weeks before the AV nodal ablation and the initial pacing rate after ablation is set at 70–90 bpm.^{565,566} The procedure does not worsen LV function⁵⁶⁷ and may even improve LVEF in selected patients.⁵⁶⁸⁻⁵⁷⁰ In some 1657 1658 1659 1660 1661 patients in heart failure treated with biventricular pacing (cardiac resynchronization therapy), AF can

1662 terminate,⁵⁷¹ although such a 'rhythm control' effect of cardiac resynchronization therapy is likely to be small

1663 and clearly needs confirmation.⁵⁷² AV nodal ablation renders patients pacemaker-dependent for the rest of their

- 1664 lives, limiting AV nodal ablation and pacing to patients whose symptoms cannot be managed by rate controlling
- 1665 medication or by reasonable rhythm control interventions. The choice of pacing therapy (right ventricular or
- 1666 biventricular pacing with or without an implantable defibrillator) will depend on individual patient characteristics, including LVEF.573,574
- 1667 1668
- 1669 Recommendations for rate control

Recommendations	Class ^a	Level ^b	Refs ^c
Beta-blocker, digoxin, diltiazem, or verapamil are recommended to control heart rate in AF patients with LVEF \ge 40%	I	В	225, 526, 528, 531, 532, 541, 555, 575
Beta-blocker and/or digoxin are recommended to control heart rate in AF patients with LVEF < 40%	I	В	23, 225, 526, 533, 554, 575, 576
Combination therapy comprising different rate controlling agents should be considered if a single agent does not achieve the necessary heart rate target	lla	С	23, 554, 577
In cases of haemodynamic instability or severe depression in LVEF, amiodarone may be considered for acute control of heart rate	llb	В	536-538
In patients with permanent AF (i.e. where no attempt to restore sinus rhythm is planned), antiarrhythmic drugs should not routinely be used for rate control	III (harm)	A	41, 578, 579
A resting heart rate of < 110 bpm (i.e. lenient rate control) should be considered as the initial heart rate target for rate control therapy	lla	В	560
Rhythm rather than rate control strategies should be considered as the preferred management in pre-excited AF and AF during pregnancy	lla	С	
Atrioventricular node ablation should be considered to control heart rate in patients unresponsive or intolerant to intensive rate and rhythm control therapy, accepting that these patients will become pacemaker dependent	lla	В	184, 564, 569

- 1670 AF = atrial fibrillation; bpm = beats per minute; LVEF = left ventricular ejection fraction.
- 1671 Digitoxin is a suitable alternative to digoxin, where available. In patients with heart failure with reduced ejection
- 1672 fraction (LVEF < 40%), recommended beta-blockers are bisoprolol, carvedilol, long-acting metoprolol, and
- 1673 nebivolol.
- 1674 ^aClass of recommendation.

^bLevel of evidence.
^c Reference(s) supporting recommendations.
Table 15 Rate control therapy in AF

		ontrol therapy in A		Side offect profile	Commonto	
Thera		Acute intravenous rate control	Long-term oral rate control	Side-effect profile	Comments	
Beta-	blockers	а				
Bisop	orolol	Not available	1.25–20 mg once daily or split	Most common reported adverse	Bronchospasm is rare – in cases of	
Carve		Not available	3.125–50 mg twice daily	symptoms are lethargy, headache,	asthma, recommend beta-1 selective	
	prolol	2.5–10 mg intravenous bolus (repeated as required)	100–200 mg total daily dose (according to preparation)	peripheral oedema, upper respiratory tract symptoms, gastrointestinal upset,	agents (avoid carvedilol). Contraindicated in acute cardiac failure	
Nebiv		N/A	2.5–10 mg once daily or split	and dizziness. Adverse effects	and a history of severe	
Esmo	lol	0.5 mg intravenous bolus over 1 min; then 0.05– 0.25 mcg/kg/min		include bradycardia, atrioventricular block, and hypotension	bronchospasm	
Calciu	um-chan	nel blockers				
Diltia	zem	15–25 mg intravenous bolus (repeated as required)	60 mg three times daily up to 360 mg total daily dose (120–360 mg once daily modified release)	Most common reported adverse symptoms are dizziness, malaise, lethargy, headache, hot flushes,	Use with caution in combination with beta-blockers. Reduce dose with hepatic impairment and start with smaller	
Veraț	pamil	2.5–10 mg intravenous bolus (repeated as required)	40–120 mg three times daily (120– 480 mg once daily modified release)	gastrointestinal upset, and oedema. Adverse effects include bradycardia, atrioventricular block, and hypotension (prolonged hypotension possible with verapamil)	dose in renal impairment. Contraindicated in LV failure with pulmonary congestion or LVEF < 40%	
Cardi	ac glyco	sides				
Digo>		0.5 mg intravenous bolus (0.75–1.5 mg over 24 h in divided doses)	0.0625–0.25 mg daily dose	Most common reported adverse symptoms are gastrointestinal upset, dizziness, blurred	High plasma levels associated with increased risk of death. Check renal function before	
Digito	oxin ific indica	0.4–0.6 mg intravenous bolus	0.05–0.3 mg daily dose	vision, headache, and rash. In toxic states (serum levels > 2 ng/mL), digoxin is proarrhythmic and can aggravate heart failure, particularly with coexistent hypokalaemia	starting and adapt dose in patients with CKD. Contraindicated in accessory conducting pathways, ventricular tachycardia, and hypertrophic cardiomyopathy with outflow tract obstruction	
	darone	300 mg	200 mg daily	Hypotension,	Suggested as	

intravenously diluted in 250 mL 5% dextrose over 30–60 min (preferably via central venous cannula) ^b	bradycardia, nausea, QT prolongation, pulmonary toxicity, skin discolouration, thyroid dysfunction, corneal deposits, and cutaneous reaction with extravasation	adjunctive therapy in patients where heart rate control cannot be achieved using combination therapy
---	--	--

- 1679 AF = atrial fibrillation; CKD = chronic kidney disease; LV = left ventricular; LVEF = left ventricular ejection 1680 fraction.
- 1681 ^aA number of other beta-blockers are also available, but are not recommended as specific rate control therapy in
- 1682 AF. These include atenolol (25–100 mg once daily with a short biological half-life), propranolol (non-selective,
- 1683 1 mg over 1 min and repeat up to 3 mg at 2-min intervals [acute] or 10–40 mg three times daily [long-term]), or
- 1684 labetalol (non-selective, 1–2 mg/min [acute]).
- 1685 ^bIf ongoing requirement for amiodarone, follow with 900 mg intravenous over 24 hours diluted in 500–1000 mL 1686 via a central venous cannula.
- 1687

1688 **11 Rhythm control therapy in atrial fibrillation**

- 1689
- 1690
- 1691
- Restoring and maintaining sinus rhythm is an integral part of AF management. Antiarrhythmic drugs approximately double the rate of sinus rhythm compared with placebo.⁵⁸⁰⁻⁵⁸⁴ Catheter ablation or combination therapy is often effective when antiarrhythmic drugs fail.^{226, 585-587} Although many clinicians believe that maintaining sinus rhythm can improve outcomes in AF patients,⁵⁸⁸ all trials that have compared rhythm control 1692
- 1693 to rate control (with appropriate anticoagulation) therapy have resulted in neutral outcomes.^{41,5}
- 1694 Whether modern rhythm control management involving catheter ablation, combination therapy, and early
- 1695 therapy leads to a reduction in major cardiovascular events (e.g. stroke and cardiovascular death) is currently
- 1696 under investigation (e.g. in the EAST [Early treatment of Atrial fibrillation for Stroke prevention Trial] -AFNET 4⁴⁰ and CABANA [Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial]⁵⁹⁴ 1697
- 1698 trials). For now, rhythm control therapy is indicated to improve symptoms in AF patients who remain
- 1699 symptomatic on adequate rate control therapy.
- 1700

1701 **11.1**. Acute restoration of sinus rhythm


1702 11.1.1. Antiarrhythmic drugs for acute restoration of sinus rhythm

('pharmacological cardioversion') 1703

1704 Antiarrhythmic drug can restore sinus rhythm in patients with AF (pharmacological cardioversion) as

shown in small controlled trials, meta-analyses,^{41, 584, 595, 596} and in a few larger controlled trials.⁵⁹⁷⁻⁶⁰ 1705

- Outside of Europe, dofetilide is available and can convert recent-onset AF.⁶⁰⁶ Pharmacological cardioversion 1706
- restores sinus rhythm in approximately 50% of patients with recent-onset AF (Table 16).607-609 In the short term, 1707
- electrical cardioversion restores sinus rhythm quicker and more effectively than pharmacological cardioversion and is associated with shorter hospitalization.⁶⁰⁹⁻⁶¹³ Pharmacological cardioversion, conversely, does not require 1708 1709
- 1710 sedation or fasting (Figure 16).
- Flecainide and propafenone are effective for pharmacological cardioversion,^{595, 602-605, 614, 615} but their 1711 use is restricted largely to patients without structural heart disease. Ibutilide is an alternative where available, but carries a risk of torsades de pointes.⁶¹⁵ Vernakalant⁶⁰²⁻⁶⁰⁵ can be given to patients with mild heart failure 1712 1713
- 1714
- (NYHA Class I or II), including those with ischaemic heart disease, provided they do not present with hypotension or severe aortic stenosis.⁶¹⁶⁻⁶¹⁸ Amiodarone can be used in patients with heart failure and in patients 1715
- 1716 with ischaemic heart disease (although patients with severe heart failure were excluded in most of the AF
- cardioversion trials).⁵⁹⁶ Amiodarone also slows heart rate by 10-12 bpm after 8-12 hours when given 1717
- intravenously.⁵⁹⁶ Both amiodarone and flecainide appear more effective than sotalol in restoring sinus rhythm.^{600, 601, 619} 1718
- 1719



AF = atrial fibrillation; HFmrEF = heart failure with mid-range ejection fraction; HFrEF = heart failure with reduced ejection fraction.

1724 ^aIbutilide should not be used in patients with long QT interval.

1725

 $\begin{array}{c} 1720\\1721 \end{array}$

1726 **11.1.2.** 'Pill in the pocket' cardioversion performed by patients

1727 In selected patients with infrequent symptomatic episodes of paroxysmal AF, a single bolus of oral flecainide 1728 (200–300 mg) or propafenone (450–600 mg) can be self-administered by the patient at home ('pill in the pocket'

therapy) to restore sinus rhythm, after safety has been established in the hospital setting.⁶²⁰ This approach seems

marginally less effective than hospital-based cardioversion,⁶²¹ but is practical and provides control and

1731 reassurance to selected patients.

1732

1733 **Table 16** Antiarrhythmic drugs for pharmacological cardioversion

Drug	Route	First dose	Follow-up dose	Risks	Referenc es
Flecainide Oral 200–300 m		200–300 mg	N/A	Avoid in patients with IHD and/or significant structural heart disease. Hypotension, atrial flutter with 1:1	595, 598
	IV	1.5–2 mg/kg over 10 min		conduction, QT prolongation	
Amiodarone	IV ^a	5–7 mg/kg over 1–2 h	50 mg/h to a maximum of 1.0 g over 24 h	Phlebitis, hypotension, bradycardia/AV block. Will slow ventricular rate. Delayed conversion to sinus rhythm (8–12 h)	596-601
Propafenone	IV	1.5–2 mg/kg over 10 min		Avoid in patients with IHD and/or significant structural heart disease. Hypotension, atrial flutter with 1:1	622-625

	Oral	450–600 mg		conduction, QRS prolongation (mild)	614, 615
Ibutilide ^b	IV	1 mg over 10 min	1 mg over 10 min after waiting for 10 min	mg over min afterAvoid in patients with QT prolongation, hypokalemia, severe LVH, or low ejection fraction.10 minQT prolongation, polymorphic ventricular tachycardia/torsades de pointes (3–4% of patients). Will slow ventricular rate	
Vernakalant	IV	3 mg/kg over 10 min	2 mg/kg over 10 min after waiting for 15 min	Avoid in patients with systolic blood pressure < 100 mmHg, recent (< 30 days) ACS, NYHA Class III and IV heart failure, QT interval prolongation (uncorrected QT > 440 ms), and severe aortic stenosis. Hypotension, non-sustained ventricular arrhythmias, QT and QRS prolongation	602-605, 61

1734 ACS = acute coronary syndromes; IHD = ischaemic heart disease; IV = intravenous; LVH = left ventricular1735

hypertrophy; NYHA = New York Heart Association.

1736 ^aUse a large peripheral vessel and change to oral amiodarone within 24 h of IV (central line) administration. ^bIbutilide is only available in selected European countries.

1737 1738

1739 **Electrical cardioversion** 11.1.3.

1740 Synchronized direct current electrical cardioversion quickly and effectively converts AF to sinus rhythm and is

1741 the method of choice in severely haemodynamically compromised patients with new-onset AF (Figure 16).⁶²⁶⁻

1742 ⁶²⁸ Electrical cardioversion can be performed safely in sedated patients treated with intravenous midazolam

and/or propofol. Continuous monitoring of blood pressure and oximetry during the procedure is important.⁶²⁹ 1743 1744

Skin burns may occasionally be observed. Intravenous atropine or isoproterenol or temporary transcutaneous 1745

pacing should be available to mitigate post-cardioversion bradycardia. Biphasic defibrillators are more effective than monophasic waveforms, and have become industry standard.^{626, 628} Anterior–posterior electrode positions 1746

1747 generate a stronger shock field in the left atrium than anterolaterally positioned electrodes, and restore sinus

rhythm more effectively. 626, 627, 630 1748

Pretreatment with amiodarone (requiring a few weeks of therapy),^{631, 632} sotalol,⁶³¹ ibutilide,⁶³³ or 1749

vernakalant⁶³⁴ can improve efficacy of electrical cardioversion, and similar effects are likely for flecainide⁵⁸⁴ and propafenone.⁶³⁵ Beta-blockers,⁶³⁶ verapamil, diltiazem,⁶³⁷⁻⁶³⁹ and digoxin^{640, 641} do not reliably terminate AF or facilitate electrical cardioversion. When antiarrhythmic drug therapy is planned to maintain sinus rhythm 1750 1751

1752

1753 after cardioversion, it seems prudent to start therapy 1–3 days before cardioversion (amiodarone: a few weeks)

1754 to promote pharmacological conversion and to achieve effective drug levels.^{584, 601} 1755

1756 11.1.4. Anticoagulation in patients undergoing cardioversion

Cardioversion carries an inherent risk of stroke in non-anticoagulated patients,⁶⁴² which is reduced substantially 1757 by the administration of anticoagulation.⁶⁴³ Immediate initiation of anticoagulation is important in all patients 1758 scheduled for cardioversion.⁶⁴⁴⁻⁶⁴⁶ Patients who have been in AF for longer than 48 hours should start OAC at 1759

1760 least 3 weeks before cardioversion and continue it for 4 weeks afterwards (in patients without a need for long-

1761 term anticoagulation), and continue it indefinitely in patients at risk of stroke. This practice has never been

evaluated in controlled trials, but seemed safe in a large observational data set from Finland.⁶⁴⁷ When early 1762

1763 cardioversion is desired, TOE can exclude the majority of left atrial thrombi, allowing immediate

cardioversion.^{648, 649} Ongoing studies will inform about the safety and efficacy of newly initiated anticoagulation 1764 1765 using NOACs in patients scheduled for electrical cardioversion.

1766

Long-term antiarrhythmic drug therapy 1767 11.2.

The aim of antiarrhythmic drug therapy is improvement in AF-related symptoms.^{41, 580} Hence, the decision to 1768 1769 initiate long-term antiarrhythmic drug therapy needs to balance symptom burden, possible adverse drug

1770 reactions, and patient preferences. The principles of antiarrhythmic drug therapy outlined in the 2010 ESC AF guidelines³⁶⁹ are still relevant and should be observed: 1771

- 1772 Treatment is aimed at reducing AF-related symptoms; 1.
- 1773 Efficacy of antiarrhythmic drugs to maintain sinus rhythm is modest; 2.

1774 3. Clinically successful antiarrhythmic drug therapy may reduce rather than eliminate the recurrence of 1775 AF:

- 1776 4. If one antiarrhythmic drug 'fails', a clinically acceptable response may be achieved with another agent; 1777
 - Drug-induced proarrhythmia or extra-cardiac side-effects are frequent; 5.
 - Safety rather than efficacy considerations should primarily guide the choice of antiarrhythmic drug. 6.
- 1778 1779

1780 Antiarrhythmic drug therapy approximately doubles sinus rhythm maintenance compared with no therapy.⁵⁸⁰ There is no appreciable effect on mortality or cardiovascular complications, but rhythm control therapy can slightly increase the risk of hospitalizations (often for AF).^{41, 578, 579, 582, 589-593} To reduce the risk of side-1781 1782 1783 effects,^{201, 580} a shorter duration of antiarrhythmic drug therapy seems desirable. As an example, short-term 1784 treatment (4 weeks) with flecainide for 4 weeks after cardioversion of AF was well-tolerated and prevented most (80%) AF recurrences when compared with long-term treatment.⁵⁸⁴ Short-term antiarrhythmic drug 1785 therapy is also used to avoid early AF recurrences after catheter ablation⁶⁵⁰ and may be reasonable in patients 1786 1787 deemed at increased risk of antiarrhythmic drug side-effects or in those with a low perceived risk of recurrent 1788 AF. 1789 In addition to antiarrhythmic drug therapy and catheter ablation (see Section 10.3), management of

1790 concomitant cardiovascular conditions can reduce symptom burden in AF and facilitate maintenance of sinus rhvthm.^{203, 204, 296, 312} This includes weight reduction, blood pressure control, heart failure treatment, increasing 1791 1792 cardiorespiratory fitness, and other measures (see Chapter $\hat{6}$). 1793

1794 11.2.1. Selection of antiarrhythmic drugs for long-term therapy: Safety first!

1795 Usually, the safety of antiarrhythmic drug therapy determines the initial choice of antiarrhythmic drugs (Figure 1796 17). The following major antiarrhythmic drugs are available to prevent AF:

1797

1798 Amiodarone is an effective multichannel blocker, reduces ventricular rate, and is safe in patients with heart 1799 failure.^{582, 651} Torsades de pointes proarrhythmia can occur, and QT interval and TU waves should be monitored on therapy (see Table 17).⁶⁵² Amiodarone often causes extracardiac side-effects, especially on long-term 1800 therapy, ^{653, 654} rendering it a second-line treatment in patients who are suitable for other antiarrhythmic drugs. 1801 1802 Amiodarone appears less suitable to episodic short-term therapy (unless after catheter ablation),⁶⁵⁵ probably 1803 because of its long biological half-life.

1804

1805 Dronedarone maintains sinus rhythm, reduces ventricular rate, and prevents cardiovascular hospitalizations (mostly due to AF) and cardiovascular death in patients with paroxysmal or persistent AF or flutter who had at least one relevant cardiovascular comorbidity.^{583, 588, 656} Dronedarone increases mortality in patients with 1806 1807 recently decompensated heart failure (with or without AF)⁶⁵⁷ and in patients with permanent AF in whom sinus 1808 rhythm is not restored.⁶⁵⁸ Dronedarone moderately increases serum creatinine, reflecting a reduction in 1809 creatinine excretion rather than a decline in kidney function.⁶⁵⁹ 1810

1811

Flecainide and propafenone are effective in preventing recurrent AF.^{581, 584, 620} They should only be used in 1812 patients without significant ischaemic heart disease or heart failure to avoid the risk of life-threatening 1813 ventricular arrhythmias.⁶⁶⁰ High ventricular rates resulting from the conversion of AF into atrial flutter with 1:1 1814

1815 conduction by flecainide or propafenone can be prevented by preadministering a beta-blocker, verapamil, or diltiazem. 1816

1817

1818 Quinidine and disopyramide have been associated with an increase in all-cause mortality (OR 2.39; 95% CI 1.03–5.59; number needed to harm 109; 95% CI 34–4985) at 1-year follow-up,^{580, 661} likely due to ventricular arrhythmias (torsades de pointes).^{580, 661} Although this proarrhythmic effect is more common at higher doses, 1819 1820 1821 they are less commonly used for rhythm control in AF. Disopyramide may be useful in 'vagally mediated' AF 1822 (e.g. AF occurring in athletes and/or during sleep⁷⁶), and has been shown to reduce LV outflow gradient and improve symptoms in patients with hypertrophic cardiomyopathy. 662-664 1823 1824

1825 Sotalol has a relevant risk of torsades de pointes (1% in the Prevention of Atrial Fibrillation After Cardioversion 1826 [PAFAC] trial¹¹⁸). Its d-enantiomer is associated with an increased mortality compared to placebo in patients with LV dysfunction post-myocardial infarction,⁶⁶⁵ probably due to ventricular arrhythmias (OR 2.47; 95% CI 1.2–5.05; number needed to harm 166; 95% CI 61–1159).^{580, 665} On the other hand, d,l sotalol has been used in AF patients without safety signals in two controlled trials.^{581, 601} 1827 1828 1829

1830


1831 **Dofetilide** is another potassium channel blocker that is mainly available outside of Europe. Dofetilide restores

and maintains sinus rhythm in heart failure patients⁶⁶⁶ and occasionally in patients refractory to other 1832

antiarrhythmic drugs.66 1833

1834

- 1835 Overall, it seems prudent to limit the use of quinidine, disopyramide, dofetilide, and sotalol to specific
- 1836 situations. Similarly, combinations of QT-prolonging antiarrhythmic drugs should generally be avoided (Table 1837 17).



1838	
1839	Figure 17 Initiation of rhythm control therapy in symptomatic patients.
1840	AF = atrial fibrillation; HF = heart failure; LVH = left ventricular hypertrophy;
1841	^a Sotalol requires careful evaluation of proarrhythmic risk.
1842	^b Catheter ablation should isolate pulmonary veins and can be performed using radiofrequency or cryoballoon
1843	catheters.
1844	^c Catheter ablation as a first-line therapy is usually reserved for heart failure patients with tachycardiomyopathy.
1845	^d Amiodarone is a second-choice therapy in many patients because of its extracardiac side-effects.
1846	
1847	11.2.2. Twelve-lead electrocardiogram as a tool to identify patients at risk of
1848	proarrhythmia
1849	Identifying patients at risk of proarrhythmia can help to mitigate the proarrhythmic risk of antiarrhythmic
1850	drugs. ⁶⁶⁸ In addition to the clinical characteristics mentioned above, monitoring PR, QT, and QRS durations
1851	during initiation of antiarrhythmic drug therapy can identify patients at higher risk of drug-induced

1852 1853

during initiation of antiarrhythmic drug therapy can identify patients at higher risk of drug-induced proarrhythmia on longer-term treatment.⁶⁶⁹⁻⁶⁷¹ In addition, the presence of 'abnormal TU waves' is a sign of imminent torsades de pointes.⁶⁵² Periodic ECG analysis for proarrhythmia signs has been used successfully in recent antiarrhythmic drug trials.^{118, 584, 672} Specifically, ECG monitoring was used systematically on days 1–3 in 1854

patients receiving flecainide, propafenone, or sotalol to identify those at risk of proarrhythmia.^{118, 584, 601} Based 1855

1856 on this evaluated practice, we suggest to record an ECG in all patients before initiation of antiarrhythmic drugs.

1857 Scheduled ECGs during the initiation period seem reasonable (Table 17).

1858

1859 Table 17 Oral antiarrhythmic drugs used for maintaining sinus rhythm after cardioversion.

ESC AF Guidelines

Drug	precautions warra				Suggested ECG monitoring during initiation	
Amiodarone	600 mg in divided doses for 4 weeks, 400 mg for 4 weeks, then 200 mg once daily	Caution when using concomitant therapy with QT-prolonging drugs and in patients with sinoatrial node or atrioventricular node and conduction disease. The dose of VKAs and of digitalis should be reduced. Increased risk of myopathy with statins. Caution in patients with pre- existing liver disease	QT prolongation > 500 ms	10–12 bpm in AF	Baseline, 1 week, 4 weeks	
Dronedarone	400 mg twice daily	Contraindicated in NYHA class III or IV or unstable heart failure, during concomitant therapy with QT-prolonging drugs, or powerful CYP3A4 inhibitors (e.g. verapamil, diltiazem, azole antifungal agents), and when CrCl < 30 mg/mL. The dose of digitalis, beta-blockers, and of some statins should be reduced. Elevations in serum creatinine of 0.1–0.2 mg/dL are common and do not reflect a decline in renal function. Caution in patients with pre- existing liver disease	QT prolongation > 500 ms	10–12 bpm in AF	Baseline, 1 week, 4 weeks	
Flecainide Flecainide slow release	100–150 mg twice daily 200 mg once daily	Contraindicated if CrCl < 50 mg/mL, liver disease, IHD, or reduced LVEF. Caution in the presence of sinoatrial node or atrioventricular node or conduction system disease. CYP2D6 inhibitors (e.g. fluoxetine, tricyclic) increase plasma concentration	QRS duration increases > 25% above baseline	None	Baseline, day 1, day 2–3	
Propafenone	150–300 mg three times daily	Contraindicated in IHD or reduced LV ejection fraction. Caution in the presence of sinoatrial node or atrioventricular node and conduction system disease, renal or liver impairment, and asthma. Increases concentration of digitalis and warfarin	QRS duration increase > 25% above baseline	Slight	Baseline, day 1, day 2–3	
Propafenone SR	225–425 mg twice daily					
d,l sotalol	80–160 mg twice daily	Contraindicated in the presence of significant LV hypertrophy, systolic heart failure, asthma, pre-existing QT prolongation, hypokalaemia, CrCl < 50 mg/mL. Moderate renal dysfunction requires careful adaptation of dose	QT interval > 500 ms, QT prolongation by > 60 ms upon therapy initiation	Similar to high-dose blockers	Baseline, day 1, day 2–3	

1860AF = atrial fibrillation; bpm = beats per minute; CrCl = creatinine clearance; ECG = electrocardiogram; IHD =1861ischaemic heart disease; LV = left ventricular; LVEF = left ventricular ejection fraction; NYHA = New York1862Heart Association; VKA = vitamin K antagonist.

1863

1864 **11.2.3.** New antiarrhythmic drugs

Several compounds that inhibit the ultrarapid potassium current (I_{Kur}) and other inhibitors of atypical ion channels are in clinical development.⁶⁷³⁻⁶⁷⁵ They are not available for clinical use at present. The antianginal 1865 1866 compound ranolazine inhibits potassium and sodium currents and increases glucose metabolism at the expense of free fatty acid metabolism, thereby enhancing efficient use of oxygen.^{676, 677} Ranolazine was safe in patients 1867 1868 1869 with non-ST-segment elevation myocardial infarction and unstable angina evaluated in the MERLIN 1870 (Metabolic Efficiency With Ranolazine for Less Ischemia in Non ST-Elevation Acute Coronary Syndrome) trial.⁶⁷⁸ In a post-hoc analysis of continuous ECG recordings obtained during the first 7 days after 1871 1872 randomization, patients assigned to ranolazine had a trend towards fewer episodes of AF than those on placebo (75 [2.4%] vs. 55 [1.7%] patients; P = 0.08).⁶⁷⁹ In the HARMONY (A Study to Evaluate the Effect of 1873 1874 Ranolazine and Dronedarone When Given Alone and in Combination in Patients With Paroxysmal Atrial 1875 Fibrillation) trial, the highest tested dose of a combination of ranolazine (750 mg twice daily) and dronedarone 1876 (225 mg twice daily) slightly reduced AF burden in 134 subjects with paroxysmal AF and dual-chamber pacemakers.⁶⁸⁰ Small, open-label studies suggest that ranolazine might enhance the antiarrhythmic effect of 1877 amiodarone for cardioversion,⁶⁸¹⁻⁶⁸³ whereas the results from a controlled trial of ranolazine and the ranolazine– 1878 dronedarone combination to prevent AHRE in pacemaker patients were ambiguous.⁶⁸⁴ At present, there is 1879 1880 insufficient evidence to recommend ranolazine as an antiarrhythmic drug, alone or in combination with other 1881 antiarrhythmic drugs. Of note, the 'funny channel blocker' ivabradine, which is used for angina and heart 1882 failure, increases the risk of AF.685 1883 1884 Antiarrhythmic effects of non-antiarrhythmic drugs 11.2.4.

ACE inhibitors or ARBs appear to prevent new-onset AF in patients with LV dysfunction and in hypertensive patients with LV hypertrophy.^{219, 236, 237, 239, 246, 250, 686} Neprilysin inhibition needs to be studied further, but does 1885 1886 not seem to enhance this effect.²²⁴ A Danish cohort study also suggested that initial treatment of uncomplicated 1887 hypertension with ACE inhibitors or ARBs reduces incident AF compared with other hypertensive agents.²⁴⁵ 1888 ARB therapy did not reduce the AF burden in patients with AF without structural heart disease.²⁴¹ Thus, ACE 1889 inhibitors or ARBs are unlikely to have a relevant direct antiarrhythmic effect. However, it might be justified to 1890 1891 consider adding ACE inhibitors or ARB therapy to antiarrhythmic drugs to reduce AF recurrences after cardioversion.^{248, 249, 687} 1892 Compared with placebo, beta-blockers are associated with a reduced risk of new-onset AF in patients 1893

1893 Compared with placebo, beta-blockers are associated with a reduced risk of new-onset AF in patients 1894 with reduced ejection fraction and sinus rhythm.²³ Beta-blockers have also been reported to reduce symptomatic 1895 AF recurrences,^{580, 636, 688} but this finding may be driven by the beneficial effect of rate control, which will

1896 render AF more often asymptomatic.

Perioperative statin therapy appeared to reduce the risk of postoperative AF in a number of small
 RCTs^{689, 690}; however, an adequately powered placebo-controlled trial has shown no effect of perioperative
 rosuvastatin therapy on postoperative AF.⁶⁹¹ Statin treatment does not prevent AF in other settings.^{692, 693}
 Similarly, polyunsaturated fatty acids failed to show convincing benefit.^{241, 694-698} The role of aldosterone

antagonists in the management of AF has not been extensively investigated in humans; although preliminary

1902 evidence from trials of eplerenone is encouraging for primary prevention,²⁴³ at present there is no robust

evidence to make any recommendation for the use of aldosterone antagonists for secondary prevention of AF.⁶⁹⁹⁻ 701

- 1905
- 1906 **Recommendations for rhythm control therapy**

Recommendations	Class ^a	Level ^b	Refs ^d
General recommendations			
Management of cardiovascular risk factors and avoidance of AF triggers should be pursued in patients on rhythm control therapy to facilitate maintenance of sinus rhythm	lla	В	203, 204, 296, 312
Rhythm control therapy is indicated for symptom improvement in patients with AF	I	В	120, 586, 601
With the exception of AF associated with haemodynamic instability, the choice between electrical and pharmacological cardioversion	lla	С	

should be guided by patient and physician preferences			
Cardioversion of AF	1		
Electrical cardioversion of AF is recommended in patients with acute naemodynamic instability to acutely restore cardiac output	1	В	612, 702- 704
Cardioversion of AF (either electrical or pharmacological) is ecommended in symptomatic patients with persistent or long- standing persistent AF as part of rhythm control therapy	I	В	584, 601, 627, 628, 648, 705
Pretreatment with amiodarone, flecainide, ibutilide, or propafenone should be considered to enhance success of electrical cardioversion and prevent recurrent AF	lla	В	248, 584, 633
n patients with no history of ischaemic or structural heart disease, lecainide, propafenone, or vernakalant are recommended for pharmacological cardioversion of new-onset AF	I	A	602-605, 614, 618, 622, 706, 707
n patients with no history of ischaemic or structural heart disease, butilide should be considered for pharmacological conversion of AF	lla	В	
n selected patients with recent-onset AF and no significant structural or ischaemic heart disease, a single oral dose of flecainide or propafenone (the 'pill in the pocket' approach) should be considered or patient-led cardioversion, following safety assessment	lla	В	620, 621
n patients with ischaemic and/or structural heart disease, amiodarone is recommended for cardioversion of AF	I	A	597-601
/ernakalant may be considered as an alternative to amiodarone for oharmacological conversion of AF in patients without hypotension, severe heart failure, or severe structural heart disease (especially aortic stenosis)	llb	В	602-605, 616, 618
Stroke prevention in patients designated for cardioversion of AF			
Anticoagulation with heparin or a NOAC should be initiated as soon as possible before every cardioversion of AF or atrial flutter	lla	В	708, 709
For cardioversion of AF/atrial flutter, effective anticoagulation is ecommended for a minimum of 3 weeks before cardioversion	I	В	648, 708
Fransoesophageal echocardiography (TOE) is recommended to exclude cardiac thrombus, as an alternative to preprocedural anticoagulation when early cardioversion is planned	I	В	648, 708
Early cardioversion can be performed without TOE in patients with a definite duration of $AF < 48$ hours	lla	В	648
n patients at risk for stroke (e.g. presence of CHA ₂ DS ₂ -VASc actors), anticoagulant therapy should be continued long-term after cardioversion according to the long-term anticoagulation ecommendations, irrespective of the method of cardioversion or the apparent maintenance of sinus rhythm. In patients without stroke risk actors, anticoagulation is recommended for 4 weeks after cardioversion	I	В	353, 710
n patients where thrombus is identified on TOE, effective anticoagulation is recommended for at least 3 weeks	I	С	
A repeat TOE to ensure thrombus resolution should be considered	lla	С	

The choice of antiarrhythmic drug needs to be carefully evaluated, taking into account the presence of comorbidities, cardiovascular risk and potential for serious proarrhythmia, extracardiac toxic effects, patient preferences, and symptom burden	1	A	41, 580
Dronedarone, flecainide, propafenone, or sotalol are recommended for prevention of recurrent symptomatic AF in patients with normal left ventricular function and without pathological left ventricular hypertrophy.	1	A	581, 583, 584, 588, 601
Dronedarone is recommended for prevention of recurrent symptomatic AF in patients with stable coronary artery disease, and without heart failure	I	A	583, 588
Amiodarone is recommended for prevention of recurrent symptomatic AF in patients with heart failure	1	В	596-598
Amiodarone is more effective in preventing AF recurrences than other antiarrhythmic drugs but extracardiac toxic effects are common and increase with time. For this reason, other antiarrhythmic drugs should be considered first	lla	С	596-598
Patients on antiarrhythmic drug therapy should be periodically evaluated to confirm their eligibility for treatment	lla	С	583, 588, 657, 658, 660
ECG recording during the initiation of antiarrhythmic drug therapy should be considered to monitor heart rate, detect QRS and QT interval prolongation, and the occurrence of atrioventricular block	lla	В	584 582, 583, 588, 601
Antiarrhythmic drug therapy is not recommended in patients with prolonged QT interval (> 0.5 s) or with significant sinoatrial node disease or atrioventricular node dysfunction who do not have a functioning permanent pacemaker	III (harm)	С	
Adding atrial-based bradycardia pacing to drug treatment that induces or exacerbates sinus node dysfunction should be considered to allow continuation of antiarrhythmic drug therapy in patients in whom AF ablation is declined or not indicated	lla	В	/11, /12
Continuation of antiarrhythmic drug therapy beyond the blanking period after AF ablation should be considered to maintain sinus rhythm when recurrences seem likely	lla	В	713
Antiarrhythmic effects of non-antiarrhythmic drugs			
ACE inhibitors, ARBs, and beta-blockers should be considered for prevention of new-onset AF in patients with heart failure and reduced ejection fraction	lla	A	23, 219, 236 237, 239, 250, 714
ACE inhibitors and ARBs should be considered for prevention of new- onset AF in patients with hypertension, particularly with LV hypertrophy	lla	В	238, 246, 686, 714
Pretreatment with ACE inhibitors or ARBs may be considered in patients with recurrent AF undergoing electrical cardioversion and receiving antiarrhythmic drug therapy	llb	В	236, 237, 248, 249
ARBs or ACE inhibitors are not recommended for the secondary prevention of paroxysmal AF in patients with little or no underlying heart disease.	III (no benefit)	В	241, 697
ACE = angiotensin-converting enzyme: $AE =$ atrial fibrillation: $ABB =$ angiotensi		1.1	CILL DC

1907 ACE = angiotensin-converting enzyme; AF = atrial fibrillation; ARB = angiotensin receptor blocker; CHA_2DS_2 -

1908 VASc = Congestive Heart failure, hypertension, Age \geq 75 (doubled), Diabetes, Stroke (doubled), Vascular

1909 disease, Age 65–74, and Sex (female); ECG = electrocardiogram; NOAC = non-vitamin K antagonist oral

1910 anticoagulant; TOE = transoesophageal echocardiography.

1911 ^aClass of recommendation.

1912 ^bLevel of evidence.

1913 ^cReference(s) supporting recommendations.

1914

1915 11.3. Catheter ablation

1916 Since the initial description of triggers in the pulmonary veins that initiate paroxysmal AF,¹⁰⁸ catheter ablation 1917 of AF has developed from a specialized, experimental procedure into a common treatment to prevent recurrent 1918 AF.^{587, 715} This is primarily achieved through isolation of the pulmonary veins, probably requiring complete 1919 isolation for full effectiveness,⁷¹⁶ and additional ablation in the posterior left atrial wall. AF ablation, when 1920 performed in experienced centres by adequately trained teams, is more effective than antiarrhythmic drug 1921 therapy in maintaining sinus rhythm, and the complication rate, though not negligible, is similar to the

1922 complication rate for antiarrhythmic drugs.^{585, 717,} 1923

1924 **11.3.1**. Indications

1925 Catheter ablation of AF is effective in restoring and maintaining sinus rhythm in patients with symptomatic 1926 paroxysmal, persistent, and probably long-standing persistent AF - in general as second-line treatment after 1927 failure of or intolerance to antiarrhythmic drug therapy. In such patients, catheter ablation is more effective than 1928 antiarrhythmic drug therapy.^{185, 586, 713, 717-720} As first-line treatment for paroxysmal AF, randomized trials 1929 showed only modestly improved rhythm outcome with catheter ablation compared to antiarrhythmic drug 1930 therapy.^{585, 721-723} Complication rates were similar, but ablation was performed in expert centres, justifying 1931 catheter ablation as first-line therapy in selected patients with paroxysmal AF who ask for interventional 1932 therapy. Fewer data are available reporting the effectiveness and safety of catheter ablation in patients with 1933 persistent or long-standing persistent AF, but all point to lower recurrence rates after catheter ablation compared to antiarrhythmic drug therapy with or without cardioversion.^{185, 717, 723-726, 1039} In patients who experience 1934 symptomatic recurrences of AF despite antiarrhythmic drug therapy, all RCTs showed better sinus rhythm maintenance with catheter ablation than on antiarrhythmic drugs.^{586, 713, 727, 728} There is no current indication for 1935 1936 catheter ablation to prevent cardiovascular outcomes (or desired withdrawal of anticoagulation), or to reduce 1937 hospitalization.40, 594 1938 1939

1940 11.3.2. Techniques and technologies

1941 Complete pulmonary vein isolation (PVI) on an atrial level is the best documented target for catheter ablation,^{716, 729-731} achievable by point-by-point radiofrequency ablation, linear lesions encircling the pulmonary veins, or cryoballoon ablation, with similar outcomes.⁷³²⁻⁷³⁴ Complete isolation of the pulmonary veins has better rhythm outcomes than incomplete isolation.⁷¹⁶ PVI was initially tested in patients with paroxysmal AF, 1942 1943 1944 1945 but appears to be non-inferior to more extensive ablation in persistent AF as well.^{729, 735} More extensive 1946 ablations have been used in patients with persistent AF, but there are insufficient data to guide the use of these at present.^{117, 718, 719, 735-737} Extended ablation procedures (beyond PVI) consistently require longer procedures and 1947 more ionizing radiation, potentially creating risk for patients. Left atrial macro-reentrant tachycardia is relatively 1948 uncommon after PVI (\approx 5%). It also seems even less common after cryoballoon ablation,⁷³⁴ but may occur in up 1949 to 25% of patients after left atrial substrate modification ablation, often due to incomplete ablation lines. Thus, 1950 1951 for patients with persistent AF, ablation of complex fractionated electrograms, ablation of rotors, or routine deployment of linear lesions or other additional ablations does not seem justified in the first procedure.^{735, 738, 739} 1952 1953 However, additional ablation on top of complete PVI⁷¹⁶ may be considered in patients with recurrent AF after the initial ablation procedure.^{719, 740, 741} In patients with documented right atrial isthmus-dependent flutter 1954 1955 undergoing AF ablation, right atrial isthmus ablation is recommended. Adenosine testing to identify patients in need of additional ablation remains controversial after evaluation in several reports.^{739, 742-744} Ablation of so-1956 1957 called 'rotors' guided by body surface mapping or endocardial mapping is under evaluation and cannot be 1958 recommended for routine clinical use at present.

1959

1960 **11.3.3.** Outcome and complications

The rhythm outcome after catheter ablation of AF is difficult to predict in individual patients.^{173, 227, 713, 728} Most 1961 patients require more than one procedure to achieve symptom control.^{713, 726, 728} In general, better rhythm 1962 1963 outcome and lower procedure-related complications can be expected in younger patients with a short history of AF and frequent, short AF episodes in the absence of significant structural heart disease.⁷⁴⁵ Catheter ablation is 1964 1965 more effective than antiarrhythmic drug therapy in maintaining sinus rhythm (Web Addenda Figure 2).⁷⁴⁶ 1966 Sinus rhythm without severely symptomatic recurrences of AF is found in up to 70% of patients with paroxysmal AF, and around 50% in persistent AF.^{713, 728, 735, 1042} Very late recurrence of AF after years of sinus 1967 1968 rhythm is not uncommon and may reflect disease progression, with important implications for continuation of 1969 AF therapies.⁷²⁸ Multiple variables have been identified as risk factors for recurrence after catheter ablation of 1970 AF, but their predictive power is weak. The decision for catheter ablation thus should be based on a shared 1971 decision-making process⁷⁴⁷ (see Chapter 7), following thorough explanation of the potential benefits and risks, 1972 and of the alternatives such as antiarrhythmic drug or acceptance of current symptoms without rhythm control 1973 therapy.¹⁷⁵

1974 Complications of catheter ablation for AF

1975 There is a clear need to systematically capture complications in clinical practice to improve the quality of AF 1976 ablation procedures.¹⁷⁵ The median length of hospital stay in AF patients undergoing their first ablation as part

1977 of the EURObservational Research Programme (EORP) was 3 days (interquartile range 2-4 days), based on

1978 data from 1391 patients from hospitals performing at least 50 ablations per year. Five to seven per cent of

1979

patients will suffer severe complications after catheter ablation of AF, and 2–3% will experience life-threatening but usually manageable complications.^{727, 748-750} Intraprocedural death has been reported, but is rare (< 0.2%).⁷⁵¹ 1980

1981 The most important severe complications are stroke/TIA (<1%), cardiac tamponade (1-2%), pulmonary vein

1982 stenosis, and severe oesophageal injury leading to atrio-oesophageal fistula weeks after ablation (Table 18).

1983 'Silent strokes' (i.e. white matter lesions detectable by brain MRI), have been observed in around 10% of 1984 patients treated with radiofrequency and cryoballoon ablation.⁷⁵² The clinical relevance of this observation is

unclear.⁷⁴⁹ Post-procedure complications include stroke, with the highest risk within the first week,⁷⁵³ late pericardial tamponade several days after catheter ablation,⁷⁵¹ and oesophageal fistulas, which usually become 1985

1986

1987 apparent 7-30 days after ablation. Timely detection of atrio-oesophageal fistulas can be life-saving and should 1988 be based on the typical triad of infection without a clear focus, retrosternal pain, and stroke or TIA.⁷⁴

1989

1990	Table 18 Complications related to catheter ablation of AF
------	---

Complication severity	Complication type	Rate ^{727, 748, 750, 754-759}
	Periprocedural death	< 0.2%
	Oesophageal injury (perforation/fistula) ^a	< 0.5%
Life-threatening complications	Periprocedural stroke (including TIA/air embolism)	< 1%
	Cardiac tamponade	1–2%
	Pulmonary vein stenosis	< 1%
Course courseling time	Persistent phrenic nerve palsy	1–2%
Severe complications	Vascular complications	2–4%
	Other severe complications	≈ 1%
Other moderate or minor complications		1–2%
Unknown significance	Asymptomatic cerebral embolism (silent stroke) ^b	5–20%
	Radiation exposure	

1991 AF = atrial fibrillation; TIA = transient ischaemic attack.

1992 ^aOesophageal fistula should be suspected in patients presenting with the triad of unspecific signs of infection,

1993 chest pain, and stroke or TIA in the first weeks after an ablation procedure. It requires immediate therapy.

1994 b < 10% for cryoablation or radiofrequency ablation, > 20% for phased radiofrequency ablation

1995

1996 Anticoagulation – before, during, and after ablation 11.3.4.

Patients anticoagulated with VKAs should continue therapy during ablation (with an INR of 2–3).⁷⁶⁰ Anticoagulation with NOACs is an alternative to warfarin.^{478, 761-765} There is no safety signal from observational 1997 1998 1999 cohorts treated with uninterrupted NOAC therapy undergoing catheter ablation in experienced centres.^{761, 763, 766,} ⁷⁶⁷ The first controlled trial, enrolling around 200 patients, has recently been published, ⁷⁶⁸ as well as several 2000 observational data sets.^{761, 769, 770} Ongoing studies compare uninterrupted VKA with NOAC therapy in AF 2001 2002 patients undergoing ablation (e.g. AXAFA - AFNET 5 [Apixaban During Atrial Fibrillation Catheter Ablation: 2003 Comparison to Vitamin K Antagonist Therapy – Anticoagulation using the direct factor Xa inhibitor apixaban 2004 during Atrial Fibrillation catheter Ablation: Comparison to vitamin K antagonist therapy; NCT02227550] and 2005 RE-CIRCUIT [Randomized Evaluation of dabigatran etexilate Compared to warfarin in pulmonaRy vein

ablation: assessment of different peri-proCedUral anticoagulation sTrategies; NCT02348723]). During ablation,
heparin should be given to maintain an activated clotting time > 300 seconds. Anticoagulation should be
maintained for at least 8 weeks after ablation for all patients. The true incidence of thromboembolic events after
catheter ablation has never been systematically studied and the expected stroke risk has been adopted from nonablation AF cohorts. Although observational studies suggest a relatively low stroke rate in the first few years

2011 after catheter ablation of AF, $^{737, 771-776}$ the long-term risk of recurrent AF and the safety profile of

2012 anticoagulation in ablated patients need to be considered. In the absence of controlled trial data, OAC after

2013 catheter ablation should follow general anticoagulation recommendations, regardless of the presumed rhythm 2014 outcome.

2015

2016 **11.3.5.** Ablation of atrial fibrillation in heart failure patients

2017 Catheter ablation, compared with amiodarone therapy, significantly reduces recurrent AF in AF patients with 2018 HFrEF.⁷⁷⁷ Selected patients with HFrEF and AF can achieve recovery of LV systolic function after catheter 2019 ablation (probably reflecting tachycardiomyopathy). Several smaller trials suggest improved LV function after 2020 catheter ablation in HFrEF patients^{185, 226-228, 778, 779} and reduced hospitalizations,^{720, 777} especially in patients 2021 without a previous myocardial infarction.⁷⁸⁰ Larger trials are warranted to confirm these findings. Catheter 2022 ablation can be demanding in these patients. Thus, indications for catheter ablation in HFrEF patients should be 2023 carefully balanced, and the procedures performed in experienced centres.

2025 **11.3.6.** Follow-up after catheter ablation


Patients and physicians involved in the follow-up after catheter ablation should know the signs and symptoms of late complications to allow swift referral for treatment. Patient should also be aware that symptomatic and asymptomatic AF recurrences are frequent after catheter ablation.^{119, 781, 782} In line with the primary goal of rhythm control therapy, asymptomatic episodes should generally not trigger further rhythm control therapy. Patients should be seen at least once by a rhythm specialist in the first 12 months after ablation. Further rhythm control options should be considered in patients with symptomatic recurrences, including discussion in a Heart Team (*Figure 17*).

2032 Team (2033


2034 11.4. Atrial fibrillation surgery

2035 **11.4.1.** Concomitant atrial fibrillation surgery

2036 The Cox maze procedure was first performed 30 years ago as a 'cut-and-sew' technique, including isolation of 2037 the posterior left atrium, a connection to the posterior mitral annulus, a cavotricuspid connection, a cavocaval connection, and exclusion of the LAA (Figure 18).⁷⁸³ Thereby, the Cox maze procedure creates an electrical 2038 2039 labyrinth (maze) of passages through which the sinoatrial node impulse finds a route to the atrioventricular node 2040 while preventing fibrillatory conduction. The Cox maze procedure and other, often simpler, forms of AF surgery have mainly been used in patients undergoing other open heart surgical procedures.^{461, 466, 784-798} In a systematic 2041 2042 review commissioned for these guidelines, concomitant AF surgery resulted in greater freedom from AF, atrial 2043 flutter, and atrial tachycardia (RR 1.94, 95% CI 1.51–2.49; n = 554 from seven RCTs) (Web Addenda Figure 2044 3).¹⁰⁴⁰ Patients undergoing the Cox maze procedure required pacemaker implantation more often (RR 1.69, 95% 2045 CI 1.12–2.54; n = 1631 from 17 RCTs), without a detectable difference in other outcomes or complications. 2046 These findings are underpinned by an analysis of Society of Thoracic Surgeons database comprising 67,389 2047 patients in AF: mortality or major morbidity was not affected by concomitant AF surgery (adjusted OR 1.00; 95% CI 0.83–1.20), but pacemaker implantation was more frequent (adjusted OR 1.26; 95% CI 1.07–1.49).⁷⁹⁹ 2048 2049 Predictors of AF recurrence after surgery include left atrial dilatation, older age, > 10-year history of AF, and non-paroxysmal AF.⁸⁰⁰⁻⁸⁰⁴ Regarding AF type, surgical PVI seems effective in paroxysmal AF.⁸⁰⁵ Biatrial lesion patterns may be more effective in persistent and long-standing persistent AF.^{797, 803, 806} The suggested 2050 2051 2052 management of patients with AF-related symptoms undergoing cardiac surgery is displayed in Figure 19, with 2053 an important contribution of the AF Heart Team to advise and inform patient choice.



- 2054
 2055 Figure 18 A. Surgical lesion sets for
 2056 Right panel: left atrial lesions.
 2057 B: Left atrial lesions in a thoracosco
 2058 appendage exclusion (double line). Figure 18 A. Surgical lesion sets for the biatrial Cox maze procedure. Left and middle panel: right atrial lesions.
- B: Left atrial lesions in a thoracoscopic minimally invasive surgical procedure (dashed lines), including left



2059

2039	
2060	Figure 19 Surgical rhythm control in patients undergoing cardiac surgery.
2061	AF = atrial fibrillation; CABG = coronary artery bypass graft; LAA = left atrial appendage; PVI = pulmonary
2062	vein isolation.
2063	^a AF surgery may be PVI in paroxysmal AF and biatrial maze in persistent or long-standing persistent AF.
2064	^b Oral anticoagulation should be continued in patients at risk of stroke irrespective of AF surgery or LAA
2065	exclusion.
2066	
2067	

2068 **11.4.2.** Stand-alone rhythm control surgery

Current technology (e.g. bipolar radiofrequency or cryothermy) renders the procedure easier and more reproducible and feasible via a mini-thoracotomy.^{786, 807, 808} Thoracoscopic PVI with bipolar radiofrequency 2069 2070 prevents recurrence of paroxysmal AF (69–91% freedom from arrhythmias at 1 year, see Figure 18B for lesion 2071 set),^{468, 809, 810} and seems effective in patients refractory to catheter ablation.⁸¹¹ The average length of hospital stay for thoracoscopic ablation varies from 3.6 to 6.0 days.^{468, 812, 813} The FAST (Atrial Fibrillation Catheter 2072 2073 Ablation vs Surgical Ablation Treatment) trial,⁴⁶⁸ and another smaller trial,⁸¹⁴ suggested that thoracoscopic AF 2074 surgery could be more effective than catheter ablation for the maintenance of sinus rhythm,^{468, 814} while also causing more complications (*Table 19*).⁸¹⁵ To improve results,^{468, 816-818} more extensive lesion sets have been 2075 2076 performed, connecting lines between the PVI encircling and towards the mitral annulus.^{812, 819-822} To improve the 2077 generation of transmural lesions,⁷¹⁶ endo-epicardial ablation strategies have recently been proposed.^{812, 823-825} 2078 2079 Although preliminary experience with hybrid simultaneous ablation shows promise, procedural time and rates of 2080 bleeding complications are higher.^{812, 823} 2081

2082 Table 19 Complications of thoracoscopic AF surgery
Complication

Complication	Rate ^{468, 815, 822, 826}
Conversion to sternotomy	0–1.6%
Pacemaker implantation	0–3.3%
Drainage for pneumothorax	0–3.3%
Pericardial tamponade	0–6.0%
Transient ischaemic attack ^a	0–3.0%


2083 AF = atrial fibrillation.

2084 ^aThe rate of asymptomatic cerebral embolism is unknown

2085

2086 11.5. Choice of rhythm control following treatment failure

2087 There is insufficient evidence on which to base clear recommendations on how to treat patients with recurrent 2088 AF after catheter ablation. Early recurrences of AF or atrial tachycardias after ablation (occurring within 8 2089 weeks) may be treated with cardioversion. Many of the published series of patients undergoing AF ablation 2090 included those who failed antiarrhythmic drug therapy. Thus, considering ablation therapy in patients who have 2091 symptomatic recurrences on antiarrhythmic drug therapy is often reasonable. Alternatively, trialling another 2092 antiarrhythmic drug can be considered. Combining antiarrhythmic drug with ablation ('hybrid therapy', see 2093 Section 11) should be considered based on the different and possibly synergistic effects of these drugs with AF 2094 ablation, possibly benefitting patients in whom either treatment alone was previously ineffective. Rate control 2095 without rhythm control, surgical ablation, or repeat catheter ablation should be considered as well as third-line 2096 options (Figure 20). Patient preferences and local access to therapy are important considerations to inform the 2097 therapy choice in patients who are in need of further rhythm control therapy after an initial therapy failure.



2098 2099 Figure 20 Choice of rhythm control approaches following treatment failure. 2100 AAD = antiarrhythmic drug; AF = atrial fibrillation; PVI = pulmonary vein isolation. 2101 ^a catheter ablation should target PVI. Class I level B for paroxysmal AF and Class IIa level B for persistent AF. ^b AF surgery may be PVI (e.g. in paroxysmal AF) or maze surgery (e.g. in therapy-refractory or long-standing 2102 2103 persistent AF). 2104 ^c Hybrid therapy involves combination of antiarrhythmic drugs, catheter ablation, and/or AF surgery. 2105 2106 11.6. The atrial fibrillation Heart Team 2107 In view of the complexity of the different treatment options in patients with failed rhythm control therapy but 2108 who still require or demand further rhythm control therapy, this Task Force proposes that decisions involving

AF surgery or extensive AF ablation should be based on advice from an AF Heart Team. This will also apply to

- 2110 reversal to a rate control strategy in patients with severe (EHRA III or IV) AF symptoms. An AF Heart Team 2111 should consist of a cardiologist with expertise in antiarrhythmic drug therapy, an interventional
- 2111 should consist of a cardiologist with expertise in antiarrhythmic drug therapy, an interventional 2112 electrophysiologist, and a cardiac surgeon with expertise in appropriate patient selection, techniques, and

- technologies for interventional or surgical AF ablation. Such AF Heart Teams and a collaborative
 - infrastructure supporting a continued interaction between physicians delivering continued care, AF
- cardiologists, interventional electrophysiologists, and AF surgeons should be established to provide optimal
- 2113 2114 2115 2116 2117 2118 2110 advice and ultimately to improve rhythm outcomes for patients in need of advanced and complex rhythm control
- interventions.

2119 Recommendations for catheter ablation of AF and AF surgery

Recommendations	Class ^a	Level ^b	Refs ^c
Catheter ablation of symptomatic paroxysmal AF is recommended to improve AF symptoms in patients who have symptomatic recurrences of AF on antiarrhythmic drug therapy (amiodarone, dronedarone, flecainide, propafenone, sotalol) and who prefer further rhythm control therapy, when performed by an electrophysiologist who has received appropriate training and is performing the procedure in an experienced centre	I	A	585-587, 713, 727
Ablation of common atrial flutter should be considered to prevent recurrent flutter as part of an AF-ablation procedure if previously documented or occurring during the AF ablation	lla	В	827
Catheter ablation of AF should be considered as first-line therapy to prevent recurrent AF and to improve symptoms in selected patients with symptomatic paroxysmal AF as an alternative to antiarrhythmic drug therapy, considering patient choice, benefit, and risk	lla	В	585
All patients should receive oral anticoagulation for stroke prevention for at least 8 weeks after catheter (IIaB) or surgical (IIaC) ablation.	lla	B/C	/2/
Anticoagulation for stroke prevention should be continued indefinitely after apparently successful catheter or surgical ablation of AF in patients at high risk of stroke	lla	С	
When catheter ablation of AF is planned, continuation of oral anticoagulation with VKA (IIaB) or NOAC (IIaC) should be considered during the procedure, maintaining effective anticoagulation	lla	B/C	760, 768
Catheter ablation should target complete isolation of the pulmonary veins using radiofrequency ablation or cryothermy balloon catheters	lla	В	585, 715, 716, 734, 735
AF ablation should be considered in symptomatic patients with AF and heart failure with reduced ejection fraction to improve symptoms and cardiac function when tachycardiomyopathy is suspected	lla	С	185, 226-228, 720, 777-779, 828
AF ablation should be considered as a strategy to avoid pacemaker implantation in patients with AF-related bradycardia	lla	С	829, 830
Catheter or surgical ablation should be considered in patients with symptomatic persistent or long-standing persistent AF refractory to antiarrhythmic drug therapy to improve symptoms, considering patient choice, benefit and risk, supported by an AF Heart Team	lla	С	468, 735, 777, 831, 832, <mark>1040</mark>
Minimally invasive surgery with epicardial pulmonary vein isolation should be considered in patients with symptomatic AF when catheter ablation has failed. Decisions on such patients should be supported by an AF Heart Team	lla	В	468 812, 819, 823
Maze surgery, possibly via a minimally invasive approach, performed by an adequately trained operator in an experienced centre, should be considered by an AF Heart Team as a treatment option for patients with symptomatic refractory persistent AF or post-ablation AF to improve symptoms	lla	С	808, 832

Maze surgery, preferably biatrial, should be considered in patients undergoing cardiac surgery to improve symptoms attributable to AF, balancing the added risk of the procedure and the benefit of rhythm control therapy	lla	A	461, 466, 790, 791, 796, 797
Concomitant biatrial maze or pulmonary vein isolation surgery may be considered in asymptomatic AF patients undergoing cardiac surgery	llb	С	796, 797, 833

- 2120 AF = atrial fibrillation; NOAC = non-vitamin K antagonist oral anticoagulant; VKA = vitamin K antagonist.
- 2121 ^aClass of recommendation.
- 2122 ^bLevel of evidence.
- 2123 ^cReference(s) supporting recommendations.
- 2124

2125 12 Hybrid rhythm control therapy

- 2126 AF has many different drivers, which are only partially targeted by antiarrhythmic drug or catheter ablation.⁹⁶
- Hence, combination or 'hybrid' rhythm control therapy seems reasonable, although there is little evidence supporting its use.
- 2128 supporting 2129

2130 12.1. Combining antiarrhythmic drugs and catheter ablation

2131 Antiarrhythmic drug therapy is commonly given for 8-12 weeks after ablation to reduce early recurrences of AF 2132 after catheter ablation, supported by a recent controlled trial where amiodarone halved early AF recurrences compared with placebo.⁶⁵⁰ Prospective studies have not been done, but a meta-analysis of the available (weak) 2133 2134 evidence suggests slightly better prevention of recurrent AF in patients treated with antiarrhythmic drugs after catheter ablation.⁷¹³ Many patients are treated with antiarrhythmic drug therapy after catheter ablation (most 2135 often amiodarone or flecainide),⁵⁸⁷ and this seems a reasonable option in patients with recurrent AF after 2136 2137 ablation. It seems common sense to consider antiarrhythmic drug therapy in patients who are in need of further 2138 rhythm control therapy after catheter ablation, but controlled trials to confirm this are desirable. 2139 Combining cavotricuspid isthmus ablation and antiarrhythmic drugs may lead to improved rhythm

2139 Combining cavotricuspid isthmus ablation and antiarrhythmic drugs may lead to improved rhythm 2140 control without the need for left atrial ablation in patients who develop 'drug-induced atrial flutter' on therapy 2141 with flecainide, propafenone, or amiodarone,⁸³⁴⁻⁸³⁶ although recurrent AF is a concern in the long term.^{837, 838} 2142

2143 12.2. Combining antiarrhythmic drugs and pacemakers

In selected patients with sick sinus syndrome and fast ventricular response during AF paroxysms requiring rate control therapy, the addition of a pacemaker not only optimizes rate control but may also help to control rhythm.^{711, 712} Moreover, when antiarrhythmic drug treatment leads to sinus node dysfunction and bradycardia, pacing may permit uptitration of the antiarrhythmic drug dose. Such strategies have never been prospectively investigated and the existing populations studied are highly selected.^{839, 840} Some patients with AF-induced bradycardia may benefit from catheter ablation of AF, obviating the need for antiarrhythmic drugs and pacemaker implantation.^{829, 830}

2151

2152 13 Specific situations

2153 13.1. Frail and 'elderly' patients

2154 Many AF patients present at an older age (e.g. > 75 or > 80 years). There are no studies suggesting that cardiovascular risk reduction is less effective in these 'elderly' AF patients than in younger patients. Rather, age 2155 is one of the strongest predictors/risk factors for ischaemic stroke in AF (Table 11).³⁸² Good data are available to 2156 2157 support the use of anticoagulants in older patients from BAFTA (Birmingham Atrial Fibrillation Treatment of 2158 the Aged Study),³⁶² the NOAC trials,³⁹ and from analyses in elderly Americans (Medicare).³⁹⁶ Elderly AF patients are at higher risk of stroke and thus are more likely to benefit from OAC than younger patients,⁸⁴¹ and yet OAC is still underutilized in the elderly.^{220, 842} Although the evidence base is smaller for other treatment 2159 2160 2161 options in AF, the available data support the use of available rate and rhythm control interventions, including 2162 pacemakers and catheter ablation, without justification to discriminate by age group. Individual patients at older 2163 age may present with multiple comorbidities including dementia, a tendency to falls, CKD, anaemia, 2164 hypertension, diabetes, and cognitive dysfunction. Such conditions may limit quality of life more than AF-2165 related symptoms. Impairment of renal and hepatic function and multiple simultaneous medications make drug 2166 interactions and adverse drug reactions more likely. Integrated AF management and careful adaptation of drug dosing seem reasonable to reduce complications of AF therapy in such patients.⁸⁴³ 2167

2168

2169 13.2. Inherited cardiomyopathies, channelopathies, and accessory pathways

2170 Several inherited cardiac conditions are associated with early-onset AF (Table 20). Treatment of the underlying 2171 cardiac condition is an important contribution to AF management in these young patients (see also ESC 2172 guidelines on the sudden cardiac death⁸⁴⁴ and hypertrophic cardiomyopathy⁸⁴⁵).

2173 2174

Table 20 Inherited cardiomyopathies, channelopathies, and pathways associated with AF

2175

Syndrome Gene **Functional alteration** AF References prevalence 846-850 IKs 🗌 Long QT syndrome KCN01 5-10% IKr 🗌 KCNH2 SCN5A INa 🗌 INa,K 🗌 ANK2 Various effects others 851-855 INa 🗌 Brugada syndrome 10-20% SCN5A GPDIL INa 🗌 SCN1B INa 🗌 CACNA1C ICa 🗌 CACNB2b ICa 🗌 others others 853, 856-858 Short QT syndrome IKr 🗌 Up to 70% KCNH2 IKs 🗌 KCN01 IK1 🗍 KCNJ2 CACNA1C ICa \square CACNB2b ICa 859-861 Abnormal Ca²⁺ release from Catecholaminergic RYR2 Variable but ventricular tachycardia CASQ2 sarcoplasmic reticulum significant 862-864 Hypertrophic 5-15% Sarcomeric cardiomyopathy genes 865 Wolff-Parkinson-White PRKAG Variable syndrome 866 Holt-Oram syndrome TBX5 Variable 867, 868 Arrhythmogenic right Several >40% in ventricular desmosomal patients with cardiomyopathy genes. VTs unknown gene loci

2176 AF = atrial fibrillation.

2177

2178 13.2.1. Wolff–Parkinson–White syndrome

2179 Patients with pre-excitation and AF are at risk of rapid conduction across the accessory pathway, resulting in a 2180 fast ventricular rate, possibly ventricular fibrillation, and sudden death. In AF patients with evidence of an antegrade accessory pathway, catheter ablation of the pathway is recommended.^{869, 870} This procedure is safe and 2181 effective and may be considered as a prophylactic treatment strategy.^{871, 872} In AF patients surviving a sudden death event with evidence of an accessory pathway, urgent catheter ablation of the pathway is recommended.⁸⁶⁹ 2182 2183 2184 A documented short pre-excited RR interval (< 250 ms) during spontaneous or induced AF is one of the risk 2185 markers for sudden death in Wolff-Parkinson-White syndrome (WPW) syndrome, in addition to a history of 2186 symptomatic tachycardia, the presence of multiple accessory pathways, and Ebstein's anomaly. Intravenous procainamide, propafenone, or ajmaline can be used to acutely slow ventricular rate,^{873, 874} whereas digoxin, verapamil, and diltiazem are contraindicated.⁸⁷⁵ Intravenous amiodarone should be used with caution, as there 2187 2188 2189 are case reports of accelerated ventricular rhythms and ventricular fibrillation in patients with pre-excited AF 2190 receiving intravenous amiodarone infusion.8 2191

2192 13.2.2. Hypertrophic cardiomyopathy

2193 AF is the most common arrhythmia in patients with hypertrophic cardiomyopathy, affecting approximately onequarter of this population.⁸⁷⁷ Observational data highlight a high stroke risk in hypertrophic cardiomyopathy 2194

patients with AF, confirming the need for OAC.⁸⁷⁸ While there is more experience with VKAs, there are no data 2195 to suggest that NOACs cannot be used in these patients.⁸⁴⁵ Studies of rate or rhythm control medications in 2196 2197 patients with hypertrophic cardiomyopathy are relatively scarce. Beta-blockers and diltiazem or verapamil seem 2198 reasonable treatment options for rate control in these patients. In the absence of significant LV outflow tract obstruction, digoxin can be used alone or in combination with beta-blockers.⁸⁴⁵ Amiodarone seems a safe 2199 antiarrhythmic drug in AF patients with hypertrophic cardiomyopathy,⁸⁷⁹ and expert opinion suggests that 2200 disopyramide may be beneficial in those with outflow tract obstruction. AF ablation is effective to suppress symptomatic AF recurrences.⁸⁸⁰⁻⁸⁸⁴ Surgical treatment of AF may be appropriate in patients with hypertrophic 2201 2202 2203 cardiomyopathy undergoing surgery (e.g. for LV outflow tract obstruction or mitral valve surgery), but 2204 experience is limited.

2204 exj

2206 13.2.3. Channelopathies and arrhythmogenic right ventricular cardiomyopathy

2207 Many channelopathies and inherited cardiomyopathies are associated with AF. AF prevalence ranges from 5% 2208 to 20% in patients with long QT syndrome or Brugada syndrome, and is up to 70% in short QT syndrome (Table 20).^{853, 856-858} Penetrance of disease phenotype including AF is variable.^{61, 852, 885, 886} Both shortening as 2209 2210 well as prolongation of the atrial action potential have been demonstrated as likely mechanisms underlying AF 2211 in these diseases. It seems reasonable to consider antiarrhythmic drugs that reverse the suspected channel defect in AF patients with inherited cardiomyopathies (e.g. a sodium channel blocker in LQT3⁸⁵² and quinidine in 2212 2213 Brugada syndrome⁸⁸⁷). More importantly, new-onset AF in young, otherwise healthy individuals should trigger 2214 a careful search for such inherited conditions, including clinical history, family history, ECG phenotype, and 2215 echocardiography and/or other cardiac imaging.

2216 Monogenic defects only account for 3–5% of all patients with AF, even in younger populations.^{846, 848,} 2217 ⁸⁸⁸⁻⁸⁹⁰ Furthermore, there is no clear link between detected mutations and specific outcomes or therapeutic needs. 2218 For these reasons, genetic testing is not recommended in the general AF population.⁷⁷ Other guidelines have

2219 described the indications for genetic testing in patients with inherited arrhythmogenic diseases.^{844, 85}

2220

2221 **Recommendations for inherited cardiomyopathies** 2222

Recommendations	Class ^a	Level ^b	Refs ^c
WPW syndrome			
Catheter ablation of the accessory pathway in WPW patients with AF and rapid conduction over the accessory pathway is recommended to prevent sudden cardiac death	I	В	892-894
Catheter ablation of the accessory pathway is recommended without delay in WPW patients who survive sudden cardiac death	Ι	С	869
Asymptomatic patients with overt pre-excitation and AF should be considered for accessory pathway ablation after careful counselling	IIa	В	872, 895
Hypertrophic cardiomyopathy			
Lifelong oral anticoagulation to prevent stroke is recommended in hypertrophic cardiomyopathy patients who develop AF	Ι	В	878
Restoration of sinus rhythm by electrical or pharmacological cardioversion to improve symptoms is recommended in hypertrophic cardiomyopathy patients with symptomatic new-onset AF	I	В	845
In haemodynamically stable hypertrophic cardiomyopathy patients with AF, ventricular rate control using beta-blockers and diltiazem/verapamil is recommended	Ι	С	845
Treatment of LV outflow tract obstruction should be considered in AF patients with hypertrophic cardiomyopathy to improve symptoms	IIa	В	896
Amiodarone should be considered to achieve rhythm control and maintain sinus rhythm in hypertrophic cardiomyopathy patients	IIa	С	845, 897
Inherited cardiomyopathies and channelopathies			
Targeted genetic testing should be considered in patients with AF and a suspicion of inherited cardiomyopathies or channelopathies based on clinical history, family history, or electrocardiographic phenotype	IIa	А	852

AF = atrial fibrillation; LV = left ventricular; WPW = Wolff–Parkinson–White syndrome.

2224 ^aClass of recommendation.

2225 ^bLevel of evidence.

2226 ^cReference(s) supporting recommendations.

2227

2228 13.3. Sports and atrial fibrillation

2229 Physical activity improves cardiovascular health, which translates into a lower risk of AF.⁸⁹⁸ Therefore, physical activity is a cornerstone of preventing AF. Intensive sports practice, especially endurance sports (> 1500 h of endurance sports practice), ⁸⁹⁹ increases the risk of AF later in life, ⁹⁰⁰⁻⁹⁰² probably mediated by altered autonomic tone, volume load during exercise, atrial hypertrophy, and dilatation. ^{903, 904} This results in a U-shaped relationship of physical activity and incident AF. ^{214, 898, 902, 905, 906} Detraining can reduce AF in models⁹⁰⁴ and 2230 2231 2232 2233 reduces ventricular arrhythmias in athletes,⁹⁰⁷ but the role of detraining for AF in human athletes is unknown. 2234 2235 The management of athletes with AF is similar to general AF management, but requires a few special 2236 considerations. Clinical risk factors will determine the need for anticoagulation. Sports with direct bodily 2237 contact or prone to trauma should be avoided in patients on OAC. Beta-blockers are not well tolerated and at 2238 times prohibited, and digoxin, verapamil, and diltiazem are often not potent enough to slow heart rate during 2239 exertional AF. Catheter ablation for AF probably has similar outcomes in athletes as in non-athletes, ^{908, 909} but 2240 further data are needed. Pill-in-the-pocket therapy has been used as well.⁶²⁰ After ingestion of flecainide or 2241 propafenone as pill-in-the-pocket, patients should refrain from sports as long as AF persists and until two half-2242 lives of the antiarrhythmic drug have elapsed. Prophylactic ablation of the flutter circuit may be considered in 2243 athletes treated with sodium channel blockers.⁹

2244

2245 **Recommendations for physical activity in patients with AF**

Recommendations	Class ^a	Level ^b	Refs ^c
Moderate regular physical activity is recommended to prevent AF, while athletes should be counselled that long-lasting, more intense sports participation can promote AF	I	А	214, 898, 900- 902, 905, 906
AF ablation should be considered to prevent recurrent AF in athletes	IIa	В	908, 909
The ventricular rate while exercising with AF should be evaluated in every athlete (by symptoms and/or by monitoring), and titrated rate control should be instituted	IIa	С	
After ingestion of pill-in-the-pocket Class I antiarrhythmic drugs, patients should refrain from sports as long as AF persists and until two half-lives of the antiarrhythmic drug have elapsed	IIa	С	620

2246 AF = atrial fibrillation.

- 2247 ^aClass of recommendation.
- 2248 ^bLevel of evidence.
- 2249 ^cReference(s) supporting recommendations.
- 2250

2251 **13.4. Pregnancy**

AF in pregnant women is rare and is usually associated with pre-existing heart disease. AF is associated with increased complications for the mother and foetus.^{911, 912} Better treatment of congenital heart diseases will probably increase the incidence of AF during pregnancy in the future.⁹¹³ Pregnant women with AF should be managed as high-risk pregnancies in close collaboration with cardiologists, obstetricians, and neonatologists.

2256

2257 **13.4.1.** Rate control

2258 Owing to a lack of specific data, beta-blockers, verapamil, diltiazem, and digoxin all carry a US Food and Drug 2259 Administration pregnancy safety category of C (benefits may outweigh risk), except for atenolol (category D: 2260 positive evidence of risk). Their use should be at the lowest dose and for the shortest time required. None of the agents are teratogenic, but they readily cross the placenta.⁹¹⁴ Beta-blockers are commonly used in clinical 2261 2262 practice (e.g. for management of gestational hypertension and pre-eclampsia), but may be associated with intrauterine growth retardation,⁹¹⁵ and hence growth scans after 20 weeks gestation are recommended. Digoxin 2263 2264 is considered safe for maternal and foetal arrhythmias.⁹¹⁶ There are insufficient data to comment on verapamil or 2265 diltiazem, hence rate control using beta-blockers and/or digoxin is recommended.917 With regards to

breastfeeding, all rate control agents are present in breast milk, although levels of beta-blockers, digoxin, and

- 2267 verapamil are too low to be considered harmful. Diltiazem will be present at high levels and should be
- 2268 considered second-line treatment.⁹¹⁸
- 2269

2270 13.4.2. Rhythm control

Rhythm control therapy in pregnant patients with AF has only been reported in case studies. Amiodarone is associated with severe adverse foetal side-effects and should only be considered for emergency situations.⁹¹⁹ 2271

2272 Flecainide and sotalol can both be used for conversion of foetal arrhythmias without major adverse effects,⁹²⁰ 2273

2274 and thus are likely to be safe to treat maternal symptomatic AF. Electrical cardioversion can be effective for

2275 restoration of sinus rhythm when tachyarrhythmia is causing haemodynamic instability, with low rates of

2276 adverse outcomes for both mother and foetus.⁹²¹ However, in view of the risk of foetal distress, electrical 2277

cardioversion should only be carried out where facilities are available for foetal monitoring and emergency 2278 caesarean section. As with other emergencies during pregnancy, patients should receive 100% oxygen,

2279 intravenous access should be established early, and the mother should be positioned in the left lateral position to

2280 improve venous return.922 2281

2282 Anticoagulation 13.4.3.

2283 VKAs should be avoided in the first trimester because of teratogenic effects, and in the 2-4 weeks preceding 2284 delivery to avoid foetal bleeding. Low-molecular-weight heparins are a safe substitute, as they do not cross the 2285 placenta.⁹²³ In the third trimester, frequent laboratory checks for adequate anticoagulation (e.g. every 10-14 2286 days) and corresponding dose adjustments are advised, given that in some women high doses of both VKA and 2287 heparin may be needed to maintain adequate anticoagulation. Pregnant patients with AF and mechanical 2288 prosthetic valves who elect to stop VKA treatment in consultation with their specialist team between 6 and 12

2289 weeks of gestation, should receive continuous, dose-adjusted unfractionated heparin or dose-adjusted

2290 subcutaneous low-molecular-weight heparin. As only limited data are available about teratogenesis for NOACs, 2291 these drugs should be avoided during pregnancy.

2292

2293 Recommendations during pregnancy

Recommendations	Class ^a	Level ^b	Refs ^c
Electrical cardioversion can be performed safely at all stages of pregnancy, and is recommended in patients who are haemodynamically unstable due to AF, and whenever the risk of ongoing AF is considered high, for the mother or the foetus	I	С	
Anticoagulation is recommended in pregnant patients with AF at risk of stroke. To minimize teratogenic risk and intrauterine bleeding, dose-adjusted heparins are recommended during the first trimester of pregnancy and in the 2–4 weeks before delivery. Vitamin K antagonists or heparin can be used in the remaining parts of the pregnancy	I	В	923
NOACs should be avoided in pregnancy and in women planning a pregnancy	III (harm)	С	

- 2294 NOAC = non-vitamin K antagonist oral anticoagulants
- 2295 ^aClass of recommendation.
- 2296 ^bLevel of evidence.
- 2297 ^cReference(s) supporting recommendations.
- 2298

2299 **Postoperative atrial fibrillation** 13.5.

AF is common after cardiac surgery (occurring in 15–45% of patients),⁹²⁴⁻⁹²⁶ and is associated with increased length of hospital stay and higher rates of complications and mortality.⁹²⁷ Postoperative AF is also not 2300 2301

2302 uncommon after other major surgery, especially in elderly patients. The treatment of postoperative AF is mainly

2303 based on studies of patients undergoing cardiac surgery, with much less evidence in the non-cardiac surgery

- 2304 setting.
- 2305

Prevention of postoperative atrial fibrillation 2306 13.5.1.

2307 Beta-blockers reduce postoperative AF and supraventricular tachycardias, albeit with high heterogeneity and

2308 moderate risk of bias in a systematic review of published studies (the most commonly studied drug was

propranolol, with AF in 16.3% of the treatment group vs. 31.7% in the control group).⁹²⁵ In the majority of these 2309

2310 studies, beta-blockers were administered postoperatively, a regimen supported in a recent meta-analysis.⁹²⁸

2311 Amiodarone reduced the incidence of postoperative AF compared to a beta-blocker regimen in several meta-

analyses, also reducing hospital stay.^{925, 929-931} 2312

- Despite initial reports from meta-analyses,^{689, 932, 933} preoperative treatment with statins did not prevent postoperative AF in a prospective controlled trial.⁹³⁴ Other therapies have also been studied in small, hypothesisgenerating trials, but have not demonstrated clear beneficial effects. These include magnesium,^{925, 935, 936} n-3 polyunsaturated fatty acids,^{937,945} colchicine,⁹⁴⁶ corticosteroids,^{947, 948} and posterior pericardectomy.⁹⁴⁹ Postoperative overdrive biatrial pacing has not gained widespread use despite some suggestion of prophylactic
- 2318 effects.^{925, 950}
- 2319

2320 13.5.2. Anticoagulation

Postoperative AF is associated with an increased early stroke risk, increased morbidity, and 30-day mortality.^{927,} 2321 2322 ^{951, 952} In the long term, patients with an episode of postoperative AF have a twofold increase in cardiovascular 2323 mortality and a substantially increased risk of future AF and ischaemic stroke compared with patients that remain in sinus rhythm after surgery.⁹⁵²⁻⁹⁵⁸ OAC at discharge has been associated with a reduced long-term 2324 mortality in patients with postoperative AF,⁹⁵⁹ without evidence from controlled trials. Good quality data are 2325 needed to determine whether long-term anticoagulation can prevent strokes in patients with postoperative AF at 2326 high stroke risk, $^{368, 386}$ and to assess whether short episodes of postoperative AF (e.g. < 48 h) carry a similar risk 2327 as longer episodes.⁹⁶⁰ The indication and timing of OAC in postoperative AF patients should take into 2328 2329 consideration the risk of postoperative bleeding. 2330

2331 **13.5.3.** Rhythm control therapy in postoperative atrial fibrillation

2332 In haemodynamically unstable patients, cardioversion and consideration of antiarrhythmic drugs is

2333 recommended. Amiodarone or vernakalant have been efficient in converting postoperative AF to sinus

2334 rhythm.^{603, 950, 961} A recent medium-sized trial randomizing patients with postoperative AF to either rhythm

2335 control therapy with amiodarone or to rate control did not find a difference in hospital admissions during a 60-

2336 day follow-up,⁹⁶² underpinning that the aim of rhythm control therapy should be to improve AF-related

symptoms in postoperative AF. In asymptomatic patients and in those with acceptable symptoms, rate control or

2338 deferred cardioversion preceded by anticoagulation is a reasonable approach.

2339

2340 Recommendations for preventing postoperative AF

Recommendations	Class ^a	Level ^b	Refs ^c
Perioperative oral beta-blocker therapy is recommended for the prevention of postoperative AF after cardiac surgery	I	В	925, 928
Restoration of sinus rhythm by electrical cardioversion or antiarrhythmic drugs is recommended in postoperative AF with haemodynamic instability	I	С	
Long-term anticoagulation should be considered in patients with AF after cardiac surgery at risk for stroke, considering individual stroke and bleeding risk	lla	В	368, 386
Antiarrhythmic drugs should be considered for recurrent or symptomatic postoperative AF after cardiac surgery in an attempt to restore sinus rhythm	lla	С	
Perioperative amiodarone should be considered for prophylactic therapy to prevent AF after cardiac surgery	lla	А	925
Intravenous vernakalant may be considered for cardioversion of postoperative AF in patients without severe heart failure, hypotension, or severe structural heart disease (especially aortic stenosis)	llb	В	603
Asymptomatic postoperative AF should initially be managed with rate control and anticoagulation	lla	В	962

2341 AF = atrial fibrillation.

- 2342 ^aClass of recommendation.
- 2343 ^bLevel of evidence.
- 2344 ^cReference(s) supporting recommendations.
- 2345

2346 13.6. Atrial arrhythmias in grown-up patients with congenital heart disease

Atrial arrhythmias (AF, atrial flutter, atrial tachycardias) often occur late after surgical repair of congenital heart defects, occurring in 15–40% of grown-up patients with congenital heart disease (GUCH). They are associated with heart failure, syncope, thromboembolic events, and sudden death.⁹⁶³⁻⁹⁶⁷ The pathophysiological substrate is complex, associated with hypertrophy, fibrosis, hypoxaemia, chronic haemodynamic overload, and surgical scars and patches. Additionally, related primary anomalies in the conduction pathways can lead to reentrant atrial and ventricular tachycardia, heart block, and sinus node dysfunction.⁹⁶³ Macro-reentrant atrial tachycardia or atypical atrial flutter may be seen after nearly any surgical procedure involving atriotomy or atrial patches.

2355 **13.6.1.** General management of atrial arrhythmias in grown-up patients with

2356 congenital heart disease

2357 The conventional stroke risk factors should be used to inform decisions on long-term anticoagulation in GUCH

patients with AF. In addition, anticoagulation should be considered in GUCH patients with atrial arrhythmias when they present with intracardial repair, cyanosis, Fontan palliation, or systemic right ventricle, in addition to those with conventional stroke risk factors.⁹⁶⁸ Beta-blockers, verapamil, diltiazem, and digitalis can be used. Care should be taken to avoid bradycardia and hypotension.

2362 Sodium channel blockers suppress approximately half of atrial arrhythmias in Fontan patients.⁹⁶⁹ 2363 Amiodarone is more effective, but long-term treatment with an antiarrhythmic drugs carries a high risk of 2364 extracardiac side-effects in this relatively young population. Intracardiac thrombi are common in GUCH 2365 patients undergoing cardioversion for AF, but also in patients with atrial tachycardias or atrial flutter.⁹⁷⁰ 2366 Therefore, both a TOE and anticoagulation for a few weeks before the planned cardioversion should be 2367 considered.⁹⁶⁴ Radiofrequency ablation may be a good option for symptomatic GUCH patients with atrial 2368 arrhythmias, especially in those with atrial flutter and other macro-reentrant tachycardias. Interventions should 2369 be performed in adequately qualified centres by specialized teams.

2370

2371 13.6.2. Atrial tachyarrhythmias and atrial septal defects

Atrial flutter and fibrillation occur in 14–22% of adults with unoperated atrial septal defects, especially in older patients,⁹⁷¹ and can lead to heart failure.⁹⁷² Early repair can reduce but not eliminate the risk of AF.⁹⁷³ Biatrial volume overload,⁹⁷⁴ pulmonary hypertension,⁹⁷⁵ and possibly the arrhythmogenic effect of atrial patches can contribute to these arrhythmias.⁹⁷⁶ Anticoagulation should be decided based on stroke risk factors. In patients with a history of paroxysmal or persistent AF, AF surgery could be considered at the time of surgical closure, or catheter ablation in patients undergoing interventional atrial septal defect closure. Catheter ablation of late atrial arrhythmias has shown to be effective in 46 consecutive patients after surgical atrial septal defect.⁹⁷⁷

2380 13.6.3. Atrial tachyarrhythmias after Fontan operation

2381 Atrial arrhythmias occur in up to 40% of patients with a Fontan circulation, and can manifest as atrial flutter, 2382 primary atrial tachycardia, AF, and accelerated junctional rhythm or junctional tachycardia⁹⁷⁸ with or without sinoatrial node dysfunction.⁹⁷⁹ Patients with atriopulmonary anastomoses (possibly due to higher atrial volume 2383 2384 and pressure load) and those with early postoperative atrial arrhythmias are more likely to develop long-term 2385 atrial arrhythmias.⁹⁸⁰ Atrial arrhythmias can also be the first manifestation of obstruction of the atriopulmonary 2386 anastomosis, a complication that must be identified. Right atrial thrombus formation is common in Fontan patients with atrial arrhythmias and requires oral anticoagulation.⁹⁸¹ Operative conversion to total 2387 cavopulmonary artery connection with concomitant arrhythmia surgery can in some patients improve heart failure symptoms and reduce recurrent arrhythmias,^{969, 982} with low recurrence rates of clinically apparent atrial 2388 2389 arrhythmias in the first few years after repeat surgery.⁹⁸³⁻⁹⁸⁵ Catheter ablation of atrial arrhythmia in Fontan 2390 2391 patients has been successful in selected patients.⁹ 2392

2393 13.6.4. Atrial tachyarrhythmias after tetralogy of Fallot correction

Approximately one-third of patients after repair of tetralogy of Fallot develop atrial arrhythmias, including intraatrial reentrant tachycardia, focal atrial tachycardia, and AF.⁹⁸⁷ Circuits involving the cavotricuspid isthmus and areas of presumed surgical right atrial scaring have been described as responsible for atrial arrhythmias.

2397

2398 **Recommendations in patients with GUCH**

Recommendations	Class ^a	Level ^b	Refs ^c
Atrial septal defect closure should be considered before the fourth decade of life to diminish the chance of atrial flutter and fibrillation	lla	С	971, 972, 974

In patients who need surgical closure of an atrial septal defect and who have a history of symptomatic atrial arrhythmia, atrial ablation should be considered at the time of surgical closure	lla	С	204, 988, 989
Cox maze surgery should be considered in patients with symptomatic AF and an indication for corrective repair of congenital heart defects. All such surgery should be done in experienced centres	lla	С	988, 990
Oral anticoagualtion should be considered in all adult patients with intracardiac repair, cyanosis, Fontan palliation, or systemic right ventricle and a history of AF, atrial flutter, or intra-atrial reentrant tachycardia. In all other congenital heart disease patients with AF, anticoagulation should be considered if the CHA ₂ DS ₂ - VAS _C score is ≥ 1	lla	С	968
Catheter ablation of atrial arrhythmias associated with congenital heart defects may be considered when performed in experienced centres	llb	С	991
In patients with congenital heart disease, transoesophageal echocardiography may be considered together with 3-week anticoagulation therapy before cardioversion	llb	С	964, 970, 988, 990

- 2399 AF = atrial fibrillation; CHA₂DS₂-VASc = Congestive Heart failure, hypertension, Age \geq 75 (doubled),
- 2400 Diabetes, Stroke (doubled), Vascular disease, Age 65–74, and Sex (female); GUCH = grown-up patients with 2401 congenital heart disease; OAC = oral anticoagulation; TOE = transoesophageal echocardiography.
- 2402 ^aClass of recommendation.
- 2403 ^bLevel of evidence.
- 2404 ^cReference(s) supporting recommendations.
- 2405

2406 13.7. **Management of atrial flutter**

The goals for the management of atrial flutter are similar to those for AF.⁹⁹² Based on the available evidence, the 2407 stroke risk in patients with atrial flutter is not much different from that in AF.⁸²⁷ Furthermore, many patients diagnosed with atrial flutter develop AF.⁹⁹³⁻⁹⁹⁵ Thus, anticoagulation should be used in patients with atrial flutter 2408 2409 2410 similar to that in patients with AF. Rate control in atrial flutter is achieved with the same medications as in AF, 2411 but is often more difficult to achieve. Flecainide, propafenone, dofetilide, and intravenous ibutilide are useful for 2412 cardioversion of atrial flutter. They should be combined with a rate-controlling agent to avoid 1:1 conduction of slowing flutter waves to the ventricles. Ibutilide is more effective for conversion of atrial flutter than AF, whereas vernakalant is less effective in converting typical atrial flutter.^{996, 997} Electrical cardioversion of atrial flutter can be performed using lower energies (50–100 J) than for AF.^{998, 999} Atrial overdrive pacing through pacemaker leads or endocardial or transesophageal catheters can convert atrial flutter to sinus rhythm.^{1000, 1001} 2413 2414 2415

- 2416
- 2417 Anticoagulation and transoesophageal echocardiography around cardioversion or overdrive pacing should be 2418 used similar to that in AF.
- 2419 Ablation of the cavotricuspid isthmus for isthmus-dependent right atrial flutter (either the common 2420 counter-clockwise atrial flutter or the less-common clockwise atrial flutter) restores and maintains sinus rhythm with a success rate of 90–95%.¹⁰⁰² It may also reduce AF recurrences in selected patients,^{1003, 1004} and help to prevent hospitalizations.^{1004, 1005} Isthmus ablation is comparably safe and more effective than antiarrhythmic drug therapy, and is recommended for recurrent atrial flutter.^{585-587, 713} Catheter ablation of left atrial macro-2421 2422 2423 reentrant tachycardia is more complex, with lower success rates and higher recurrence rates.^{1006, 100} 2424
- 2425

2426 Recommendations for management of atrial flutter

Recommendations	Class ^a	Level ^b	Ref s ^c
For patients with atrial flutter, antithrombotic therapy is recommended according to the same risk profile used for AF	Ι	В	827
Overdrive atrial pacing of atrial flutter should be considered as an alternative to electrical cardioversion, depending on local availability and experience	IIa	В	1000, 1001

Management of typical atrial flutter with ablation of the cavotricuspid isthmus is recommended for patients failing antiarrhythmic drug therapy or as first-line treatment considering patient preference	Ι	В	158
If atrial flutter has been documented before AF ablation, ablation of the cavotricuspid isthmus should be considered as part of the AF ablation procedure	IIa	С	

2427 AF = atrial fibrillation.

- 2428 ^aClass of recommendation.
- 2429 ^bLevel of evidence.
- 2430 ^cReference(s) supporting recommendations.
- 2431

2432 14 Patient involvement, education and self-management

- 2433 A fundamental aspect of a structured AF management programme is the focus on patient-centred care.
- 2434

2435 **14.1**. **Patient-centred care**

2436 Autonomous, informed patients are better placed to adhere to long-term therapy, and it is very likely that long-2437 term management of chronic conditions such as AF will benefit from informed patients involved in the disease

management who are aware of their own responsibilities.³²⁸ Shared decision-making⁷⁴⁷ and patient-centred 2438

organization of care can help to ensure adherence to management and empower patients, and respect individual patient preferences, needs, and values (see Chapter 7.2).^{326, 1008, 1009} Patients in an active role tend to have better 2439 2440

2441 health outcomes and care experiences, and engagement itself can be considered as an intermediate outcome,

- 2442 particularly where related to improved clinical outcomes.¹⁰¹⁰
- 2443

2444 14.2. **Integrated patient education**

2445 Education is a prerequisite for informed, involved patients and patient-centred care. However, lack of AFrelated knowledge in patients is common, even in those who have received verbal and written information,^{32, 1011,} 2446

¹⁰¹² indicating the need to further develop structured patient education. Several patient-information tools have been developed, largely focusing on oral anticoagulation.¹⁰¹³⁻¹⁰¹⁶ Understanding patients' perceptions and 2447

2448

attitudes towards AF and its management can improve AF management and related outcomes.¹⁰¹⁷ This includes 2449 tailored patient education focusing on the disease, symptom recognition, therapy, modifiable risk factors for AF, and self-management activities.^{1018, 1019}

- 2450 2451
- 2452

2453 14.3. Self-management and shared decision-making

2454 Self-management is primarily focused on tasks to manage the condition, such as adhering to a therapeutic

regimen or modifying behaviour (e.g. resulting in smoking cessation or weight loss).¹⁰²⁰ It requires 2455

understanding of the treatment modalities and goals.³⁵⁰ Within a multidisciplinary team, allied health 2456

2457 professionals can guide this interactive process in which communication, trust, and reciprocal respect foster

patient engagement.¹⁰²¹ Shared decision-making should be considered as a routine part of the decision-making process,⁷⁴⁷ supported by decision aids where applicable.¹⁰²² Models of care that integrate education, engagement, and shared decision making are now available,¹⁰²³ and may be of particular value in the 2458

2459

2460 2461 management of AF.

2462

2463 Recommendations for patient involvement, education, and self-management

Recommendations	Class ^a	Level ^b	Refs ^c
Tailored patient education is recommended in all phases of AF management to support patients' perception of AF and to improve management	I	С	1014, 1017
Patient involvement in the care process should be considered to encourage self-management and responsibility for lifestyle changes	lla	С	328, 1010
Shared decision-making should be considered to ensure that care is based on the best available evidence and fits the needs, values, and preferences of the patient	lla	С	747

2464 AF = atrial fibrillation.

2465 ^aClass of recommendation.

2466 ^bLevel of evidence.

- 2467 ^cReference(s) supporting recommendations.
- 2468

2469 15 Gaps in evidence

2470 There are some areas of AF management that are supported by excellent evidence from multiple, adequately

2471 powered randomized trials (e.g. oral anticoagulation. Other areas, such as rhythm control therapy, integrated AF

2472 management, and lifestyle modifications are clearly developing the required evidence, while areas such as rate control are in dire need of better studies to underpin future guidelines. Here we identify areas in need of further

- 2473 2474 research.
- 2475

2476 Major health modifiers causing atrial fibrillation 15.1.

- Atrial fibrillation has different causes in different patients. More research is needed into the major causes (and electrophysiological mechanisms) of AF in different patient groups.^{176, 1024} Such research should consider the 2477
- 2478
- 2479 major comorbidities associated with AF, and characterize the response to AF therapy in patients with different, pathophysiologically distinct types of AF.
- 2480 2481

2482 15.2. How much atrial fibrillation constitutes a mandate for therapy?

2483 Technological advances allow screening for an irregular pulse using patient-operated ECG devices,

2484 smartphones, and a variety of other technologies. These may be very useful to detect silent, undiagnosed AF.¹⁵⁷

- 2485 Adequately powered studies evaluating the diagnostic accuracy of such technologies, the diagnostic yield in
- 2486 different populations, the shortest duration of atrial arrhythmias conveying a stroke risk, and ideally the effect of
- 2487 ECG screening on outcomes are needed.
- 2488

2489 15.3. Atrial high-rate episodes and need for anticoagulation

2490 All of the information on the benefit of OAC has been in patients with AF diagnosed by ECG. Technological 2491 advances allow ready detection of AHRE in patients with implanted devices and an atrial lead. Such patients are 2492 at increased stroke risk, but it is unclear whether they benefit from OAC. Controlled trials evaluating OAC in 2493 AHRE patients are ongoing and will provide evidence on the best antithrombotic therapy in these patients.

2494

2495 15.4. Stroke risk in specific populations

2496 Several specific AF groups should be studied to better characterize their risk for AF, stroke, and other AF-2497 related complications (e.g. patients with one stroke risk factor, and non-Caucasian patients). Confounding 2498 factors (e.g. different therapy of concomitant cardiovascular diseases) may help to explain the variability in the 2499 reported rates of incident AF, prevalent AF, and AF complications. This also applies to the effect of gender in 2500 AF patients.47 2501

2502 15.5. Anticoagulation in patients with severe chronic kidney disease

2503 The use of NOACs has not been tested in patients with creatinine clearance < 30 mL/min, and there is very little 2504 evidence on the effects of OAC in patients on haemodialysis or on other forms of renal-replacement therapy. 2505 Studies evaluating OAC in patients with severe chronic kidney disease are needed to inform the best

- 2506 management in this patient group at high risk for stroke and bleeding.
- 2507

2508 15.6. Left atrial appendage occlusion for stroke prevention

2509 The most common justification for LAA occlusion devices in clinical practice is a perceived high bleeding risk

and, less often, contraindications for OAC.⁴⁵⁹ Unfortunately, LAA occluders have not been tested in such 2510

2511 populations. Furthermore, LAA occluders have not been compared with NOAC therapy in patients at risk for

- 2512 bleeding, or with thoracoscopic LAA clipping. There is a clear need to conduct adequately designed and 2513 powered trials to define the clinical role of LAA occluders compared with NOAC therapy in patients with
- 2514 relative or absolute contraindications for anticoagulation, and/or in those suffering from an ischaemic stroke on
- 2515 anticoagulant therapy.
- 2516

2517 Anticoagulation in atrial fibrillation patients after a bleeding or stroke event 15.7.

2518 At least 2% of anticoagulated patients with AF will experience a serious bleeding event per year. Observational

- data suggest that OAC can be reinitiated even after an intracerebral bleeding event. 460, 484 Controlled studies 2519 2520 evaluating different anticoagulation and stroke prevention interventions are urgently needed to provide evidence
- 2521 on the best management of patients who have suffered a bleeding event that would usually lead to withholding

2522 OAC. Some studies (e.g. APACHE II¹⁰²⁵) are ongoing, but adequately powered trials are needed. Similarly,

- prospectively collected data are needed on the efficacy and bleeding risk following (re-)initiation of OAC after stroke or intracranial bleeding.
- 2525

2526 15.8. Anticoagulation and optimal timing of non-acute cardioversion

Based on retrospective data, previous recommendations on the safe time-window in which a cardioversion can be performed in new-onset AF used \leq 48 hours as the 'gold standard' for non-protected cardioversion. However, new evidence has emerged that initiating precardioversion anticoagulation in patients with AF episodes of < 24 hours or even < 12 hours would provide even better safety.^{642, 647, 1026-1028} Further research is needed to establish a clear safety margin in this clinical situation.

2532

2533 15.9. Competing causes of stroke or transient ischaemic attack in atrial fibrillationpatients

Prospective RCTs have demonstrated the superiority of carotid endarterectomy compared to stenting in patients with symptomatic high-degree stenosis of the internal carotid artery.¹⁰²⁹ As endartectomy minimizes the need for combination therapy with OAC and antiplatelets,¹⁰³⁰ this approach has appeal in patients with AF to reduce bleeding risk. However, few of these studies included patients with AF. In a large observational study, the composite of in-hospital mortality, post-procedural stroke, and cardiac complications was higher in AF patients undergoing carotid stenting (457/7668; 6.0%) compared with endarterectomy (4438/51320; 8.6%; *P* <

2541 0.0001).¹⁰³¹ Despite adjustment for baseline risk, this may just reflect the type of patients referred for each

procedure, and further randomized studies are needed to confirm the optimal treatment strategy in AF patients with carotid disease.

2543

254515.10. Anticoagulation in patients with biological heart valves (including transcatheter2546aortic valve implantation) and non-rheumatic valve disease

2547 The optimal antithrombotic therapy in the first months after biological valve replacement (including after 2548 catheter-based valve replacement) is not known. VKAs remain the mainstay during the initial postoperative 2549 period; NOACs probably deliver the same protection. In patients without AF, many centres use platelet 2550 inhibitors only. NOACs appear to be equally effective as VKAs in patients with moderate aortic stenosis, based 2551 on a subanalysis from the ROCKET-AF (Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) trial¹⁰³² as well as the Loire Valley AF project.¹⁰³³ Further data would be helpful to confirm these observations.¹⁰³⁴ The safety 2552 2553 2554 and efficacy of NOACs in patients with rheumatic mitral valve disease has not been evaluated and should be 2555 studied.

2556

2557 15.11. Anticoagulation after 'successful' catheter ablation

2558 In view of the long-term recurrence rates of AF, this Task Force recommends to continue OAC in AF patients 2559 after 'successful' catheter ablation. Nonetheless, observational data suggest that the stroke risk may be lower

2560 after catheter ablation of AF compared with other AF patients. The ongoing EAST (Early treatment of Atrial

2561 fibrillation for Stroke prevention Trial) trial will inform in a more general way whether rhythm control therapy

2562 can reduce stroke rates in anticoagulated AF patients. If confirmed, there may be a place for a controlled trial

- 2563 evaluating the termination of OAC therapy at an interval after 'successful' catheter ablation.
- 2564

2565 15.12. Comparison of rate control agents

Although the use of rate control therapy is very common in AF patients, robust data comparing rate control therapies are scant, with the majority of studies being small uncontrolled trials over short periods of follow up

therapies are scant, with the majority of studies being small uncontrolled trials over short periods of follow-up. Some studies are funded (e.g. RATE-AF [Rate Control Therapy Evaluation in Permanent Atrial Fibrillation]⁵⁵⁹ and will investigate the potential benefits of different rate controlling agents, characteristics, or biomarkers that can help to personalize the use of rate control, and the adverse-event profile of specific drugs in defined groups

- 2571 of patients (e.g. AF with HFrEF).
- 2572

2573 15.13. Catheter ablation in persistent and long-standing persistent AF

2574 While a few recent randomized studies support the use of catheter or surgical ablation in patients with persistent

2575 AF and long-standing persistent AF, there is a clear need for more data evaluating this intervention in

2576 adequately powered randomized trials.

2577

2578 15.14. Optimal technique for repeat catheter ablation

PVI emerges as the most important target for catheter ablation of AF. Although a plethora of different additional ablation techniques have been published, their added value is questionable in patients undergoing a first catheter ablation, including those with persistent AF.⁷³⁵ Many patients are in need of multiple catheter-ablation procedures, and such interventions often follow local or operator-specific protocols without clear evidence to support the choice of ablation target or intervention. There is a clear clinical need to define the best approach in

- 2584 patients who are in need of a second ablation procedure.
- 2585

2586 15.15. Combination therapy for maintenance of sinus rhythm

2587 In the follow-up after initially successful catheter ablation, even when done in experienced centres, many

- 2588 patients will experience symptomatic recurrences of AF. These patients are often managed with antiarrhythmic
- 2589 drugs. There is a surprising paucity of data evaluating different rhythm control interventions in patients with
- 2590 recurrent AF after catheter ablation. Such studies seem reasonable and feasible.
- 2591

2592 15.16. Can rhythm control therapy convey a prognostic benefit in atrial fibrillationpatients?

2594 The progress in rhythm control therapy (catheter ablation, new antiarrhythmic drugs) and observational long-

2595 term analyses suggest that rhythm control therapy may have a prognostic benefit. Ongoing trials such as

2596 CABANA and EAST - AFNET 4 will provide initial answers to this important question, but more data are

- 2597 needed, in addition to trials of surgical ablation techniques.
- 2598

2599 15.17. Thoracoscopic 'stand-alone' atrial fibrillation surgery

2600 Minimally invasive epicardial ablation surgery for the treatment of stand-alone AF was reported a decade 2601 ago.¹⁰³⁵ The procedure has since evolved towards a totally thoracoscopic procedure,¹⁰³⁶ and lesion sets were

2602 extended to a complete left atrial maze.⁸²² With such rapid development and the coexistence of different

2603 techniques and lesion sets, scientific evidence on long-term results is still limited. Randomized trials using a

- 2604 standardized procedure are urgently needed to clearly define the benefits and risks of thoracoscopic AF ablation,
- 2605 and to further support decisions of the AF Heart Team.
- 2606

2607 15.18. Surgical exclusion of the left atrial appendage

2608 Exclusion of the LAA has been performed by cardiothoracic surgeons for decades, but prospective randomized

2609 studies comparing the rate of ischaemic stroke with or without left appendage exclusion are presently lacking.

2610 The LAAOS (Left Atrial Appendage Occlusion Study) III is currently randomizing cardiac surgery patients with

2611 AF to undergo concomitant occlusion or no occlusion of the appendage.⁴⁶⁷ More data are also needed to confirm

the safety and efficacy of thoracoscopic exclusion, following early positive observational data.¹⁰³⁷

2613

2614 15.19. Concomitant atrial fibrillation surgery

Adequately powered randomized trials are needed, employing systematic follow-up, uniform lesion sets and energy sources to evaluate the benefits and risks of concomitant AF surgery in symptomatic AF patients. An

2010 energy sources to evaluate the benefits and fisks of concomitant AF surgery in symptomatic AF patients. An 2617 RCT on non-uniform lesion sets with long-term follow-up is due to publish shortly.¹⁰³⁸ These will assist the AF

2617 Ker on non-uniform resion sets with long-term ronow-up is due to publish shortly. These will assist the AP 2618 Heart Team to decide on optimal therapy for individual patients, including the full repertoire of medical and

- 2619 surgical options for the treatment of AF.
- 2620

2621 16 To do and not to do messages from the Guidelines

Recommendations for diagnosis and screening of AF	Class	Level
ECG documentation is required to establish the diagnosis of AF	Ι	В
Opportunistic screening for AF is recommended by pulse taking or ECG rhythm strip in patients > 65 years of age		В
In patients with TIA or ischaemic stroke, screening for AF is recommended by short-term ECG recording followed by continuous ECG monitoring for at least 72 hours	I	В
It is recommended to interrogate pacemakers and ICDs on a regular basis for atrial high rate episodes (AHRE). Patients with AHRE should undergo further ECG monitoring to document AF before initiating AF therapy	Ι	В
Recommendations for general management of AF	Class	Level
Tailored patient education is recommended in all phases of AF management to support patients' perception of AF and to improve management	Ι	С
A full cardiovascular evaluation, including an accurate history, careful clinical examination, and assessment of concomitant conditions, is recommended in all AF patients	Ι	С
Use of the modified EHRA symptom scale is recommended in clinical practice and research studies to quantify AF-related symptoms	Ι	С
Transthoracic echocardiography is recommended in all AF patients to guide management	Ι	C
The assessment of kidney function by serum creatinine or creatinine clearance is recommended in all AF patients to detect kidney disease and to support correct dosing of AF therapy	Ι	А
Recommendations for stroke prevention in AF	Class	Level
		Lever
The CHA ₂ DS ₂ -VASc score is recommended for stroke risk prediction in patients with AF	I	A
with AF Oral anticoagulation therapy to prevent thromboembolism is recommended for	I	
		A
with AF Oral anticoagulation therapy to prevent thromboembolism is recommended for all male AF patients with a CHA ₂ DS ₂ -VASc score of 2 or more Oral anticoagulation therapy to prevent thromboembolism is recommended in all	I	A
with AF Oral anticoagulation therapy to prevent thromboembolism is recommended for all male AF patients with a CHA ₂ DS ₂ -VASc score of 2 or more Oral anticoagulation therapy to prevent thromboembolism is recommended in all female AF patients with a CHA ₂ DS ₂ -VASc score of 3 or more When oral anticoagulation is initiated in a patient with AF who is eligible for a non vitamin-K-antagonist oral anticoagulant (NOAC, apixaban, dabigatran, edoxaban, or rivaroxaban), a NOAC is recommended in preference to a Vitamin K antagonist Vitamin K antagonist therapy (INR 2.0–3.0 or higher) is recommended for stroke prevention in AF patients with moderate-to-severe mitral stenosis or mechanical	I	A A A
with AF Oral anticoagulation therapy to prevent thromboembolism is recommended for all male AF patients with a CHA ₂ DS ₂ -VASc score of 2 or more Oral anticoagulation therapy to prevent thromboembolism is recommended in all female AF patients with a CHA ₂ DS ₂ -VASc score of 3 or more When oral anticoagulation is initiated in a patient with AF who is eligible for a non vitamin-K-antagonist oral anticoagulant (NOAC, apixaban, dabigatran, edoxaban, or rivaroxaban), a NOAC is recommended in preference to a Vitamin K antagonist Vitamin K antagonist therapy (INR 2.0–3.0 or higher) is recommended for stroke prevention in AF patients with moderate-to-severe mitral stenosis or mechanical heart valves NOACs (apixaban, dabigatran, edoxaban, and rivaroxaban) are not recommended in patients with mechanical heart valves (Level of evidence B) or moderate-to-	I I I	A A A A
with AF Oral anticoagulation therapy to prevent thromboembolism is recommended for all male AF patients with a CHA ₂ DS ₂ -VASc score of 2 or more Oral anticoagulation therapy to prevent thromboembolism is recommended in all female AF patients with a CHA ₂ DS ₂ -VASc score of 3 or more When oral anticoagulation is initiated in a patient with AF who is eligible for a non vitamin-K-antagonist oral anticoagulant (NOAC, apixaban, dabigatran, edoxaban, or rivaroxaban), a NOAC is recommended in preference to a Vitamin	I I I I	A A A A B

inhibition		
In male or female AF patients without additional stroke risk factors, anticoagulant or antiplatelet therapy is not recommended for stroke prevention	III (harm)	В
Antiplatelet monotherapy is not recommended for stroke prevention in AF patients, regardless of stroke risk	III (harm)	А
After surgical occlusion or exclusion of the left atrial appendage, it is recommended to continue anticoagulation in at-risk patients with AF for stroke prevention	I	В
Genetic testing before the initiation of vitamin K antagonist therapy is not recommended.	III (no benefit) B	
In AF patients with severe active bleeding events, it is recommended to interrupt oral anticoagulation therapy until the underlying cause is resolved	Ι	С
NOACs should be avoided in pregnancy and in women planning a pregnancy	III (harm)	С
For patients with atrial flutter, antithrombotic therapy is recommended according to the same risk profile used for AF	Ι	В
Management of typical atrial flutter with ablation of the cavotricuspid isthmus is recommended for patients failing antiarrhythmic drug therapy or as first-line treatment considering patient preference	I	В
Lifelong oral anticoagulation to prevent stroke is recommended in hypertrophic cardiomyopathy patients who develop AF	Ι	В
Anticoagulation with heparin or low-molecular-weight heparin immediately after ischaemic stroke is not recommended in AF patients	III (harm)	А
Systemic thrombolysis with a recombinant tissue plasminogen activator is not recommended if the INR is above 1.7 (or, for patients on dabigatran, if activated partial thromboplastin time is outside the normal range)	III (harm)	С
After TIA or stroke, combination therapy of OAC and an antiplatelet is not recommended	III (harm)	В
Recommendations for rate control of AF	Class	Level
Beta-blocker, digoxin, diltiazem, or verapamil is recommended to control heart rate in AF patients with LVEF $\geq 40\%$	I	В
Beta-blocker and/or digoxin is recommended to control heart rate in AF patients with $LVEF < 40\%$	Ι	В
In patients with permanent AF (i.e. where no attempt to restore sinus rhythm is planned), antiarrhythmic drugs should not routinely be used for rate control	III (harm)	А
Recommendations for rhythm control of AF	Class	Level
Rhythm control therapy is indicated for symptom improvement in patients with AF	Ι	В
Cardioversion of AF (either electrical or pharmacological) is recommended in symptomatic patients with persistent or long-standing persistent AF as part of rhythm control therapy	Ι	В
In patients with no history of ischaemic or structural heart disease, flecainide,		

Ι	А
Ι	В
Ι	В
I	А
I	А
Ι	А
I	В
III (harm)	С
Ι	A
III (no benefit)	В
I	А
	I I I I I I III (harm) I III (no benefit)

2623 2624 2625

2626 2627	17 A	short summary of the management of AF patients					
2628 2629 2630		Here, we provide 17 simple rules to guide diagnosis and management of AF patients according to the 2016 ESC/EACTS/ESO Guidelines for the management of atrial fibrillation					
2630 2631 2632	1.	Use ECG screening in at risk populations for atrial fibrillation, especially stroke survivors and the Elderly.					
2633	2.	Document AF by ECG before starting treatment.					
2634 2635	3.	Evaluate all AF patients by clinical evaluation, ECG, and echocardiogram for underlying cardiovascular conditions such as hypertension, heart failure, valvular heart disease, and others.					
2636 2637	4.	Provide tailored information and education to AF patients to empower them to support AF management.					
2638	5.	Propose life style changes to all suitable AF patients to make their management more effective.					
2639 2640 2641	6.	Treat underlying cardiovascular conditions adequately, e.g. valve repair or replacement in AF patients with significant valvular heart disease, treatment of heart failure, or management of hypertension, among others.					
2642 2643	7.	Use oral anticoagulation in all AF patients unless they are at low risk for stroke based on the CHA_2DS_2VASc score or have true contraindications for anticoagulant therapy.					
2644 2645	8.	Anticoagulate patients with atrial flutter similar to atrial fibrillation. Offer isthmus ablation to symptomatic flutter patients.					
2646 2647 2648 2649	9.	Reduce all modifiable bleeding risk factors in all AF patients on oral anticoagulation, e.g. by treating hypertension, minimising the duration and intensity of concomitant antiplatelet and NSAID therapy, treating anaemia and eliminating causes for blood loss, maintaining stable INR values in patients on vitamin K antagonists, and moderating alcohol intake					
2650 2651	10.	Check ventricular rate in all AF patients and use rate control medications to achieve lenient rate control.					
2652 2653 2654	11.	Evaluate AF-related symptoms in all AF patients using the modified EHRA score. Whenever patients have AF-related symptoms, aim to improve symptoms by adjustment of rate control therapy and by offering antiarrhythmic drugs, cardioversion, or catheter or surgical ablation.					
2655 2656	12.	Select antiarrhythmic drugs based on their safety profile and consider catheter or surgical ablation when antiarrhythmic drugs fail.					
2657 2658	13.	Do not offer routine genetic testing in AF patients unless there is a suspicion for an inherited cardiac condition.					
2659	14.	Do not use antiplatelet therapy for stroke prevention in AF.					
2660 2661	15.	Do not permanently discontinue oral anticoagulation in AF patients at increased risk of stroke unless such a decision is taken by a multidisciplinary team.					
2662 2663	16.	Do neither use rhythm control therapy in asymptomatic AF patients, nor in patients with permanent AF.					
2664 2665	17.	Do not perform cardioversion or catheter ablation without anticoagulation unless an atrial thrombus has been ruled out by transesophageal echocardiogram.					
2666 2667							

2668

2669 18 Web Addenda

All Web figures and Web tables are available in the Web addenda, available at European Heart Journal online
and also via the ESC Website (www.escardio.org/guidelines).

2673 **19 Appendix**

2674 ESC Committee for Practice Guidelines (CPG): Jose Luis Zamorano (Chairperson) (Spain), Victor Aboyans 2675 (France), Stephan Achenbach (Germany), Stefan Agewall (Norway), Lina Badimon (Spain), Gonzalo Barón-2676 Esquivias (Spain), Helmut Baumgartner (Germany), Jeroen J. Bax (The Netherlands), Héctor Bueno (Spain), 2677 Scipione Carerj (Italy), Veronica Dean (France), Çetin Erol (Turkey), Donna Fitzsimons (UK), Oliver 2678 Gaemperli (Switzerland), Paulus Kirchhof (UK/Germany), Philippe Kolh (Belgium), Patrizio Lancellotti 2679 (Belgium), Gregory Y. H. Lip (UK), Petros Nihoyannopoulos (UK), Massimo F. Piepoli (Italy), Piotr 2680 Ponikowski (Poland), Marco Roffi (Switzerland), Adam Torbicki (Poland), António Vaz Carneiro (Portugal), 2681 Stephan Windecker (Switzerland). 26822683 ESC National Cardiac Societies actively involved in the review process of the 2016 ESC Guidelines for the 2684 management of atrial fibrillation developed in collaboration with EACTS 2685 2686 Armenia: Armenian Cardiologists Association, Hamlet G. Hayrapetyan; Austria: Austrian Society of 2687 Cardiology, Franz Xaver Roithinger; Azerbaijan: Azerbaijan Society of Cardiology, Farid Aliyev; Belarus: 2688 Belorussian Scientific Society of Cardiologists, Alexandr Chasnoits; Belgium: Belgian Society of Cardiology, 2689 Georges H. Mairesse; Bosnia and Herzegovina: Association of Cardiologists of Bosnia and Herzegovina, 2690 Daniela Loncar Matičević; Bulgaria: Bulgarian Society of Cardiology, Tchavdar Shalganov; Croatia: Croatian 2691 Cardiac Society, Boško Skorić; Cyprus: Cyprus Society of Cardiology, Loizos Antoniades; Czech Republic: 2692 Czech Society of Cardiology, Milos Taborsky; Denmark: Danish Society of Cardiology, Steen Pehrson; 2693 Egypt: Egyptian Society of Cardiology, Said Khaled; Estonia: Estonian Society of Cardiology, Priit Kampus; 2694 Finland: Finnish Cardiac Society, Antti Hedman; The Former Yugoslav Republic of Macedonia: 2695 Macedonian FYR Society of Cardiology, Lidija Poposka; France: French Society of Cardiology, Jean-Yves Le 2696 Heuzey; Georgia: Georgian Society of Cardiology, Kakhaber Estadashvili; Germany: German Cardiac 2697 Society, Dietmar Bänsch; Hungary: Hungarian Society of Cardiology, Zoltán Csanádi; Icelandi: Icelandic 2698 Society of Cardiology, David O. Arnar; Ireland: Irish Cardiac Society, David Keane; Israel: Israel Heart 2699 Society, Roy Beinart; Italy: Italian Federation of Cardiology, Francesco Romeo; Kazakhstan: Association of 2700 Cardiologists of Kazakhstan, Kulzida Koshumbayeva; Kosovo: Kosovo Society of Cardiology, Gani Bajraktari; 2701 **Kyrgyzstan:** Kyrgyz Society of Cardiology, Aibek Mirrakhimov, **Latvia:** Latvian Society of Cardiology, 2702 Oskars Kalejs; Lebanon: Lebanese Society of Cardiology, Samer Nasr; Lithuania: Lithuanian Society of 2703 Cardiology, Germanas Marinskis; Luxembourg: Luxembourg Society of Cardiology, Carlo Dimmer; Malta: 2704 Maltese Cardiac Society, Mark Sammut; Moldova: Moldavian Society of Cardiology, Aurel Grosu; Morocco: 2705 Moroccan Society of Cardiology, Salima Abdelali; The Netherlands: Netherlands Society of Cardiology, 2706 Martin E. W. Hemels; Norway: Norwegian Society of Cardiology, Ole-Gunnar Anfinsen; Poland: Polish 2707 Cardiac Society, Beata Sredniawa; Portugal: Portuguese Society of Cardiology, Pedro Adragao; Romania: 2708 Romanian Society of Cardiology, Gheorghe-Andrei Dan; Russian Federation: Russian Society of Cardiology, 2709 Evgeny N. Mikhaylov; San Marino: San Marino Society of Cardiology, Marco Zavatta; Serbia: Cardiology 2710 Society of Serbia, Tatjana Potpara; Slovakia: Slovak Society of Cardiology, Peter Hlivak Slovenia: Slovenian 2711 Society of Cardiology, Igor Zupan; Spain: Spanish Society of Cardiology, Angel Arenal; Sweden: Swedish 2712 Society of Cardiology, Frieder Braunschweig; Switzerland: Swiss Society of Cardiology, Dipen Shah; Tunisia: 2713 Tunisian Society of Cardiology and Cardio-Vascular Surgery, Ag Sana Ouali; Turkey: Turkish Society of 2714 Cardiology, Mesut Demir; Ukraine: Ukrainian Association of Cardiology, Oleg Sychov; United Kingdom: 2715 British Cardiovascular Society, Ed Duncan. 2716

2717

2718 2719 **20 References** 2720 2721 2722 Chugh SS, Havmoeller R, Narayanan K, Singh D, Rienstra M, Benjamin EJ, Gillum RF, Kim 1. 2723 YH, McAnulty JH, Jr., Zheng ZJ, Forouzanfar MH, Naghavi M, Mensah GA, Ezzati M, Murray CJ. 2724 Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation 2725 2014;129:837-847. 2726 Colilla S, Crow A, Petkun W, Singer DE, Simon T, Liu X. Estimates of current and future 2. 2727 incidence and prevalence of atrial fibrillation in the U.S. adult population. Am J Cardiol 2728 2013;**112**:1142-1147. 2729 Heeringa J, van der Kuip DA, Hofman A, Kors JA, van Herpen G, Stricker BH, Stijnen T, Lip 3. 2730 GY, Witteman JC. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur 2731 Heart J 2006;27:949-953. 2732 Lloyd-Jones DM, Wang TJ, Leip EP, Larson MG, Levy D, Vasan RS, D'Agostino RB, Massaro 4. 2733 JM, Beiser A, Wolf PA, Benjamin EJ. Lifetime risk for development of atrial fibrillation: the 2734 Framingham Heart Study. Circulation 2004;110:1042-1046. 2735 Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, Singer DE. Prevalence of 2736 diagnosed atrial fibrillation in adults; national implications for rhythm management and stroke 2737 prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2738 2001;285:2370-2375. 2739 Krijthe BP, Kunst A, Benjamin EJ, Lip GY, Franco OH, Hofman A, Witteman JC, Stricker BH, 6. 2740 Heeringa J. Projections on the number of individuals with atrial fibrillation in the European Union, from 2741 2000 to 2060. Eur Heart J 2013;34:2746-2751. 2742 Zoni-Berisso M, Lercari F, Carazza T, Domenicucci S. Epidemiology of atrial fibrillation: 7. 2743 European perspective. Clin Epidemiol 2014;6:213-220. 2744 Bjorck S, Palaszewski B, Friberg L, Bergfeldt L. Atrial fibrillation, stroke risk, and warfarin 8. 2745 therapy revisited: a population-based study. Stroke 2013;44:3103-3108. 2746 Haim M, Hoshen M, Reges O, Rabi Y, Balicer R, Leibowitz M. Prospective national study of 9. 2747 the prevalence, incidence, management and outcome of a large contemporary cohort of patients with 2748 incident non-valvular atrial fibrillation. J Am Heart Assoc 2015;4:e001486. 2749 10. McManus DD, Rienstra M, Benjamin EJ. An update on the prognosis of patients with atrial 2750 fibrillation. Circulation 2012;126:e143-146. 2751 11. Ball J, Carrington MJ, McMurray JJ, Stewart S. Atrial fibrillation: profile and burden of an 2752 evolving epidemic in the 21st century. Int J Cardiol 2013;167:1807-1824. 2753 12. Kannel WB, Wolf PA, Benjamin EJ, Levy D. Prevalence, incidence, prognosis, and 2754 predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol 1998;82:2N-2755 9N. 2756 13. Nguyen TN, Hilmer SN, Cumming RG. Review of epidemiology and management of atrial 2757 fibrillation in developing countries. Int J Cardiol 2013;167:2412-2420. 2758 Oldgren J, Healey JS, Ezekowitz M, Commerford P, Avezum A, Pais P, Zhu J, Jansky P, 14. Sigamani A, Morillo CA, Liu L, Damasceno A, Grinvalds A, Nakamya J, Reilly PA, Keltai K, Van 2759 2760 Gelder IC, Yusufali AH, Watanabe E, Wallentin L, Connolly SJ, Yusuf S, RE-LY Atrial Fibrillation 2761 Registry Investigators. Variations in cause and management of atrial fibrillation in a prospective 2762 registry of 15,400 emergency department patients in 46 countries: the RE-LY Atrial Fibrillation 2763 Registry. Circulation 2014;129:1568-1576. 2764 15. Chiang CE, Naditch-Brule L, Murin J, Goethals M, Inoue H, O'Neill J, Silva-Cardoso J, 2765 Zharinov O, Gamra H, Alam S, Ponikowski P, Lewalter T, Rosenqvist M, Steg PG. Distribution and 2766 risk profile of paroxysmal, persistent, and permanent atrial fibrillation in routine clinical practice: insight 2767 from the real-life global survey evaluating patients with atrial fibrillation international registry. Circ 2768 Arrhythm Electrophysiol 2012;5:632-639. 2769 Wang TJ, Larson MG, Levy D, Vasan RS, Leip EP, Wolf PA, D'Agostino RB, Murabito JM, 16. 2770 Kannel WB, Benjamin EJ. Temporal relations of atrial fibrillation and congestive heart failure and their 2771 joint influence on mortality: the Framingham Heart Study. Circulation 2003;107:2920-2925. 2772 Kishore A, Vail A, Majid A, Dawson J, Lees KR, Tyrrell PJ, Smith CJ. Detection of atrial 17. 2773 fibrillation after ischemic stroke or transient ischemic attack: a systematic review and meta-analysis. 2774 Stroke 2014;45:520-526. 2775 Sanna T, Diener HC, Passman RS, Di Lazzaro V, Bernstein RA, Morillo CA, Rymer MM, Thijs 18. 2776 V, Rogers T, Beckers F, Lindborg K, Brachmann J, CRYSTAL AF Investigators. Cryptogenic stroke

2777 and underlying atrial fibrillation. *N Engl J Med* 2014;**370**:2478-2486.

2778 19. Schnabel RB, Yin X, Gona P, Larson MG, Beiser AS, McManus DD, Newton-Cheh C, Lubitz 2779 SA, Magnani JW, Ellinor PT, Seshadri S, Wolf PA, Vasan RS, Benjamin EJ, Levy D. 50 year trends in 2780 atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a 2781 cohort study. Lancet 2015;386:154-162. 2782 Benjamin EJ, Wolf PA, D'Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial 20. 2783 fibrillation on the risk of death: the Framingham Heart Study. Circulation 1998;98:946-952. 2784 Stewart S, Hart CL, Hole DJ, McMurray JJ. A population-based study of the long-term risks 21. 2785 associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. Am J Med 2786 2002;113:359-364. 2787 Andersson T, Magnuson A, Bryngelsson IL, Frobert O, Henriksson KM, Edvardsson N, Poci 22. 2788 D. All-cause mortality in 272,186 patients hospitalized with incident atrial fibrillation 1995-2008: a 2789 Swedish nationwide long-term case-control study. Eur Heart J 2013;34:1061-1067. 2790 Kotecha D, Holmes J, Krum H, Altman DG, Manzano L, Cleland JG, Lip GY, Coats AJ, 23 2791 Andersson B, Kirchhof P, von Lueder TG, Wedel H, Rosano G, Shibata MC, Rigby A, Flather MD. 2792 Beta-Blockers in Heart Failure Collaborative Group. Efficacy of beta blockers in patients with heart 2793 failure plus atrial fibrillation: an individual-patient data meta-analysis. Lancet 2014;384:2235-2243. 2794 24. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the 2795 Framingham Study. Stroke 1991;22:983-988. 2796 25. Krahn AD, Manfreda J, Tate RB, Mathewson FA, Cuddy TE. The natural history of atrial 2797 fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study. Am J Med 2798 1995;98:476-484. 2799 26. Henriksson KM, Farahmand B, Asberg S, Edvardsson N, Terent A. Comparison of 2800 cardiovascular risk factors and survival in patients with ischemic or hemorrhagic stroke. Int J Stroke 2801 2012;7:276-281. 2802 27. Grond M, Jauss M, Hamann G, Stark E, Veltkamp R, Nabavi D, Horn M, Weimar C, 2803 Kohrmann M, Wachter R, Rosin L, Kirchhof P. Improved detection of silent atrial fibrillation using 72-2804 hour Holter ECG in patients with ischemic stroke: a prospective multicenter cohort study. Stroke 2805 2013;44:3357-3364. 2806 28. Ott A, Breteler MM, de Bruyne MC, van Harskamp F, Grobbee DE, Hofman A. Atrial 2807 fibrillation and dementia in a population-based study. The Rotterdam Study. Stroke 1997;28:316-321. 2808 29. Knecht S, Oelschlager C, Duning T, Lohmann H, Albers J, Stehling C, Heindel W, Breithardt 2809 G, Berger K, Ringelstein EB, Kirchhof P, Wersching H. Atrial fibrillation in stroke-free patients is 2810 associated with memory impairment and hippocampal atrophy. Eur Heart J 2008;29:2125-2132. 2811 30. Ball J, Carrington MJ, Stewart S, SAFETY investigators. Mild cognitive impairment in high-risk 2812 patients with chronic atrial fibrillation: a forgotten component of clinical management? Heart 2813 2013:99:542-547. 2814 Marzona I, O'Donnell M, Teo K, Gao P, Anderson C, Bosch J, Yusuf S. Increased risk of 31. 2815 cognitive and functional decline in patients with atrial fibrillation: results of the ONTARGET and 2816 TRANSCEND studies. CMAJ 2012;184:E329-336. 2817 Thrall G, Lane D, Carroll D, Lip GY. Quality of life in patients with atrial fibrillation: a 32. 2818 systematic review. Am J Med 2006;119:448 e441-419. 2819 von Eisenhart Rothe A, Hutt F, Baumert J, Breithardt G, Goette A, Kirchhof P, Ladwig KH. 33. 2820 Depressed mood amplifies heart-related symptoms in persistent and paroxysmal atrial fibrillation 2821 patients: a longitudinal analysis - data from the German Competence Network on Atrial Fibrillation. 2822 Europace 2015;17:1354-1362. Steinberg BA, Kim S, Fonarow GC, Thomas L, Ansell J, Kowey PR, Mahaffey KW, Gersh BJ, 2823 34. 2824 Hylek E, Naccarelli G, Go AS, Reiffel J, Chang P, Peterson ED, Piccini JP. Drivers of hospitalization 2825 for patients with atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of 2826 Atrial Fibrillation (ORBIT-AF). Am Heart J 2014;167:735-742 e732. 2827 Kirchhof P, Schmalowsky J, Pittrow D, Rosin L, Kirch W, Wegscheider K, Meinertz T. 35. 2828 Management of patients with atrial fibrillation by primary care physicians in Germany: 1-year results of 2829 the ATRIUM registry. Clin Cardiol 2014;37:277-284. 2830 36. Stewart S, Murphy N, Walker A, McGuire A, McMurray JJV. Cost of an emerging epidemic: 2831 an economic analysis of atrial fibrillation in the UK. Heart 2004;90:286-292. 2832 Kim MH, Johnston SS, Chu BC, Dalal MR, Schulman KL. Estimation of total incremental 37. 2833 health care costs in patients with atrial fibrillation in the United States. Circ Cardiovasc Qual 2834 Outcomes 2011;4:313-320. 2835 Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in 38. 2836 patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007;146:857-867.

2837 39. Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, Camm 2838 AJ, Weitz JI, Lewis BS, Parkhomenko A, Yamashita T, Antman EM. Comparison of the efficacy and 2839 safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of 2840 randomised trials. Lancet 2014;383:955-962. 2841 Kirchhof P, Breithardt G, Camm AJ, Crijns HJ, Kuck KH, Vardas P, Wegscheider K. Improving 40. 2842 outcomes in patients with atrial fibrillation: rationale and design of the Early treatment of Atrial 2843 fibrillation for Stroke prevention Trial. Am Heart J 2013;166:442-448. 2844 Al-Khatib SM, Allen LaPointe NM, Chatterjee R, Crowley MJ, Dupre ME, Kong DF, Lopes RD, 41. 2845 Povsic TJ, Raju SS, Shah B, Kosinski AS, McBroom AJ, Sanders GD. Rate- and rhythm-control 2846 therapies in patients with atrial fibrillation: a systematic review. Ann Intern Med 2014;160:760-773. 2847 Lip GY, Laroche C, Ioachim PM, Rasmussen LH, Vitali-Serdoz L, Petrescu L, Darabantiu D, 42. 2848 Crijns HJ, Kirchhof P, Vardas P, Tavazzi L, Maggioni AP, Boriani G. Prognosis and treatment of atrial 2849 fibrillation patients by European cardiologists: one year follow-up of the EURObservational Research 2850 Programme-Atrial Fibrillation General Registry Pilot Phase (EORP-AF Pilot registry). Eur Heart J 2851 2014;35:3365-3376. 2852 43. Marijon E, Le Heuzey JY, Connolly S, Yang S, Pogue J, Brueckmann M, Eikelboom J, 2853 Themeles E, Ezekowitz M, Wallentin L, Yusuf S, RE-LY Investigators. Causes of death and 2854 influencing factors in patients with atrial fibrillation: a competing-risk analysis from the randomized 2855 evaluation of long-term anticoagulant therapy study. Circulation 2013;128:2192-2201. 2856 Senoo K, Lip GY, Lane DA, Buller HR, Kotecha D. Residual risk of stroke and death in 44. 2857 anticoagulated patients according to the type of atrial fibrillation: AMADEUS Trial. Stroke 2858 2015;46:2523-2528. 2859 Soliman EZ, Safford MM, Muntner P, Khodneva Y, Dawood FZ, Zakai NA, Thacker EL, Judd 45. 2860 S, Howard VJ, Howard G, Herrington DM, Cushman M. Atrial fibrillation and the risk of myocardial 2861 infarction. JAMA Intern Med 2014;174:107-114. 2862 46. Emdin CA, Wong CX, Hsiao AJ, Altman DG, Peters SA, Woodward M, Odutayo AA. Atrial 2863 fibrillation as risk factor for cardiovascular disease and death in women compared with men: 2864 systematic review and meta-analysis of cohort studies. BMJ 2016;532:h7013. 2865 47. Ko D, Rahman F, Schnabel RB, Yin X, Benjamin EJ, Christophersen IE. Atrial fibrillation in women: epidemiology, pathophysiology, presentation, and prognosis. Nat Rev Cardiol 2016:[Epub 2866 2867 ahead of print]. 2868 48. Andersson T, Magnuson A, Bryngelsson IL, Frobert O, Henriksson KM, Edvardsson N, Poci 2869 D. Gender-related differences in risk of cardiovascular morbidity and all-cause mortality in patients 2870 hospitalized with incident atrial fibrillation without concomitant diseases: A nationwide cohort study of 2871 9519 patients. Int J Cardiol 2014;177:91-99. 2872 Fang MC, Singer DE, Chang Y, Hylek EM, Henault LE, Jensvold NG, Go AS. Gender 49. 2873 differences in the risk of ischemic stroke and peripheral embolism in atrial fibrillation: the 2874 AnTicoagulation and Risk factors In Atrial fibrillation (ATRIA) study. Circulation 2005;112:1687-1691. 2875 Pancholy SB, Sharma PS, Pancholy DS, Patel TM, Callans DJ, Marchlinski FE. Meta-analysis 50. 2876 of gender differences in residual stroke risk and major bleeding in patients with nonvalvular atrial 2877 fibrillation treated with oral anticoagulants. Am J Cardiol 2014;113:485-490. 2878 Potpara TS, Marinkovic JM, Polovina MM, Stankovic GR, Seferovic PM, Ostojic MC, Lip GY. 51. 2879 Gender-related differences in presentation, treatment and long-term outcome in patients with first-2880 diagnosed atrial fibrillation and structurally normal heart: the Belgrade atrial fibrillation study. Int J 2881 Cardiol 2012;161:39-44. 2882 Ball J, Carrington MJ, Wood KA, Stewart S, SAFETY Investigators. Women versus men with 52. 2883 chronic atrial fibrillation: insights from the Standard versus Atrial Fibrillation spEcific managemenT 2884 studY (SAFETY). PLoS One 2013;8:e65795. 2885 53. Hughes M, Lip GY. Risk factors for anticoagulation-related bleeding complications in patients 2886 with atrial fibrillation: a systematic review. Qim 2007;100:599-607. 2887 Roten L, Rimoldi SF, Schwick N, Sakata T, Heimgartner C, Fuhrer J, Delacretaz E, Tanner H. 54. 2888 Gender differences in patients referred for atrial fibrillation management to a tertiary center. Pacing 2889 Clin Electrophysiol 2009;32:622-626. 2890 Forleo GB, Tondo C, De Luca L, Dello Russo A, Casella M, De Sanctis V, Clementi F, 55 2891 Fagundes RL, Leo R, Romeo F, Mantica M. Gender-related differences in catheter ablation of atrial 2892 fibrillation. Europace 2007;9:613-620. 2893 56. Henry L, Hunt S, Holmes SD, Martin LM, Ad N. Are there gender differences in outcomes 2894 after the Cox-Maze procedure for atrial fibrillation? Innovations (Phila) 2013;8:190-198. 2895 Michelena HI, Powell BD, Brady PA, Friedman PA, Ezekowitz MD. Gender in atrial fibrillation: 57. 2896 Ten years later. Gend Med 2010;7:206-217.

2897 58. Fox CS, Parise H, D'Agostino RB, Sr., Lloyd-Jones DM, Vasan RS, Wang TJ, Levy D, Wolf 2898 PA, Benjamin EJ. Parental atrial fibrillation as a risk factor for atrial fibrillation in offspring. JAMA 2899 2004;291:2851-2855. 2900 Oyen N, Ranthe MF, Carstensen L, Boyd HA, Olesen MS, Olesen SP, Wohlfahrt J, Melbye M. 59. Familial aggregation of lone atrial fibrillation in young persons. J Am Coll Cardiol 2012;60:917-921. 2901 2902 60. Ellinor PT, Lunetta KL, Albert CM, Glazer NL, Ritchie MD, Smith AV, Arking DE, Muller-2903 Nurasyid M, Krijthe BP, Lubitz SA, Bis JC, Chung MK, Dorr M, Ozaki K, Roberts JD, Smith JG, 2904 Pfeufer A, Sinner MF, Lohman K, Ding J, Smith NL, Smith JD, Rienstra M, Rice KM, Van Wagoner 2905 DR, Magnani JW, Wakili R, Clauss S, Rotter JI, Steinbeck G, Launer LJ, Davies RW, Borkovich M, 2906 Harris TB, Lin H, Volker U, Volzke H, Milan DJ, Hofman A, Boerwinkle E, Chen LY, Soliman EZ, 2907 Voight BF, Li G, Chakravarti A, Kubo M, Tedrow UB, Rose LM, Ridker PM, Conen D, Tsunoda T, 2908 Furukawa T, Sotoodehnia N, Xu S, Kamatani N, Levy D, Nakamura Y, Parvez B, Mahida S, Furie KL, 2909 Rosand J. Muhammad R, Psaty BM, Meitinger T, Perz S, Wichmann HE, Witteman JC, Kao WH, 2910 Kathiresan S. Roden DM. Uitterlinden AG. Rivadeneira F. McKnight B. Siogren M. Newman AB. Liu 2911 Y, Gollob MH, Melander O, Tanaka T, Stricker BH, Felix SB, Alonso A, Darbar D, Barnard J, 2912 Chasman DI, Heckbert SR, Benjamin EJ, Gudnason V, Kaab S. Meta-analysis identifies six new 2913 susceptibility loci for atrial fibrillation. Nat Genet 2012;44:670-675. 2914 61. Olesen MS, Nielsen MW, Haunso S, Svendsen JH. Atrial fibrillation: the role of common and 2915 rare genetic variants. Eur J Hum Genet 2014;22:297-306. 2916 Sinner MF, Tucker NR, Lunetta KL, Ozaki K, Smith JG, Trompet S, Bis JC, Lin H, Chung MK, 62. 2917 Nielsen JB, Lubitz SA, Krijthe BP, Magnani JW, Ye J, Gollob MH, Tsunoda T, Muller-Nurasyid M, 2918 Lichtner P, Peters A, Dolmatova E, Kubo M, Smith JD, Psaty BM, Smith NL, Jukema JW, Chasman 2919 DI, Albert CM, Ebana Y, Furukawa T, Macfarlane PW, Harris TB, Darbar D, Dorr M, Holst AG, 2920 Svendsen JH, Hofman A, Uitterlinden AG, Gudnason V, Isobe M, Malik R, Dichgans M, Rosand J, 2921 Van Wagoner DR, METASTROKE Consortium, AFGen Consortium, Benjamin EJ, Milan DJ, Melander 2922 O, Heckbert SR, Ford I, Liu Y, Barnard J, Olesen MS, Stricker BH, Tanaka T, Kaab S, Ellinor PT. 2923 Integrating genetic, transcriptional, and functional analyses to identify 5 novel genes for atrial 2924 fibrillation. Circulation 2014;130:1225-1235. 2925 63. Gudbjartsson DF, Arnar DO, Helgadottir A, Gretarsdottir S, Holm H, Sigurdsson A, 2926 Jonasdottir A, Baker A, Thorleifsson G, Kristjansson K, Palsson A, Blondal T, Sulem P, Backman VM, 2927 Hardarson GA, Palsdottir E, Helgason A, Sigurjonsdottir R, Sverrisson JT, Kostulas K, Ng MC, Baum 2928 L, So WY, Wong KS, Chan JC, Furie KL, Greenberg SM, Sale M, Kelly P, MacRae CA, Smith EE, 2929 Rosand J. Hillert J. Ma RC. Ellinor PT, Thorgeirsson G, Gulcher JR, Kong A, Thorsteinsdottir U. 2930 Stefansson K. Variants conferring risk of atrial fibrillation on chromosome 4q25. Nature 2007;448:353-2931 357. 2932 Lubitz SA, Lunetta KL, Lin H, Arking DE, Trompet S, Li G, Krijthe BP, Chasman DI, Barnard J, 64. 2933 Kleber ME, Dorr M, Ozaki K, Smith AV, Muller-Nurasyid M, Walter S, Agarwal SK, Bis JC, Brody JA, 2934 Chen LY, Everett BM, Ford I, Franco OH, Harris TB, Hofman A, Kaab S, Mahida S, Kathiresan S, 2935 Kubo M, Launer LJ, Macfarlane PW, Magnani JW, McKnight B, McManus DD, Peters A, Psaty BM, 2936 Rose LM, Rotter JI, Silbernagel G, Smith JD, Sotoodehnia N, Stott DJ, Taylor KD, Tomaschitz A, 2937 Tsunoda T, Uitterlinden AG, Van Wagoner DR, Volker U, Volzke H, Murabito JM, Sinner MF, 2938 Gudnason V, Felix SB, Marz W, Chung M, Albert CM, Stricker BH, Tanaka T, Heckbert SR, Jukema 2939 JW, Alonso A, Benjamin EJ, Ellinor PT. Novel genetic markers associate with atrial fibrillation risk in 2940 Europeans and Japanese. J Am Coll Cardiol 2014;63:1200-1210. 2941 Lemmens R, Buysschaert I, Geelen V, Fernandez-Cadenas I, Montaner J, Schmidt H, 65. 2942 Schmidt R, Attia J, Maguire J, Levi C, Jood K, Blomstrand C, Jern C, Wnuk M, Slowik A, Lambrechts 2943 D, Thijs V, International Stroke Genetics Consortium. The association of the 4q25 susceptibility 2944 variant for atrial fibrillation with stroke is limited to stroke of cardioembolic etiology. Stroke 2945 2010;**41**:1850-1857. 2946 Tada H, Shiffman D, Smith JG, Sjogren M, Lubitz SA, Ellinor PT, Louie JZ, Catanese JJ, 66. 2947 Engstrom G, Devlin JJ, Kathiresan S, Melander O. Twelve-single nucleotide polymorphism genetic 2948 risk score identifies individuals at increased risk for future atrial fibrillation and stroke. Stroke 2949 2014;45:2856-2862. 2950 67. Wang J, Klysik E, Sood S, Johnson RL, Wehrens XH, Martin JF. Pitx2 prevents susceptibility 2951 to atrial arrhythmias by inhibiting left-sided pacemaker specification. Proc Natl Acad Sci U S A 2952 2010;107:9753-9758. 2953 68. Franco D, Chinchilla A, Daimi H, Dominguez JN, Aranega A. Modulation of conductive 2954 elements by Pitx2 and their impact on atrial arrhythmogenesis. Cardiovasc Res 2011;91:223-231. 2955 Kirchhof P, Kahr PC, Kaese S, Piccini I, Vokshi I, Scheld HH, Rotering H, Fortmueller L, 69. 2956 Laakmann S, Verheule S, Schotten U, Fabritz L, Brown NA. PITX2c is expressed in the adult left

2957 atrium, and reducing Pitx2c expression promotes atrial fibrillation inducibility and complex changes in 2958 gene expression. Circ Cardiovasc Genet 2011;4:123-133. 2959 Wang J, Bai Y, Li N, Ye W, Zhang M, Greene SB, Tao Y, Chen Y, Wehrens XH, Martin JF. 70. 2960 Pitx2-microRNA pathway that delimits sinoatrial node development and inhibits predisposition to atrial 2961 fibrillation. Proc Natl Acad Sci U S A 2014. 2962 Husser D, Adams V, Piorkowski C, Hindricks G, Bollmann A. Chromosome 4q25 variants and 71. 2963 atrial fibrillation recurrence after catheter ablation. J Am Coll Cardiol 2010;55:747-753. 2964 Parvez B, Shoemaker MB, Muhammad R, Richardson R, Jiang L, Blair MA, Roden DM, 72. 2965 Darbar D. Common genetic polymorphism at 4q25 locus predicts atrial fibrillation recurrence after 2966 successful cardioversion. Heart Rhythm 2013;10:849-855. 2967 Benjamin Shoemaker M, Muhammad R, Parvez B, White BW, Streur M, Song Y, Stubblefield 73. 2968 T, Kucera G, Blair M, Rytlewski J, Parvathaneni S, Nagarakanti R, Saavedra P, Ellis CR, Patrick 2969 Whalen S, Roden DM, Darbar RD. Common atrial fibrillation risk alleles at 4g25 predict recurrence 2970 after catheter-based atrial fibrillation ablation. Heart Rhythm 2013;10:394-400. 2971 Parvez B. Vaglio J. Rowan S. Muhammad R. Kucera G. Stubblefield T. Carter S. Roden D. 74. 2972 Darbar D. Symptomatic response to antiarrhythmic drug therapy is modulated by a common single 2973 nucleotide polymorphism in atrial fibrillation. J Am Coll Cardiol 2012;60:539-545. 2974 75. Kirchhof P, Sipido KR, Cowie MR, Eschenhagen T, Fox KA, Katus H, Schroeder S, Schunkert 2975 H, Priori S, ESC CRT R&D and European Affairs Work Shop on Personalized Medicine. The 2976 continuum of personalized cardiovascular medicine: a position paper of the European Society of 2977 Cardiology. Eur Heart J 2014;35:3250-3257. 2978 Kirchhof P, Breithardt G, Aliot E, Al Khatib S, Apostolakis S, Auricchio A, Bailleul C, Bax J, 76. 2979 Benninger G, Blomstrom-Lundqvist C, Boersma L, Boriani G, Brandes A, Brown H, Brueckmann M, 2980 Calkins H, Casadei B, Clemens A, Crijns H, Derwand R, Dobrev D, Ezekowitz M, Fetsch T, Gerth A, 2981 Gillis A, Gulizia M, Hack G, Haegeli L, Hatem S, Georg Hausler K, Heidbuchel H, Hernandez-Brichis J, Jais P, Kappenberger L, Kautzner J, Kim S, Kuck KH, Lane D, Leute A, Lewalter T, Meyer R, Mont 2982 2983 L, Moses G, Mueller M, Munzel F, Nabauer M, Nielsen JC, Oeff M, Oto A, Pieske B, Pisters R, 2984 Potpara T, Rasmussen L, Ravens U, Reiffel J, Richard-Lordereau I, Schafer H, Schotten U, Stegink 2985 W, Stein K, Steinbeck G, Szumowski L, Tavazzi L, Themistoclakis S, Thomitzek K, Van Gelder IC, 2986 von Stritzky B, Vincent A, Werring D, Willems S, Lip GY, Camm AJ. Personalized management of 2987 atrial fibrillation: Proceedings from the fourth Atrial Fibrillation competence NETwork/European Heart 2988 Rhythm Association consensus conference. Europace 2013;15:1540-1556. 2989 77. Ackerman MJ, Priori SG, Willems S, Berul C, Brugada R, Calkins H, Camm AJ, Ellinor PT, 2990 Gollob M, Hamilton R, Hershberger RE, Judge DP, Le Marec H, McKenna WJ, Schulze-Bahr E, 2991 Semsarian C, Towbin JA, Watkins H, Wilde A, Wolpert C, Zipes DP, Heart Rhythm Society, European 2992 Heart Rhythm Association. HRS/EHRA expert consensus statement on the state of genetic testing for 2993 the channelopathies and cardiomyopathies: this document was developed as a partnership between 2994 the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA). Europace 2995 2011;13:1077-1109. 2996 78. Anne W, Willems R, Roskams T, Sergeant P, Herijgers P, Holemans P, Ector H, Heidbuchel 2997 H. Matrix metalloproteinases and atrial remodeling in patients with mitral valve disease and atrial 2998 fibrillation. Cardiovasc Res 2005;67:655-666. 2999 79. Chimenti C, Russo MA, Carpi A, Frustaci A. Histological substrate of human atrial fibrillation. 3000 Biomed Pharmacother 2010;64:177-183. 3001 Nguyen BL, Fishbein MC, Chen LS, Chen PS, Masroor S. Histopathological substrate for 80. 3002 chronic atrial fibrillation in humans. Heart Rhythm 2009;6:454-460. 3003 81. Frustaci A, Chimenti C, Bellocci F, Morgante E, Russo MA, Maseri A. Histological substrate of 3004 atrial biopsies in patients with lone atrial fibrillation. Circulation 1997;96:1180-1184. 3005 Venteclef N, Guglielmi V, Balse E, Gaborit B, Cotillard A, Atassi F, Amour J, Leprince P, 82. 3006 Dutour A, Clement K, Hatem SN. Human epicardial adipose tissue induces fibrosis of the atrial 3007 myocardium through the secretion of adipo-fibrokines. Eur Heart J 2013. 3008 Rocken C, Peters B, Juenemann G, Saeger W, Klein HU, Huth C, Roessner A, Goette A. 83. 3009 Atrial amyloidosis: an arrhythmogenic substrate for persistent atrial fibrillation. Circulation 3010 2002;**106**:2091-2097. 3011 Schotten U, Ausma J, Stellbrink C, Sabatschus I, Vogel M, Frechen D, Schoendube F, 84. 3012 Hanrath P, Allessie MA. Cellular mechanisms of depressed atrial contractility in patients with chronic 3013 atrial fibrillation. Circulation 2001;103:691-698. 3014 Allessie MA, de Groot NM, Houben RP, Schotten U, Boersma E, Smeets JL, Crijns HJ. 85. 3015 Electropathological substrate of long-standing persistent atrial fibrillation in patients with structural 3016 heart disease: longitudinal dissociation. Circ Arrhythm Electrophysiol 2010;3:606-615.

3017 86. Spach MS, Josephson ME. Initiating reentry: the role of nonuniform anisotropy in small 3018 circuits. J Cardiovasc Electrophysiol 1994;5:182-209. 3019 87. Shinagawa K, Shi YF, Tardif JC, Leung TK, Nattel S. Dynamic nature of atrial fibrillation 3020 substrate during development and reversal of heart failure in dogs. Circulation 2002;105:2672-2678. 3021 Lim HS, Willoughby SR, Schultz C, Gan C, Alasady M, Lau DH, Leong DP, Brooks AG, 88. Young GD, Kistler PM, Kalman JM, Worthley MI, Sanders P. Effect of atrial fibrillation on atrial 3022 3023 thrombogenesis in humans: impact of rate and rhythm. J Am Coll Cardiol 2013;61:852-860. 3024 Hijazi Z, Oldgren J, Siegbahn A, Granger CB, Wallentin L. Biomarkers in atrial fibrillation: a 89. 3025 clinical review. *Eur Heart J* 2013;**34**:1475-1480. 3026 90. Xu J, Cui G, Esmailian F, Plunkett M, Marelli D, Ardehali A, Odim J, Laks H, Sen L. Atrial 3027 extracellular matrix remodeling and the maintenance of atrial fibrillation. Circulation 2004;109:363-3028 368. 3029 91. Gramley F, Lorenzen J, Plisiene J, Rakauskas M, Benetis R, Schmid M, Autschbach R, 3030 Knackstedt C. Schimpf T. Mischke K. Gressner A. Hanrath P. Kelm M. Schauerte P. Decreased 3031 plasminogen activator inhibitor and tissue metalloproteinase inhibitor expression may promote 3032 increased metalloproteinase activity with increasing duration of human atrial fibrillation. J Cardiovasc 3033 Electrophysiol 2007;18:1076-1082. 3034 92. Hatem SN, Sanders P. Epicardial adipose tissue and atrial fibrillation. Cardiovasc Res 3035 2014;102:205-213. 3036 Leone O, Boriani G, Chiappini B, Pacini D, Cenacchi G, Martin Suarez S, Rapezzi C, Bacchi 93. 3037 Reggiani ML, Marinelli G. Amyloid deposition as a cause of atrial remodelling in persistent valvular 3038 atrial fibrillation. Eur Heart J 2004;25:1237-1241. 3039 Dobrev D, Friedrich A, Voigt N, Jost N, Wettwer E, Christ T, Knaut M, Ravens U. The G 94. 3040 protein-gated potassium current I(K,ACh) is constitutively active in patients with chronic atrial fibrillation. Circulation 2005;112:3697-3706. 3041 3042 95. Van Wagoner DR, Pond AL, Lamorgese M, Rossie SS, McCarthy PM, Nerbonne JM. Atrial L-3043 type Ca2+ currents and human atrial fibrillation. Circ Res 1999;85:428-436. 3044 Schotten U, Verheule S, Kirchhof P, Goette A. Pathophysiological mechanisms of atrial 96. 3045 fibrillation: a translational appraisal. Physiol Rev 2011;91:265-325. 3046 97. Voigt N, Heijman J, Wang Q, Chiang DY, Li N, Karck M, Wehrens XH, Nattel S, Dobrev D. 3047 Cellular and molecular mechanisms of atrial arrhythmogenesis in patients with paroxysmal atrial 3048 fibrillation. Circulation 2014;129:145-156. 3049 98. Voigt N, Li N, Wang Q, Wang W, Trafford AW, Abu-Taha I, Sun Q, Wieland T, Ravens U, 3050 Nattel S, Wehrens XH, Dobrev D. Enhanced sarcoplasmic reticulum Ca2+ leak and increased Na+-3051 Ca2+ exchanger function underlie delayed afterdepolarizations in patients with chronic atrial 3052 fibrillation. Circulation 2012;125:2059-2070. 3053 99. Polontchouk L, Haefliger JA, Ebelt B, Schaefer T, Stuhlmann D, Mehlhorn U, Kuhn-Regnier F, 3054 De Vivie ER, Dhein S. Effects of chronic atrial fibrillation on gap junction distribution in human and rat 3055 atria. J Am Coll Cardiol 2001;38:883-891. Aime-Sempe C, Folliguet T, Rucker-Martin C, Krajewska M, Krajewska S, Heimburger M, 3056 100. Aubier M, Mercadier JJ, Reed JC, Hatem SN. Myocardial cell death in fibrillating and dilated human 3057 3058 right atria. J Am Coll Cardiol 1999;34:1577-1586. 3059 101. Spach MS, Heidlage JF, Barr RC, Dolber PC. Cell size and communication: role in structural 3060 and electrical development and remodeling of the heart. Heart Rhythm 2004;1:500-515. 3061 Skalidis EI, Hamilos MI, Karalis IK, Chlouverakis G, Kochiadakis GE, Vardas PE. Isolated 102. 3062 atrial microvascular dysfunction in patients with lone recurrent atrial fibrillation. J Am Coll Cardiol 3063 2008;51:2053-2057. 3064 103. Barretto AC, Mady C, Nussbacher A, Ianni BM, Oliveira SA, Jatene A, Ramires JA. Atrial 3065 fibrillation in endomyocardial fibrosis is a marker of worse prognosis. Int J Cardiol 1998;67:19-25. 3066 104. Levy S. Factors predisposing to the development of atrial fibrillation. Pacing Clin 3067 Electrophysiol 1997;20:2670-2674. 3068 105. Chen PS, Chen LS, Fishbein MC, Lin SF, Nattel S. Role of the autonomic nervous system in 3069 atrial fibrillation: pathophysiology and therapy. Circ Res 2014;114:1500-1515. 3070 106. Christ T. Rozmaritsa N. Engel A. Berk E. Knaut M. Metzner K. Canteras M. Ravens U. 3071 Kaumann A. Arrhythmias, elicited by catecholamines and serotonin, vanish in human chronic atrial 3072 fibrillation. Proc Natl Acad Sci U S A 2014;111:11193-11198. 3073 107. Greiser M, Kerfant BG, Williams GS, Voigt N, Harks E, Dibb KM, Giese A, Meszaros J, 3074 Verheule S, Ravens U, Allessie MA, Gammie JS, van der Velden J, Lederer WJ, Dobrev D, Schotten 3075 U. Tachycardia-induced silencing of subcellular Ca2+ signaling in atrial myocytes. J Clin Invest 3076 2014;**124**:4759-4772.

3077 108. Haissaguerre M, Jais P, Shah DC, Takahashi A, Hocini M, Quiniou G, Garrigue S, Le 3078 Mouroux A, Le Metayer P, Clementy J. Spontaneous initiation of atrial fibrillation by ectopic beats 3079 originating in the pulmonary veins. N Engl J Med 1998;339:659-666. 3080 Patterson E, Jackman WM, Beckman KJ, Lazzara R, Lockwood D, Scherlag BJ, Wu R, Po S. 109. 3081 Spontaneous pulmonary vein firing in man: relationship to tachycardia-pause early 3082 afterdepolarizations and triggered arrhythmia in canine pulmonary veins in vitro. J Cardiovasc 3083 Electrophysiol 2007;18:1067-1075. 3084 110. Atienza F, Almendral J, Moreno J, Vaidyanathan R, Talkachou A, Kalifa J, Arenal A, 3085 Villacastin JP, Torrecilla EG, Sanchez A, Ploutz-Snyder R, Jalife J, Berenfeld O. Activation of inward 3086 rectifier potassium channels accelerates atrial fibrillation in humans: evidence for a reentrant 3087 mechanism. Circulation 2006;114:2434-2442. 3088 Mandapati R, Skanes A, Chen J, Berenfeld O, Jalife J. Stable microreentrant sources as a 111. 3089 mechanism of atrial fibrillation in the isolated sheep heart. Circulation 2000;101:194-199. 3090 112. Sahadevan J. Rvu K. Peltz L. Khrestian CM. Stewart RW. Markowitz AH. Waldo AL. 3091 Epicardial mapping of chronic atrial fibrillation in patients: preliminary observations. Circulation 3092 2004;110:3293-3299. 3093 113. Sanders P, Nalliah CJ, Dubois R, Takahashi Y, Hocini M, Rotter M, Rostock T, Sacher F, Hsu 3094 LF, Jonsson A, O'Neill MD, Jais P, Haissaguerre M. Frequency mapping of the pulmonary veins in 3095 paroxysmal versus permanent atrial fibrillation. J Cardiovasc Electrophysiol 2006;17:965-972. 3096 114. Moe GK, Abildskov JA. Atrial fibrillation as a self-sustaining arrhythmia independent of focal 3097 discharge. Am Heart J 1959;58:59-70. 3098 Cox JL, Canavan TE, Schuessler RB, Cain ME, Lindsay BD, Stone C, Smith PK, Corr PB, 115. 3099 Boineau JP. The surgical treatment of atrial fibrillation. II. Intraoperative electrophysiologic mapping 3100 and description of the electrophysiologic basis of atrial flutter and atrial fibrillation. J Thorac 3101 Cardiovasc Surg 1991;101:406-426. 3102 116. Narayan SM, Krummen DE, Shivkumar K, Clopton P, Rappel WJ, Miller JM. Treatment of 3103 atrial fibrillation by the ablation of localized sources: CONFIRM (Conventional Ablation for Atrial 3104 Fibrillation With or Without Focal Impulse and Rotor Modulation) trial. J Am Coll Cardiol 2012;60:628-3105 636. 3106 117. Haissaguerre M, Hocini M, Denis A, Shah AJ, Komatsu Y, Yamashita S, Daly M, Amraoui S, 3107 Zellerhoff S, Picat MQ, Quotb A, Jesel L, Lim H, Ploux S, Bordachar P, Attuel G, Meillet V, Ritter P, 3108 Derval N, Sacher F, Bernus O, Cochet H, Jais P, Dubois R. Driver domains in persistent atrial 3109 fibrillation. Circulation 2014;130:530-538. 3110 118. Fetsch T, Bauer P, Engberding R, Koch HP, Lukl J, Meinertz T, Oeff M, Seipel L, Trappe HJ, 3111 Treese N, Breithardt G. Prevention of atrial fibrillation after cardioversion: results of the PAFAC trial. 3112 Eur Heart J 2004;25:1385-1394. 3113 119. Hindricks G, Piorkowski C, Tanner H, Kobza R, Gerds-Li JH, Carbucicchio C, Kottkamp H. 3114 Perception of atrial fibrillation before and after radiofrequency catheter ablation: relevance of 3115 asymptomatic arrhythmia recurrence. Circulation 2005;112:307-313. 3116 Kirchhof P, Bax J, Blomstrom-Lundquist C, Calkins H, Camm AJ, Cappato R, Cosio F, Crijns 120. 3117 H, Diener HC, Goette A, Israel CW, Kuck KH, Lip GY, Nattel S, Page RL, Ravens U, Schotten U, 3118 Steinbeck G, Vardas P, Waldo A, Wegscheider K, Willems S, Breithardt G. Early and comprehensive 3119 management of atrial fibrillation: executive summary of the proceedings from the 2nd AFNET-EHRA 3120 consensus conference 'research perspectives in AF'. Eur Heart J 2009;30:2969-2977c. 3121 Xiong Q, Proietti M, Senoo K, Lip GY. Asymptomatic versus symptomatic atrial fibrillation: A 121. 3122 systematic review of age/gender differences and cardiovascular outcomes. Int J Cardiol 3123 2015;191:172-177. 3124 122. Savelieva I, Camm AJ. Clinical relevance of silent atrial fibrillation: prevalence, prognosis, 3125 quality of life, and management. J Interv Card Electrophysiol 2000;4:369-382. 3126 123. Friberg L, Hammar N, Rosenqvist M. Stroke in paroxysmal atrial fibrillation: report from the 3127 Stockholm Cohort of Atrial Fibrillation. Eur Heart J 2010;31:967-975. 3128 124. Vanassche T, Lauw MN, Eikelboom JW, Healey JS, Hart RG, Alings M, Avezum A, Diaz R, 3129 Hohnloser SH, Lewis BS, Shestakovska O, Wang J, Connolly SJ. Risk of ischaemic stroke according 3130 to pattern of atrial fibrillation: analysis of 6563 aspirin-treated patients in ACTIVE-A and AVERROES. 3131 Eur Heart J 2015;36:281-287a. 3132 Steinberg BA, Hellkamp AS, Lokhnygina Y, Patel MR, Breithardt G, Hankey GJ, Becker RC, 125. 3133 Singer DE, Halperin JL, Hacke W, Nessel CC, Berkowitz SD, Mahaffey KW, Fox KA, Califf RM, 3134 Piccini JP. Higher risk of death and stroke in patients with persistent vs. paroxysmal atrial fibrillation: 3135 results from the ROCKET-AF Trial. Eur Heart J 2015;36:288-296.

3136 126. Fitzmaurice DA, Hobbs FD, Jowett S, Mant J, Murray ET, Holder R, Raftery JP, Bryan S, 3137 Davies M, Lip GY, Allan TF. Screening versus routine practice in detection of atrial fibrillation in 3138 patients aged 65 or over: cluster randomised controlled trial. BMJ 2007;335:383. 3139 Rizos T, Guntner J, Jenetzky E, Marquardt L, Reichardt C, Becker R, Reinhardt R, Hepp T, 127. 3140 Kirchhof P, Aleynichenko E, Ringleb P, Hacke W, Veltkamp R. Continuous stroke unit 3141 electrocardiographic monitoring versus 24-hour Holter electrocardiography for detection of 3142 paroxysmal atrial fibrillation after stroke. Stroke 2012;43:2689-2694. 3143 128. Gladstone DJ, Spring M, Dorian P, Panzov V, Thorpe KE, Hall J, Vaid H, O'Donnell M, 3144 Laupacis A, Cote R, Sharma M, Blakely JA, Shuaib A, Hachinski V, Coutts SB, Sahlas DJ, Teal P, Yip 3145 S, Spence JD, Buck B, Verreault S, Casaubon LK, Penn A, Selchen D, Jin A, Howse D, Mehdiratta M, 3146 Boyle K, Aviv R, Kapral MK, Mamdani M, EMBRACE Investigators and Coordinators. Atrial fibrillation 3147 in patients with cryptogenic stroke. N Engl J Med 2014;370:2467-2477. 3148 129. Friberg L, Engdahl J, Frykman V, Svennberg E, Levin LA, Rosengvist M. Population 3149 screening of 75- and 76-year-old men and women for silent atrial fibrillation (STROKESTOP). 3150 Europace 2013:15:135-140. 3151 Davis RC, Hobbs FD, Kenkre JE, Roalfe AK, Iles R, Lip GY, Davies MK. Prevalence of atrial 130. 3152 fibrillation in the general population and in high-risk groups: the ECHOES study. Europace 3153 2012;14:1553-1559. 3154 Hobbs FD, Fitzmaurice DA, Mant J, Murray E, Jowett S, Bryan S, Raftery J, Davies M, Lip G. 131. 3155 A randomised controlled trial and cost-effectiveness study of systematic screening (targeted and total 3156 population screening) versus routine practice for the detection of atrial fibrillation in people aged 65 3157 and over. The SAFE study. Health Technol Assess 2005;9:iii-iv, ix-x, 1-74. 3158 132. Aronsson M, Svennberg E, Rosengvist M, Engdahl J, Al-Khalili F, Friberg L, Frykman-Kull V, 3159 Levin LA. Cost-effectiveness of mass screening for untreated atrial fibrillation using intermittent ECG 3160 recording. Europace 2015;17:1023-1029. Levin LA. Husberg M, Sobocinski PD, Kull VF, Friberg L, Rosenqvist M, Davidson T. A cost-3161 133. 3162 effectiveness analysis of screening for silent atrial fibrillation after ischaemic stroke. Europace 3163 2015;17:207-214. 3164 134. Lowres N, Neubeck L, Redfern J, Freedman SB. Screening to identify unknown atrial 3165 fibrillation. A systematic review. Thromb Haemost 2013;110:213-222. 3166 135. Engdahl J, Andersson L, Mirskaya M, Rosenqvist M. Stepwise screening of atrial fibrillation in 3167 a 75-year-old population: implications for stroke prevention. Circulation 2013;127:930-937. 3168 136. Kaleschke G, Hoffmann B, Drewitz I, Steinbeck G, Naebauer M, Goette A, Breithardt G, 3169 Kirchhof P. Prospective, multicentre validation of a simple, patient-operated electrocardiographic 3170 system for the detection of arrhythmias and electrocardiographic changes. Europace 2009;11:1362-3171 1368. 3172 137. Tieleman RG, Plantinga Y, Rinkes D, Bartels GL, Posma JL, Cator R, Hofman C, Houben RP. 3173 Validation and clinical use of a novel diagnostic device for screening of atrial fibrillation. Europace 3174 2014;**16**:1291-1295. 3175 Barrett PM, Komatireddy R, Haaser S, Topol S, Sheard J, Encinas J, Fought AJ, Topol EJ. 138. 3176 Comparison of 24-hour Holter monitoring with 14-day novel adhesive patch electrocardiographic 3177 monitoring. Am J Med 2014;**127**:95 e11-97. 3178 139. Lowres N, Neubeck L, Salkeld G, Krass I, McLachlan AJ, Redfern J, Bennett AA, Briffa T, 3179 Bauman A, Martinez C, Wallenhorst C, Lau JK, Brieger DB, Sy RW, Freedman SB. Feasibility and 3180 cost-effectiveness of stroke prevention through community screening for atrial fibrillation using iPhone 3181 ECG in pharmacies. The SEARCH-AF study. Thromb Haemost 2014;111:1167-1176. 3182 140. Quinn FR, Gladstone D. Screening for undiagnosed atrial fibrillation in the community. Curr 3183 Opin Cardiol 2014;29:28-35. 3184 141. Healey JS, Connolly SJ, Gold MR, Israel CW, Van Gelder IC, Capucci A, Lau CP, Fain E, 3185 Yang S, Bailleul C, Morillo CA, Carlson M, Themeles E, Kaufman ES, Hohnloser SH, ASSERT 3186 Investigators. Subclinical atrial fibrillation and the risk of stroke. N Engl J Med 2012;366:120-129. 3187 142. Hindricks G, Pokushalov E, Urban L, Taborsky M, Kuck KH, Lebedev D, Rieger G, 3188 Purerfellner H. Performance of a new leadless implantable cardiac monitor in detecting and 3189 quantifying atrial fibrillation - results of the XPECT trial. Circ Arrhythm Electrophysiol 2010;3:141-147. 3190 143. Brambatti M, Connolly SJ, Gold MR, Morillo CA, Capucci A, Muto C, Lau CP, Van Gelder IC, 3191 Hohnloser SH, Carlson M, Fain E, Nakamya J, Mairesse GH, Halytska M, Deng WQ, Israel CW, 3192 Healey JS, ASSERT Investigators. Temporal relationship between subclinical atrial fibrillation and 3193 embolic events. Circulation 2014;129:2094-2099. 3194 Boriani G, Glotzer TV, Santini M, West TM, De Melis M, Sepsi M, Gasparini M, Lewalter T, 144. 3195 Camm JA, Singer DE. Device-detected atrial fibrillation and risk for stroke: an analysis of >10,000

patients from the SOS AF project (Stroke prevention Strategies based on Atrial Fibrillation

information from implanted devices). *Eur Heart J* 2014;**35**:508-516.

3198 145. Santini M, Gasparini M, Landolina M, Lunati M, Proclemer A, Padeletti L, Catanzariti D, Molon

3199 G, Botto GL, La Rocca L, Grammatico A, Boriani G. Device-detected atrial tachyarrhythmias predict 3200 adverse outcome in real-world patients with implantable biventricular defibrillators. *J Am Coll Cardiol*

3201 2011;**57**:167-172.

146. Daoud EG, Glotzer TV, Wyse DG, Ezekowitz MD, Hilker C, Koehler J, Ziegler PD. Temporal
 relationship of atrial tachyarrhythmias, cerebrovascular events, and systemic emboli based on stored
 device data: a subgroup analysis of TRENDS. *Heart Rhythm* 2011;8:1416-1423.

3205 147. Glotzer TV, Daoud EG, Wyse DG, Singer DE, Ezekowitz MD, Hilker C, Miller C, Qi D, Ziegler 3206 PD. The relationship between daily atrial tachyarrhythmia burden from implantable device diagnostics 3207 and stroke risk: the TRENDS study. *Circ Arrhythm Electrophysiol* 2009;**2**:474-480.

3208 148. Lamas G. How much atrial fibrillation is too much atrial fibrillation? *N Engl J Med* 3209 2012;**366**:178-180.

3210 149. Kirchhof P, Lip GY, Van Gelder IC, Bax J, Hylek E, Kaab S, Schotten U, Wegscheider K,

3211 Boriani G, Brandes A, Ezekowitz M, Diener H, Haegeli L, Heidbuchel H, Lane D, Mont L, Willems S,

3212 Dorian P, Aunes-Jansson M, Blomstrom-Lundqvist C, Borentain M, Breitenstein S, Brueckmann M,

- 3213 Cater N, Clemens A, Dobrev D, Dubner S, Edvardsson NG, Friberg L, Goette A, Gulizia M, Hatala R,
- Horwood J, Szumowski L, Kappenberger L, Kautzner J, Leute A, Lobban T, Meyer R, Millerhagen J, Murgan J, M
- 3215 Morgan J, Muenzel F, Nabauer M, Baertels C, Oeff M, Paar D, Polifka J, Ravens U, Rosin L, Stegink 3216 W, Steinbeck G, Vardas P, Vincent A, Walter M, Breithardt G, Camm AJ. Comprehensive risk
- 3216 W, Steinbeck G, Vardas P, Vincent A, Walter M, Breithardt G, Camm AJ. Comprehensive risk 3217 reduction in patients with atrial fibrillation: emerging diagnostic and therapeutic options--a report from
- 3217 reduction in patients with athan infinitation, emerging diagnostic and therapeutic options--a report from 3218 the 3rd Atrial Fibrillation Competence NETwork/European Heart Rhythm Association consensus
- 3219 conference. Europace 2012;14:8-27.

3220 150. Kirchhof P, Lip GY, Van Gelder IC, Bax J, Hylek E, Kaab S, Schotten U, Wegscheider K, 3221 Boriani G, Ezekowitz M, Diopar H, Holdbuchel H, Lana D, Mant L, Williams S, Darian D, Vardas D,

Boriani G, Ezekowitz M, Diener H, Heidbuchel H, Lane D, Mont L, Willems S, Dorian P, Vardas P, Breithardt G, Camm AJ. Comprehensive risk reduction in patients with atrial fibrillation: Emerging diagnostic and therapeutic options. Executive summary of the report from the 3rd AFNET/EHRA consensus conference. *Thromb Haemost* 2011;**106**:1012-1019.

3225 151. Sposato LA, Cipriano LE, Saposnik G, Ruiz Vargas E, Riccio PM, Hachinski V. Diagnosis of 3226 atrial fibrillation after stroke and transient ischaemic attack: a systematic review and meta-analysis. 3227 *Lancet Neurol* 2015;**14**:377-387.

152. Thijs VN, Brachmann J, Morillo CA, Passman RS, Sanna T, Bernstein RA, Diener HC, Di Lazzaro V, Rymer MM, Hogge L, Rogers TB, Ziegler PD, Assar MD. Predictors for atrial fibrillation detection after cryptogenic stroke: Results from CRYSTAL AF. *Neurology* 2016;**86**:261-269.

3231 153. Adams HP, Jr., Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, Marsh EE, 3rd.
3232 Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial.
3233 TOAST. Trial of Org 10172 in Acute Stroke Treatment. *Stroke* 1993;**24**:35-41.

3234 154. Hart RG, Diener HC, Coutts SB, Easton JD, Granger CB, O'Donnell MJ, Sacco RL, Connolly
3235 SJ, Cryptogenic Stroke/ESUS International Working Group. Embolic strokes of undetermined source:
3236 the case for a new clinical construct. *Lancet Neurol* 2014;13:429-438.

3237 155. Mant J, Fitzmaurice DA, Hobbs FD, Jowett S, Murray ET, Holder R, Davies M, Lip GY.

Accuracy of diagnosing atrial fibrillation on electrocardiogram by primary care practitioners and interpretative diagnostic software: analysis of data from screening for atrial fibrillation in the elderly

3240 (SAFE) trial. *BMJ* 2007;**335**:380.

3241 156. Israel CW, Gronefeld G, Ehrlich JR, Li YG, Hohnloser SH. Long-term risk of recurrent atrial

fibrillation as documented by an implantable monitoring device: implications for optimal patient care. *J Am Coll Cardiol* 2004;**43**:47-52.

3244 157. Svennberg E, Engdahl J, Al-Khalili F, Friberg L, Frykman V, Rosenqvist M. Mass Screening

3245 for Untreated Atrial Fibrillation: The STROKESTOP Study. Circulation 2015;131:2176-2184.

3246 158. Bun SS, Latcu DG, Marchlinski F, Saoudi N. Atrial flutter: more than just one of a kind. *Eur* 3247 *Heart J* 2015;**36**:2356-2363.

3248 159. Granada J, Uribe W, Chyou PH, Maassen K, Vierkant R, Smith PN, Hayes J, Eaker E,

Vidaillet H. Incidence and predictors of atrial flutter in the general population. *J Am Coll Cardiol* 2000;**36**:2242-2246.

3251 160. Halligan SC, Gersh BJ, Brown RD, Jr., Rosales AG, Munger TM, Shen WK, Hammill SC,

3252 Friedman PA. The natural history of lone atrial flutter. Ann Intern Med 2004;140:265-268.

- 3253 161. Jahangir A, Lee V, Friedman PA, Trusty JM, Hodge DO, Kopecky SL, Packer DL, Hammill
- SC, Shen WK, Gersh BJ. Long-term progression and outcomes with aging in patients with lone atrial fibrillation: a 30-year follow-up study. *Circulation* 2007;**115**:3050-3056.

3256 162. Gillis AM, Rose MS. Temporal patterns of paroxysmal atrial fibrillation following DDDR 3257 pacemaker implantation. Am J Cardiol 2000;85:1445-1450. 3258 163. Charitos EI, Purerfellner H, Glotzer TV, Ziegler PD. Clinical classifications of atrial fibrillation 3259 poorly reflect its temporal persistence: insights from 1,195 patients continuously monitored with 3260 implantable devices. J Am Coll Cardiol 2014;63:2840-2848. 164. 3261 Banerjee A, Taillandier S, Olesen JB, Lane DA, Lallemand B, Lip GY, Fauchier L. Pattern of 3262 atrial fibrillation and risk of outcomes: the Loire Valley Atrial Fibrillation Project. Int J Cardiol 3263 2013;167:2682-2687. 3264 Lee G, Sanders P, Kalman JM. Catheter ablation of atrial arrhythmias: state of the art. Lancet 165. 3265 2012;380:1509-1519. 3266 Wyse DG, Van Gelder IC, Ellinor PT, Go AS, Kalman JM, Narayan SM, Nattel S, Schotten U, 166. 3267 Rienstra M. Lone atrial fibrillation: does it exist? J Am Coll Cardiol 2014;63:1715-1723. 3268 167. Andrade J, Khairy P, Dobrev D, Nattel S. The clinical profile and pathophysiology of atrial 3269 fibrillation: relationships among clinical features, epidemiology, and mechanisms. Circ Res 3270 2014:114:1453-1468. 3271 168. Chao TF, Suenari K, Chang SL, Lin YJ, Lo LW, Hu YF, Tuan TC, Tai CT, Tsao HM, Li CH, 3272 Ueng KC, Wu TJ, Chen SA. Atrial substrate properties and outcome of catheter ablation in patients 3273 with paroxysmal atrial fibrillation associated with diabetes mellitus or impaired fasting glucose. Am J 3274 Cardiol 2010;106:1615-1620. 3275 Albertsen IE, Rasmussen LH, Lane DA, Overvad TF, Skjoth F, Overvad K, Lip GY, Larsen 169. 3276 TB. The impact of smoking on thromboembolism and mortality in patients with incident atrial 3277 fibrillation: insights from the Danish Diet, Cancer, and Health study. Chest 2014;145:559-566. 3278 170. Overvad TF, Rasmussen LH, Skjoth F, Overvad K, Albertsen IE, Lane DA, Lip GY, Larsen 3279 TB. Alcohol intake and prognosis of atrial fibrillation. *Heart* 2013;99:1093-1099. Daccarett M, Badger TJ, Akoum N, Burgon NS, Mahnkopf C, Vergara G, Kholmovski E, 3280 171. 3281 McGann CJ, Parker D, Brachmann J, Macleod RS, Marrouche NF. Association of left atrial fibrosis 3282 detected by delayed-enhancement magnetic resonance imaging and the risk of stroke in patients with 3283 atrial fibrillation. J Am Coll Cardiol 2011;57:831-838. 3284 172. Neilan TG, Shah RV, Abbasi SA, Farhad H, Groarke JD, Dodson JA, Coelho-Filho O, 3285 McMullan CJ, Heydari B, Michaud GF, John RM, van der Geest R, Steigner ML, Blankstein R, 3286 Jerosch-Herold M, Kwong RY. The incidence, pattern, and prognostic value of left ventricular 3287 myocardial scar by late gadolinium enhancement in patients with atrial fibrillation. J Am Coll Cardiol 3288 2013;62:2205-2214. 3289 173. Marrouche NF, Wilber D, Hindricks G, Jais P, Akoum N, Marchlinski F, Kholmovski E, Burgon 3290 N. Hu N. Mont L. Deneke T. Duvtschaever M. Neumann T. Mansour M. Mahnkopf C. Herweg B. 3291 Daoud E, Wissner E, Bansmann P, Brachmann J. Association of atrial tissue fibrosis identified by 3292 delayed enhancement MRI and atrial fibrillation catheter ablation: the DECAAF study. JAMA 3293 2014;311:498-506. 3294 174. Bonizzi P, Zeemering S, Karel JM, Di Marco LY, Uldry L, Van Zaen J, Vesin JM, Schotten U. 3295 Systematic comparison of non-invasive measures for the assessment of atrial fibrillation complexity: a 3296 step forward towards standardization of atrial fibrillation electrogram analysis. Europace 2014. 3297 Kirchhof P, Breithardt G, Bax J, Benninger G, Blomstrom-Lundqvist C, Boriani G, Brandes A, 175. 3298 Brown H, Brueckmann M, Calkins H, Calvert M, Christoffels V, Crijns H, Dobrev D, Ellinor P, Fabritz 3299 L, Fetsch T, Freedman SB, Gerth A, Goette A, Guasch E, Hack G, Haegeli L, Hatem S, Haeusler KG, 3300 Heidbuchel H, Heinrich-Nols J, Hidden-Lucet F, Hindricks G, Juul-Moller S, Kaab S, Kappenberger L, 3301 Kespohl S, Kotecha D, Lane DA, Leute A, Lewalter T, Meyer R, Mont L, Munzel F, Nabauer M, 3302 Nielsen JC, Oeff M, Oldgren J, Oto A, Piccini JP, Pilmeyer A, Potpara T, Ravens U, Reinecke H, 3303 Rostock T, Rustige J, Savelieva I, Schnabel R, Schotten U, Schwichtenberg L, Sinner MF, Steinbeck 3304 G, Stoll M, Tavazzi L, Themistoclakis S, Tse HF, Van Gelder IC, Vardas PE, Varpula T, Vincent A, 3305 Werring D, Willems S, Ziegler A, Lip GY, Camm AJ. A roadmap to improve the quality of atrial 3306 fibrillation management: proceedings from the fifth Atrial Fibrillation Network/European Heart Rhythm 3307 Association consensus conference. Europace 2016;18:37-50. 3308 176. Fabritz L, Guasch E, Antoniades C, Bardinet I, Benninger G, Betts TR, Brand E, Breithardt G, 3309 Bucklar-Suchankova G, Camm AJ, Cartlidge D, Casadei B, Chua WW, Crijns HJ, Deeks J, Hatem S, 3310 Hidden-Lucet F, Kaab S, Maniadakis N, Martin S, Mont L, Reinecke H, Sinner MF, Schotten U, 3311 Southwood T, Stoll M, Vardas P, Wakili R, West A, Ziegler A, Kirchhof P. Expert consensus 3312 document: Defining the major health modifiers causing atrial fibrillation: a roadmap to underpin 3313 personalized prevention and treatment. Nat Rev Cardiol 2016;13:230-237.

3314 177. Dorian P, Jung W, Newman D, Paquette M, Wood K, Ayers GM, Camm J, Akhtar M, Luderitz 3315 B. The impairment of health-related quality of life in patients with intermittent atrial fibrillation: 3316 implications for the assessment of investigational therapy. J Am Coll Cardiol 2000;36:1303-1309. 3317 Sears SF, Serber ER, Alvarez LG, Schwartzman DS, Hovt RH, Ujhelvi MR. Understanding 178. 3318 atrial symptom reports: objective versus subjective predictors. Pacing Clin Electrophysiol 3319 2005;28:801-807. 3320 179. Peinado R, Arribas F, Ormaetxe JM, Badia X. Variation in quality of life with type of atrial 3321 fibrillation. Rev Esp Cardiol 2010;63:1402-1409. 3322 180. Steg PG, Alam S, Chiang CE, Gamra H, Goethals M, Inoue H, Krapf L, Lewalter T, Merioua I, 3323 Murin J, Naditch-Brule L, Ponikowski P, Rosenqvist M, Silva-Cardoso J, Zharinov O, Brette S, Neill 3324 JO, RealiseAF investigators. Symptoms, functional status and quality of life in patients with controlled 3325 and uncontrolled atrial fibrillation: data from the RealiseAF cross-sectional international registry. Heart 3326 2012;98:195-201. 3327 Gronefeld GC, Lilienthal J, Kuck KH, Hohnloser SH, Pharmacological Intervention in Atrial 181. 3328 Fibrillation (PIAF) Study investigators. Impact of rate versus rhythm control on guality of life in patients 3329 with persistent atrial fibrillation. Results from a prospective randomized study. Eur Heart J 3330 2003;24:1430-1436. 3331 182. Pepine CJ. Effects of pharmacologic therapy on health-related quality of life in elderly patients 3332 with atrial fibrillation: a systematic review of randomized and nonrandomized trials. Clin Med Insights 3333 Cardiol 2013;7:1-20. 3334 Hagens VE, Ranchor AV, Van Sonderen E, Bosker HA, Kamp O, Tijssen JG, Kingma JH, 183. 3335 Crijns HJ, Van Gelder IC, RACE Study Group. Effect of rate or rhythm control on quality of life in 3336 persistent atrial fibrillation. Results from the Rate Control Versus Electrical Cardioversion (RACE) 3337 Study. J Am Coll Cardiol 2004;43:241-247. 3338 184. Weerasooriya R, Davis M, Powell A, Szili-Torok T, Shah C, Whalley D, Kanagaratnam L, 3339 Heddle W, Leitch J, Perks A, Ferguson L, Bulsara M. The Australian intervention randomized control 3340 of rate in atrial fibrillation trial (AIRCRAFT). J Am Coll Cardiol 2003;41:1697-1702. 3341 185. Jones DG, Haldar SK, Hussain W, Sharma R, Francis DP, Rahman-Haley SL, McDonagh TA, 3342 Underwood SR, Markides V, Wong T. A randomized trial to assess catheter ablation versus rate 3343 control in the management of persistent atrial fibrillation in heart failure. J Am Coll Cardiol 3344 2013;61:1894-1903. 3345 186. Rienstra M, Lubitz SA, Mahida S, Magnani JW, Fontes JD, Sinner MF, Van Gelder IC, Ellinor 3346 PT, Benjamin EJ. Symptoms and functional status of patients with atrial fibrillation: state of the art and 3347 future research opportunities. Circulation 2012;125:2933-2943. 3348 Arribas F. Ormaetxe JM. Peinado R. Perulero N. Ramirez P. Badia X. Validation of the AF-187. 3349 QoL, a disease-specific quality of life questionnaire for patients with atrial fibrillation. Europace 3350 2010;12:364-370. 3351 Spertus J, Dorian P, Bubien R, Lewis S, Godejohn D, Reynolds MR, Lakkireddy DR, Wimmer 188. 3352 AP, Bhandari A, Burk C. Development and validation of the Atrial Fibrillation Effect on QualiTy-of-Life 3353 (AFEQT) Questionnaire in patients with atrial fibrillation. Circ Arrhythm Electrophysiol 2011;4:15-25. 3354 Dorian P, Burk C, Mullin CM, Bubien R, Godejohn D, Reynolds MR, Lakkireddy DR, Wimmer 189. 3355 AP, Bhandari A, Spertus J. Interpreting changes in quality of life in atrial fibrillation: How much change 3356 is meaningful? Am Heart J 2013;**166**:381-387.e388. 3357 190. Ware JE, Jr., Gandek B. Overview of the SF-36 Health Survey and the International Quality of 3358 Life Assessment (IQOLA) Project. J Clin Epidemiol 1998;51:903-912. 3359 191. Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, Bonsel G, Badia X. 3360 Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life 3361 Res 2011;20:1727-1736. 3362 192. Kirchhof P, Auricchio A, Bax J, Crijns H, Camm J, Diener HC, Goette A, Hindricks G, 3363 Hohnloser S, Kappenberger L, Kuck KH, Lip GY, Olsson B, Meinertz T, Priori S, Ravens U, Steinbeck 3364 G, Svernhage E, Tijssen J, Vincent A, Breithardt G. Outcome parameters for trials in atrial fibrillation: 3365 executive summary. Eur Heart J 2007;28:2803-2817. Dorian P, Cvitkovic SS, Kerr CR, Crystal E, Gillis AM, Guerra PG, Mitchell LB, Roy D, Skanes 3366 193. 3367 AC, Wyse DG. A novel, simple scale for assessing the symptom severity of atrial fibrillation at the 3368 bedside: the CCS-SAF scale. Can J Cardiol 2006;22:383-386. 3369 Kirchhof P, Ammentorp B, Darius H, De Caterina R, Le Heuzey JY, Schilling RJ, Schmitt J, 194. 3370 Zamorano JL. Management of atrial fibrillation in seven European countries after the publication of the 3371 2010 ESC Guidelines on atrial fibrillation: primary results of the PREvention oF thromboemolic events--European Registry in Atrial Fibrillation (PREFER in AF). Europace 2014;16:6-14. 3372

3373 195. Lip GY, Laroche C, Popescu MI, Rasmussen LH, Vitali-Serdoz L, Dan GA, Kalarus Z, Crijns 3374 HJ, Oliveira MM, Tavazzi L, Maggioni AP, Boriani G. Improved outcomes with European Society of 3375 Cardiology guideline-adherent antithrombotic treatment in high-risk patients with atrial fibrillation: a 3376 report from the EORP-AF General Pilot Registry. Europace 2015;17:1777-1786. 3377 Freeman JV, Simon DN, Go AS, Spertus J, Fonarow GC, Gersh BJ, Hylek EM, Kowey PR, 196. 3378 Mahaffey KW, Thomas LE, Chang P, Peterson ED, Piccini JP, Outcomes Registry for Better Informed 3379 Treatment of Atrial Fibrillation (ORBIT-AF) Investigators and Patients. Association Between Atrial 3380 Fibrillation Symptoms, Quality of Life, and Patient Outcomes: Results From the Outcomes Registry for 3381 Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). Circ Cardiovasc Qual Outcomes 3382 2015;8:393-402. 3383 Boriani G, Laroche C, Diemberger I, Fantecchi E, Popescu MI, Rasmussen LH, Sinagra G, 197. 3384 Petrescu L, Tavazzi L, Maggioni AP, Lip GY. Asymptomatic atrial fibrillation: clinical correlates, 3385 management, and outcomes in the EORP-AF Pilot General Registry. Am J Med 2015;128:509-518 3386 e502. 3387 198. Szymanski FM, Filipiak KJ, Karpinski G, Platek AE, Opolski G. Occurrence of poor sleep 3388 quality in atrial fibrillation patients according to the EHRA score. Acta Cardiol 2014;69:291-296. 3389 199. Wynn GJ, Todd DM, Webber M, Bonnett L, McShane J, Kirchhof P, Gupta D. The European 3390 Heart Rhythm Association symptom classification for atrial fibrillation: validation and improvement 3391 through a simple modification. *Europace* 2014;**16**:965-972. 3392 Meinertz T, Kirch W, Rosin L, Pittrow D, Willich SN, Kirchhof P, ATRIUM investigators. 200. 3393 Management of atrial fibrillation by primary care physicians in Germany: baseline results of the 3394 ATRIUM registry. Clin Res Cardiol 2011;100:897-905. 3395 201. Nabauer M, Gerth A, Limbourg T, Schneider S, Oeff M, Kirchhof P, Goette A, Lewalter T, 3396 Ravens U, Meinertz T, Breithardt G, Steinbeck G. The Registry of the German Competence NETwork on Atrial Fibrillation: Patient characteristics and initial management. Europace 2009;11:423-434. 3397 3398 202. von Eisenhart Rothe AF, Goette A, Kirchhof P, Breithardt G, Limbourg T, Calvert M, Baumert 3399 J, Ladwig KH. Depression in paroxysmal and persistent atrial fibrillation patients: a cross-sectional 3400 comparison of patients enroled in two large clinical trials. Europace 2014;16:812-819. 3401 Pathak RK, Middeldorp ME, Lau DH, Mehta AB, Mahajan R, Twomey D, Alasady M, Hanley 203. 3402 L, Antic NA, McEvoy RD, Kalman JM, Abhayaratna WP, Sanders P. Aggressive risk factor reduction 3403 study for atrial fibrillation and implications for the outcome of ablation: the ARREST-AF cohort study. J 3404 Am Coll Cardiol 2014;64:2222-2231. 3405 204. Abed HS, Wittert GA, Leong DP, Shirazi MG, Bahrami B, Middeldorp ME, Lorimer MF, Lau 3406 DH, Antic NA, Brooks AG, Abhayaratna WP, Kalman JM, Sanders P. Effect of weight reduction and 3407 cardiometabolic risk factor management on symptom burden and severity in patients with atrial 3408 fibrillation: a randomized clinical trial. JAMA 2013;310:2050-2060. 3409 205. Psaty BM, Manolio TA, Kuller LH, Kronmal RA, Cushman M, Fried LP, White R, Furberg CD, Rautaharju PM. Incidence of and risk factors for atrial fibrillation in older adults. Circulation 3410 3411 1997;96:2455-2461. 3412 Selmer C, Olesen JB, Hansen ML, Lindhardsen J, Olsen AM, Madsen JC, Faber J, Hansen 206. 3413 PR, Pedersen OD, Torp-Pedersen C, Gislason GH. The spectrum of thyroid disease and risk of new 3414 onset atrial fibrillation: a large population cohort study. *BMJ* 2012;**345**:e7895. 3415 207. Kim EJ, Lyass A, Wang N, Massaro JM, Fox CS, Benjamin EJ, Magnani JW. Relation of 3416 hypothyroidism and incident atrial fibrillation (from the Framingham Heart Study). Am Heart J 3417 2014;167:123-126. 3418 Vermond RA, Geelhoed B, Verweij N, Tieleman RG, Van der Harst P, Hillege HL, Van Gilst 208. 3419 WH, Van Gelder IC, Rienstra M. Incidence of atrial fibrillation and relationship with cardiovascular 3420 events, heart failure, and mortality: A community-based study from the netherlands. J Am Coll Cardiol 3421 2015;66:1000-1007. 3422 Buch P, Friberg J, Scharling H, Lange P, Prescott E. Reduced lung function and risk of atrial 209. 3423 fibrillation in the Copenhagen City Heart Study. Eur Respir J 2003;21:1012-1016. 3424 210. Gami AS, Hodge DO, Herges RM, Olson EJ, Nykodym J, Kara T, Somers VK. Obstructive 3425 sleep apnea, obesity, and the risk of incident atrial fibrillation. J Am Coll Cardiol 2007;49:565-571. 3426 Baber U, Howard VJ, Halperin JL, Soliman EZ, Zhang X, McClellan W, Warnock DG, Muntner 211 3427 P. Association of chronic kidney disease with atrial fibrillation among adults in the United States: 3428 REasons for Geographic and Racial Differences in Stroke (REGARDS) Study. Circ Arrhythm 3429 Electrophysiol 2011;4:26-32. 3430 212. Chamberlain AM, Agarwal SK, Folsom AR, Duval S, Soliman EZ, Ambrose M, Eberly LE, 3431 Alonso A. Smoking and incidence of atrial fibrillation: results from the Atherosclerosis Risk in 3432 Communities (ARIC) study. Heart Rhythm 2011;8:1160-1166.

3433 213. Larsson SC, Drca N, Wolk A. Alcohol consumption and risk of atrial fibrillation: a prospective 3434 study and dose-response meta-analysis. J Am Coll Cardiol 2014;64:281-289. 3435 214. Aizer A, Gaziano JM, Cook NR, Manson JE, Buring JE, Albert CM. Relation of vigorous 3436 exercise to risk of atrial fibrillation. Am J Cardiol 2009;103:1572-1577. 3437 Guha K, McDonagh T. Heart failure epidemiology: European perspective. Curr Cardiol Rev 215. 3438 2013;9:123-127. 3439 216. Braunschweig F, Cowie MR, Auricchio A. What are the costs of heart failure? Europace 3440 2011;**13 Suppl 2**:ii13-17. 3441 217. Wodchis WP, Bhatia RS, Leblanc K, Meshkat N, Morra D. A review of the cost of atrial 3442 fibrillation. Value Health 2012;15:240-248. 3443 218. Kotecha D, Piccini JP. Atrial fibrillation in heart failure: what should we do? Eur Heart J 3444 2015;36:3250-3257. 3445 219. Olsson LG, Swedberg K, Ducharme A, Granger CB, Michelson EL, McMurray JJ, Puu M, 3446 Yusuf S. Pfeffer MA. Atrial fibrillation and risk of clinical events in chronic heart failure with and without 3447 left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of 3448 Reduction in Mortality and morbidity (CHARM) program. J Am Coll Cardiol 2006;47:1997-2004. 3449 220. Kotecha D, Chudasama R, Lane DA, Kirchhof P, Lip GY. Atrial fibrillation and heart failure 3450 due to reduced versus preserved ejection fraction: A systematic review and meta-analysis of death 3451 and adverse outcomes. Int J Cardiol 2016;203:660-666. 3452 Mamas MA, Caldwell JC, Chacko S, Garratt CJ, Fath-Ordoubadi F, Neyses L. A meta-221. 3453 analysis of the prognostic significance of atrial fibrillation in chronic heart failure. Eur J Heart Fail 3454 2009;11:676-683. 3455 AUTHORS TO BE ADDED, The Task Force for the diagnosis and teatment of acute and 222. 3456 chronic heart failure of the European Society of Cardiology (ESC). 2016 ESC Guidelines for the 3457 diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2016. 3458 223. Lip GY, Heinzel FR, Gaita F, Juanatey JR, Le Heuzey JY, Potpara T, Svendsen JH, Vos MA, 3459 Anker SD, Coats AJ, Haverkamp W, Manolis AS, Chung MK, Sanders P, Pieske B, Gorenek B, Lane 3460 D, Boriani G, Linde C, Hindricks G, Tsutsui H, Homma S, Brownstein S, Nielsen JC, Lainscak M, 3461 Crespo-Leiro M, Piepoli M, Seferovic P, Savelieva I. European Heart Rhythm Association/Heart 3462 Failure Association joint consensus document on arrhythmias in heart failure, endorsed by the Heart 3463 Rhythm Society and the Asia Pacific Heart Rhythm Society. Europace 2016;18:12-36. 3464 224. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, 3465 Solomon SD, Swedberg K, Zile MR, PARADIGM-HF Investigators and Committees. Angiotensin-3466 neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014;371:993-1004. 3467 Ziff OJ, Lane DA, Samra M, Griffith M, Kirchhof P, Lip GY, Steeds RP, Townend J, Kotecha 225. 3468 D. Safety and efficacy of digoxin: systematic review and meta-analysis of observational and controlled 3469 trial data. BMJ 2015;351:h4451. 3470 Anselmino M, Matta M, D'Ascenzo F, Bunch TJ, Schilling RJ, Hunter RJ, Pappone C, 226. 3471 Neumann T, Noelker G, Fiala M, Bertaglia E, Frontera A, Duncan E, Nalliah C, Jais P, Weerasooriya 3472 R, Kalman JM, Gaita F. Catheter ablation of atrial fibrillation in patients with left ventricular systolic 3473 dysfunction: a systematic review and meta-analysis. Circ Arrhythm Electrophysiol 2014;7:1011-1018. 3474 Ganesan AN, Nandal S, Luker J, Pathak RK, Mahajan R, Twomey D, Lau DH, Sanders P. 227. 3475 Catheter ablation of atrial fibrillation in patients with concomitant left ventricular impairment: a 3476 systematic review of efficacy and effect on ejection fraction. Heart Lung Circ 2015;24:270-280. 3477 Khan MN, Jais P, Cummings J, Di Biase L, Sanders P, Martin DO, Kautzner J, Hao S, 228. 3478 Themistoclakis S, Fanelli R, Potenza D, Massaro R, Wazni O, Schweikert R, Saliba W, Wang P, Al-3479 Ahmad A, Beheiry S, Santarelli P, Starling RC, Dello Russo A, Pelargonio G, Brachmann J, Schibgilla 3480 V, Bonso A, Casella M, Raviele A, Haissaguerre M, Natale A, PABA-CHF Investigators. Pulmonary-3481 vein isolation for atrial fibrillation in patients with heart failure. N Engl J Med 2008;359:1778-1785. 3482 Gupta S, Figueredo VM. Tachycardia mediated cardiomyopathy: pathophysiology, 229. 3483 mechanisms, clinical features and management. Int J Cardiol 2014;172:40-46. 3484 Kusunose K, Yamada H, Nishio S, Tomita N, Niki T, Yamaguchi K, Koshiba K, Yagi S, 230. 3485 Taketani Y, Iwase T, Soeki T, Wakatsuki T, Akaike M, Sata M. Clinical utility of single-beat E/e' 3486 obtained by simultaneous recording of flow and tissue Doppler velocities in atrial fibrillation with 3487 preserved systolic function. JACC Cardiovasc Imaging 2009;2:1147-1156. 3488 231. Li C, Zhang J, Zhou C, Huang L, Tang H, Rao L. Will simultaneous measurement of E/e' 3489 index facilitate the non-invasive assessment of left ventricular filling pressure in patients with non-3490 valvular atrial fibrillation? Eur J Echocardiogr 2010;11:296-301.

3491 232. Senechal M, O'Connor K, Deblois J, Magne J, Dumesnil JG, Pibarot P, Bergeron S, Poirier P. 3492 A simple Doppler echocardiography method to evaluate pulmonary capillary wedge pressure in 3493 patients with atrial fibrillation. Echocardiography 2008;25:57-63. 3494 Sohn DW, Song JM, Zo JH, Chai IH, Kim HS, Chun HG, Kim HC. Mitral annulus velocity in 233. 3495 the evaluation of left ventricular diastolic function in atrial fibrillation. J Am Soc Echocardiogr 3496 1999;**12**:927-931. 3497 Wada Y, Murata K, Tanaka T, Nose Y, Kihara C, Uchida K, Okuda S, Susa T, Kishida Y, 234. 3498 Matsuzaki M. Simultaneous Doppler tracing of transmitral inflow and mitral annular velocity as an 3499 estimate of elevated left ventricular filling pressure in patients with atrial fibrillation. Circ J 3500 2012;76:675-681. 3501 235. Kelly JP, Mentz RJ, Mebazaa A, Voors AA, Butler J, Roessig L, Fiuzat M, Zannad F, Pitt B, 3502 O'Connor CM, Lam CS. Patient selection in heart failure with preserved ejection fraction clinical trials. 3503 J Am Coll Cardiol 2015;65:1668-1682. 3504 Schneider MP. Hua TA. Bohm M. Wachtell K. Kieldsen SE. Schmieder RE. Prevention of 236. 3505 atrial fibrillation by Renin-Angiotensin system inhibition a meta-analysis. J Am Coll Cardiol 3506 2010;55:2299-2307. 3507 237. Healey JS, Baranchuk A, Crystal E, Morillo CA, Garfinkle M, Yusuf S, Connolly SJ. 3508 Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor 3509 blockers: a meta-analysis. J Am Coll Cardiol 2005;45:1832-1839. 3510 238. Jibrini MB, Molnar J, Arora RR. Prevention of atrial fibrillation by way of abrogation of the 3511 renin-angiotensin system: a systematic review and meta-analysis. Am J Ther 2008;15:36-43. 3512 239. Ducharme A, Swedberg K, Pfeffer MA, Cohen-Solal A, Granger CB, Maggioni AP, Michelson 3513 EL, McMurray JJ, Olsson L, Rouleau JL, Young JB, Olofsson B, Puu M, Yusuf S, CHARM 3514 Investigators. Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by 3515 candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity 3516 (CHARM) program. Am Heart J 2006;152:86-92. 3517 240. GISSI-AF Investigators, Disertori M, Latini R, Barlera S, Franzosi MG, Staszewsky L, 3518 Maggioni AP, Lucci D, Di Pasquale G, Tognoni G. Valsartan for prevention of recurrent atrial 3519 fibrillation. N Engl J Med 2009;360:1606-1617. 3520 241. Goette A, Schon N, Kirchhof P, Breithardt G, Fetsch T, Hausler KG, Klein HU, Steinbeck G, 3521 Wegscheider K, Meinertz T. Angiotensin II-antagonist in paroxysmal atrial fibrillation (ANTIPAF) trial. 3522 Circ Arrhythm Electrophysiol 2012;5:43-51. 3523 242. Active I Investigators, Yusuf S, Healey JS, Pogue J, Chrolavicius S, Flather M, Hart RG, 3524 Hohnloser SH, Joyner CD, Pfeffer MA, Connolly SJ. Irbesartan in patients with atrial fibrillation. N 3525 Engl J Med 2011;364:928-938. 3526 Swedberg K, Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Shi H, Vincent J, Pitt B. 243. 3527 Eplerenone and atrial fibrillation in mild systolic heart failure: results from the EMPHASIS-HF 3528 (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure) study. J Am Coll 3529 Cardiol 2012;59:1598-1603. 3530 244. Goette A, Staack T, Rocken C, Arndt M, Geller JC, Huth C, Ansorge S, Klein HU, Lendeckel 3531 U. Increased expression of extracellular signal-regulated kinase and angiotensin-converting enzyme 3532 in human atria during atrial fibrillation. J Am Coll Cardiol 2000;35:1669-1677. 3533 245. Marott SC, Nielsen SF, Benn M, Nordestgaard BG. Antihypertensive treatment and risk of 3534 atrial fibrillation: a nationwide study. Eur Heart J 2014;35:1205-1214. 3535 Wachtell K, Lehto M, Gerdts E, Olsen MH, Hornestam B, Dahlof B, Ibsen H, Julius S, 246. 3536 Kjeldsen SE, Lindholm LH, Nieminen MS, Devereux RB. Angiotensin II receptor blockade reduces 3537 new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For 3538 End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol 2005;45:712-719. 3539 247. Manolis AJ, Rosei EA, Coca A, Cifkova R, Erdine SE, Kjeldsen S, Lip GY, Narkiewicz K, 3540 Parati G, Redon J, Schmieder R, Tsioufis C, Mancia G. Hypertension and atrial fibrillation: diagnostic 3541 approach, prevention and treatment. Position paper of the Working Group 'Hypertension Arrhythmias 3542 and Thrombosis' of the European Society of Hypertension. J Hypertens 2012;30:239-252. 3543 248. Madrid AH, Bueno MG, Rebollo JM, Marin I, Pena G, Bernal E, Rodriguez A, Cano L, Cano 3544 JM, Cabeza P, Moro C. Use of irbesartan to maintain sinus rhythm in patients with long-lasting 3545 persistent atrial fibrillation: a prospective and randomized study. *Circulation* 2002;**106**:331-336. Ueng K-C, Tsai T-P, Yu W-C, Tsai C-F, Lin M-C, Chan K-C, Chen C-Y, Wu D-J, Lin C-S, 3546 249. 3547 Chen S-A. Use of enalapril to facilitate sinus rhythm maintenance after external cardioversion of long-3548 standing persistent atrial fibrillation. Results of a prospective and controlled study. Eur Heart J 3549 2003;24:2090-2098.

3550 250. Anand K, Mooss AN, Hee TT, Mohiuddin SM. Meta-analysis: inhibition of renin-angiotensin 3551 system prevents new-onset atrial fibrillation. Am Heart J 2006;152:217-222. 3552 251. Tveit A, Seljeflot I, Grundvold I, Abdelnoor M, Smith P, Arnesen H. Effect of candesartan and 3553 various inflammatory markers on maintenance of sinus rhythm after electrical cardioversion for atrial fibrillation. Am J Cardiol 2007;99:1544-1548. 3554 Furberg CD, Psaty BM, Manolio TA, Gardin JM, Smith VE, Rautaharju PM. Prevalence of 3555 252. 3556 atrial fibrillation in elderly subjects (the Cardiovascular Health Study). Am J Cardiol 1994;74:236-241. Vahanian A, Alfieri O, Andreotti F, Antunes MJ, Baron-Esquivias G, Baumgartner H, Borger 3557 253. MA, Carrel TP, De Bonis M, Evangelista A, Falk V, lung B, Lancellotti P, Pierard L, Price S, Schafers 3558 3559 HJ, Schuler G, Stepinska J, Swedberg K, Takkenberg J, Von Oppell UO, Windecker S, Zamorano JL, 3560 Zembala M, Joint Task Force on the Management of Valvular Heart Disease of the European Society 3561 of Cardiology (ESC), European Association for Cardio-Thoracic Surgery (EACTS). Guidelines on the 3562 management of valvular heart disease (version 2012). Eur Heart J 2012;33:2451-2496. 3563 Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP, 3rd, Guyton RA, O'Gara PT, 254. 3564 Ruiz CE, Skubas NJ, Sorajja P, Sundt TM, 3rd, Thomas JD. 2014 AHA/ACC guideline for the 3565 management of patients with valvular heart disease: executive summary: a report of the American 3566 College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll 3567 Cardiol 2014;63:2438-2488. 3568 Nieuwlaat R, Capucci A, Camm AJ, Olsson SB, Andresen D, Davies DW, Cobbe S, Breithardt 255. 3569 G, Le Heuzey JY, Prins MH, Levy S, Crijns HJ. Atrial fibrillation management: a prospective survey in 3570 ESC member countries: the Euro Heart Survey on Atrial Fibrillation. Eur Heart J 2005;26:2422-2434. 3571 Moretti M, Fabris E, Morosin M, Merlo M, Barbati G, Pinamonti B, Gatti G, Pappalardo A, 256. 3572 Sinagra G. Prognostic significance of atrial fibrillation and severity of symptoms of heart failure in 3573 patients with low gradient aortic stenosis and preserved left ventricular ejection fraction. Am J Cardiol 3574 2014;114:1722-1728. 3575 257. Ngaage DL, Schaff HV, Mullany CJ, Barnes S, Dearani JA, Daly RC, Orszulak TA, Sundt TM, 3576 3rd. Influence of preoperative atrial fibrillation on late results of mitral repair: is concomitant ablation 3577 justified? Ann Thorac Surg 2007;84:434-442; discussion 442-433. 3578 258. Ngaage DL, Schaff HV, Barnes SA, Sundt TM, 3rd, Mullany CJ, Dearani JA, Daly RC, 3579 Orszulak TA. Prognostic implications of preoperative atrial fibrillation in patients undergoing aortic 3580 valve replacement: is there an argument for concomitant arrhythmia surgery? Ann Thorac Surg 3581 2006;82:1392-1399. 3582 259. Eguchi K, Ohtaki E, Matsumura T, Tanaka K, Tohbaru T, Iguchi N, Misu K, Asano R, 3583 Nagayama M, Sumiyoshi T, Kasegawa H, Hosoda S. Pre-operative atrial fibrillation as the key 3584 determinant of outcome of mitral valve repair for degenerative mitral regurgitation. Eur Heart J 3585 2005;**26**:1866-1872. 3586 Lim E, Barlow CW, Hosseinpour AR, Wisbey C, Wilson K, Pidgeon W, Charman S, Barlow 260. JB, Wells FC. Influence of atrial fibrillation on outcome following mitral valve repair. Circulation 3587 3588 2001;104:159-63. 3589 261. Maan A, Heist EK, Passeri J, Inglessis I, Baker J, Ptaszek L, Vlahakes G, Ruskin JN, 3590 Palacios I, Sundt T, Mansour M. Impact of atrial fibrillation on outcomes in patients who underwent 3591 transcatheter aortic valve replacement. Am J Cardiol 2015;115:220-226. 3592 262. Barbash IM, Minha S, Ben-Dor I, Dvir D, Torguson R, Aly M, Bond E, Satler LF, Pichard AD, 3593 Waksman R. Predictors and clinical implications of atrial fibrillation in patients with severe aortic 3594 stenosis undergoing transcatheter aortic valve implantation. Catheter Cardiovasc Interv 2015;85:468-3595 477. 3596 263. Halperin JL, Hart RG. Atrial fibrillation and stroke: new ideas, persisting dilemmas. Stroke 3597 1988;**19**:937-941. 3598 264. Messika-Zeitoun D, Bellamy M, Avierinos JF, Breen J, Eusemann C, Rossi A, Behrenbeck T, 3599 Scott C, Tajik JA, Enriquez-Sarano M. Left atrial remodelling in mitral regurgitation--methodologic 3600 approach, physiological determinants, and outcome implications: a prospective quantitative Doppler-3601 echocardiographic and electron beam-computed tomographic study. Eur Heart J 2007;28:1773-1781. 3602 265. Calvo N, Bisbal F, Guiu E, Ramos P, Nadal M, Tolosana JM, Arbelo E, Berruezo A, Sitges M, 3603 Brugada J, Mont L. Impact of atrial fibrillation-induced tachycardiomyopathy in patients undergoing 3604 pulmonary vein isolation. Int J Cardiol 2013;168:4093-4097. 3605 Edner M, Caidahl K, Bergfeldt L, Darpo B, Edvardsson N, Rosengvist M. Prospective study of 266. 3606 left ventricular function after radiofrequency ablation of atrioventricular junction in patients with atrial

3607 fibrillation. Br Heart J 1995;**74**:261-267.

3608 267. Gertz ZM, Raina A, Saghy L, Zado ES, Callans DJ, Marchlinski FE, Keane MG, Silvestry FE. 3609 Evidence of atrial functional mitral regurgitation due to atrial fibrillation: reversal with arrhythmia 3610 control. J Am Coll Cardiol 2011;58:1474-1481. 3611 Kihara T, Gillinov AM, Takasaki K, Fukuda S, Song JM, Shiota M, Shiota T. Mitral 268. regurgitation associated with mitral annular dilation in patients with lone atrial fibrillation: an 3612 3613 echocardiographic study. *Echocardiography* 2009;26:885-889. 3614 Zhou X, Otsuji Y, Yoshifuku S, Yuasa T, Zhang H, Takasaki K, Matsukida K, Kisanuki A, 269. 3615 Minagoe S, Tei C. Impact of atrial fibrillation on tricuspid and mitral annular dilatation and valvular 3616 regurgitation. Circ J 2002;66:913-916. Ring L, Dutka DP, Wells FC, Fynn SP, Shapiro LM, Rana BS. Mechanisms of atrial mitral 3617 270. 3618 regurgitation: insights using 3D transoesophageal echo. Eur Heart J Cardiovasc Imaging 3619 2014;**15**:500-508. 3620 271. Vahanian A, Alfieri O, Andreotti F, Antunes MJ, Baron-Esquivias G, Baumgartner H, Borger 3621 MA, Carrel TP, De Bonis M, Evangelista A, Falk V, Lung B, Lancellotti P, Pierard L, Price S, Schafers 3622 HJ, Schuler G, Stepinska J, Swedberg K, Takkenberg J, Von Oppell UO, Windecker S, Zamorano JL, 3623 Zembala M, ESC Committee for Practice Guidelines (CPG), Joint Task Force on the Management of 3624 Valvular Heart Disease of the European Society of Cardiology (ESC), European Association for 3625 Cardio-Thoracic Surgery (EACTS). Guidelines on the management of valvular heart disease (version 3626 2012): the Joint Task Force on the Management of Valvular Heart Disease of the European Society of 3627 Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur J 3628 Cardiothorac Surg 2012;42:S1-44. 3629 Molteni M, Polo Friz H, Primitz L, Marano G, Boracchi P, Cimminiello C. The definition of 272. 3630 valvular and non-valvular atrial fibrillation: results of a physicians' survey. Europace 2014;16:1720-3631 1725. 3632 273. Blackshear JL, Odell JA. Appendage obliteration to reduce stroke in cardiac surgical patients 3633 with atrial fibrillation. Ann Thorac Surg 1996;61:755-759. 3634 274. Szekely P. Systemic Embolism and Anticoagulant Prophylaxis in Rheumatic Heart Disease. 3635 Br Med J 1964;1:1209-1212. 3636 275. De Caterina R, Camm AJ. What is 'valvular' atrial fibrillation? A reappraisal. Eur Heart J 3637 2014;35:3328-3335. 3638 276. Goldstone AB, Patrick WL, Cohen JE, Aribeana CN, Popat R, Woo YJ. Early surgical 3639 intervention or watchful waiting for the management of asymptomatic mitral regurgitation: a 3640 systematic review and meta-analysis. Ann Cardiothorac Surg 2015;4:220-229. 3641 277. Schoen T, Pradhan AD, Albert CM, Conen D. Type 2 diabetes mellitus and risk of incident 3642 atrial fibrillation in women. J Am Coll Cardiol 2012;60:1421-1428. 3643 Du X, Ninomiya T, de Galan B, Abadir E, Chalmers J, Pillai A, Woodward M, Cooper M, 278. 3644 Harrap S, Hamet P, Poulter N, Lip GY, Patel A. Risks of cardiovascular events and effects of routine 3645 blood pressure lowering among patients with type 2 diabetes and atrial fibrillation: results of the 3646 ADVANCE study. Eur Heart J 2009;30:1128-1135. 3647 Rizzo MR, Sasso FC, Marfella R, Siniscalchi M, Paolisso P, Carbonara O, Capoluongo MC, 279. 3648 Lascar N, Pace C, Sardu C, Passavanti B, Barbieri M, Mauro C, Paolisso G. Autonomic dysfunction is 3649 associated with brief episodes of atrial fibrillation in type 2 diabetes. J Diabetes Complications 3650 2015;**29**:88-92. 3651 280. Olson TM, Terzic A. Human K(ATP) channelopathies: diseases of metabolic homeostasis. 3652 Pflugers Arch 2010;460:295-306. 3653 281. Chung MK, Martin DO, Sprecher D, Wazni O, Kanderian A, Carnes CA, Bauer JA, Tchou PJ, 3654 Niebauer MJ, Natale A, Van Wagoner DR. C-reactive protein elevation in patients with atrial 3655 arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation. Circulation 3656 2001;104:2886-2891. 3657 282. Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory disease. Nat Rev Immunol 3658 2011;11:98-107. 3659 Ziolo MT, Mohler PJ. Defining the role of oxidative stress in atrial fibrillation and diabetes. J 283. 3660 Cardiovasc Electrophysiol 2015;26:223-225. 3661 284. Fatemi O, Yuriditsky E, Tsioufis C, Tsachris D, Morgan T, Basile J, Bigger T, Cushman W, 3662 Goff D, Soliman EZ, Thomas A, Papademetriou V. Impact of intensive glycemic control on the 3663 incidence of atrial fibrillation and associated cardiovascular outcomes in patients with type 2 diabetes 3664 mellitus (from the Action to Control Cardiovascular Risk in Diabetes Study). Am J Cardiol

3665 2014;**114**:1217-1222.

3666 285. Overvad TF, Skjoth F, Lip GY, Lane DA, Albertsen IE, Rasmussen LH, Larsen TB. Duration 3667 of Diabetes Mellitus and Risk of Thromboembolism and Bleeding in Atrial Fibrillation: Nationwide 3668 Cohort Study. Stroke 2015;46:2168-2174. 3669 Chang S-H, Wu L-S, Chiou M-J, Liu J-R, Yu K-H, Kuo C-F, Wen M-S, Chen W-J, Yeh Y-H, 286. 3670 See L-C. Association of metformin with lower atrial fibrillation risk among patients with type 2 diabetes 3671 mellitus: a population-based dynamic cohort and in vitro studies. Cardiovasc Diabetol 2014;13:123. 3672 Lip GY, Clementy N, Pierre B, Boyer M, Fauchier L. The impact of associated diabetic 287. 3673 retinopathy on stroke and severe bleeding risk in diabetic patients with atrial fibrillation: the Loire 3674 valley atrial fibrillation project. Chest 2015;147:1103-1110. 3675 288. Huxley RR, Misialek JR, Agarwal SK, Loehr LR, Soliman EZ, Chen LY, Alonso A. Physical 3676 activity, obesity, weight change, and risk of atrial fibrillation: the Atherosclerosis Risk in Communities 3677 study. Circ Arrhythm Electrophysiol 2014;7:620-625. 3678 289. Murphy NF, MacIntyre K, Stewart S, Hart CL, Hole D, McMurray JJ. Long-term cardiovascular 3679 consequences of obesity: 20-year follow-up of more than 15 000 middle-aged men and women (the 3680 Renfrew-Paisley study). Eur Heart J 2006;27:96-106. 3681 290. Wanahita N, Messerli FH, Bangalore S, Gami AS, Somers VK, Steinberg JS. Atrial fibrillation 3682 and obesity--results of a meta-analysis. Am Heart J 2008;155:310-315. 3683 291. Wang TJ, Parise H, Levy D, D'Agostino RB, Sr., Wolf PA, Vasan RS, Benjamin EJ. Obesity 3684 and the risk of new-onset atrial fibrillation. JAMA 2004;292:2471-2477. 3685 Overvad TF, Rasmussen LH, Skjoth F, Overvad K, Lip GY, Larsen TB. Body mass index and 292. 3686 adverse events in patients with incident atrial fibrillation. Am J Med 2013;126:640.e649-617. 3687 Karason K, Molgaard H, Wikstrand J, Sjostrom L. Heart rate variability in obesity and the 293. 3688 effect of weight loss. Am J Cardiol 1999;83:1242-1247. 3689 294. Russo C, Jin Z, Homma S, Rundek T, Elkind MS, Sacco RL, Di Tullio MR. Effect of obesity 3690 and overweight on left ventricular diastolic function: a community-based study in an elderly cohort. J 3691 Am Coll Cardiol 2011;57:1368-1374. 3692 295. Visser M, Bouter LM, McQuillan GM, Wener MH, Harris TB. Elevated C-reactive protein levels 3693 in overweight and obese adults. Jama 1999;282:2131-2135. 3694 296. Pathak RK, Middeldorp ME, Meredith M, Mehta AB, Mahajan R, Wong CX, Twomey D, Elliott 3695 AD, Kalman JM, Abhayaratna WP, Lau DH, Sanders P. Long-Term Effect of Goal-Directed Weight 3696 Management in an Atrial Fibrillation Cohort: A Long-Term Follow-Up Study (LEGACY). J Am Coll 3697 Cardiol 2015;65:2159-2169. 3698 297. Pathak RK, Elliott A, Middeldorp ME, Meredith M, Mehta AB, Mahajan R, Hendriks JM, 3699 Twomey D, Kalman JM, Abhayaratna WP, Lau DH, Sanders P. Impact of CARDIOrespiratory FITness 3700 on Arrhythmia Recurrence in Obese Individuals With Atrial Fibrillation: The CARDIO-FIT Study. J Am 3701 Coll Cardiol 2015:66:985-996. 3702 298. Cha YM, Friedman PA, Asirvatham SJ, Shen WK, Munger TM, Rea RF, Brady PA, Jahangir 3703 A, Monahan KH, Hodge DO, Meverden RA, Gersh BJ, Hammill SC, Packer DL. Catheter ablation for 3704 atrial fibrillation in patients with obesity. Circulation 2008;117:2583-2590. 3705 Jongnarangsin K, Chugh A, Good E, Mukerji S, Dey S, Crawford T, Sarrazin JF, Kuhne M, 299. 3706 Chalfoun N, Wells D, Boonyapisit W, Pelosi F, Jr., Bogun F, Morady F, Oral H. Body mass index, 3707 obstructive sleep apnea, and outcomes of catheter ablation of atrial fibrillation. J Cardiovasc 3708 Electrophysiol 2008;19:668-672. 3709 300. Guijian L, Jinchuan Y, Rongzeng D, Jun Q, Jun W, Wenging Z. Impact of body mass index on 3710 atrial fibrillation recurrence: a meta-analysis of observational studies. Pacing Clin Electrophysiol 3711 2013;36:748-756. 3712 301. Zhuang J, Lu Y, Tang K, Peng W, Xu Y. Influence of body mass index on recurrence and 3713 quality of life in atrial fibrillation patients after catheter ablation: a meta-analysis and systematic 3714 review. Clin Cardiol 2013;36:269-275. 3715 Ector J, Dragusin O, Adriaenssens B, Huybrechts W, Willems R, Ector H, Heidbuchel H. 302. 3716 Obesity is a major determinant of radiation dose in patients undergoing pulmonary vein isolation for 3717 atrial fibrillation. J Am Coll Cardiol 2007;50:234-242. 3718 303. Shoemaker MB, Muhammad R, Farrell M, Parvez B, White BW, Streur M, Stubblefield T, 3719 Rytlewski J, Parvathaneni S, Nagarakanti R, Roden DM, Saavedra P, Ellis C, Whalen SP, Darbar D. 3720 Relation of morbid obesity and female gender to risk of procedural complications in patients 3721 undergoing atrial fibrillation ablation. Am J Cardiol 2013;111:368-373. 3722 304. Vizzardi E, Sciatti E, Bonadei I, D'Aloia A, Curnis A, Metra M. Obstructive sleep apnoea-3723 hypopnoea and arrhythmias: new updates. J Cardiovasc Med (Hagerstown) 2014. 3724 Digby GC, Baranchuk A. Sleep apnea and atrial fibrillation; 2012 update. Curr Cardiol Rev 305. 3725 2012;8:265-272.

3726 306. Lin YK, Lai MS, Chen YC, Cheng CC, Huang JH, Chen SA, Chen YJ, Lin CI. Hypoxia and 3727 reoxygenation modulate the arrhythmogenic activity of the pulmonary vein and atrium. Clin Sci (Lond) 3728 2012;122:121-132. 3729 Linz D. Atrial fibrillation in obstructive sleep apnea: atrial arrhythmogenic substrate of a 307. 3730 different sort. Am J Cardiol 2012;110:1071. 3731 308. Patel D, Mohanty P, Di Biase L, Shaheen M, Lewis WR, Quan K, Cummings JE, Wang P, Al-3732 Ahmad A, Venkatraman P, Nashawati E, Lakkireddy D, Schweikert R, Horton R, Sanchez J, 3733 Gallinghouse J, Hao S, Beheiry S, Cardinal DS, Zagrodzky J, Canby R, Bailey S, Burkhardt JD, 3734 Natale A. Safety and efficacy of pulmonary vein antral isolation in patients with obstructive sleep 3735 apnea: the impact of continuous positive airway pressure. Circ Arrhythm Electrophysiol 2010;3:445-3736 451. 3737 Fein AS, Shvilkin A, Shah D, Haffajee CI, Das S, Kumar K, Kramer DB, Zimetbaum PJ, 309. 3738 Buxton AE, Josephson ME, Anter E. Treatment of obstructive sleep apnea reduces the risk of atrial 3739 fibrillation recurrence after catheter ablation. J Am Coll Cardiol 2013;62:300-305. 3740 Naruse Y, Tada H, Satoh M, Yanagihara M, Tsuneoka H, Hirata Y, Ito Y, Kuroki K, Machino 310. 3741 T, Yamasaki H, Igarashi M, Sekiguchi Y, Sato A, Aonuma K. Concomitant obstructive sleep apnea 3742 increases the recurrence of atrial fibrillation following radiofrequency catheter ablation of atrial 3743 fibrillation: clinical impact of continuous positive airway pressure therapy. Heart Rhythm 2013;10:331-3744 337. 3745 Neilan TG, Farhad H, Dodson JA, Shah RV, Abbasi SA, Bakker JP, Michaud GF, van der 311. 3746 Geest R, Blankstein R, Steigner M, John RM, Jerosch-Herold M, Malhotra A, Kwong RY. Effect of 3747 sleep apnea and continuous positive airway pressure on cardiac structure and recurrence of atrial 3748 fibrillation. J Am Heart Assoc 2013;2:e000421. 3749 312. Li L, Wang ZW, Li J, Ge X, Guo LZ, Wang Y, Guo WH, Jiang CX, Ma CS. Efficacy of catheter 3750 ablation of atrial fibrillation in patients with obstructive sleep appoea with and without continuous 3751 positive airway pressure treatment: a meta-analysis of observational studies. Europace 3752 2014;16:1309-1314. 3753 313. Cowie MR, Woehrle H, Wegscheider K, Angermann C, d'Ortho MP, Erdmann E, Levy P, 3754 Simonds AK, Somers VK, Zannad F, Teschler H. Adaptive Servo-Ventilation for Central Sleep Apnea 3755 in Systolic Heart Failure. N Engl J Med 2015;373:1095-1105. 3756 314. Bitter T, Nolker G, Vogt J, Prinz C, Horstkotte D, Oldenburg O. Predictors of recurrence in 3757 patients undergoing cryoballoon ablation for treatment of atrial fibrillation: the independent role of 3758 sleep-disordered breathing. J Cardiovasc Electrophysiol 2012;23:18-25. 3759 315. Ng CY, Liu T, Shehata M, Stevens S, Chugh SS, Wang X. Meta-analysis of obstructive sleep 3760 apnea as predictor of atrial fibrillation recurrence after catheter ablation. Am J Cardiol 2011;108:47-3761 51. 3762 316. Hart RG, Eikelboom JW, Brimble KS, McMurtry MS, Ingram AJ. Stroke prevention in atrial 3763 fibrillation patients with chronic kidney disease. Can J Cardiol 2013;29:S71-78. 3764 Roldan V, Marin F, Fernandez H, Manzano-Fernandez S, Gallego P, Valdes M, Vicente V, Lip 317. 3765 GY. Renal impairment in a "real-life" cohort of anticoagulated patients with atrial fibrillation (implications for thromboembolism and bleeding). Am J Cardiol 2013;111:1159-1164. 3766 3767 Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, 318. 3768 Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, 3769 Joyner CD, Wallentin L, RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in 3770 patients with atrial fibrillation. N Engl J Med 2009;361:1139-1151. 3771 319. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, 3772 Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, 3773 Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, 3774 Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW, Zhu J, Wallentin L, 3775 ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. 3776 N Engl J Med 2011;365:981-992. 3777 Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, 320. 3778 Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KA, Califf RM, 3779 ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 3780 2011;365:883-891. 3781 Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, Waldo AL, 321. 3782 Ezekowitz MD, Weitz JI, Spinar J, Ruzyllo W, Ruda M, Koretsune Y, Betcher J, Shi M, Grip LT, Patel 3783 SP, Patel I, Hanyok JJ, Mercuri M, Antman EM, Investigators EA-T. Edoxaban versus warfarin in 3784 patients with atrial fibrillation. N Engl J Med 2013;369:2093-2104.

3785 322. Page K, Marwick TH, Lee R, Grenfell R, Abhayaratna WP, Aggarwal A, Briffa TG, Cameron J, 3786 Davidson PM, Driscoll A, Garton-Smith J, Gascard DJ, Hickey A, Korczyk D, Mitchell JA, Sanders R, 3787 Spicer D, Stewart S, Wade V. A systematic approach to chronic heart failure care: a consensus 3788 statement. Med J Aust 2014;201:146-150. 3789 Stock S, Pitcavage JM, Simic D, Altin S, Graf C, Feng W, Graf TR. Chronic care model 323. 3790 strategies in the United States and Germany deliver patient-centered, high-quality diabetes care. 3791 Health Aff (Millwood) 2014;33:1540-1548. 3792 324. Lundstrom H, Siersma V, Nielsen AB, Brodersen J, Reventlow S, Andersen PK, de Fine 3793 Olivarius N. The effectiveness of structured personal care of type 2 diabetes on recurrent outcomes: a 3794 19 year follow-up of the study Diabetes Care in General Practice (DCGP). Diabetologia 3795 2014;57:1119-1123. 3796 Berti D, Hendriks JM, Brandes A, Deaton C, Crijns HJ, Camm AJ, Hindricks G, Moons P, 325. 3797 Heidbuchel H. A proposal for interdisciplinary, nurse-coordinated atrial fibrillation expert programmes 3798 as a way to structure daily practice. Eur Heart J 2013;34:2725-2730. 3799 Wagner EH, Austin BT, Von Korff M. Organizing care for patients with chronic illness. Milbank 326. 3800 Q 1996;74:511-544. 3801 327. Nieuwlaat R, Olsson SB, Lip GY, Camm AJ, Breithardt G, Capucci A, Meeder JG, Prins MH, 3802 Levy S, Crijns HJ, Euro Heart Survey Investigators. Guideline-adherent antithrombotic treatment is 3803 associated with improved outcomes compared with undertreatment in high-risk patients with atrial 3804 fibrillation. The Euro Heart Survey on Atrial Fibrillation. Am Heart J 2007;153:1006-1012. 3805 Nuno R, Coleman K, Bengoa R, Sauto R. Integrated care for chronic conditions: the 328. 3806 contribution of the ICCC Framework. Health Policy 2012;105:55-64. 3807 329. Kirchhof P, Nabauer M, Gerth A, Limbourg T, Lewalter T, Goette A, Wegscheider K, Treszl A, 3808 Meinertz T, Oeff M, Ravens U, Breithardt G, Steinbeck G. Impact of the type of centre on 3809 management of AF patients: surprising evidence for differences in antithrombotic therapy decisions. 3810 Thromb Haemost 2011;105:1010-1023. 3811 330. Hendriks JM, de Wit R, Crijns HJ, Vrijhoef HJ, Prins MH, Pisters R, Pison LA, Blaauw Y, 3812 Tieleman RG. Nurse-led care vs. usual care for patients with atrial fibrillation: results of a randomized 3813 trial of integrated chronic care vs. routine clinical care in ambulatory patients with atrial fibrillation. Eur 3814 Heart J 2012;33:2692-2699. 3815 331. Hendriks J, Tomini F, van Asselt T, Crijns H, Vrijhoef H. Cost-effectiveness of a specialized 3816 atrial fibrillation clinic vs. usual care in patients with atrial fibrillation. Europace 2013;15:1128-1135. 3817 332. Stewart S, Ball J, Horowitz JD, Marwick TH, Mahadevan G, Wong C, Abhayaratna WP, Chan 3818 YK, Esterman A, Thompson DR, Scuffham PA, Carrington MJ. Standard versus atrial fibrillation-3819 specific management strategy (SAFETY) to reduce recurrent admission and prolong survival: 3820 pragmatic, multicentre, randomised controlled trial. Lancet 2015;385:775-784. 3821 333. Tran HN, Tafreshi J, Hernandez EA, Pai SM, Torres VI, Pai RG. A multidisciplinary atrial 3822 fibrillation clinic. Curr Cardiol Rev 2013;9:55-62. 3823 Conti A, Canuti E, Mariannini Y, Viviani G, Poggioni C, Boni V, Pini R, Vanni S, Padeletti L, 334. 3824 Gensini GF. Clinical management of atrial fibrillation: early interventions, observation, and structured 3825 follow-up reduce hospitalizations. Am J Emerg Med 2012;30:1962-1969. 3826 Carter L, Gardner M, Magee K, Fearon A, Morgulis I, Doucette S, Sapp JL, Gray C, 335. 3827 Abdelwahab A, Parkash R. An Integrated Management Approach to Atrial Fibrillation. J Am Heart 3828 Assoc 2016;5:e002950. 3829 Peterson ED, Ho PM, Barton M, Beam C, Burgess LH, Casey DE, Jr., Drozda JP, Jr., 336. 3830 Fonarow GC, Goff D, Jr., Grady KL, King DE, King ML, Masoudi FA, Nielsen DR, Stanko S. 3831 ACC/AHA/AACVPR/AAFP/ANA Concepts for Clinician-Patient Shared Accountability in Performance 3832 Measures: A Report of the American College of Cardiology/American Heart Association Task Force on Performance Measures. Circulation 2014. 3833 3834 Lane DA, Aguinaga L, Blomstrom-Lundqvist C, Boriani G, Dan GA, Hills MT, Hylek EM, 337. 3835 LaHaye SA, Lip GY, Lobban T, Mandrola J, McCabe PJ, Pedersen SS, Pisters R, Stewart S, Wood K, 3836 Potpara TS, Gorenek B, Conti JB, Keegan R, Power S, Hendriks J, Ritter P, Calkins H, Violi F, 3837 Hurwitz J. Cardiac tachyarrhythmias and patient values and preferences for their management: the 3838 European Heart Rhythm Association (EHRA) consensus document endorsed by the Heart Rhythm 3839 Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de 3840 Estimulacion Cardiaca y Electrofisiologia (SOLEACE). Europace 2015;17:1747-1769. 3841 338. Hendriks JM, de Wit R, Vrijhoef HJ, Tieleman RG, Crijns HJ. An integrated chronic care 3842 program for patients with atrial fibrillation: study protocol and methodology for an ongoing prospective

3843 randomised controlled trial. *Int J Nurs Stud* 2010;**47**:1310-1316.

3844 339. Donal E, Lip GY, Galderisi M, Goette A, Shah D, Marwan M, Lederlin M, Mondillo S. 3845 Edvardsen T, Sitges M, Grapsa J, Garbi M, Senior R, Gimelli A, Potpara TS, Van Gelder IC, Gorenek 3846 B, Mabo P, Lancellotti P, Kuck KH, Popescu BA, Hindricks G, Habib G, Cosyns B, Delgado V, 3847 Haugaa KH, Muraru D, Nieman K, Cohen A. EACVI/EHRA Expert Consensus Document on the role 3848 of multi-modality imaging for the evaluation of patients with atrial fibrillation. Eur Heart J Cardiovasc 3849 Imaging 2016;**17**:355-383. 3850 340. Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, Flachskampf FA, Foster 3851 E, Goldstein SA, Kuznetsova T, Lancellotti P, Muraru D, Picard MH, Rietzschel ER, Rudski L, 3852 Spencer KT, Tsang W, Voigt JU. Recommendations for cardiac chamber quantification by 3853 echocardiography in adults: an update from the american society of echocardiography and the 3854 European association of cardiovascular imaging. Eur Heart J Cardiovasc Imaging 2015;16:233-271. 3855 341. Filion KB, Agarwal SK, Ballantyne CM, Eberg M, Hoogeveen RC, Huxley RR, Loehr LR, 3856 Nambi V, Soliman EZ, Alonso A. High-sensitivity cardiac troponin T and the risk of incident atrial 3857 fibrillation: The Atherosclerosis Risk in Communities (ARIC) study. Am Heart J 2015;169:31-38 3858 Aviles RJ, Martin DO, Apperson-Hansen C, Houghtaling PL, Rautaharju P, Kronmal RA, 342. 3859 Tracy RP, Van Wagoner DR, Psaty BM, Lauer MS, Chung MK. Inflammation as a risk factor for atrial 3860 fibrillation. Circulation 2003;108:3006-3010. 3861 343. Patton KK, Ellinor PT, Heckbert SR, Christenson RH, DeFilippi C, Gottdiener JS, Kronmal 3862 RA. N-terminal pro-B-type natriuretic peptide is a major predictor of the development of atrial 3863 fibrillation: the Cardiovascular Health Study. Circulation 2009;120:1768-1774. 3864 344. Bartel T, Erbel R, Acute Trial Investigators. Transoesophageal echocardiography for 3865 immediate and safe cardioversion in patients with atrial fibrillation. Eur Heart J 2001;22:2041-2044. 3866 345. Mahnkopf C, Mitlacher M, Brachmann J. [Relevance of magnetic resonance imaging for 3867 catheter ablation of atrial fibrillation]. Herzschrittmacherther Elektrophysiol 2014;25:252-257. 3868 346. Haemers P, Claus P, Willems R. The use of cardiac magnetic resonance imaging in the 3869 diagnostic workup and treatment of atrial fibrillation. Cardiol Res Pract 2012;2012:658937. 3870 347. Ling LH, Kistler PM, Ellims AH, Iles LM, Lee G, Hughes GL, Kalman JM, Kaye DM, Taylor AJ. 3871 Diffuse ventricular fibrosis in atrial fibrillation: noninvasive evaluation and relationships with aging and 3872 systolic dysfunction. J Am Coll Cardiol 2012;60:2402-2408. 3873 348. Lewalter T, Ibrahim R, Albers B, Camm AJ. An update and current expert opinions on 3874 percutaneous left atrial appendage occlusion for stroke prevention in atrial fibrillation. Europace 3875 2013;15:652-656. 3876 349. Kirchhof P, Auricchio A, Bax J, Criins H, Camm J, Diener HC, Goette A, Hindricks G, 3877 Hohnloser S, Kappenberger L, Kuck KH, Lip GY, Olsson B, Meinertz T, Priori S, Ravens U, Steinbeck 3878 G, Svernhage E, Tijssen J, Vincent A, Breithardt G. Outcome parameters for trials in atrial fibrillation: 3879 executive summary: Recommendations from a consensus conference organized by the German Atrial 3880 Fibrillation Competence NETwork (AFNET) and the European Heart Rhythm Association (EHRA). Eur 3881 Heart J 2007;28:2803-2817. 3882 Alonso-Coello P, Montori VM, Sola I, Schunemann HJ, Devereaux P, Charles C, Roura M, 350. 3883 Diaz MG, Souto JC, Alonso R, Oliver S, Ruiz R, Coll-Vinent B, Diez AI, Gich I, Guyatt G. Values and 3884 preferences in oral anticoagulation in patients with atrial fibrillation, physicians' and patients' 3885 perspectives: protocol for a two-phase study. BMC Health Serv Res 2008;8:221. 3886 351. Lip GY, Al-Khatib SM, Cosio FG, Banerjee A, Savelieva I, Ruskin J, Blendea D, Nattel S, De 3887 Bono J, Conroy JM, Hess PL, Guasch E, Halperin JL, Kirchhof P, MD GC, Camm AJ. Contemporary 3888 management of atrial fibrillation: what can clinical registries tell us about stroke prevention and current 3889 therapeutic approaches? J Am Heart Assoc 2014;3. 3890 352. Gorst-Rasmussen A, Skjoth F, Larsen TB, Rasmussen LH, Lip GY, Lane DA. Dabigatran 3891 adherence in atrial fibrillation patients during the first year after diagnosis: a nationwide cohort study. J 3892 Thromb Haemost 2015;13:495-504. 3893 Hart RG, Pearce LA, Aguilar MI. Adjusted-dose warfarin versus aspirin for preventing stroke 353. 3894 in patients with atrial fibrillation. Ann Intern Med 2007;147:590-592. 3895 354. Connolly SJ, Eikelboom J, Joyner C, Diener HC, Hart R, Golitsyn S, Flaker G, Avezum A, 3896 Hohnloser SH, Diaz R, Talajic M, Zhu J, Pais P, Budaj A, Parkhomenko A, Jansky P, Commerford P, 3897 Tan RS, Sim KH, Lewis BS, Van Mieghem W, Lip GY, Kim JH, Lanas-Zanetti F, Gonzalez-Hermosillo 3898 A, Dans AL, Munawar M, O'Donnell M, Lawrence J, Lewis G, Afzal R, Yusuf S, AVERROES Steering 3899 Committee Investigators. Apixaban in patients with atrial fibrillation. N Engl J Med 2011;364:806-817. 3900 355. Frankel DS, Parker SE, Rosenfeld LE, Gorelick PB. HRS/NSA 2014 Survey of Atrial 3901 Fibrillation and Stroke: Gaps in Knowledge and Perspective, Opportunities for Improvement. Heart 3902 Rhythm 2015.

3903 356. Le Heuzey JY, Ammentorp B, Darius H, De Caterina R, Schilling RJ, Schmitt J, Zamorano JL, 3904 Kirchhof P. Differences among western European countries in anticoagulation management of atrial 3905 fibrillation. Data from the PREFER IN AF registry. Thromb Haemost 2014;111:833-841. 3906 O'Brien EC, Holmes DN, Ansell JE, Allen LA, Hylek E, Kowey PR, Gersh BJ, Fonarow GC, 357. 3907 Koller CR, Ezekowitz MD, Mahaffey KW, Chang P, Peterson ED, Piccini JP, Singer DE. Physician 3908 practices regarding contraindications to oral anticoagulation in atrial fibrillation: findings from the 3909 Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. Am Heart 3910 J 2014;**167**:601-609 e601. 3911 Fang MC, Go AS, Chang Y, Borowsky LH, Pomernacki NK, Udaltsova N, Singer DE. Warfarin 358. 3912 discontinuation after starting warfarin for atrial fibrillation. Circ Cardiovasc Qual Outcomes 3913 2010;**3**:624-631. 3914 Zalesak M, Siu K, Francis K, Yu C, Alvrtsyan H, Rao Y, Walker D, Sander S, Miyasato G, 359. 3915 Matchar D, Sanchez H. Higher persistence in newly diagnosed nonvalvular atrial fibrillation patients 3916 treated with dabigatran versus warfarin. Circ Cardiovasc Qual Outcomes 2013:6:567-574. 3917 Donze J, Clair C, Hug B, Rodondi N, Waeber G, Cornuz J, Aujesky D. Risk of falls and major 360. 3918 bleeds in patients on oral anticoagulation therapy. Am J Med 2012;125:773-778. 3919 361. Man-Son-Hing M, Nichol G, Lau A, Laupacis A. Choosing antithrombotic therapy for elderly 3920 patients with atrial fibrillation who are at risk for falls. Arch Intern Med 1999;159:677-685. 3921 362. Mant J, Hobbs FD, Fletcher K, Roalfe A, Fitzmaurice D, Lip GY, Murray E, BAFTA 3922 investigators, Midland Research Practices Network (MidReC). Warfarin versus aspirin for stroke 3923 prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation 3924 Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet 2007;370:493-503. 3925 Diener HC, Eikelboom J, Connolly SJ, Joyner CD, Hart RG, Lip GY, O'Donnell M, Hohnloser 363. 3926 SH, Hankey GJ, Shestakovska O, Yusuf S, AVERROES Steering Committee and Investigators. 3927 Apixaban versus aspirin in patients with atrial fibrillation and previous stroke or transient ischaemic 3928 attack: a predefined subgroup analysis from AVERROES, a randomised trial. Lancet Neurol 3929 2012;11:225-231. 3930 364. The SPAF III Writing Committee for the Stroke Prevention in Atrial Fibrillation Investigators. 3931 Patients with nonvalvular atrial fibrillation at low risk of stroke during treatment with aspirin: Stroke 3932 Prevention in Atrial Fibrillation III Study. JAMA 1998;279:1273-1277. 3933 365. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of 3934 clinical classification schemes for predicting stroke: results from the National Registry of Atrial 3935 Fibrillation. JAMA 2001;285:2864-2870. 3936 366. van Walraven C, Hart RG, Wells GA, Petersen P, Koudstaal PJ, Gullov AL, Hellemons BS, 3937 Koefed BG. Laupacis A. A clinical prediction rule to identify patients with atrial fibrillation and a low 3938 risk for stroke while taking aspirin. Arch Intern Med 2003;163:936-943. 3939 367. Wang TJ, Massaro JM, Levy D, Vasan RS, Wolf PA, D'Agostino RB, Larson MG, Kannel WB, 3940 Benjamin EJ. A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation 3941 in the community: the Framingham Heart Study. JAMA 2003;290:1049-1056. 3942 368. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for 3943 predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: 3944 the euro heart survey on atrial fibrillation. *Chest* 2010;**137**:263-272. 3945 Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S, Van Gelder IC, Al-Attar N, 369. 3946 Hindricks G, Prendergast B, Heidbuchel H, Alfieri O, Angelini A, Atar D, Colonna P, De Caterina R, 3947 De Sutter J, Goette A, Gorenek B, Heldal M, Hohloser SH, Kolh P, Le Heuzey JY, Ponikowski P, 3948 Rutten FH, ESC Committee for Practice Guidelines, European Heart Rhythm Association, European 3949 Association for Cardio-Thoracic Surgery. Guidelines for the management of atrial fibrillation: the Task 3950 Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). 3951 Europace 2010;12:1360-1420. 3952 Kirchhof P, Curtis AB, Skanes AC, Gillis AM, Samuel Wann L, Camm AJ. Atrial fibrillation 370. 3953 guidelines across the Atlantic: a comparison of the current recommendations of the European Society 3954 of Cardiology/European Heart Rhythm Association/European Association of Cardiothoracic Surgeons, 3955 the American College of Cardiology Foundation/American Heart Association/Heart Rhythm Society, 3956 and the Canadian Cardiovascular Society. Eur Heart J 2013;34:1471-1474. 3957 Olesen JB, Lip GY, Hansen ML, Hansen PR, Tolstrup JS, Lindhardsen J, Selmer C, Ahlehoff 371. 3958 O, Olsen AM, Gislason GH, Torp-Pedersen C. Validation of risk stratification schemes for predicting 3959 stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. BMJ 3960 2011;**342**:d124.

3961 372. Chao TF, Liu CJ, Wang KL, Lin YJ, Chang SL, Lo LW, Hu YF, Tuan TC, Chen TJ, Lip GY, 3962 Chen SA. Should atrial fibrillation patients with 1 additional risk factor of the CHA2DS2-VASc score 3963 (beyond sex) receive oral anticoagulation? J Am Coll Cardiol 2015;65:635-642. 3964 Lip GY, Skjoth F, Rasmussen LH, Larsen TB. Oral anticoagulation, aspirin, or no therapy in 373. 3965 patients with nonvalvular AF with 0 or 1 stroke risk factor based on the CHA2DS2-VASc score. J Am 3966 Coll Cardiol 2015;65:1385-1394. 3967 374. Fauchier L, Lecoq C, Clementy N, Bernard A, Angoulvant D, Ivanes F, Babuty D, Lip GY. Oral 3968 Anticoagulation and the Risk of Stroke or Death in Patients With Atrial Fibrillation and One Additional 3969 Stroke Risk Factor: The Loire Valley Atrial Fibrillation Project. Chest 2016;149:960-968. 3970 375. Joundi RA, Cipriano LE, Sposato LA, Saposnik G, Stroke Outcomes Research Working 3971 Group. Ischemic Stroke Risk in Patients With Atrial Fibrillation and CHA2DS2-VASc Score of 1: 3972 Systematic Review and Meta-Analysis. Stroke 2016;47:1364-1367. 3973 376. Friberg L, Skeppholm M, Terent A. Benefit of anticoagulation unlikely in patients with atrial 3974 fibrillation and a CHA2DS2-VASc score of 1. J Am Coll Cardiol 2015;65:225-232. 3975 Lip GY, Skjoth F, Nielsen PB, Larsen TB. Non-valvular atrial fibrillation patients with none or 377. 3976 one additional risk factor of the CHA2DS2-VASc score. A comprehensive net clinical benefit analysis 3977 for warfarin, aspirin, or no therapy. Thromb Haemost 2015;114:826-834. 3978 378. Mikkelsen AP, Lindhardsen J, Lip GY, Gislason GH, Torp-Pedersen C, Olesen JB. Female 3979 sex as a risk factor for stroke in atrial fibrillation: a nationwide cohort study. J Thromb Haemost 3980 2012;10:1745-1751. 3981 Wagstaff AJ, Overvad TF, Lip GY, Lane DA. Is female sex a risk factor for stroke and 379. 3982 thromboembolism in patients with atrial fibrillation? A systematic review and meta-analysis. Qim 3983 2014;107:955-967. 3984 380. Hijazi Z, Oldgren J, Andersson U, Connolly SJ, Ezekowitz MD, Hohnloser SH, Reilly PA, Vinereanu D, Siegbahn A, Yusuf S, Wallentin L. Cardiac biomarkers are associated with an increased 3985 3986 risk of stroke and death in patients with atrial fibrillation: a Randomized Evaluation of Long-term 3987 Anticoagulation Therapy (RE-LY) substudy. Circulation 2012;125:1605-1616. 3988 Hijazi Z, Wallentin L, Siegbahn A, Andersson U, Christersson C, Ezekowitz J, Gersh BJ, 381. 3989 Hanna M, Hohnloser S, Horowitz J, Huber K, Hylek EM, Lopes RD, McMurray JJ, Granger CB. N-3990 terminal pro-B-type natriuretic peptide for risk assessment in patients with atrial fibrillation: insights 3991 from the ARISTOTLE Trial (Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation). 3992 J Am Coll Cardiol 2013;61:2274-2284. 3993 382. Hijazi Z, Lindback J, Alexander JH, Hanna M, Held C, Hylek EM, Lopes RD, Oldgren J, 3994 Siegbahn A, Stewart RA, White HD, Granger CB, Wallentin L, ARISTOTLE and STABILITY 3995 Investigators. The ABC (age, biomarkers, clinical history) stroke risk score: a biomarker-based risk 3996 score for predicting stroke in atrial fibrillation. Eur Heart J 2016: [Epub ahead of print]. 3997 383. Gage BF, Yan Y, Milligan PE, Waterman AD, Culverhouse R, Rich MW, Radford MJ. Clinical 3998 classification schemes for predicting hemorrhage: results from the National Registry of Atrial 3999 Fibrillation (NRAF). Am Heart J 2006;151:713-719. 4000 Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score 384. 4001 (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart 4002 Survey. Chest 2010;138:1093-1100. 4003 Fang MC, Go AS, Chang Y, Borowsky LH, Pomernacki NK, Udaltsova N, Singer DE. A new 385. 4004 risk scheme to predict warfarin-associated hemorrhage: The ATRIA (Anticoagulation and Risk Factors 4005 in Atrial Fibrillation) Study. J Am Coll Cardiol 2011;58:395-401. 4006 Friberg L, Rosenqvist M, Lip GY. Evaluation of risk stratification schemes for ischaemic stroke 386. 4007 and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. Eur 4008 Heart J 2012;33:1500-1510. 4009 387. Hijazi Z, Oldgren J, Lindback J, Alexander JH, Connolly SJ, Eikelboom JW, Ezekowitz MD, 4010 Held C, Hylek EM, Lopes RD, Siegbahn A, Yusuf S, Granger CB, Wallentin L, ARISTOTLE and RE-4011 LY Investigators. The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk 4012 score for patients with atrial fibrillation: a derivation and validation study. Lancet 2016: [Epub ahead of 4013 print]. 4014 388. O'Brien EC, Simon DN, Thomas LE, Hylek EM, Gersh BJ, Ansell JE, Kowey PR, Mahaffey 4015 KW, Chang P, Fonarow GC, Pencina MJ, Piccini JP, Peterson ED. The ORBIT bleeding score: a 4016 simple bedside score to assess bleeding risk in atrial fibrillation. Eur Heart J 2015;36:3258-3264. 4017 389. Loewen P, Dahri K. Risk of bleeding with oral anticoagulants: an updated systematic review 4018 and performance analysis of clinical prediction rules. Ann Hematol 2011;90:1191-1200. 4019 Olesen JB, Lip GY, Hansen PR, Lindhardsen J, Ahlehoff O, Andersson C, Weeke P, Hansen 390. 4020 ML, Gislason GH, Torp-Pedersen C. Bleeding risk in 'real world' patients with atrial fibrillation:

4021 comparison of two established bleeding prediction schemes in a nationwide cohort. J Thromb 4022 Haemost 2011;9:1460-1467. 4023 Van Staa TP, Setakis E, Di Tanna GL, Lane DA, Lip GY. A comparison of risk stratification 391. 4024 schemes for stroke in 79,884 atrial fibrillation patients in general practice. J Thromb Haemost 4025 2011;**9**:39-48. 4026 392. Roldan V, Marin F, Manzano-Fernandez S, Gallego P, Vilchez JA, Valdes M, Vicente V, Lip 4027 GY. The HAS-BLED score has better prediction accuracy for major bleeding than CHADS2 or 4028 CHA2DS2-VASc scores in anticoagulated patients with atrial fibrillation. J Am Coll Cardiol 4029 2013;62:2199-2204. 4030 393. Wallentin L, Hijazi Z, Andersson U, Alexander JH, De Caterina R, Hanna M, Horowitz JD, 4031 Hylek EM, Lopes RD, Asberg S, Granger CB, Siegbahn A, ARISTOTLE Investigators. Growth 4032 differentiation factor 15, a marker of oxidative stress and inflammation, for risk assessment in patients 4033 with atrial fibrillation: insights from the Apixaban for Reduction in Stroke and Other Thromboembolic 4034 Events in Atrial Fibrillation (ARISTOTLE) trial. Circulation 2014;130:1847-1858. 4035 Raunso J. Selmer C. Olesen JB. Charlot MG. Olsen AM. Bretler DM. Nielsen JD. Dominguez 394. 4036 H, Gadsboll N, Kober L, Gislason GH, Torp-Pedersen C, Hansen ML. Increased short-term risk of 4037 thrombo-embolism or death after interruption of warfarin treatment in patients with atrial fibrillation. 4038 Eur Heart J 2012;33:1886-1892. 4039 Sjogren V, Grzymala-Lubanski B, Renlund H, Friberg L, Lip GY, Svensson PJ, Sjalander A. 395. 4040 Safety and efficacy of well managed warfarin. A report from the Swedish quality register Auricula. 4041 Thromb Haemost 2015;113:1370-1377. 4042 Graham DJ, Reichman ME, Wernecke M, Zhang R, Southworth MR, Levenson M, Sheu TC, 396. 4043 Mott K, Goulding MR, Houstoun M, MaCurdy TE, Worrall C, Kelman JA. Cardiovascular, bleeding, 4044 and mortality risks in elderly medicare patients treated with dabigatran or warfarin for nonvalvular 4045 atrial fibrillation. Circulation 2015;131:157-164. 4046 397. Apostolakis S, Sullivan RM, Olshansky B, Lip GY. Factors affecting quality of anticoagulation 4047 control among patients with atrial fibrillation on warfarin: the SAMe-TT(2)R(2) score. Chest 4048 2013;144:1555-1563. 4049 398. Lip GY, Haguenoer K, Saint-Etienne C, Fauchier L. Relationship of the SAMe-TT(2)R(2) 4050 score to poor-quality anticoagulation, stroke, clinically relevant bleeding, and mortality in patients with 4051 atrial fibrillation. Chest 2014;146:719-726. 4052 399. Gallego P, Roldan V, Marin F, Galvez J, Valdes M, Vicente V, Lip GY. SAMe-TT2R2 score, 4053 time in therapeutic range, and outcomes in anticoagulated patients with atrial fibrillation. Am J Med 4054 2014;127:1083-1088. 4055 Eikelboom JW. Connolly SJ. Brueckmann M. Granger CB. Kappetein AP. Mack MJ. 400. 4056 Blatchford J, Devenny K, Friedman J, Guiver K, Harper R, Khder Y, Lobmeyer MT, Maas H, Voigt JU, 4057 Simoons ML, Van de Werf F, RE-ALIGN Investigators. Dabigatran versus warfarin in patients with 4058 mechanical heart valves. N Engl J Med 2013;369:1206-1214. 4059 Olesen JB, Sorensen R, Hansen ML, Lamberts M, Weeke P, Mikkelsen AP, Kober L, 401. 4060 Gislason GH, Torp-Pedersen C, Fosbol EL. Non-vitamin K antagonist oral anticoagulation agents in 4061 anticoagulant naive atrial fibrillation patients: Danish nationwide descriptive data 2011-2013. 4062 *Europace* 2015;**17**:187-193. 4063 402. Hylek EM, Held C, Alexander JH, Lopes RD, De Caterina R, Wojdyla DM, Huber K, Jansky P, 4064 Steg PG, Hanna M, Thomas L, Wallentin L, Granger CB. Major bleeding in patients with atrial 4065 fibrillation receiving apixaban or warfarin: The ARISTOTLE Trial (Apixaban for Reduction in Stroke 4066 and Other Thromboembolic Events in Atrial Fibrillation): Predictors, Characteristics, and Clinical 4067 Outcomes. J Am Coll Cardiol 2014;63:2141-2147. 4068 403. Flaker GC, Eikelboom JW, Shestakovska O, Connolly SJ, Kaatz S, Budaj A, Husted S, Yusuf 4069 S, Lip GY, Hart RG. Bleeding during treatment with aspirin versus apixaban in patients with atrial 4070 fibrillation unsuitable for warfarin: the apixaban versus acetylsalicylic acid to prevent stroke in atrial 4071 fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment (AVERROES) 4072 trial. Stroke 2012;43:3291-3297. 4073 Connolly SJ, Ezekowitz MD, Yusuf S, Reilly PA, Wallentin L, Randomized Evaluation of Long-404. 4074 Term Anticoagulation Therapy Investigators. Newly identified events in the RE-LY trial. N Engl J Med 4075 2010;363:1875-1876. Ruff CT, Giugliano RP, Braunwald E, Morrow DA, Murphy SA, Kuder JF, Deenadayalu N, 4076 405. 4077 Jarolim P, Betcher J, Shi M, Brown K, Patel I, Mercuri M, Antman EM. Association between edoxaban 4078 dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised,

4079 double-blind ENGAGE AF-TIMI 48 trial. Lancet 2015;385:2288-2295.

4080 406. Beyer-Westendorf J, Forster K, Pannach S, Ebertz F, Gelbricht V, Thieme C, Michalski F, 4081 Kohler C, Werth S, Sahin K, Tittl L, Hansel U, Weiss N. Rates, management, and outcome of 4082 rivaroxaban bleeding in daily care: results from the Dresden NOAC registry. Blood 2014;124:955-962. 4083 Camm AJ, Amarenco P, Haas S, Hess S, Kirchhof P, Kuhls S, van Eickels M, Turpie AG, 407. 4084 XANTUS Investigators. XANTUS: a real-world, prospective, observational study of patients treated 4085 with rivaroxaban for stroke prevention in atrial fibrillation. Eur Heart J 2016;37:1145-1153. 4086 Wallentin L, Yusuf S, Ezekowitz MD, Alings M, Flather M, Franzosi MG, Pais P, Dans A, 408. 4087 Eikelboom J, Oldgren J, Pogue J, Reilly PA, Yang S, Connolly SJ, RE-LY investigators. Efficacy and 4088 safety of dabigatran compared with warfarin at different levels of international normalised ratio control 4089 for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet 2010;376:975-983. 4090 409. Piccini JP, Hellkamp AS, Lokhnygina Y, Patel MR, Harrell FE, Singer DE, Becker RC, 4091 Breithardt G, Halperin JL, Hankey GJ, Berkowitz SD, Nessel CC, Mahaffey KW, Fox KA, Califf RM, 4092 ROCKET AF Investigators. Relationship between time in therapeutic range and comparative 4093 treatment effect of rivaroxaban and warfarin: results from the ROCKET AF trial. J Am Heart Assoc 4094 2014:3:e000521. 4095 410. Olesen JB, Lip GY, Kamper AL, Hommel K, Kober L, Lane DA, Lindhardsen J, Gislason GH, 4096 Torp-Pedersen C. Stroke and bleeding in atrial fibrillation with chronic kidney disease. N Engl J Med 4097 2012;367:625-635. 4098 Albertsen IE, Rasmussen LH, Overvad TF, Graungaard T, Larsen TB, Lip GY. Risk of stroke 411. 4099 or systemic embolism in atrial fibrillation patients treated with warfarin: A systematic review and meta-4100 analysis. Stroke 2013;44:1329-1336. 4101 412. Hart RG, Pearce LA, Asinger RW, Herzog CA. Warfarin in atrial fibrillation patients with 4102 moderate chronic kidney disease. Clin J Am Soc Nephrol 2011;6:2599-2604. 4103 413. Friberg L, Benson L, Lip GY. Balancing stroke and bleeding risks in patients with atrial 4104 fibrillation and renal failure: the Swedish Atrial Fibrillation Cohort study. Eur Heart J 2014. 4105 414. Jun M, James MT, Manns BJ, Quinn RR, Ravani P, Tonelli M, Perkovic V, Winkelmayer WC, 4106 Ma Z, Hemmelgarn BR. The association between kidney function and major bleeding in older adults 4107 with atrial fibrillation starting warfarin treatment: population based observational study. BMJ 4108 2015;350:h246. 4109 415. Del-Carpio Munoz F, Gharacholou SM, Munger TM, Friedman PA, Asirvatham SJ, Packer 4110 DL, Noseworthy PA. Meta-Analysis of Renal Function on the Safety and Efficacy of Novel Oral 4111 Anticoagulants for Atrial Fibrillation. Am J Cardiol 2016;**117**:69-75. 4112 416. Heidbuchel H, Verhamme P, Alings M, Antz M, Diener HC, Hacke W, Oldgren J, Sinnaeve P, 4113 Camm AJ, Kirchhof P. Updated European Heart Rhythm Association Practical Guide on the use of 4114 non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace 4115 2015;17:1467-1507. 4116 417. Zimmerman D, Sood MM, Rigatto C, Holden RM, Hiremath S, Clase CM. Systematic review 4117 and meta-analysis of incidence, prevalence and outcomes of atrial fibrillation in patients on dialysis. 4118 Nephrol Dial Transplant 2012;27:3816-3822. 4119 Marinigh R, Lane DA, Lip GY. Severe renal impairment and stroke prevention in atrial 418. 4120 fibrillation: implications for thromboprophylaxis and bleeding risk. J Am Coll Cardiol 2011;57:1339-4121 1348. 4122 419. Wizemann V, Tong L, Satayathum S, Disney A, Akiba T, Fissell RB, Kerr PG, Young EW, 4123 Robinson BM. Atrial fibrillation in hemodialysis patients: clinical features and associations with 4124 anticoagulant therapy. Kidney Int 2010;77:1098-1106. 4125 Chan KE, Lazarus JM, Thadhani R, Hakim RM. Warfarin use associates with increased risk 420. 4126 for stroke in hemodialysis patients with atrial fibrillation. J Am Soc Nephrol 2009;20:2223-2233. 4127 421. Winkelmayer WC, Liu J, Setoguchi S, Choudhry NK. Effectiveness and safety of warfarin 4128 initiation in older hemodialysis patients with incident atrial fibrillation. Clin J Am Soc Nephrol 4129 2011;6:2662-2668. 4130 Shah M, Avgil Tsadok M, Jackevicius CA, Essebag V, Eisenberg MJ, Rahme E, Humphries 422. 4131 KH, Tu JV, Behlouli H, Guo H, Pilote L. Warfarin use and the risk for stroke and bleeding in patients 4132 with atrial fibrillation undergoing dialysis. Circulation 2014;129:1196-1203. 4133 Bonde AN, Lip GY, Kamper AL, Hansen PR, Lamberts M, Hommel K, Hansen ML, Gislason 423 4134 GH, Torp-Pedersen C, Olesen JB. Net clinical benefit of antithrombotic therapy in patients with atrial 4135 fibrillation and chronic kidney disease: a nationwide observational cohort study. J Am Coll Cardiol 4136 2014;64:2471-2482. 4137 Chan KE, Edelman ER, Wenger JB, Thadhani RI, Maddux FW. Dabigatran and rivaroxaban 424. 4138 use in atrial fibrillation patients on hemodialysis. Circulation 2015;131:972-979.

4139 425. Hijazi Z, Hohnloser SH, Oldgren J, Andersson U, Connolly SJ, Eikelboom JW, Ezekowitz MD, 4140 Reilly PA, Siegbahn A, Yusuf S, Wallentin L. Efficacy and safety of dabigatran compared with warfarin 4141 in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation 4142 of Long-term Anticoagulation Therapy) trial analysis. Circulation 2014;129:961-970. 4143 Fox KA, Piccini JP, Wojdyla D, Becker RC, Halperin JL, Nessel CC, Paolini JF, Hankey GJ, 426. 4144 Mahaffey KW, Patel MR, Singer DE, Califf RM. Prevention of stroke and systemic embolism with 4145 rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal 4146 impairment. Eur Heart J 2011;32:2387-2394. 4147 427. Hohnloser SH, Hijazi Z, Thomas L, Alexander JH, Amerena J, Hanna M, Keltai M, Lanas F, 4148 Lopes RD, Lopez-Sendon J, Granger CB, Wallentin L. Efficacy of apixaban when compared with 4149 warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE 4150 trial. Eur Heart J 2012;33:2821-2830. 4151 428. Stroke Prevention in Atrial Fibrillation Investigators. Stroke Prevention in Atrial Fibrillation 4152 Study. Final results. Circulation 1991;84:527-539. 4153 429. Olesen JB, Lip GY, Lindhardsen J, Lane DA, Ahlehoff O, Hansen ML, Raunso J, Tolstrup JS, 4154 Hansen PR, Gislason GH, Torp-Pedersen C. Risks of thromboembolism and bleeding with 4155 thromboprophylaxis in patients with atrial fibrillation: A net clinical benefit analysis using a 'real world' 4156 nationwide cohort study. Thromb Haemost 2011;106:739-749. 4157 Sjalander S, Sjalander A, Svensson PJ, Friberg L. Atrial fibrillation patients do not benefit 430. 4158 from acetylsalicylic acid. Europace 2014;16:631-638. 4159 431. ACTIVE Writing Group of the ACTIVE Investigators, Connolly S, Pogue J, Hart R, Pfeffer M, 4160 Hohnloser S, Chrolavicius S, Pfeffer M, Hohnloser S, Yusuf S. Clopidogrel plus aspirin versus oral 4161 anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for 4162 prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 2006;367:1903-4163 1912. Connolly SJ, Pogue J, Eikelboom J, Flaker G, Commerford P, Franzosi MG, Healey JS. Yusuf 4164 432. 4165 S, ACTIVE W Investigators. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation 4166 depends on the quality of international normalized ratio control achieved by centers and countries as 4167 measured by time in therapeutic range. Circulation 2008;118:2029-2037. 4168 433. Connolly SJ, Pogue J, Hart RG, Hohnloser SH, Pfeffer M, Chrolavicius S, Yusuf S, ACTIVE 4169 Investigators. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med 4170 2009;360:2066-2078. 4171 434. van Walraven C, Hart RG, Connolly S, Austin PC, Mant J, Hobbs FD, Koudstaal PJ, Petersen 4172 P, Perez-Gomez F, Knottnerus JA, Boode B, Ezekowitz MD, Singer DE. Effect of age on stroke 4173 prevention therapy in patients with atrial fibrillation: the atrial fibrillation investigators. Stroke 4174 2009:40:1410-1416. 4175 435. Olesen KH. The natural history of 271 patients with mitral stenosis under medical treatment. 4176 Br Heart J 1962;24:349-357. 4177 Perez-Gomez F, Alegria E, Berjon J, Iriarte JA, Zumalde J, Salvador A, Mataix L, NASPEAF 436. 4178 Investigators. Comparative effects of antiplatelet, anticoagulant, or combined therapy in patients with 4179 valvular and nonvalvular atrial fibrillation: a randomized multicenter study. J Am Coll Cardiol 4180 2004;44:1557-1566. 4181 437. Rowe JC, Bland EF, Sprague HB, White PD. The course of mitral stenosis without surgery: 4182 ten- and twenty-year perspectives. Ann Intern Med 1960;52:741-749. 4183 438. Wilson JK, Greenwood WF. The natural history of mitral stenosis. Can Med Assoc J 4184 1954;**71**:323-331. 4185 Cannegieter SC, van der Meer FJ, Briet E, Rosendaal FR. Warfarin and aspirin after heart-439. 4186 valve replacement. N Engl J Med 1994;330:507-508; author reply 508-509. 4187 440. Chiang CW, Lo SK, Ko YS, Cheng NJ, Lin PJ, Chang CH. Predictors of systemic embolism in 4188 patients with mitral stenosis. A prospective study. Ann Intern Med 1998;128:885-889. 4189 441. Wan Y, Heneghan C, Perera R, Roberts N, Hollowell J, Glasziou P, Bankhead C, Xu Y. 4190 Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: a systematic 4191 review. Circ Cardiovasc Qual Outcomes 2008;1:84-91. 4192 442. Morgan CL, McEwan P, Tukiendorf A, Robinson PA, Clemens A, Plumb JM. Warfarin 4193 treatment in patients with atrial fibrillation: observing outcomes associated with varying levels of INR 4194 control. Thromb Res 2009;124:37-41. 4195 443. Gallagher AM, Setakis E, Plumb JM, Clemens A, van Staa TP. Risks of stroke and mortality 4196 associated with suboptimal anticoagulation in atrial fibrillation patients. Thromb Haemost

4197 2011;**106**:968-977.

4198 444. De Caterina R, Husted S, Wallentin L, Andreotti F, Arnesen H, Bachmann F, Baigent C 4199 Huber K, Jespersen J, Kristensen SD, Lip GY, Morais J, Rasmussen LH, Siegbahn A, Verheugt FW, 4200 Weitz JI. Vitamin K antagonists in heart disease: current status and perspectives (Section III). Position 4201 paper of the ESC Working Group on Thrombosis--Task Force on Anticoagulants in Heart Disease. 4202 Thromb Haemost 2013;110:1087-1107. 4203 445. Dans AL, Connolly SJ, Wallentin L, Yang S, Nakamya J, Brueckmann M, Ezekowitz M, 4204 Oldgren J, Eikelboom JW, Reilly PA, Yusuf S. Concomitant use of antiplatelet therapy with dabigatran 4205 or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial. 4206 Circulation 2013;127:634-640. 4207 Bajaj NS, Parashar A, Agarwal S, Sodhi N, Poddar KL, Garg A, Tuzcu EM, Kapadia SR. 446. 4208 Percutaneous left atrial appendage occlusion for stroke prophylaxis in nonvalvular atrial fibrillation: a 4209 systematic review and analysis of observational studies. JACC Cardiovasc Interv 2014;7:296-304. 4210 447. Lewalter T, Kanagaratnam P, Schmidt B, Rosengvist M, Nielsen-Kudsk JE, Ibrahim R, Albers 4211 BA. Camm AJ. Ischaemic stroke prevention in patients with atrial fibrillation and high bleeding risk: 4212 opportunities and challenges for percutaneous left atrial appendage occlusion. Europace 4213 2014;16:626-630. 4214 448. Meier B, Blaauw Y, Khattab AA, Lewalter T, Sievert H, Tondo C, Glikson M. EHRA/EAPCI 4215 expert consensus statement on catheter-based left atrial appendage occlusion. Europace 4216 2014;**16**:1397-1416. 4217 Holmes DR, Jr., Kar S, Price MJ, Whisenant B, Sievert H, Doshi SK, Huber K, Reddy VY. 449. 4218 Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients 4219 with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial. J Am Coll Cardiol 4220 2014;**64**:1-12. 4221 Holmes DR, Reddy VY, Turi ZG, Doshi SK, Sievert H, Buchbinder M, Mullin CM, Sick P. 450. 4222 Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in 4223 patients with atrial fibrillation: a randomised non-inferiority trial. Lancet 2009;374:534-542. 4224 451. Reddy VY, Doshi SK, Sievert H, Buchbinder M, Neuzil P, Huber K, Halperin JL, Holmes D. 4225 Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-4226 Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection 4227 in Patients with Atrial Fibrillation) Trial. Circulation 2013;127:720-729. 4228 452. Reddy VY, Sievert H, Halperin J, Doshi SK, Buchbinder M, Neuzil P, Huber K, Whisenant B, 4229 Kar S, Swarup V, Gordon N, Holmes D, PROTECT AF Steering Committee and Investigators. 4230 Percutaneous left atrial appendage closure vs warfarin for atrial fibrillation: a randomized clinical trial. 4231 JAMA 2014;312:1988-1998. 4232 Holmes DR, Jr., Doshi SK, Kar S, Price MJ, Sanchez JM, Sievert H, Valderrabano M, Reddy 453. 4233 VY. Left Atrial Appendage Closure as an Alternative to Warfarin for Stroke Prevention in Atrial 4234 Fibrillation: A Patient-Level Meta-Analysis. J Am Coll Cardiol 2015;65:2614-2623. 4235 454. Reddy VY, Mobius-Winkler S, Miller MA, Neuzil P, Schuler G, Wiebe J, Sick P, Sievert H. Left 4236 atrial appendage closure with the Watchman device in patients with a contraindication for oral 4237 anticoagulation: the ASAP study (ASA Plavix Feasibility Study With Watchman Left Atrial Appendage 4238 Closure Technology). J Am Coll Cardiol 2013;61:2551-2556. 4239 Santoro G, Meucci F, Stolcova M, Rezzaghi M, Mori F, Palmieri C, Paradossi U, Pastormerlo 455. 4240 LE, Rosso G, Berti S. Percutaneous left atrial appendage occlusion in patients with non-valvular atrial 4241 fibrillation: implantation and up to four years follow-up of the AMPLATZER Cardiac Plug. 4242 EuroIntervention 2014. 4243 Badheka AO, Chothani A, Mehta K, Patel NJ, Deshmukh A, Hoosien M, Shah N, Singh V, 456. 4244 Grover P, Savani GT, Panaich SS, Rathod A, Patel N, Arora S, Bhalara V, Coffey JO, O'Neill W, 4245 Makkar R, Grines CL, Schreiber T, Di Biase L, Natale A, Viles-Gonzalez JF. Utilization and adverse 4246 outcomes of percutaneous left atrial appendage closure for stroke prevention in atrial fibrillation in the 4247 United States: influence of hospital volume. Circ Arrhythm Electrophysiol 2015;8:42-48. 4248 Pison L, Potpara TS, Chen J, Larsen TB, Bongiorni MG, Blomstrom-Lundqvist C. Left atrial 457. 4249 appendage closure-indications, techniques, and outcomes: results of the European Heart Rhythm 4250 Association Survey. Europace 2015;17:642-646. 4251 Price MJ, Gibson DN, Yakubov SJ, Schultz JC, Di Biase L, Natale A, Burkhardt JD, Pershad 458 4252 A, Byrne TJ, Gidney B, Aragon JR, Goldstein J, Moulton K, Patel T, Knight B, Lin AC, Valderrabano 4253 M. Early safety and efficacy of percutaneous left atrial appendage suture ligation: results from the 4254 U.S. transcatheter LAA ligation consortium. J Am Coll Cardiol 2014;64:565-572. 4255 Boersma LV, Schmidt B, Betts TR, Sievert H, Tamburino C, Teiger E, Pokushalov E, Kische 459. 4256 S, Schmitz T, Stein KM, Bergmann MW, EWOLUTION investigators. Implant success and safety of

4257 left atrial appendage closure with the WATCHMAN device: peri-procedural outcomes from the 4258 EWOLUTION registry. Eur Heart J 2016: [Epub ahead of print]. 4259 Kuramatsu JB, Gerner ST, Schellinger PD, Glahn J, Endres M, Sobesky J, Flechsenhar J, 460. 4260 Neugebauer H, Juttler E, Grau A, Palm F, Rother J, Michels P, Hamann GF, Huwel J, Hagemann G, Barber B, Terborg C, Trostdorf F, Bazner H, Roth A, Wohrle J, Keller M, Schwarz M, Reimann G. 4261 4262 Volkmann J, Mullges W, Kraft P, Classen J, Hobohm C, Horn M, Milewski A, Reichmann H, Schneider 4263 H, Schimmel E, Fink GR, Dohmen C, Stetefeld H, Witte O, Gunther A, Neumann-Haefelin T, Racs 4264 AE, Nueckel M, Erbguth F, Kloska SP, Dorfler A, Kohrmann M, Schwab S, Huttner HB. Anticoagulant 4265 reversal, blood pressure levels, and anticoagulant resumption in patients with anticoagulation-related 4266 intracerebral hemorrhage. JAMA 2015;313:824-836. 4267 Budera P, Straka Z, Osmancik P, Vanek T, Jelinek S, Hlavicka J, Fojt R, Cervinka P, Hulman 461. 4268 M, Smid M, Maly M, Widimsky P. Comparison of cardiac surgery with left atrial surgical ablation vs. 4269 cardiac surgery without atrial ablation in patients with coronary and/or valvular heart disease plus 4270 atrial fibrillation: final results of the PRAGUE-12 randomized multicentre study. Eur Heart J 4271 2012:33:2644-2652. 4272 462. Healey JS, Crystal E, Lamy A, Teoh K, Semelhago L, Hohnloser SH, Cybulsky I, Abouzahr L, 4273 Sawchuck C, Carroll S, Morillo C, Kleine P, Chu V, Lonn E, Connolly SJ. Left Atrial Appendage 4274 Occlusion Study (LAAOS): results of a randomized controlled pilot study of left atrial appendage 4275 occlusion during coronary bypass surgery in patients at risk for stroke. Am Heart J 2005;150:288-293. 4276 Tsai YC, Phan K, Munkholm-Larsen S, Tian DH, La Meir M, Yan TD. Surgical left atrial 463. 4277 appendage occlusion during cardiac surgery for patients with atrial fibrillation: a meta-analysis. Eur J 4278 Cardiothorac Surg 2015;47:847-854. 4279 464. Whitlock RP, Vincent J, Blackall MH, Hirsh J, Fremes S, Novick R, Devereaux PJ, Teoh K, 4280 Lamy A, Connolly SJ, Yusuf S, Carrier M, Healey JS. Left Atrial Appendage Occlusion Study II 4281 (LAAOS II). Can J Cardiol 2013;29:1443-1447. 4282 465. Aryana A, Singh SK, Singh SM, Gearoid O'Neill P, Bowers MR, Allen SL, Lewandowski SL, 4283 Vierra EC, d'Avila A. Association between incomplete surgical ligation of left atrial appendage and 4284 stroke and systemic embolization. Heart Rhythm 2015;12:1431-1437. 4285 466. Gillinov AM, Gelijns AC, Parides MK, DeRose JJ, Jr., Moskowitz AJ, Voisine P, Ailawadi G, 4286 Bouchard D, Smith PK, Mack MJ, Acker MA, Mullen JC, Rose EA, Chang HL, Puskas JD, Couderc 4287 JP, Gardner TJ, Varghese R, Horvath KA, Bolling SF, Michler RE, Geller NL, Ascheim DD, Miller MA, 4288 Bagiella E, Moguete EG, Williams P, Taddei-Peters WC, O'Gara PT, Blackstone EH, Argenziano M, 4289 CTSN Investigators. Surgical ablation of atrial fibrillation during mitral-valve surgery. N Engl J Med 4290 2015;**372**:1399-1409. 4291 Whitlock R, Healey J, Vincent J, Brady K, Teoh K, Royse A, Shah P, Guo Y, Alings M, 467 4292 Folkeringa RJ, Paparella D, Colli A, Meyer SR, Legare JF, Lamontagne F, Reents W, Boning A, 4293 Connolly S. Rationale and design of the Left Atrial Appendage Occlusion Study (LAAOS) III. Ann 4294 Cardiothorac Surg 2014;3:45-54. 4295 Boersma LV, Castella M, van Boven W, Berruezo A, Yilmaz A, Nadal M, Sandoval E, Calvo 468. 4296 N, Brugada J, Kelder J, Wijffels M, Mont L. Atrial fibrillation catheter ablation versus surgical ablation 4297 treatment (FAST): a 2-center randomized clinical trial. Circulation 2012;125:23-30. 4298 Grau AJ, Weimar C, Buggle F, Heinrich A, Goertler M, Neumaier S, Glahn J, Brandt T, Hacke 469. 4299 W, Diener H. Risk factors, outcome, and treatment in subtypes of ischemic stroke: the German stroke 4300 data bank. Stroke 2001;32:2559-2566. 4301 470. Giles MF, Rothwell PM. Risk of stroke early after transient ischaemic attack: a systematic 4302 review and meta-analysis. Lancet Neurol 2007;6:1063-1072. 4303 471. Emberson J, Lees KR, Lyden P, Blackwell L, Albers G, Bluhmki E, Brott T, Cohen G, Davis S, 4304 Donnan G, Grotta J, Howard G, Kaste M, Koga M, von Kummer R, Lansberg M, Lindley RI, Murray G, 4305 Olivot JM, Parsons M, Tilley B, Toni D, Toyoda K, Wahlgren N, Wardlaw J, Whiteley W, Del Zoppo 4306 GJ, Baigent C, Sandercock P, Hacke W, Stroke Thrombolysis Trialists' Collaborative Group. Effect of 4307 treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for 4308 acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials. Lancet 4309 2014. 4310 472. Diener HC, Stanford S, Abdul-Rahim A, Christensen L, Hougaard KD, Bakhai A, Veltkamp R, 4311 Worthmann H. Anti-thrombotic therapy in patients with atrial fibrillation and intracranial hemorrhage. 4312 Expert Rev Neurother 2014;14:1019-1028. 4313 473. Hankey GJ, Norrving B, Hacke W, Steiner T. Management of acute stroke in patients taking novel oral anticoagulants. Int J Stroke 2014;9:627-632. 4314 4315 474. Xian Y, Liang L, Smith EE, Schwamm LH, Reeves MJ, Olson DM, Hernandez AF, Fonarow 4316 GC, Peterson ED. Risks of intracranial hemorrhage among patients with acute ischemic stroke

 4318 2608. 4319 475. Pollack CV, Jr., Reilly PA, Eikelboom J, Glund S, Verhamme P, Bernstein RA, Dubiel R, 4320 Huisman MV, Hylek EM, Kamphuisen PW, Kreuzer J, Levy JH, Sellke FW, Stangier J, Steiner T, 4321 Wang B, Kam CW, Weitz JI. Idarucizumab for Dabigatran Reversal. <i>N Engl J Med</i> 2015;373:511-52 476. Badhiwala JH, Nassiri F, Alhazzani W, Selim MH, Farrokhyar F, Spears J, Kulkarni AV, Sir 4323 S, Alqahtani A, Rochwerg B, Alshahrani M, Murty NK, Alhazzani A, Yarascavitch B, Reddy K, Zaida 4324 OO, Almenawer SA. Endovascular Thrombectomy for Acute Ischemic Stroke: A Meta-analysis. <i>Jar</i> 4325 2015;314:1832-1843. 4376. Paciaroni M, Agnelli G, Micheli S, Caso V. Efficacy and safety of anticoagulant treatment ir 4328 478. Heidbuchel H, Verhamme P, Alings M, Antz M, Hacke W, Oldgren J, Sinnaeve P, Camm A 4329 Kirchhof P. European Heart Rhythm Association Practical Guide on the use of new oral 4330 anticoagulants in patients with non-valvular atrial fibrillation. <i>Europace</i> 2013;15:625-651. 4331 479. Diener HC, Connolly SJ, Ezekowitz MD, Wallentin L, Reilly PA, Yang S, Xavier D, Di 4332 Pasquale G, Yusuf S. Dabigatran compared with warfarin in patients with atrial fibrillation and 4333 previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial. <i>Lancet Neuro</i> 4334 480. Hankey GJ, Patel MR, Stevens SR, Becker RC, Breithardt G, Carolei A, Diener HC, Donna 4336 GA, Halperin JL, Mahaffey KW, Mas JL, Massaro A, Norrving B, Nessel CC, Paolini JF, Roine RO, 4338 Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transie 	-
 Huisman MV, Hylek EM, Kamphuisen PW, Kreuzer J, Levy JH, Sellke FW, Stangier J, Steiner T, Wang B, Kam CW, Weitz JI. Idarucizumab for Dabigatran Reversal. <i>N Engl J Med</i> 2015;373:511-57 476. Badhiwala JH, Nassiri F, Alhazzani W, Selim MH, Farrokhyar F, Spears J, Kulkarni AV, Sir S, Alqahtani A, Rochwerg B, Alshahrani M, Murty NK, Alhazzani A, Yarascavitch B, Reddy K, Zaida OO, Almenawer SA. Endovascular Thrombectomy for Acute Ischemic Stroke: A Meta-analysis. <i>Jan</i> 2015;314:1832-1843. 477. Paciaroni M, Agnelli G, Micheli S, Caso V. Efficacy and safety of anticoagulant treatment in acute cardioembolic stroke: a meta-analysis of randomized controlled trials. <i>Stroke</i> 2007;38:423-43 478. Heidbuchel H, Verhamme P, Alings M, Antz M, Hacke W, Oldgren J, Sinnaeve P, Camm A Kirchhof P. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. <i>Europace</i> 2013;15:625-651. 4331 479. Diener HC, Connolly SJ, Ezekowitz MD, Wallentin L, Reilly PA, Yang S, Xavier D, Di Pasquale G, Yusuf S. Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial. <i>Lancet Neuro</i> 2010;9:1157-1163. 480. Hankey GJ, Patel MR, Stevens SR, Becker RC, Breithardt G, Carolei A, Diener HC, Donna GA, Halperin JL, Mahaffey KW, Mas JL, Massaro A, Norrving B, Nessel CC, Paolini JF, Roine RO, Singer DE, Wong L, Califf RM, Fox KA, Hacke W, ROCKET AF Steering Committee Investigators. 	
 4322 476. Badhiwala JH, Nassiri F, Alhazzani W, Selim MH, Farrokhyar F, Spears J, Kulkarni AV, Sir 4323 S, Alqahtani A, Rochwerg B, Alshahrani M, Murty NK, Alhazzani A, Yarascavitch B, Reddy K, Zaida 4324 OO, Almenawer SA. Endovascular Thrombectomy for Acute Ischemic Stroke: A Meta-analysis. Jar 4325 2015;314:1832-1843. 4326 477. Paciaroni M, Agnelli G, Micheli S, Caso V. Efficacy and safety of anticoagulant treatment in 4327 acute cardioembolic stroke: a meta-analysis of randomized controlled trials. <i>Stroke</i> 2007;38:423-432 478. Heidbuchel H, Verhamme P, Alings M, Antz M, Hacke W, Oldgren J, Sinnaeve P, Camm A 4329 Kirchhof P. European Heart Rhythm Association Practical Guide on the use of new oral 4330 anticoagulants in patients with non-valvular atrial fibrillation. <i>Europace</i> 2013;15:625-651. 479. Diener HC, Connolly SJ, Ezekowitz MD, Wallentin L, Reilly PA, Yang S, Xavier D, Di 4332 Pasquale G, Yusuf S. Dabigatran compared with warfarin in patients with atrial fibrillation and 4334 previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial. <i>Lancet Neuro</i> 4335 480. Hankey GJ, Patel MR, Stevens SR, Becker RC, Breithardt G, Carolei A, Diener HC, Donnat 4336 GA, Halperin JL, Mahaffey KW, Mas JL, Massaro A, Norrving B, Nessel CC, Paolini JF, Roine RO, 4337 Singer DE, Wong L, Califf RM, Fox KA, Hacke W, ROCKET AF Steering Committee Investigators. 	
 4323 S, Alqahtani A, Rochwerg B, Alshahrani M, Murty NK, Alhazzani A, Yarascavitch B, Reddy K, Zaida 4324 OO, Almenawer SA. Endovascular Thrombectomy for Acute Ischemic Stroke: A Meta-analysis. <i>Jar</i> 4325 2015;314:1832-1843. 4326 477. Paciaroni M, Agnelli G, Micheli S, Caso V. Efficacy and safety of anticoagulant treatment in acute cardioembolic stroke: a meta-analysis of randomized controlled trials. <i>Stroke</i> 2007;38:423-432 478. Heidbuchel H, Verhamme P, Alings M, Antz M, Hacke W, Oldgren J, Sinnaeve P, Camm A Kirchhof P. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. <i>Europace</i> 2013;15:625-651. 4331 479. Diener HC, Connolly SJ, Ezekowitz MD, Wallentin L, Reilly PA, Yang S, Xavier D, Di Pasquale G, Yusuf S. Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial. <i>Lancet Neuro</i> 4334 2010;9:1157-1163. 4335 480. Hankey GJ, Patel MR, Stevens SR, Becker RC, Breithardt G, Carolei A, Diener HC, Donna GA, Halperin JL, Mahaffey KW, Mas JL, Massaro A, Norrving B, Nessel CC, Paolini JF, Roine RO, Singer DE, Wong L, Califf RM, Fox KA, Hacke W, ROCKET AF Steering Committee Investigators. 	
 4324 OO, Almenawer SA. Endovascular Thrombectomy for Acute Ischemic Stroke: A Meta-analysis. Jan 4325 2015;314:1832-1843. 4326 477. Paciaroni M, Agnelli G, Micheli S, Caso V. Efficacy and safety of anticoagulant treatment in 4327 acute cardioembolic stroke: a meta-analysis of randomized controlled trials. <i>Stroke</i> 2007;38:423-43 478. Heidbuchel H, Verhamme P, Alings M, Antz M, Hacke W, Oldgren J, Sinnaeve P, Camm A 4329 Kirchhof P. European Heart Rhythm Association Practical Guide on the use of new oral 4330 anticoagulants in patients with non-valvular atrial fibrillation. <i>Europace</i> 2013;15:625-651. 479. Diener HC, Connolly SJ, Ezekowitz MD, Wallentin L, Reilly PA, Yang S, Xavier D, Di 4332 Pasquale G, Yusuf S. Dabigatran compared with warfarin in patients with atrial fibrillation and 4334 2010;9:1157-1163. 480. Hankey GJ, Patel MR, Stevens SR, Becker RC, Breithardt G, Carolei A, Diener HC, Donna 4336 GA, Halperin JL, Mahaffey KW, Mas JL, Massaro A, Norrving B, Nessel CC, Paolini JF, Roine RO, 4337 Singer DE, Wong L, Califf RM, Fox KA, Hacke W, ROCKET AF Steering Committee Investigators. 	
 4325 2015;314:1832-1843. 4326 477. Paciaroni M, Agnelli G, Micheli S, Caso V. Efficacy and safety of anticoagulant treatment in acute cardioembolic stroke: a meta-analysis of randomized controlled trials. <i>Stroke</i> 2007;38:423-4345. 478. Heidbuchel H, Verhamme P, Alings M, Antz M, Hacke W, Oldgren J, Sinnaeve P, Camm A Kirchhof P. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. <i>Europace</i> 2013;15:625-651. 4331 479. Diener HC, Connolly SJ, Ezekowitz MD, Wallentin L, Reilly PA, Yang S, Xavier D, Di Pasquale G, Yusuf S. Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial. <i>Lancet Neuro</i> 2010;9:1157-1163. 480. Hankey GJ, Patel MR, Stevens SR, Becker RC, Breithardt G, Carolei A, Diener HC, Donna GA, Halperin JL, Mahaffey KW, Mas JL, Massaro A, Norrving B, Nessel CC, Paolini JF, Roine RO, Singer DE, Wong L, Califf RM, Fox KA, Hacke W, ROCKET AF Steering Committee Investigators. 	
 4327 acute cardioembolic stroke: a meta-analysis of randomized controlled trials. <i>Stroke</i> 2007;38:423-43 4328 478. Heidbuchel H, Verhamme P, Alings M, Antz M, Hacke W, Oldgren J, Sinnaeve P, Camm A 4329 Kirchhof P. European Heart Rhythm Association Practical Guide on the use of new oral 4330 anticoagulants in patients with non-valvular atrial fibrillation. <i>Europace</i> 2013;15:625-651. 4331 479. Diener HC, Connolly SJ, Ezekowitz MD, Wallentin L, Reilly PA, Yang S, Xavier D, Di 4332 Pasquale G, Yusuf S. Dabigatran compared with warfarin in patients with atrial fibrillation and 4334 2010;9:1157-1163. 430. Hankey GJ, Patel MR, Stevens SR, Becker RC, Breithardt G, Carolei A, Diener HC, Donna 4336 GA, Halperin JL, Mahaffey KW, Mas JL, Massaro A, Norrving B, Nessel CC, Paolini JF, Roine RO, 4337 Singer DE, Wong L, Califf RM, Fox KA, Hacke W, ROCKET AF Steering Committee Investigators. 	<i>i</i> a
 4328 478. Heidbuchel H, Verhamme P, Alings M, Antz M, Hacke W, Oldgren J, Sinnaeve P, Camm A 4329 Kirchhof P. European Heart Rhythm Association Practical Guide on the use of new oral 4330 anticoagulants in patients with non-valvular atrial fibrillation. <i>Europace</i> 2013;15:625-651. 4331 479. Diener HC, Connolly SJ, Ezekowitz MD, Wallentin L, Reilly PA, Yang S, Xavier D, Di 4332 Pasquale G, Yusuf S. Dabigatran compared with warfarin in patients with atrial fibrillation and 4333 previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial. <i>Lancet Neuro</i> 4334 2010;9:1157-1163. 480. Hankey GJ, Patel MR, Stevens SR, Becker RC, Breithardt G, Carolei A, Diener HC, Donna 4336 GA, Halperin JL, Mahaffey KW, Mas JL, Massaro A, Norrving B, Nessel CC, Paolini JF, Roine RO, 4337 Singer DE, Wong L, Califf RM, Fox KA, Hacke W, ROCKET AF Steering Committee Investigators. 	
 4329 Kirchhof P. European Heart Rhythm Association Practical Guide on the use of new oral 4330 anticoagulants in patients with non-valvular atrial fibrillation. <i>Europace</i> 2013;15:625-651. 4331 479. Diener HC, Connolly SJ, Ezekowitz MD, Wallentin L, Reilly PA, Yang S, Xavier D, Di 4332 Pasquale G, Yusuf S. Dabigatran compared with warfarin in patients with atrial fibrillation and 4333 previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial. <i>Lancet Neuro</i> 4335 480. Hankey GJ, Patel MR, Stevens SR, Becker RC, Breithardt G, Carolei A, Diener HC, Donna 4336 GA, Halperin JL, Mahaffey KW, Mas JL, Massaro A, Norrving B, Nessel CC, Paolini JF, Roine RO, 4337 Singer DE, Wong L, Califf RM, Fox KA, Hacke W, ROCKET AF Steering Committee Investigators. 	
 4330 anticoagulants in patients with non-valvular atrial fibrillation. <i>Europace</i> 2013;15:625-651. 4331 479. Diener HC, Connolly SJ, Ezekowitz MD, Wallentin L, Reilly PA, Yang S, Xavier D, Di 4332 Pasquale G, Yusuf S. Dabigatran compared with warfarin in patients with atrial fibrillation and 4333 previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial. <i>Lancet Neuro</i> 4334 2010;9:1157-1163. 4335 480. Hankey GJ, Patel MR, Stevens SR, Becker RC, Breithardt G, Carolei A, Diener HC, Donna 4336 GA, Halperin JL, Mahaffey KW, Mas JL, Massaro A, Norrving B, Nessel CC, Paolini JF, Roine RO, 4337 Singer DE, Wong L, Califf RM, Fox KA, Hacke W, ROCKET AF Steering Committee Investigators. 	J,
 4331 479. Diener HC, Connolly SJ, Ezekowitz MD, Wallentin L, Reilly PA, Yang S, Xavier D, Di 4332 Pasquale G, Yusuf S. Dabigatran compared with warfarin in patients with atrial fibrillation and 4333 previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial. <i>Lancet Neuro</i> 4334 2010;9:1157-1163. 4335 480. Hankey GJ, Patel MR, Stevens SR, Becker RC, Breithardt G, Carolei A, Diener HC, Donna 4336 GA, Halperin JL, Mahaffey KW, Mas JL, Massaro A, Norrving B, Nessel CC, Paolini JF, Roine RO, 4337 Singer DE, Wong L, Califf RM, Fox KA, Hacke W, ROCKET AF Steering Committee Investigators. 	
 previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial. <i>Lancet Neuro</i> 2010;9:1157-1163. 4335 480. Hankey GJ, Patel MR, Stevens SR, Becker RC, Breithardt G, Carolei A, Diener HC, Donna GA, Halperin JL, Mahaffey KW, Mas JL, Massaro A, Norrving B, Nessel CC, Paolini JF, Roine RO, Singer DE, Wong L, Califf RM, Fox KA, Hacke W, ROCKET AF Steering Committee Investigators. 	
 4334 2010;9:1157-1163. 4335 480. Hankey GJ, Patel MR, Stevens SR, Becker RC, Breithardt G, Carolei A, Diener HC, Donna 4336 GA, Halperin JL, Mahaffey KW, Mas JL, Massaro A, Norrving B, Nessel CC, Paolini JF, Roine RO, 4337 Singer DE, Wong L, Califf RM, Fox KA, Hacke W, ROCKET AF Steering Committee Investigators. 	
 4335 480. Hankey GJ, Patel MR, Stevens SR, Becker RC, Breithardt G, Carolei A, Diener HC, Donna 4336 GA, Halperin JL, Mahaffey KW, Mas JL, Massaro A, Norrving B, Nessel CC, Paolini JF, Roine RO, 4337 Singer DE, Wong L, Califf RM, Fox KA, Hacke W, ROCKET AF Steering Committee Investigators. 	
4336 GA, Halperin JL, Mahaffey KW, Mas JL, Massaro A, Norrving B, Nessel CC, Paolini JF, Roine RO, 4337 Singer DE, Wong L, Califf RM, Fox KA, Hacke W, ROCKET AF Steering Committee Investigators.	n
4338 Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transie	
4339 ischaemic attack: a subgroup analysis of ROCKET AF. Lancet Neurol 2012;11:315-322.	nt
4339 Ischaemic attack. a subgroup analysis of ROCKET AF. <i>Lancet Neurol</i> 2012, 11.315-322. 4340 481. Easton JD, Lopes RD, Bahit MC, Wojdyla DM, Granger CB, Wallentin L, Alings M, Goto S,	
4341 Lewis BS, Rosenqvist M, Hanna M, Mohan P, Alexander JH, Diener HC, ARISTOTLE Committees	
4342 and Investigators. Apixaban compared with warfarin in patients with atrial fibrillation and previous	
4343 stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial. <i>Lancet Neurol</i> 4344 2012; 11 :503-511.	
4344 2012; 11 :503-511. 4345 482. Ntaios G, Papavasileiou V, Diener HC, Makaritsis K, Michel P. Nonvitamin-K-antagonist or	al
4346 anticoagulants in patients with atrial fibrillation and previous stroke or transient ischemic attack: a	
4347 systematic review and meta-analysis of randomized controlled trials. <i>Stroke</i> 2012; 43 :3298-3304.	
4348 483. Paciaroni M, Agnelli G. Should oral anticoagulants be restarted after warfarin-associated 4349 cerebral haemorrhage in patients with atrial fibrillation? <i>Thromb Haemost</i> 2014; 111 :14-18.	
4349 cerebral haemorrhage in patients with atrial fibrillation? <i>Thromb Haemost</i> 2014; 111 :14-18. 4350 484. Nielsen PB, Larsen TB, Skjoth F, Gorst-Rasmussen A, Rasmussen LH, Lip GY. Restarting	
4351 Anticoagulant Treatment After Intracranial Hemorrhage in Patients With Atrial Fibrillation and the	
4352 Impact on Recurrent Stroke, Mortality, and Bleeding: A Nationwide Cohort Study. <i>Circulation</i>	
 4353 2015;132:517-525. 4354 485. Weber R, Brenck J, Diener HC. Antiplatelet therapy in cerebrovascular disorders. <i>Handb E</i> 	vn
4355 Pharmacol 2012:519-546.	γp
4356 486. Flaker GC, Gruber M, Connolly SJ, Goldman S, Chaparro S, Vahanian A, Halinen MO,	
4357 Horrow J, Halperin JL. Risks and benefits of combining aspirin with anticoagulant therapy in patient	S
4358 with atrial fibrillation: an exploratory analysis of stroke prevention using an oral thrombin inhibitor in 4359 atrial fibrillation (SPORTIF) trials. <i>Am Heart J</i> 2006; 152 :967-973.	
4360 487. Yung D, Kapral MK, Asllani E, Fang J, Lee DS, Investigators of the Registry of the Canadia	n
4361 Stroke Network. Reinitiation of anticoagulation after warfarin-associated intracranial hemorrhage ar	
4362 mortality risk: the Best Practice for Reinitiating Anticoagulation Therapy After Intracranial Bleeding	
 4363 (BRAIN) study. Can J Cardiol 2012;28:33-39. 4364 488. Roskell NS, Samuel M, Noack H, Monz BU. Major bleeding in patients with atrial fibrillation 	
4365 receiving vitamin K antagonists: a systematic review of randomized and observational studies.	
4366 Europace 2013; 15 :787-797.	
4367 489. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M, Christiaens T, Cifkova	
4368 De Backer G, Dominiczak A, Galderisi M, Grobbee DE, Jaarsma T, Kirchhof P, Kjeldsen SE, Laure 4369 S, Manolis AJ, Nilsson PM, Ruilope LM, Schmieder RE, Sirnes PA, Sleight P, Viigimaa M, Waeber	
4370 Zannad F, Redon J, Dominiczak A, Narkiewicz K, Nilsson PM, Burnier M, Viigimaa M, Ambrosioni I	
4371 Caufield M, Coca A, Olsen MH, Schmieder RE, Tsioufis C, van de Borne P, Zamorano JL, Achenba	ich
4372 S, Baumgartner H, Bax JJ, Bueno H, Dean V, Deaton C, Erol C, Fagard R, Ferrari R, Hasdai D, Ho	
4373 AW, Kirchhof P, Knuuti J, Kolh P, Lancellotti P, Linhart A, Nihoyannopoulos P, Piepoli MF, Ponikow 4374 P, Sirnes PA, Tamargo JL, Tendera M, Torbicki A, Wijns W, Windecker S, Clement DL, Coca A,	SKI
4375 Gillebert TC, Tendera M, Rosei EA, Ambrosioni E, Anker SD, Bauersachs J, Hitij JB, Caulfield M, E	е
4376 Buyzere M, De Geest S, Derumeaux GA, Erdine S, Farsang C, Funck-Brentano C, Gerc V, Germa	

4377 G, Gielen S, Haller H, Hoes AW, Jordan J, Kahan T, Komajda M, Lovic D, Mahrholdt H, Olsen MH, 4378 Ostergren J, Parati G, Perk J, Polonia J, Popescu BA, Reiner Z, Ryden L, Sirenko Y, Stanton A, 4379 Struijker-Boudier H, Tsioufis C, van de Borne P, Vlachopoulos C, Volpe M, Wood DA. 2013 ESH/ESC 4380 guidelines for the management of arterial hypertension: the Task Force for the Management of 4381 Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of 4382 Cardiology (ESC). Eur Heart J 2013;34:2159-2219. 4383 Eikelboom JW, Wallentin L, Connolly SJ, Ezekowitz M, Healey JS, Oldgren J, Yang S, Alings 490. 4384 M, Kaatz S, Hohnloser SH, Diener HC, Franzosi MG, Huber K, Reilly P, Varrone J, Yusuf S. Risk of 4385 bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial 4386 fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. 4387 Circulation 2011;123:2363-2372. 4388 Goodman SG, Wojdyla DM, Piccini JP, White HD, Paolini JF, Nessel CC, Berkowitz SD, 491. 4389 Mahaffey KW, Patel MR, Sherwood MW, Becker RC, Halperin JL, Hacke W, Singer DE, Hankey GJ, 4390 Breithardt G. Fox KA. Califf RM, ROCKET AF Investigators. Factors associated with major bleeding 4391 events: insights from the ROCKET AF trial (rivaroxaban once-daily oral direct factor Xa inhibition 4392 compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation). J 4393 Am Coll Cardiol 2014;63:891-900. 4394 492. Chang HY, Zhou M, Tang W, Alexander GC, Singh S. Risk of gastrointestinal bleeding 4395 associated with oral anticoagulants: population based retrospective cohort study. BMJ 4396 2015;350:h1585. 4397 493. Abraham NS, Singh S, Alexander GC, Heien H, Haas LR, Crown W, Shah ND. Comparative 4398 risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort 4399 study. Bmj 2015;350:h1857. 4400 494. Björck F, Renlund H, Lip GYH, Wester P, Svensson PJ, Själander A. Outcomes in a Warfarin-4401 Treated Population With Atrial Fibrillation. JAMA Cardiology 2016. 4402 495. Jacobs LG, Billett HH, Freeman K, Dinglas C, Jumaquio L. Anticoagulation for stroke 4403 prevention in elderly patients with atrial fibrillation, including those with falls and/or early-stage 4404 dementia: a single-center, retrospective, observational study. Am J Geriatr Pharmacother 2009;7:159-4405 166. 4406 496. Banerjee A, Clementy N, Haguenoer K, Fauchier L, Lip GY. Prior history of falls and risk of 4407 outcomes in atrial fibrillation: the Loire Valley Atrial Fibrillation Project. Am J Med 2014;127:972-978. 4408 497. Palareti G, Cosmi B. Bleeding with anticoagulation therapy - who is at risk, and how best to 4409 identify such patients. Thromb Haemost 2009;102:268-278. 4410 498. van Schie RM, Wadelius MI, Kamali F, Daly AK, Manolopoulos VG, de Boer A, Barallon R, 4411 Verhoef TI, Kirchheiner J, Haschke-Becher E, Briz M, Rosendaal FR, Redekop WK, Pirmohamed M, 4412 Maitland van der Zee AH. Genotype-guided dosing of coumarin derivatives: the European 4413 pharmacogenetics of anticoagulant therapy (EU-PACT) trial design. Pharmacogenomics 4414 2009;10:1687-1695. 4415 International Warfarin Pharmacogenetics Consortium, Klein TE, Altman RB, Eriksson N, 499. 4416 Gage BF, Kimmel SE, Lee MT, Limdi NA, Page D, Roden DM, Wagner MJ, Caldwell MD, Johnson 4417 JA. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med 4418 2009;**360**:753-764. 4419 500. Schwarz UI, Ritchie MD, Bradford Y, Li C, Dudek SM, Frye-Anderson A, Kim RB, Roden DM, 4420 Stein CM. Genetic determinants of response to warfarin during initial anticoagulation. N Engl J Med 4421 2008;358:999-1008. 4422 Tang T, Liu J, Zuo K, Cheng J, Chen L, Lu C, Han S, Xu J, Jia Z, Ye M, Pei E, Zhang X, Li M. 501. 4423 Genotype-Guided Dosing of Coumarin Anticoagulants: A Meta-analysis of Randomized Controlled 4424 Trials. J Cardiovasc Pharmacol Ther 2015;20:387-394. 4425 502. Douketis JD, Spyropoulos AC, Kaatz S, Becker RC, Caprini JA, Dunn AS, Garcia DA, 4426 Jacobson A, Jaffer AK, Kong DF, Schulman S, Turpie AG, Hasselblad V, Ortel TL, BRIDGE 4427 Investigators. Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation. N Engl J Med 4428 2015;**373**:823-833. 4429 503. Cuker A, Siegal DM, Crowther MA, Garcia DA. Laboratory measurement of the anticoagulant 4430 activity of the non-vitamin K oral anticoagulants. J Am Coll Cardiol 2014;64:1128-1139. 4431 504. Niessner A, Tamargo J, Morais J, Koller L, Wassmann S, Husted SE, Torp-Pedersen C, Kjeldsen K, Lewis BS, Drexel H, Kaski JC, Atar D, Storey RF, Lip GY, Verheugt FW, Agewall S. 4432 4433 Reversal strategies for non-vitamin K antagonist oral anticoagulants: a critical appraisal of available 4434 evidence and recommendations for clinical management-a joint position paper of the European 4435 Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of 4436 Cardiology Working Group on Thrombosis. Eur Heart J 2015: [Epub ahead of print].

4437 505. Hanley JP. Warfarin reversal. J Clin Pathol 2004;57:1132-1139. 4438 506. Parry-Jones AR, Di Napoli M, Goldstein JN, Schreuder FH, Tetri S, Tatlisumak T, Yan B, van 4439 Nieuwenhuizen KM, Dequatre-Ponchelle N, Lee-Archer M, Horstmann S, Wilson D, Pomero F, 4440 Masotti L, Lerpiniere C, Godoy DA, Cohen AS, Houben R, Salman RA, Pennati P, Fenoglio L, 4441 Werring D, Veltkamp R, Wood E, Dewey HM, Cordonnier C, Klijn CJ, Meligeni F, Davis SM, 4442 Huhtakangas J, Staals J, Rosand J, Meretoja A. Reversal strategies for vitamin K antagonists in acute 4443 intracerebral hemorrhage. Ann Neurol 2015;78:54-62. 4444 507. Goldstein JN, Refaai MA, Milling TJ, Jr., Lewis B, Goldberg-Alberts R, Hug BA, Sarode R. 4445 Four-factor prothrombin complex concentrate versus plasma for rapid vitamin K antagonist reversal in 4446 patients needing urgent surgical or invasive interventions: a phase 3b, open-label, non-inferiority, 4447 randomised trial. Lancet 2015;385:2077-2087. 4448 Siegal DM, Curnutte JT, Connolly SJ, Lu G, Conley PB, Wiens BL, Mathur VS, Castillo J, 508. 4449 Bronson MD, Leeds JM, Mar FA, Gold A, Crowther MA. Andexanet Alfa for the Reversal of Factor Xa 4450 Inhibitor Activity. N Engl J Med 2015;373:2413-2424. 4451 Crowther M, Crowther MA. Antidotes for novel oral anticoagulants: current status and future 509. 4452 potential. Arterioscler Thromb Vasc Biol 2015;35:1736-1745. 4453 510. Staerk L, Lip GY, Olesen JB, Fosbol EL, Pallisgaard JL, Bonde AN, Gundlund A, Lindhardt 4454 TB, Hansen ML, Torp-Pedersen C, Gislason GH. Stroke and recurrent haemorrhage associated with 4455 antithrombotic treatment after gastrointestinal bleeding in patients with atrial fibrillation: nationwide 4456 cohort study. BMJ 2015;351:h5876. 4457 Felmeden DC, Lip GY. Antithrombotic therapy in hypertension: a Cochrane Systematic 511. 4458 review. J Hum Hypertens 2005;19:185-196. 4459 512. Sharma M, Cornelius VR, Patel JP, Davies JG, Molokhia M. Efficacy and Harms of Direct 4460 Oral Anticoagulants in the Elderly for Stroke Prevention in Atrial Fibrillation and Secondary Prevention 4461 of Venous Thromboembolism: Systematic Review and Meta-Analysis. Circulation 2015;132:194-204. 4462 513. Ruiz-Nodar JM, Marin F, Hurtado JA, Valencia J, Pinar E, Pineda J, Gimeno JR, Sogorb F, 4463 Valdes M, Lip GYH. Anticoagulant and antiplatelet therapy use in 426 patients with atrial fibrillation 4464 undergoing percutaneous coronary intervention and stent implantation implications for bleeding risk 4465 and prognosis. J Am Coll Cardiol 2008;51:818-825. 4466 514. Hansen ML, Sorensen R, Clausen MT, Fog-Petersen ML, Raunso J, Gadsboll N, Gislason 4467 GH, Folke F, Andersen SS, Schramm TK, Abildstrom SZ, Poulsen HE, Kober L, Torp-Pedersen C. 4468 Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients 4469 with atrial fibrillation. Arch Intern Med 2010;170:1433-1441. 4470 515. Lamberts M, Olesen JB, Ruwald MH, Hansen CM, Karasov D, Kristensen SL, Kober L, Torp-4471 Pedersen C, Gislason GH, Hansen ML. Bleeding after initiation of multiple antithrombotic drugs, 4472 including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary 4473 intervention: a nationwide cohort study. Circulation 2012;126:1185-1193. 4474 Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, Falk V, Filippatos G, Hamm C, Head 516. 4475 SJ, Juni P, Kappetein AP, Kastrati A, Knuuti J, Landmesser U, Laufer G, Neumann FJ, Richter DJ, 4476 Schauerte P, Sousa Uva M, Stefanini GG, Taggart DP, Torracca L, Valgimigli M, Wijns W, Witkowski 4477 A. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial 4478 Revascularization of the European Society of Cardiology (ESC) and the European Association for 4479 Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European 4480 Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 2014;35:2541-2619. 4481 Vandvik PO, Lincoff AM, Gore JM, Gutterman DD, Sonnenberg FA, Alonso-Coello P, Akl EA, 517. 4482 Lansberg MG, Guyatt GH, Spencer FA, American College of Chest Physicians. Primary and 4483 secondary prevention of cardiovascular disease: Antithrombotic Therapy and Prevention of 4484 Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice 4485 Guidelines. Chest 2012;141:e637S-668S. 4486 Rubboli A, Faxon DP, Juhani Airaksinen KE, Schlitt A, Marin F, Bhatt DL, Lip GYH. The 518. 4487 optimal management of patients on oral anticoagulation undergoing coronary artery stenting. The 4488 10th Anniversary Overview. Thromb Haemost 2014;112:1080-1087. 4489 519. Oldgren J, Wallentin L, Alexander JH, James S, Jonelid B, Steg G, Sundstrom J. New oral 4490 anticoagulants in addition to single or dual antiplatelet therapy after an acute coronary syndrome: a 4491 systematic review and meta-analysis. Eur Heart J 2013;34:1670-1680. 4492 Lip GY, Windecker S, Huber K, Kirchhof P, Marin F, Ten Berg JM, Haeusler KG, Boriani G, 520. 4493 Capodanno D, Gilard M, Zeymer U, Lane D, Storey RF, Bueno H, Collet JP, Fauchier L, Halvorsen S, 4494 Lettino M, Morais J, Mueller C, Potpara TS, Rasmussen LH, Rubboli A, Tamargo J, Valgimigli M, 4495 Zamorano JL. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute 4496 coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint

4497 consensus document of the European Society of Cardiology Working Group on Thrombosis, 4498 European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular 4499 Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the 4500 Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS). Eur Heart J 4501 2014;**35**:3155-3179. 4502 521. Mega JL, Braunwald E, Mohanavelu S, Burton P, Poulter R, Misselwitz F, Hricak V, 4503 Barnathan ES, Bordes P, Witkowski A, Markov V, Oppenheimer L, Gibson CM, ATLAS ACS-TIMI 46 4504 study group. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-4505 TIMI 46): a randomised, double-blind, phase II trial. Lancet 2009;374:29-38. 4506 Sarafoff N, Martischnig A, Wealer J, Mayer K, Mehilli J, Sibbing D, Kastrati A. Triple therapy 522. 4507 with aspirin, prasugrel, and vitamin K antagonists in patients with drug-eluting stent implantation and 4508 an indication for oral anticoagulation. J Am Coll Cardiol 2013;61:2060-2066. 4509 Jackson LR, 2nd, Ju C, Zettler M, Messenger JC, Cohen DJ, Stone GW, Baker BA, Effron M, 523 4510 Peterson ED. Wang TY. Outcomes of Patients With Acute Myocardial Infarction Undergoing 4511 Percutaneous Coronary Intervention Receiving an Oral Anticoagulant and Dual Antiplatelet Therapy: 4512 A Comparison of Clopidogrel Versus Prasugrel From the TRANSLATE-ACS Study. JACC Cardiovasc 4513 Interv 2015;8:1880-1889. 4514 524. Dewilde WJM, Oirbans T, Verheugt FWA, Kelder JC, De Smet BJGL, Herrman J-P, 4515 Adriaenssens T, Vrolix M, Heestermans AACM, Vis MM, Tijsen JGP, van 't Hof AW, ten Berg JM. Use 4516 of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing 4517 percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet 4518 2013;**381**:1107-1115. 4519 525. Braun OÖ, Bico B, Chaudhry U, Wagner H, Koul S, Tyden P, Schersten F, Jovinge S, 4520 Svensson PJ, Gustav Smith J, van der Pals J. Concomitant use of warfarin and ticagrelor as an 4521 alternative to triple antithrombotic therapy after an acute coronary syndrome. Thromb Res 4522 2015;135:26-30. 4523 Nikolaidou T, Channer KS. Chronic atrial fibrillation: a systematic review of medical heart rate 526. 4524 control management. Postgrad Med J 2009;85:303-312. 4525 527. Tamariz LJ, Bass EB. Pharmacological rate control of atrial fibrillation. Cardiol Clin 4526 2004;22:35-45. 4527 528. Segal JB, McNamara RL, Miller MR, Kim N, Goodman SN, Powe NR, Robinson K, Yu D, 4528 Bass EB. The evidence regarding the drugs used for ventricular rate control. In. J Fam Practice; 2000, 4529 47-59. 4530 529. Schreck DM, Rivera AR, Tricarico VJ. Emergency management of atrial fibrillation and flutter: 4531 intravenous diltiazem versus intravenous digoxin. Ann Emerg Med 1997;29:135-140. 4532 Siu CW, Lau CP, Lee WL, Lam KF, Tse HF. Intravenous diltiazem is superior to intravenous 530. 4533 amiodarone or digoxin for achieving ventricular rate control in patients with acute uncomplicated atrial 4534 fibrillation. Crit Care Med 2009;37:2174-2179; quiz 2180. 4535 Tisdale JE, Padhi ID, Goldberg AD, Silverman NA, Webb CR, Higgins RS, Paone G, Frank 531. 4536 DM, Borzak S. A randomized, double-blind comparison of intravenous diltiazem and digoxin for atrial 4537 fibrillation after coronary artery bypass surgery. Am Heart J 1998;135:739-747. 4538 Scheuermeyer FX, Grafstein E, Stenstrom R, Christenson J, Heslop C, Heilbron B, McGrath 532. 4539 L, Innes G. Safety and efficiency of calcium channel blockers versus beta-blockers for rate control in 4540 patients with atrial fibrillation and no acute underlying medical illness. Acad Emerg Med 2013;20:222-4541 230. 4542 533. Darby AE, Dimarco JP. Management of atrial fibrillation in patients with structural heart 4543 disease. Circulation 2012;125:945-957. 4544 534. Elkayam U. Calcium channel blockers in heart failure. Cardiology 1998;89 Suppl 1:38-46. 4545 535. Goldstein RE, Boccuzzi SJ, Cruess D, Nattel S. Diltiazem increases late-onset congestive 4546 heart failure in postinfarction patients with early reduction in ejection fraction. The Adverse Experience 4547 Committee; and the Multicenter Diltiazem Postinfarction Research Group. Circulation 1991;83:52-60. 4548 536. Clemo HF, Wood MA, Gilligan DM, Ellenbogen KA. Intravenous amiodarone for acute heart 4549 rate control in the critically ill patient with atrial tachyarrhythmias. Am J Cardiol 1998;81:594-598. 4550 537. Delle Karth G, Geppert A, Neunteufl T, Priglinger U, Haumer M, Gschwandtner M, 4551 Siostrzonek P, Heinz G. Amiodarone versus diltiazem for rate control in critically ill patients with atrial 4552 tachyarrhythmias. Crit Care Med 2001;29:1149-1153. 4553 538. Hou ZY, Chang MS, Chen CY, Tu MS, Lin SL, Chiang HT, Woosley RL. Acute treatment of 4554 recent-onset atrial fibrillation and flutter with a tailored dosing regimen of intravenous amiodarone. A

4555 randomized, digoxin-controlled study. *Eur Heart J* 1995;**16**:521-528.

4556	539. National Institute for Health and Care Excellence (NICE). <i>Atrial fibrillation: management.</i>
4557	NICE guidelines [CG180]. http://www.nice.org.uk/guidance/cg180/. Date last accessed 5 May
4558	2016 Accessed 15/09/2014; http://www.nice.org.uk/guidance/cg180/
4559	540. Kotecha D, Manzano L, Krum H, Rosano G, Holmes J, Altman DG, Collins P, Packer M,
4560	Wikstrand J, Coats AJS, Cleland JGF, Kirchhof P, von Lueder TG, Rigby A, Andersson B, Lip GYH,
4561	van Veldhuisen DJ, Shibata MC, Wedel H, Böhm M, Flather MD, Beta-Blockers in Heart Failure
4562	Collaborative Group. Effect of age and sex on efficacy and tolerability of β blockers in patients with
4563	heart failure with reduced ejection fraction: individual patient data meta-analysis. <i>BMJ</i>
4564	2016; 353 :i1855.
4565	541. Ulimoen SR, Enger S, Carlson J, Platonov PG, Pripp AH, Abdelnoor M, Arnesen H, Gjesdal
4566	K, Tveit A. Comparison of four single-drug regimens on ventricular rate and arrhythmia-related
4567	symptoms in patients with permanent atrial fibrillation. <i>Am J Cardiol</i> 2013; 111 :225-230.
4568	542. Ulimoen SR, Enger S, Pripp AH, Abdelnoor M, Arnesen H, Gjesdal K, Tveit A. Calcium
4569	channel blockers improve exercise capacity and reduce N-terminal Pro-B-type natriuretic peptide
4570	levels compared with beta-blockers in patients with permanent atrial fibrillation. Eur Heart J
4571	2014; 35 :517-524.
4572	
4573	foxglove. JAMA Intern Med 2014; 174 :151-154.
4574	544. The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients
4575	with heart failure. N Engl J Med 1997; 336 :525-533.
4576	545. Ahmed A, Rich MW, Fleg JL, Zile MR, Young JB, Kitzman DW, Love TE, Aronow WS, Adams
4577	KF, Jr., Gheorghiade M. Effects of digoxin on morbidity and mortality in diastolic heart failure: the
4578	ancillary digitalis investigation group trial. <i>Circulation</i> 2006; 114 :397-403.
4579	546. Ziff OJ, Kotecha D. Digoxin: The good and the bad. <i>Trends in Cardiovascular Medicine</i>
4580	2016:[Epub ahead of print].
4581	547. Turakhia MP, Santangeli P, Winkelmayer WC, Xu X, Ullal AJ, Than CT, Schmitt S, Holmes
4582	TH, Frayne SM, Phibbs CS, Yang F, Hoang DD, Ho PM, Heidenreich PA. Increased mortality
4583	associated with digoxin in contemporary patients with atrial fibrillation: findings from the TREAT-AF
4584	study. J Am Coll Cardiol 2014;64:660-668.
4585	548. Hallberg P, Lindback J, Lindahl B, Stenestrand U, Melhus H. Digoxin and mortality in atrial
4586	
4587	
4588	Macaulay T, Sorrell VL, Campbell CL, Gurley J, Anaya P, Nasr H, Bai R, Di Biase L, Booth DC,
4589	Jondeau G, Natale A, Roy D, Smyth S, Moliterno DJ, Elayi CS. Increased mortality among patients
4590	
4591	550. Gheorghiade M, Fonarow GC, van Veldhuisen DJ, Cleland JG, Butler J, Epstein AE, Patel K,
	Aban IB, Aronow WS, Anker SD, Ahmed A. Lack of evidence of increased mortality among patients
4593	with atrial fibrillation taking digoxin: findings from post hoc propensity-matched analysis of the
4594	AFFIRM trial. <i>Eur Heart J</i> 2013; 34 :1489-1497.
	551. Flory JH, Ky B, Haynes K, S MB, Munson J, Rowan C, Strom BL, Hennessy S. Observational
4596	cohort study of the safety of digoxin use in women with heart failure. <i>BMJ Open</i> 2012; 2 :e000888.
4597 4598	552. Andrey JL, Romero S, Garcia-Egido A, Escobar MA, Corzo R, Garcia-Dominguez G, Lechuga
4599	V, Gomez F. Mortality and morbidity of heart failure treated with digoxin. A propensity-matched study. <i>Int J Clin Pract</i> 2011; 65 :1250-1258.
4600	553. Allen LA, Fonarow GC, Simon DN, Thomas LE, Marzec LN, Pokorney SD, Gersh BJ, Go AS,
4601	Hylek EM, Kowey PR, Mahaffey KW, Chang P, Peterson ED, Piccini JP, ORBIT-AF Investigators.
4602	Digoxin Use and Subsequent Outcomes Among Patients in a Contemporary Atrial Fibrillation Cohort.
4603	J Am Coll Cardiol 2015; 65 :2691-2698.
4604	554. Khand AU, Rankin AC, Martin W, Taylor J, Gemmell I, Cleland JG. Carvedilol alone or in
4605	combination with digoxin for the management of atrial fibrillation in patients with heart failure? <i>J Am</i>
4606	Coll Cardiol 2003; 42 :1944-1951.
4607	555. Farshi R, Kistner D, Sarma JS, Longmate JA, Singh BN. Ventricular rate control in chronic
4608	atrial fibrillation during daily activity and programmed exercise: a crossover open-label study of five
4609	drug regimens. J Am Coll Cardiol 1999;33:304-310.
4610	556. Koh KK, Kwon KS, Park HB, Baik SH, Park SJ, Lee KH, Kim EJ, Kim SH, Cho SK, Kim SS.
4611	Efficacy and safety of digoxin alone and in combination with low-dose diltiazem or betaxolol to control
4612	ventricular rate in chronic atrial fibrillation. Am J Cardiol 1995;75:88-90.
4613	557. Lewis RV, McMurray J, McDevitt DG. Effects of atenolol, verapamil, and xamoterol on heart
4614	rate and exercise tolerance in digitalised patients with chronic atrial fibrillation. J Cardiovasc
4615	Pharmacol 1989; 13 :1-6.

4616 558. Tsuneda T, Yamashita T, Fukunami M, Kumagai K, Niwano S, Okumura K, Inoue H. Rate 4617 control and quality of life in patients with permanent atrial fibrillation: the Quality of Life and Atrial 4618 Fibrillation (QOLAF) Study. Circ J 2006;70:965-970. 4619 ClinicalTrials.gov. Rate Control Therapy Evaluation in Permanent Atrial Fibrillation (RATE-559. 4620 AF). https://clinicaltrials.gov/ct2/show/NCT02391337. Date last accessed 5 May 2016 4621 560. Van Gelder IC, Groenveld HF, Crijns HJ, Tuininga YS, Tijssen JG, Alings AM, Hillege HL, 4622 Bergsma-Kadijk JA, Cornel JH, Kamp O, Tukkie R, Bosker HA, Van Veldhuisen DJ, Van den Berg 4623 MP, RACE II Investigators. Lenient versus strict rate control in patients with atrial fibrillation. N Engl J 4624 Med 2010;362:1363-1373. 4625 561. Groenveld HF, Crijns HJ, Van den Berg MP, Van Sonderen E, Alings AM, Tijssen JG, Hillege 4626 HL, Tuininga YS, Van Veldhuisen DJ, Ranchor AV, Van Gelder IC, RACE II Investigators. The effect 4627 of rate control on quality of life in patients with permanent atrial fibrillation: data from the RACE II 4628 (Rate Control Efficacy in Permanent Atrial Fibrillation II) study. J Am Coll Cardiol 2011;58:1795-1803. 4629 Van Gelder IC, Wyse DG, Chandler ML, Cooper HA, Olshansky B, Hagens VE, Crijns HJ, 562. 4630 RACE and AFFIRM Investigators. Does intensity of rate-control influence outcome in atrial fibrillation? 4631 An analysis of pooled data from the RACE and AFFIRM studies. Europace 2006;8:935-942. 4632 Queiroga A, Marshall HJ, Clune M, Gammage MD. Ablate and pace revisited: long term 563. 4633 survival and predictors of permanent atrial fibrillation. Heart 2003;89:1035-1038. 4634 564. Lim KT, Davis MJ, Powell A, Arnolda L, Moulden K, Bulsara M, Weerasooriya R. Ablate and 4635 pace strategy for atrial fibrillation: long-term outcome of AIRCRAFT trial. Europace 2007;9:498-505. 4636 565. Geelen P, Brugada J, Andries E, Brugada P. Ventricular fibrillation and sudden death after 4637 radiofrequency catheter ablation of the atrioventricular junction. Pacing Clin Electrophysiol 4638 1997;20:343-348. 4639 566. Wang RX, Lee HC, Hodge DO, Cha YM, Friedman PA, Rea RF, Munger TM, Jahangir A, 4640 Srivathsan K, Shen WK. Effect of pacing method on risk of sudden death after atrioventricular node 4641 ablation and pacemaker implantation in patients with atrial fibrillation. Heart Rhythm 2013;10:696-701. 4642 567. Chatteriee NA, Upadhyay GA, Ellenbogen KA, McAlister FA, Choudhry NK, Singh JP. 4643 Atrioventricular nodal ablation in atrial fibrillation: a meta-analysis and systematic review. Circ 4644 Arrhythm Electrophysiol 2012;5:68-76. 4645 568. Bradley DJ, Shen WK. Overview of management of atrial fibrillation in symptomatic elderly 4646 patients: pharmacologic therapy versus AV node ablation. Clin Pharmacol Ther 2007;81:284-287. 4647 Wood MA, Brown-Mahoney C, Kay GN, Ellenbogen KA. Clinical outcomes after ablation and 569. 4648 pacing therapy for atrial fibrillation : a meta-analysis. Circulation 2000;101:1138-1144. 4649 Ozcan C, Jahangir A, Friedman PA, Patel PJ, Munger TM, Rea RF, Lloyd MA, Packer DL, 570. 4650 Hodge DO, Gersh BJ, Hammill SC, Shen WK. Long-term survival after ablation of the atrioventricular 4651 node and implantation of a permanent pacemaker in patients with atrial fibrillation. N Engl J Med 4652 2001;344:1043-1051. 4653 571. Hess PL, Jackson KP, Hasselblad V, Al-Khatib SM. Is cardiac resynchronization therapy an 4654 antiarrhythmic therapy for atrial fibrillation? A systematic review and meta-analysis. Curr Cardiol Rep 4655 2013;**15**:330. 4656 Hoppe UC, Casares JM, Eiskjaer H, Hagemann A, Cleland JG, Freemantle N, Erdmann E. 572. 4657 Effect of cardiac resynchronization on the incidence of atrial fibrillation in patients with severe heart 4658 failure. Circulation 2006;114:18-25. 4659 Brignole M, Auricchio A, Baron-Esquivias G, Bordachar P, Boriani G, Breithardt OA, Cleland 573. 4660 J. Deharo JC, Delgado V, Elliott PM, Gorenek B, Israel CW, Leclercg C, Linde C, Mont L, Padeletti L, 4661 Sutton R. Vardas PE, Zamorano JL, Achenbach S, Baumgartner H, Bax JJ, Bueno H, Dean V. 4662 Deaton C, Erol C, Fagard R, Ferrari R, Hasdai D, Hoes AW, Kirchhof P, Knuuti J, Kolh P, Lancellotti 4663 P, Linhart A, Nihovannopoulos P, Piepoli MF, Ponikowski P, Sirnes PA, Tamargo JL, Tendera M, 4664 Torbicki A, Wijns W, Windecker S, Kirchhof P, Blomstrom-Lundqvist C, Badano LP, Aliyev F, Bansch 4665 D, Baumgartner H, Bsata W, Buser P, Charron P, Daubert JC, Dobreanu D, Faerestrand S, Hasdai D, 4666 Hoes AW, Le Heuzey JY, Mavrakis H, McDonagh T, Merino JL, Nawar MM, Nielsen JC, Pieske B, Poposka L, Ruschitzka F, Tendera M, Van Gelder IC, Wilson CM. 2013 ESC Guidelines on cardiac 4667 4668 pacing and cardiac resynchronization therapy: the Task Force on cardiac pacing and 4669 resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration 4670 with the European Heart Rhythm Association (EHRA). Eur Heart J 2013;34:2281-2329. 4671 Chatterjee NA, Upadhyay GA, Ellenbogen KA, Hayes DL, Singh JP. Atrioventricular nodal 574. 4672 ablation in atrial fibrillation: a meta-analysis of biventricular vs. right ventricular pacing mode. Eur J 4673 Heart Fail 2012;14:661-667.

4674 575. Lewis RV, Irvine N, McDevitt DG. Relationships between heart rate, exercise tolerance and 4675 cardiac output in atrial fibrillation: the effects of treatment with digoxin, verapamil and diltiazem. Eur 4676 Heart J 1988;9:777-781. 4677 Mulder BA, Van Veldhuisen DJ, Crijns HJ, Tijssen JG, Hillege HL, Alings M, Rienstra M, Van 576. 4678 den Berg MP, Van Gelder IC, RACE II Investigators. Digoxin in patients with permanent atrial 4679 fibrillation: data from the RACE II study. Heart Rhythm 2014;11:1543-1550. 4680 Koh KK, Song JH, Kwon KS, Park HB, Baik SH, Park YS, In HH, Moon TH, Park GS, Cho SK, 577. 4681 Kim SS. Comparative study of efficacy and safety of low-dose diltiazem or betaxolol in combination 4682 with digoxin to control ventricular rate in chronic atrial fibrillation: randomized crossover study. Int J 4683 Cardiol 1995;52:167-174. 4684 Chatterjee S, Sardar P, Lichstein E, Mukherjee D, Aikat S. Pharmacologic rate versus rhythm-578. 4685 control strategies in atrial fibrillation: an updated comprehensive review and meta-analysis. PACE 4686 2013;36:122-133. 4687 de Denus S. Sanoski CA. Carlsson J. Opolski G. Spinler SA. Rate vs rhvthm control in 579. 4688 patients with atrial fibrillation: a meta-analysis. Arch Intern Med 2005:165:258-262. 4689 580. Lafuente-Lafuente C, Longas-Tejero MA, Bergmann JF, Belmin J. Antiarrhythmics for 4690 maintaining sinus rhythm after cardioversion of atrial fibrillation. Cochrane Database Syst Rev 4691 2012;5:CD005049. 4692 Roy D, Talajic M, Dorian P, Connolly S, Eisenberg MJ, Green M, Kus T, Lambert J, Dubuc M, 581. 4693 Gagne P, Nattel S, Thibault B. Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of 4694 Atrial Fibrillation Investigators. N Engl J Med 2000;342:913-920. 4695 Roy D, Talajic M, Nattel S, Wyse DG, Dorian P, Lee KL, Bourassa MG, Arnold JM, Buxton 582. 4696 AE, Camm AJ, Connolly SJ, Dubuc M, Ducharme A, Guerra PG, Hohnloser SH, Lambert J, Le 4697 Heuzey JY, O'Hara G, Pedersen OD, Rouleau JL, Singh BN, Stevenson LW, Stevenson WG, Thibault 4698 B, Waldo AL. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med 4699 2008;358:2667-2677. 4700 583. Singh BN, Connolly SJ, Crijns HJ, Roy D, Kowey PR, Capucci A, Radzik D, Aliot EM, 4701 Hohnloser SH. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N Engl J 4702 Med 2007;357:987-999. 4703 584. Kirchhof P, Andresen D, Bosch R, Borggrefe M, Meinertz T, Parade U, Ravens U, Samol A, 4704 Steinbeck G, Treszl A, Wegscheider K, Breithardt G. Short-term versus long-term antiarrhythmic drug 4705 treatment after cardioversion of atrial fibrillation (Flec-SL): a prospective, randomised, open-label, 4706 blinded endpoint assessment trial. Lancet 2012;380:238-246. 4707 585. Cosedis Nielsen J, Johannessen A, Raatikainen P, Hindricks G, Walfridsson H, Kongstad O, 4708 Pehrson S, Englund A, Hartikainen J, Mortensen LS, Hansen PS. Radiofrequency ablation as initial 4709 therapy in paroxysmal atrial fibrillation. N Engl J Med 2012;367:1587-1595. 4710 586. Wilber DJ, Pappone C, Neuzil P, De Paola A, Marchlinski F, Natale A, Macle L, Daoud EG, 4711 Calkins H, Hall B, Reddy V, Augello G, Reynolds MR, Vinekar C, Liu CY, Berry SM, Berry DA, 4712 ThermoCool AF Trial Investigators. Comparison of antiarrhythmic drug therapy and radiofrequency 4713 catheter ablation in patients with paroxysmal atrial fibrillation: a randomized controlled trial. JAMA 4714 2010;303:333-340. 4715 Arbelo E, Brugada J, Hindricks G, Maggioni AP, Tavazzi L, Vardas P, Laroche C, Anselme F, 587. 4716 Inama G, Jais P, Kalarus Z, Kautzner J, Lewalter T, Mairesse GH, Perez-Villacastin J, Riahi S, 4717 Taborsky M, Theodorakis G, Trines SA, Atrial Fibrillation Ablation Pilot Study Investigators. The atrial 4718 fibrillation ablation pilot study: a European Survey on Methodology and results of catheter ablation for 4719 atrial fibrillation conducted by the European Heart Rhythm Association. Eur Heart J 2014;35:1466-4720 1478. 4721 588. Hohnloser SH, Crijns HJ, van Eickels M, Gaudin C, Page RL, Torp-Pedersen C, Connolly SJ. 4722 Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med 2009;360:668-678. 4723 Wyse DG, Waldo AL, DiMarco JP, Domanski MJ, Rosenberg Y, Schron EB, Kellen JC, 589. 4724 Greene HL, Mickel MC, Dalquist JE, Corley SD. A comparison of rate control and rhythm control in 4725 patients with atrial fibrillation. N Engl J Med 2002;347:1825-1833. 4726 590. Van Gelder IC, Hagens VE, Bosker HA, Kingma JH, Kamp O, Kingma T, Said SA, Darmanata 4727 JI, Timmermans AJ, Tijssen JG, Crijns HJ, Rate Control versus Electrical Cardioversion for Persistent 4728 Atrial Fibrillation Study Group. A comparison of rate control and rhythm control in patients with 4729 recurrent persistent atrial fibrillation. N Engl J Med 2002;347:1834-1840. 4730 591. Opolski G, Torbicki A, Kosior DA, Szulc M, Wozakowska-Kaplon B, Kolodziej P, Achremczyk 4731 P, Investigators of the Polish How to Treat Chronic Atrial Fibrillation Study. Rate control vs rhythm control in patients with nonvalvular persistent atrial fibrillation: the results of the Polish How to Treat 4732 4733 Chronic Atrial Fibrillation (HOT CAFE) Study. Chest 2004;126:476-486.

4734 592. Kong MH, Shaw LK, O'Connor C, Califf RM, Blazing MA, Al-Khatib SM. Is rhythm-control 4735 superior to rate-control in patients with atrial fibrillation and diastolic heart failure? Ann Noninvasive 4736 Electrocardiol 2010;15:209-217. 4737 Kotecha D, Kirchhof P. Rate and rhythm control have comparable effects on mortality and 593. 4738 stroke in atrial fibrillation but better data are needed. Evid Based Med 2014;19:222-223. 4739 594. ClinicalTrials.gov. Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation 4740 Trial (CABANA). https://clinicaltrials.gov/ct2/show/NCT00911508. Date last accessed 5 May 4741 2016 NLM Identifier: NCT00911508 [Accessed 20-May-2015] 4742 595. Khan IA. Oral loading single dose flecainide for pharmacological cardioversion of recent-onset 4743 atrial fibrillation. Int J Cardiol 2003;87:121-128. 4744 596. Chevalier P, Durand-Dubief A, Burri H, Cucherat M, Kirkorian G, Touboul P. Amiodarone 4745 versus placebo and class Ic drugs for cardioversion of recent-onset atrial fibrillation: a meta-analysis. 4746 J Am Coll Cardiol 2003;41:255-262. 4747 Letelier LM, Udol K, Ena J, Weaver B, Guyatt GH. Effectiveness of amiodarone for 597. 4748 conversion of atrial fibrillation to sinus rhythm: a meta-analysis. Arch Intern Med 2003;163:777-785. 4749 598. Khan IA, Mehta NJ, Gowda RM. Amiodarone for pharmacological cardioversion of recent-4750 onset atrial fibrillation. Int J Cardiol 2003:89:239-248. 4751 599. Thomas SP, Guy D, Wallace E, Crampton R, Kijvanit P, Eipper V, Ross DL, Cooper MJ. 4752 Rapid loading of sotalol or amiodarone for management of recent onset symptomatic atrial fibrillation: 4753 a randomized, digoxin-controlled trial. Am Heart J 2004;147:E3. 4754 Vijayalakshmi K, Whittaker VJ, Sutton A, Campbell P, Wright RA, Hall JA, Harcombe AA, 600. 4755 Linker NJ, Stewart MJ, Davies A, de Belder MA. A randomized trial of prophylactic antiarrhythmic 4756 agents (amiodarone and sotalol) in patients with atrial fibrillation for whom direct current cardioversion 4757 is planned. Am Heart J 2006;151:863 e861-866. 4758 601. Singh BN, Singh SN, Reda DJ, Tang XC, Lopez B, Harris CL, Fletcher RD, Sharma SC, 4759 Atwood JE, Jacobson AK, Lewis HD, Jr., Raisch DW, Ezekowitz MD. Amiodarone versus sotalol for 4760 atrial fibrillation. N Engl J Med 2005:352:1861-1872. 4761 Roy D, Pratt CM, Torp-Pedersen C, Wyse DG, Toft E, Juul-Moller S, Nielsen T, Rasmussen 602. 4762 SL, Stiell IG, Coutu B, Ip JH, Pritchett EL, Camm AJ. Vernakalant hydrochloride for rapid conversion 4763 of atrial fibrillation: a phase 3, randomized, placebo-controlled trial. Circulation 2008;117:1518-1525. 4764 Kowey PR, Dorian P, Mitchell LB, Pratt CM, Roy D, Schwartz PJ, Sadowski J, Sobczyk D, 603. 4765 Bochenek A, Toft E. Vernakalant hydrochloride for the rapid conversion of atrial fibrillation after 4766 cardiac surgery: a randomized, double-blind, placebo-controlled trial. Circ Arrhythm Electrophysiol 4767 2009;**2**:652-659. 4768 604. Camm AJ, Capucci A, Hohnloser SH, Torp-Pedersen C, Van Gelder IC, Mangal B, Beatch G. 4769 A randomized active-controlled study comparing the efficacy and safety of vernakalant to amiodarone 4770 in recent-onset atrial fibrillation. J Am Coll Cardiol 2011;57:313-321. 4771 605. Bash LD, Buono JL, Davies GM, Martin A, Fahrbach K, Phatak H, Avetisyan R, Mwamburi M. 4772 Systematic review and meta-analysis of the efficacy of cardioversion by vernakalant and comparators 4773 in patients with atrial fibrillation. Cardiovasc Drugs Ther 2012;26:167-179. 4774 606. Falk RH, Pollak A, Singh SN, Friedrich T. Intravenous dofetilide, a class III antiarrhythmic 4775 agent, for the termination of sustained atrial fibrillation or flutter. Intravenous Dofetilide Investigators 4776 [see comments]. J Am Coll Cardiol 1997;29:385-390. 4777 Dankner R, Shahar A, Novikov I, Agmon U, Ziv A, Hod H. Treatment of stable atrial fibrillation 607. 4778 in the emergency department: a population-based comparison of electrical direct-current versus 4779 pharmacological cardioversion or conservative management. Cardiology 2009;112:270-278. 4780 608. Chen WS, Gao BR, Chen WQ, Li ZZ, Xu ZY, Zhang YH, Yang K, Guan XQ. Comparison of 4781 pharmacological and electrical cardioversion in permanent atrial fibrillation after prosthetic cardiac 4782 valve replacement: a prospective randomized trial. J Int Med Res 2013;41:1067-1073. 4783 Gitt AK, Smolka W, Michailov G, Bernhardt A, Pittrow D, Lewalter T. Types and outcomes of 609. 4784 cardioversion in patients admitted to hospital for atrial fibrillation: results of the German RHYTHM-AF 4785 Study. Clin Res Cardiol 2013;102:713-723. 4786 610. Cristoni L, Tampieri A, Mucci F, Iannone P, Venturi A, Cavazza M, Lenzi T. Cardioversion of 4787 acute atrial fibrillation in the short observation unit: comparison of a protocol focused on electrical 4788 cardioversion with simple antiarrhythmic treatment. *Emerg Med J* 2011;**28**:932-937. 4789 Bellone A, Etteri M, Vettorello M, Bonetti C, Clerici D, Gini G, Maino C, Mariani M, Natalizi A, 611. 4790 Nessi I, Rampoldi A, Colombo L. Cardioversion of acute atrial fibrillation in the emergency 4791 department: a prospective randomised trial. *Emerg Med J* 2012;29:188-191. 4792 612. Crijns HJ, Weijs B, Fairley AM, Lewalter T, Maggioni AP, Martin A, Ponikowski P, Rosenqvist 4793 M, Sanders P, Scanavacca M, Bash LD, Chazelle F, Bernhardt A, Gitt AK, Lip GY, Le Heuzey JY.

4794 Contemporary real life cardioversion of atrial fibrillation: Results from the multinational RHYTHM-AF 4795 study. Int J Cardiol 2014;172:588-594. 4796 613. Lip GY, Gitt AK, Le Heuzey JY, Bash LD, Morabito CJ, Bernhardt AA, Sisk CM, Chazelle F, 4797 Crijns HJ. Overtreatment and undertreatment with anticoagulation in relation to cardioversion of atrial 4798 fibrillation (the RHYTHM-AF study). Am J Cardiol 2014;113:480-484. 4799 614. Reisinger J, Gatterer E, Lang W, Vanicek T, Eisserer G, Bachleitner T, Niemeth C, Aicher F, 4800 Grander W, Heinze G, Kuhn P, Siostrzonek P. Flecainide versus ibutilide for immediate cardioversion 4801 of atrial fibrillation of recent onset. Eur Heart J 2004;25:1318-1324. 4802 Stambler BS, Wood MA, Ellenbogen KA, Perry KT, Wakefield LK, VanderLugt JT. Efficacy 615. 4803 and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation. 4804 Ibutilide Repeat Dose Study Investigators. Circulation 1996;94:1613-1621. 4805 616. Torp-Pedersen C, Camm AJ, Butterfield NN, Dickinson G, Beatch GN. Vernakalant: 4806 conversion of atrial fibrillation in patients with ischemic heart disease. Int J Cardiol 2013;166:147-151. 4807 Savelieva I, Graydon R, Camm AJ. Pharmacological cardioversion of atrial fibrillation with 617. 4808 vernakalant: evidence in support of the ESC Guidelines. Europace 2014;16:162-173. 4809 618. Simon A, Niederdoeckl J, Skyllouriotis E, Schuetz N, Herkner H, Weiser C, Laggner AN, 4810 Domanovits H, Spiel AO. Vernakalant is superior to ibutilide for achieving sinus rhythm in patients 4811 with recent-onset atrial fibrillation: a randomized controlled trial at the emergency department. 4812 Europace 2016;10.1093/europace/euw052:[Epub ahead of print]. 4813 Reisinger J, Gatterer E, Heinze G, Wiesinger K, Zeindlhofer E, Gattermeier M, Poelzl G, 619. 4814 Kratzer H, Ebner A, Hohenwallner W, Lenz K, Slany J, Kuhn P. Prospective comparison of flecainide 4815 versus sotalol for immediate cardioversion of atrial fibrillation. Am J Cardiol 1998;81:1450-1454. 4816 620. Alboni P, Botto GL, Baldi N, Luzi M, Russo V, Gianfranchi L, Marchi P, Calzolari M, Solano A, 4817 Baroffio R, Gaggioli G. Outpatient treatment of recent-onset atrial fibrillation with the "pill-in-the-4818 pocket" approach. N Engl J Med 2004;351:2384-2391. 4819 621. Saborido CM, Hockenhull J, Bagust A, Boland A, Dickson R, Todd D. Systematic review and 4820 cost-effectiveness evaluation of 'pill-in-the-pocket' strategy for paroxysmal atrial fibrillation compared 4821 to episodic in-hospital treatment or continuous antiarrhythmic drug therapy. Health Technol Assess 4822 2010;14:iii-iv, 1-75. 4823 622. Khan IA. Single oral loading dose of propafenone for pharmacological cardioversion of recent-4824 onset atrial fibrillation. J Am Coll Cardiol 2001;37:542-547. 4825 623. Stroobandt R, Stiels B, Hoebrechts R. Propafenone for conversion and prophylaxis of atrial 4826 fibrillation. Propafenone Atrial Fibrillation Trial Investigators. Am J Cardiol 1997;79:418-423. 4827 624. Hughes C, Sunderij R, Gin K. Oral propafenone for rapid conversion of recent onset atrial 4828 fibrillation - A review. CAN J CARDIOL. Canadian Journal of Cardiology 1997;13:839-842. 4829 Zhang N, Guo JH, Zhang H, Li XB, Zhang P, Xn Y. Comparison of intravenous ibutilide vs. 625. 4830 propafenone for rapid termination of recent onset atrial fibrillation. Int J Clin Pract 2005;59:1395-1400. 4831 Mittal S, Ayati S, Stein KM, Schwartzman D, Cavlovich D, Tchou PJ, Markowitz SM, Slotwiner 626. 4832 DJ, Scheiner MA, Lerman BB. Transthoracic cardioversion of atrial fibrillation: comparison of 4833 rectilinear biphasic versus damped sine wave monophasic shocks. *Circulation* 2000;**101**:1282-1287. 4834 Kirchhof P, Eckardt L, Loh P, Weber K, Fischer RJ, Seidl KH, Böcker D, Breithardt G, 627. 4835 Haverkamp W, Borggrefe M. Anterior-posterior versus anterior-lateral electrode positions for external 4836 cardioversion of atrial fibrillation: a randomised trial. Lancet 2002;360:1275-1279. 4837 628. Kirchhof P, Monnig G, Wasmer K, Heinecke A, Breithardt G, Eckardt L, Bocker D. A trial of 4838 self-adhesive patch electrodes and hand-held paddle electrodes for external cardioversion of atrial 4839 fibrillation (MOBIPAPA). Eur Heart J 2005;26:1292-1297. 4840 629. Furniss SS, Sneyd JR. Safe sedation in modern cardiological practice. Heart 2015;101:1526-4841 1530. 4842 630. Alp N, Rahman S, Bell J, Shahi M. Randomised comparison of antero-lateral versus antero-4843 posterior paddle positions for DC cardioversion of persistent atrial fibrillation. Int J Cardiol 4844 2000;75:211-216. 4845 Singh SN, Tang XC, Reda D, Singh BN. Systematic electrocardioversion for atrial fibrillation 631. 4846 and role of antiarrhythmic drugs: a substudy of the SAFE-T trial. Heart Rhythm 2009;6:152-155. 4847 632. Channer KS, Birchall A, Steeds RP, Walters SJ, Yeo WW, West JN, Muthusamy R, Rhoden 4848 WE, Saeed BT, Batin P, Brooksby WP, Wilson I, Grant S. A randomized placebo-controlled trial of 4849 pre-treatment and short- or long-term maintenance therapy with amiodarone supporting DC 4850 cardioversion for persistent atrial fibrillation. Eur Heart J 2004;25:144-150. 4851 Oral H, Souza JJ, Michaud GF, Knight BP, Goyal R, Strickberger SA, Morady F. Facilitating 633. 4852 transthoracic cardioversion of atrial fibrillation with ibutilide pretreatment. N Engl J Med 4853 1999;**340**:1849-1854.

4854 Mussigbrodt A, John S, Kosiuk J, Richter S, Hindricks G, Bollmann A. Vernakalant-facilitated 634. 4855 electrical cardioversion: comparison of intravenous vernakalant and amiodarone for drug-enhanced 4856 electrical cardioversion of atrial fibrillation after failed electrical cardioversion. Europace 2016;18:51-4857 56. 4858 Bianconi L, Mennuni M, Lukic V, Castro A, Chieffi M, Santini M. Effects of oral propafenone 635. 4859 administration before electrical cardioversion of chronic atrial fibrillation: a placebo-controlled study. J 4860 Am Coll Cardiol 1996;28:700-706. 4861 636. Nergardh AK, Rosenqvist M, Nordlander R, Frick M. Maintenance of sinus rhythm with 4862 metoprolol CR initiated before cardioversion and repeated cardioversion of atrial fibrillation: a 4863 randomized double-blind placebo-controlled study. Eur Heart J 2007;28:1351-1357. 4864 637. Hemels ME, Van Noord T, Crijns HJ, Van Veldhuisen DJ, Veeger NJ, Bosker HA, Wiesfeld 4865 AC, Van den Berg MP, Ranchor AV, Van Gelder IC. Verapamil versus digoxin and acute versus 4866 routine serial cardioversion for the improvement of rhythm control for persistent atrial fibrillation. J Am 4867 Coll Cardiol 2006;48:1001-1009. 4868 Villani GQ, Piepoli MF, Terracciano C, Capucci A. Effects of diltiazem pretreatment on direct-638. 4869 current cardioversion in patients with persistent atrial fibrillation: a single-blind, randomized, controlled 4870 study. Am Heart J 2000;140:e12. 4871 639. De Simone A, Stabile G, Vitale DF, Turco P, Di Stasio M, Petrazzuoli F, Gasparini M, De 4872 Matteis C, Rotunno R, Di Napoli T. Pretreatment with verapamil in patients with persistent or chronic 4873 atrial fibrillation who underwent electrical cardioversion. J Am Coll Cardiol 1999;34:810-814. 4874 The Digitalis in Acute Atrial Fibrillation (DAAF) Trial Group. Intravenous digoxin in acute atrial 640. 4875 fibrillation. Results of a randomized, placebo-controlled multicentre trial in 239 patients. Eur Heart J 4876 1997;18:649-654. 4877 641. Atarashi H, Inoue H, Fukunami M, Sugi K, Hamada C, Origasa H. Double-blind placebo-4878 controlled trial of aprindine and digoxin for the prevention of symptomatic atrial fibrillation. Circ J 4879 2002;66:553-556. 4880 642. Airaksinen KE, Gronberg T, Nuotio I, Nikkinen M, Ylitalo A, Biancari F, Hartikainen JE. 4881 Thromboembolic complications after cardioversion of acute atrial fibrillation: the FinCV (Finnish 4882 CardioVersion) study. J Am Coll Cardiol 2013;62:1187-1192. 4883 643. Hansen ML, Jepsen RM, Olesen JB, Ruwald MH, Karasoy D, Gislason GH, Hansen J, Kober 4884 L, Husted S, Torp-Pedersen C. Thromboembolic risk in 16 274 atrial fibrillation patients undergoing 4885 direct current cardioversion with and without oral anticoagulant therapy. Europace 2015;17:18-23. 4886 644. Schadlich PK, Schmidt-Lucke C, Huppertz E, Lehmacher W, Nixdorff U, Stellbrink C, Brecht 4887 JG. Economic evaluation of enoxaparin for anticoagulation in early cardioversion of persisting 4888 nonvalvular atrial fibrillation: a statutory health insurance perspective from Germany. Am J Cardiovasc 4889 Drugs 2007;7:199-217. 4890 645. Schmidt-Lucke C, Paar WD, Stellbrink C, Nixdorff U, Hofmann T, Meurer J, Grewe R, Daniel 4891 WG, Hanrath P, Mugge A, Klein HU, Schmidt-Lucke JA. Quality of anticoagulation with unfractionated 4892 heparin plus phenprocoumon for the prevention of thromboembolic complications in cardioversion for 4893 non-valvular atrial fibrillation. Sub-analysis from the Anticoagulation in Cardioversion using 4894 Enoxaparin (ACE) trial. Thromb Res 2007;119:27-34. 4895 Stellbrink C, Nixdorff U, Hofmann T, Lehmacher W, Daniel WG, Hanrath P, Geller C, Mugge 646. 4896 A, Sehnert W, Schmidt-Lucke C, Schmidt-Lucke JA. Safety and efficacy of enoxaparin compared with 4897 unfractionated heparin and oral anticoagulants for prevention of thromboembolic complications in 4898 cardioversion of nonvalvular atrial fibrillation: the Anticoagulation in Cardioversion using Enoxaparin 4899 (ACE) trial. Circulation 2004;109:997-1003. 4900 647. Nuotio I, Hartikainen JE, Gronberg T, Biancari F, Airaksinen KE. Time to cardioversion for 4901 acute atrial fibrillation and thromboembolic complications. JAMA 2014;312:647-649. 4902 648. Klein AL, Grimm RA, Murray RD, Apperson-Hansen C, Asinger RW, Black IW, Davidoff R, 4903 Erbel R, Halperin JL, Orsinelli DA, Porter TR, Stoddard MF. Use of transesophageal 4904 echocardiography to guide cardioversion in patients with atrial fibrillation. N Engl J Med 4905 2001;344:1411-1420. 4906 649. Cappato R, Ezekowitz MD, Klein AL, Camm AJ, Ma CS, Le Heuzey JY, Talajic M, 4907 Scanavacca M, Vardas PE, Kirchhof P, Hemmrich M, Lanius V, Meng IL, Wildgoose P, van Eickels M, 4908 Hohnloser SH, Investigators XV. Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial 4909 fibrillation. Eur Heart J 2014;35:3346-3355. 4910 650. Darkner S, Chen X, Hansen J, Pehrson S, Johannessen A, Nielsen JB, Svendsen JH. 4911 Recurrence of arrhythmia following short-term oral AMIOdarone after CATheter ablation for atrial 4912 fibrillation: a double-blind, randomized, placebo-controlled study (AMIO-CAT trial). Eur Heart J

4913 2014;**35**:3356-3364.

4914 651. Singh SN, Fletcher RD, Fisher SG, Singh BN, Lewis HD, Deedwania PC, Massie BM, Colling 4915 C, Lazzeri D. Amiodarone in patients with congestive heart failure and asymptomatic ventricular 4916 arrhythmia. Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure. N Engl J Med 4917 1995;**333**:77-82. 4918 652. Kirchhof P, Franz MR, Bardai A, Wilde AM. Giant T-U waves precede torsades de pointes in 4919 long QT syndrome: a systematic electrocardiographic analysis in patients with acquired and 4920 congenital QT prolongation. J Am Coll Cardiol 2009;54:143-149. 4921 Goldschlager N, Epstein AE, Naccarelli GV, Olshansky B, Singh B, Collard HR, Murphy E. A 653. 4922 practical guide for clinicians who treat patients with amiodarone: 2007. Heart Rhythm 2007;4:1250-4923 1259. 4924 654. Wolkove N, Baltzan M. Amiodarone pulmonary toxicity. Can Respir J 2009;16:43-48. 4925 655. Ahmed S, Rienstra M, Crijns HJ, Links TP, Wiesfeld AC, Hillege HL, Bosker HA, Lok DJ, Van 4926 Veldhuisen DJ, Van Gelder IC. Continuous vs episodic prophylactic treatment with amiodarone for the 4927 prevention of atrial fibrillation: a randomized trial. JAMA 2008;300:1784-1792. 4928 656. Davy JM, Herold M, Hoglund C, Timmermans A, Alings A, Radzik D, Van Kempen L. 4929 Dronedarone for the control of ventricular rate in permanent atrial fibrillation: the Efficacy and safety of 4930 dRonedArone for the cOntrol of ventricular rate during atrial fibrillation (ERATO) study. Am Heart J 4931 2008;156:527 e521-529. 4932 Kober L, Torp-Pedersen C, McMurray JJ, Gotzsche O, Levy S, Crijns H, Amlie J, Carlsen J, 657. 4933 Dronedarone Study Group. Increased mortality after dronedarone therapy for severe heart failure. N 4934 Engl J Med 2008;358:2678-2687. 4935 Connolly SJ, Camm AJ, Halperin JL, Joyner C, Alings M, Amerena J, Atar D, Avezum A, 658. 4936 Blomstrom P, Borggrefe M, Budaj A, Chen SA, Ching CK, Commerford P, Dans A, Davy JM, 4937 Delacretaz E, Di Pasquale G, Diaz R, Dorian P, Flaker G, Golitsyn S, Gonzalez-Hermosillo A, 4938 Granger CB, Heidbuchel H, Kautzner J, Kim JS, Lanas F, Lewis BS, Merino JL, Morillo C, Murin J, 4939 Narasimhan C, Paolasso E, Parkhomenko A, Peters NS, Sim KH, Stiles MK, Tanomsup S, Toivonen 4940 L, Tomcsanyi J, Torp-Pedersen C, Tse HF, Vardas P, Vinereanu D, Xavier D, Zhu J, Zhu JR, Baret-4941 Cormel L, Weinling E, Staiger C, Yusuf S, Chrolavicius S, Afzal R, Hohnloser SH. Dronedarone in 4942 high-risk permanent atrial fibrillation. N Engl J Med 2011;365:2268-2276. 4943 659. Tschuppert Y, Buclin T, Rothuizen LE, Decosterd LA, Galleyrand J, Gaud C, Biollaz J. Effect 4944 of dronedarone on renal function in healthy subjects. Br J Clin Pharmacol 2007;64:785-791. 4945 660. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: effect of 4946 encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial 4947 infarction. N Engl J Med 1989;321:406-412. 4948 Freemantle N, Lafuente-Lafuente C, Mitchell S, Eckert L, Reynolds M. Mixed treatment 661. 4949 comparison of dronedarone, amiodarone, sotalol, flecainide, and propafenone, for the management of 4950 atrial fibrillation. Europace 2011;13:329-345. 4951 Sherrid MV, Barac I, McKenna WJ, Elliott PM, Dickie S, Chojnowska L, Casey S, Maron BJ. 662. 4952 Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic 4953 cardiomyopathy. J Am Coll Cardiol 2005;45:1251-1258. 4954 Sirak TE, Sherrid MV. Oral disopyramide for the acute treatment of severe outflow obstruction 663. 4955 in hypertrophic cardiomyopathy in the ICU setting. Chest 2008;133:1243-1246. 4956 664. Sherrid MV, Shetty A, Winson G, Kim B, Musat D, Alviar CL, Homel P, Balaram SK, Swistel 4957 DG. Treatment of obstructive hypertrophic cardiomyopathy symptoms and gradient resistant to first-4958 line therapy with beta-blockade or verapamil. Circ Heart Fail 2013;6:694-702. 4959 665. Waldo AL, Camm AJ, deRuyter H, Friedman PL, MacNeil DJ, Pauls JF, Pitt B, Pratt CM, 4960 Schwartz PJ, Veltri EP. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after 4961 recent and remote myocardial infarction. The SWORD Investigators. Survival With Oral d-Sotalol. 4962 Lancet 1996;348:7-12. 4963 666. Pedersen OD, Bagger H, Keller N, Marchant B, Kober L, Torp-Pedersen C. Efficacy of 4964 dofetilide in the treatment of atrial fibrillation-flutter in patients with reduced left ventricular function: a 4965 Danish investigations of arrhythmia and mortality on dofetilide (diamond) substudy. Circulation 4966 2001;104:292-296. 4967 Shamiss Y, Khaykin Y, Oosthuizen R, Tunney D, Sarak B, Beardsall M, Seabrook C, Frost L, 667 4968 Wulffhart Z, Tsang B, Verma A. Dofetilide is safe and effective in preventing atrial fibrillation 4969 recurrences in patients accepted for catheter ablation. Europace 2009;11:1448-1455. 4970 668. Haverkamp W, Breithardt G, Camm AJ, Janse MJ, Rosen MR, Antzelevitch C, Escande D, 4971 Franz M, Malik M, Moss A, Shah R. The potential for QT prolongation and pro-arrhythmia by non-anti-4972 arrhythmic drugs: clinical and regulatory implications. Report on a Policy Conference of the European

4973 Society of Cardiology. Cardiovasc Res 2000;47:219-233.

4974 669. Kääb S, Hinterseer M, Näbauer M, Steinbeck G. Sotalol testing unmasks altered 4975 repolarization in patients with suspected acquired long-QT-syndrome-a case-control pilot study using 4976 i.v. sotalol. Eur Heart J 2003;24:649-657. 4977 Fabritz L, Kirchhof P. Predictable and less predictable unwanted cardiac drugs effects: 670. 4978 individual pre-disposition and transient precipitating factors. Basic Clin Pharmacol Toxicol 4979 2010;106:263-268. 4980 Choy AM, Darbar D, Dell'Orto S, Roden DM. Exaggerated QT prolongation after 671. 4981 cardioversion of atrial fibrillation. J Am Coll Cardiol 1999;34:396-401. 4982 672. Patten M, Maas R, Bauer P, Luderitz B, Sonntag F, Dluzniewski M, Hatala R, Opolski G, 4983 Muller HW, Meinertz T. Suppression of paroxysmal atrial tachyarrhythmias--results of the SOPAT trial. 4984 Eur Heart J 2004;25:1395-1404. 4985 Burashnikov A, Barajas-Martinez H, Hu D, Nof E, Blazek J, Antzelevitch C. Atrial-selective 673. 4986 prolongation of refractory period with AVE0118 is due principally to inhibition of sodium channel 4987 activity. J Cardiovasc Pharmacol 2012;59:539-546. 4988 Ford J, Milnes J, Wettwer E, Christ T, Rogers M, Sutton K, Madge D, Virag L, Jost N, Horvath 674. 4989 Z, Matschke K, Varro A, Ravens U. Human electrophysiological and pharmacological properties of 4990 XEN-D0101: a novel atrial-selective Kv1.5/IKur inhibitor. J Cardiovasc Pharmacol 2013;61:408-415. 4991 675. Loose S, Mueller J, Wettwer E, Knaut M, Ford J, Milnes J, Ravens U. Effects of IKur blocker 4992 MK-0448 on human right atrial action potentials from patients in sinus rhythm and in permanent atrial 4993 fibrillation. Front Pharmacol 2014;5:26. 4994 Schram G, Zhang L, Derakhchan K, Ehrlich JR, Belardinelli L, Nattel S. Ranolazine: ion-676. 4995 channel-blocking actions and in vivo electrophysiological effects. Br J Pharmacol 2004;142:1300-4996 1308. 4997 677. McCormack JG, Barr RL, Wolff AA, Lopaschuk GD. Ranolazine stimulates glucose oxidation 4998 in normoxic, ischemic, and reperfused ischemic rat hearts. Circulation 1996;93:135-142. 4999 Scirica BM, Morrow DA, Hod H, Murphy SA, Belardinelli L, Hedgepeth CM, Molhoek P, 678. 5000 Verheugt FW, Gersh BJ, McCabe CH, Braunwald E. Effect of ranolazine, an antianginal agent with 5001 novel electrophysiological properties, on the incidence of arrhythmias in patients with non ST-5002 segment elevation acute coronary syndrome: results from the Metabolic Efficiency With Ranolazine 5003 for Less Ischemia in Non ST-Elevation Acute Coronary Syndrome Thrombolysis in Myocardial 5004 Infarction 36 (MERLIN-TIMI 36) randomized controlled trial. Circulation 2007;116:1647-1652. 5005 679. Scirica BM, Belardinelli L, Chaitman BR, Waks JW, Volo S, Karwatowska-Prokopczuk E, 5006 Murphy SA, Cheng ML, Braunwald E, Morrow DA. Effect of ranolazine on atrial fibrillation in patients 5007 with non-ST elevation acute coronary syndromes: observations from the MERLIN-TIMI 36 trial. 5008 Europace 2015;17:32-37. 5009 680. Reiffel JA, Camm AJ, Belardinelli L, Zeng D, Karwatowska-Prokopczuk E, Olmsted A, Zareba 5010 W, Rosero S, Kowey P, HARMONY Investigators. The HARMONY Trial: Combined Ranolazine and 5011 Dronedarone in the Management of Paroxysmal Atrial Fibrillation: Mechanistic and Therapeutic Synergism. Circ Arrhythm Electrophysiol 2015;8:1048-1056. 5012 5013 Fragakis N, Koskinas KC, Katritsis DG, Pagourelias ED, Zografos T, Geleris P. Comparison 681. 5014 of effectiveness of ranolazine plus amiodarone versus amiodarone alone for conversion of recent-5015 onset atrial fibrillation. Am J Cardiol 2012;110:673-677. 5016 682. Simopoulos V, Tagarakis GI, Daskalopoulou SS, Daskalopoulos ME, Lenos A, Chryssagis K, 5017 Skoularingis I, Molyvdas PA, Tsilimingas NB, Aidonidis I. Ranolazine enhances the antiarrhythmic 5018 activity of amiodarone by accelerating conversion of new-onset atrial fibrillation after cardiac surgery. 5019 Angiology 2014;65:294-297. 5020 Koskinas KC, Fragakis N, Katritsis D, Skeberis V, Vassilikos V. Ranolazine enhances the 683. 5021 efficacy of amiodarone for conversion of recent-onset atrial fibrillation. Europace 2014;16:973-979. 5022 684. De Ferrari GM, Maier LS, Mont L, Schwartz PJ, Simonis G, Leschke M, Gronda E, Boriani G, 5023 Darius H, Guillamon Toran L, Savelieva I, Dusi V, Marchionni N, Quintana Rendon M, Schumacher K, 5024 Tonini G, Melani L, Giannelli S, Alberto Maggi C, Camm AJ, RAFFAELLO Investigators. Ranolazine in 5025 the treatment of atrial fibrillation: Results of the dose-ranging RAFFAELLO (Ranolazine in Atrial 5026 Fibrillation Following An ELectricaL CardiOversion) study. Heart Rhythm 2015;12:872-878. 5027 685. Martin RI, Pogoryelova O, Koref MS, Bourke JP, Teare MD, Keavney BD. Atrial fibrillation 5028 associated with ivabradine treatment: meta-analysis of randomised controlled trials. Heart 5029 2014:100:1506-1510. 5030 686. Okin PM, Wachtell K, Devereux RB, Harris KE, Jern S, Kjeldsen SE, Julius S, Lindholm LH, 5031 Nieminen MS, Edelman JM, Hille DA, Dahlof B. Regression of electrocardiographic left ventricular 5032 hypertrophy and decreased incidence of new-onset atrial fibrillation in patients with hypertension. 5033 JAMA 2006;296:1242-1248.

5034 687. Savelieva I, Kakouros N, Kourliouros A, Camm AJ. Upstream therapies for management of 5035 atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology 5036 guidelines. Part II: secondary prevention. Europace 2011;13:610-625. 5037 Kuhlkamp V, Schirdewan A, Stangl K, Homberg M, Ploch M, Beck OA. Use of metoprolol 688. 5038 CR/XL to maintain sinus rhythm after conversion from persistent atrial fibrillation: a randomized, 5039 double-blind, placebo-controlled study. J Am Coll Cardiol 2000;36:139-146. 5040 Liakopoulos OJ, Kuhn EW, Slottosch I, Wassmer G, Wahlers T. Preoperative statin therapy 689. 5041 for patients undergoing cardiac surgery. Cochrane Database Syst Rev 2012;4:Cd008493. 5042 690. Kuhn EW, Liakopoulos OJ, Stange S, Deppe AC, Slottosch I, Choi YH, Wahlers T. 5043 Preoperative statin therapy in cardiac surgery: a meta-analysis of 90,000 patients. Eur J Cardiothorac 5044 Surg 2014;45:17-26; discussion 26. 5045 Zheng Z, Jayaram R, Jiang L, Emberson J, Zhao Y, Li Q, Du J, Guarguagli S, Hill M, Chen Z, 691. 5046 Collins R, Casadei B. Perioperative Rosuvastatin in Cardiac Surgery. N Engl J Med 2016;374:1744-5047 1753. 5048 692. Rahimi K. Emberson J. McGale P. Maioni W. Merhi A. Asselbergs FW. Krane V. Macfarlane 5049 PW, PROSPER Executive. Effect of statins on atrial fibrillation: collaborative meta-analysis of 5050 published and unpublished evidence from randomised controlled trials. BMJ 2011;342:d1250. 5051 693. Pinho-Gomes AC, Reilly S, Brandes RP, Casadei B. Targeting inflammation and oxidative 5052 stress in atrial fibrillation: role of 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibition with 5053 statins. Antioxid Redox Signal 2014;20:1268-1285. 5054 Bianconi L, Calo L, Mennuni M, Santini L, Morosetti P, Azzolini P, Barbato G, Biscione F, 694. 5055 Romano P, Santini M. n-3 polyunsaturated fatty acids for the prevention of arrhythmia recurrence 5056 after electrical cardioversion of chronic persistent atrial fibrillation: a randomized, double-blind, 5057 multicentre study. Europace 2011;13:174-181. 5058 695. Kowey PR, Reiffel JA, Ellenbogen KA, Naccarelli GV, Pratt CM. Efficacy and safety of 5059 prescription omega-3 fatty acids for the prevention of recurrent symptomatic atrial fibrillation: a 5060 randomized controlled trial. JAMA 2010;304:2363-2372. 5061 696. Mozaffarian D, Marchioli R, Macchia A, Silletta MG, Ferrazzi P, Gardner TJ, Latini R, Libby P, 5062 Lombardi F, O'Gara PT, Page RL, Tavazzi L, Tognoni G, OPERA Investigators. Fish oil and 5063 postoperative atrial fibrillation: the Omega-3 Fatty Acids for Prevention of Post-operative Atrial 5064 Fibrillation (OPERA) randomized trial. JAMA 2012;308:2001-2011. 5065 697. Yamashita T, Inoue H, Okumura K, Kodama I, Aizawa Y, Atarashi H, Ohe T, Ohtsu H, Kato T, 5066 Kamakura S, Kumagai K, Kurachi Y, Koretsune Y, Saikawa T, Sakurai M, Sato T, Sugi K, Nakaya H, 5067 Hirai M, Hirayama A, Fukatani M, Mitamura H, Yamazaki T, Watanabe E, Ogawa S, J-RHYTHM II 5068 Investigators. Randomized trial of angiotensin II-receptor blocker vs. dihydropiridine calcium channel 5069 blocker in the treatment of paroxysmal atrial fibrillation with hypertension (J-RHYTHM II study). 5070 Europace 2011;13:473-479. 5071 Macchia A, Grancelli H, Varini S, Nul D, Laffaye N, Mariani J, Ferrante D, Badra R, Figal J, 698. 5072 Ramos S, Tognoni G, Doval HC, GESICA Investigators. Omega-3 fatty acids for the prevention of 5073 recurrent symptomatic atrial fibrillation: results of the FORWARD (Randomized Trial to Assess 5074 Efficacy of PUFA for the Maintenance of Sinus Rhythm in Persistent Atrial Fibrillation) trial. J Am Coll 5075 Cardiol 2013;61:463-468. 5076 Dabrowski R, Borowiec A, Smolis-Bak E, Kowalik I, Sosnowski C, Kraska A, Kazimierska B, 699. 5077 Wozniak J, Zareba W, Szwed H. Effect of combined spironolactone-β-blocker ± enalapril treatment on 5078 occurrence of symptomatic atrial fibrillation episodes in patients with a history of paroxysmal atrial 5079 fibrillation (SPIR-AF study). Am J Cardiol 2010;106:1609-1614. 5080 Ito Y, Yamasaki H, Naruse Y, Yoshida K, Kaneshiro T, Murakoshi N, Igarashi M, Kuroki K, 700. 5081 Machino T, Xu D, Kunugita F, Sekiguchi Y, Sato A, Tada H, Aonuma K. Effect of eplerenone on 5082 maintenance of sinus rhythm after catheter ablation in patients with long-standing persistent atrial 5083 fibrillation. Am J Cardiol 2013;111:1012-1018. 5084 701. Swedberg K, Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Shi H, Vincent J, Pitt B, 5085 EMPHASIS-Hf Study Investigators. Eplerenone and atrial fibrillation in mild systolic heart failure: 5086 results from the EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization And SurvIval Study in 5087 Heart Failure) study. J Am Coll Cardiol 2012;59:1598-1603. 5088 702. Coll-Vinent B, Sala X, Fernandez C, Bragulat E, Espinosa G, Miro O, Milla J, Sanchez M. 5089 Sedation for cardioversion in the emergency department: analysis of effectiveness in four protocols. 5090 Ann Emerg Med 2003;42:767-772. 5091 del Arco C, Martin A, Laguna P, Gargantilla P. Analysis of current management of atrial 703. fibrillation in the acute setting: GEFAUR-1 study. Ann Emerg Med 2005;46:424-430. 5092

5093 704. Scheuermeyer FX, Grafstein E, Heilbron B, Innes G. Emergency department management 5094 and 1-year outcomes of patients with atrial flutter. Ann Emerg Med 2011;57:564-571 e562. 5095 705. Goldner BG, Baker J, Accordino A, Sabatino L, DiGiulio M, Kalenderian D, Lin D, Zambrotta 5096 V, Stechel J, Maccaro P, Jadonath R. Electrical cardioversion of atrial fibrillation or flutter with 5097 conscious sedation in the age of cost containment. Am Heart J 1998;136:961-964. 5098 706. Martinez-Marcos FJ, Garcia-Garmendia JL, Ortega-Carpio A, Fernandez-Gomez JM, Santos 5099 JM, Camacho C. Comparison of intravenous flecainide, propafenone, and amiodarone for conversion 5100 of acute atrial fibrillation to sinus rhythm. Am J Cardiol 2000;86:950-953. 5101 Buccelletti F, Iacomini P, Botta G, Marsiliani D, Carroccia A, Gentiloni Silveri N, Franceschi F. 707. 5102 Efficacy and safety of vernakalant in recent-onset atrial fibrillation after the European medicines 5103 agency approval: systematic review and meta-analysis. J Clin Pharmacol 2012;52:1872-1878. 5104 708. Cappato R, Ezekowitz MD, Klein AL, Camm AJ, Ma CS, Le Heuzey JY, Talajic M, 5105 Scanavacca M, Vardas PE, Kirchhof P, Hemmrich M, Lanius V, Meng IL, Wildgoose P, van Eickels M, 5106 Hohnloser SH, X-VeRT Investigators. Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial 5107 fibrillation. Eur Heart J 2014. 5108 709. Nagarakanti R, Ezekowitz MD, Oldgren J, Yang S, Chernick M, Aikens TH, Flaker G, Brugada 5109 J, Kamensky G, Parekh A, Reilly PA, Yusuf S, Connolly SJ. Dabigatran versus warfarin in patients 5110 with atrial fibrillation: an analysis of patients undergoing cardioversion. Circulation 2011;123:131-136. 5111 Steinberg JS, Sadaniantz A, Kron J, Krahn A, Denny DM, Daubert J, Campbell WB, Havranek 710. 5112 E, Murray K, Olshansky B, O'Neill G, Sami M, Schmidt S, Storm R, Zabalgoitia M, Miller J, Chandler 5113 M, Nasco EM, Greene HL. Analysis of cause-specific mortality in the Atrial Fibrillation Follow-up 5114 Investigation of Rhythm Management (AFFIRM) study. Circulation 2004;109:1973-1980. Andersen HR, Nielsen JC, Thomsen PE, Thuesen L, Mortensen PT, Vesterlund T, Pedersen 5115 711. 5116 AK. Long-term follow-up of patients from a randomised trial of atrial versus ventricular pacing for sicksinus syndrome. Lancet 1997;350:1210-1216. 5117 5118 712. Connolly SJ, Kerr CR, Gent M, Roberts RS, Yusuf S, Gillis AM, Sami MH, Talajic M, Tang 5119 AS, Klein GJ, Lau C, Newman DM. Effects of physiologic pacing versus ventricular pacing on the risk 5120 of stroke and death due to cardiovascular causes. Canadian Trial of Physiologic Pacing Investigators. 5121 N Engl J Med 2000;342:1385-1391. 5122 Calkins H, Reynolds MR, Spector P, Sondhi M, Xu Y, Martin A, Williams CJ, Sledge I. 713. 5123 Treatment of atrial fibrillation with antiarrhythmic drugs or radiofrequency ablation: two systematic 5124 literature reviews and meta-analyses. Circ Arrhythm Electrophysiol 2009;2:349-361. 5125 714. Schmieder RE, Kjeldsen SE, Julius S, McInnes GT, Zanchetti A, Hua TA. Reduced incidence 5126 of new-onset atrial fibrillation with angiotensin II receptor blockade: the VALUE trial. J Hypertens 5127 2008;26:403-411. 5128 Calkins H, Kuck KH, Cappato R, Brugada J, Camm AJ, Chen SA, Crijns HJ, Damiano RJ, Jr., 715. 5129 Davies DW, DiMarco J, Edgerton J, Ellenbogen K, Ezekowitz MD, Haines DE, Haissaguerre M, 5130 Hindricks G, Iesaka Y, Jackman W, Jalife J, Jais P, Kalman J, Keane D, Kim YH, Kirchhof P, Klein G, 5131 Kottkamp H, Kumagai K, Lindsay BD, Mansour M, Marchlinski FE, McCarthy PM, Mont JL, Morady F, 5132 Nademanee K, Nakagawa H, Natale A, Nattel S, Packer DL, Pappone C, Prystowsky E, Raviele A, 5133 Reddy V, Ruskin JN, Shemin RJ, Tsao HM, Wilber D. 2012 HRS/EHRA/ECAS Expert Consensus 5134 Statement on Catheter and Surgical Ablation of Atrial Fibrillation: recommendations for patient 5135 selection, procedural techniques, patient management and follow-up, definitions, endpoints, and 5136 research trial design. Europace 2012;14:528-606. 5137 Kuck KH, Hoffmann BA, Ernst S, Wegscheider K, Treszl A, Metzner A, Eckardt L, Lewalter T, 716. 5138 Breithardt G, Willems S, Gap-AF-AFNET 1 Investigators. Impact of Complete Versus Incomplete 5139 Circumferential Lines Around the Pulmonary Veins During Catheter Ablation of Paroxysmal Atrial 5140 Fibrillation: Results From the Gap-Atrial Fibrillation-German Atrial Fibrillation Competence Network 1 5141 Trial. Circ Arrhythm Electrophysiol 2016;9:e003337. 5142 Mont L, Bisbal F, Hernandez-Madrid A, Perez-Castellano N, Vinolas X, Arenal A, Arribas F, 717. 5143 Fernandez-Lozano I, Bodegas A, Cobos A, Matia R, Perez-Villacastin J, Guerra JM, Avila P, Lopez-5144 Gil M, Castro V, Arana JI, Brugada J, SARA investigators. Catheter ablation vs. antiarrhythmic drug 5145 treatment of persistent atrial fibrillation: a multicentre, randomized, controlled trial (SARA study). Eur 5146 Heart J 2014;35:501-507. 5147 718. Schreiber D, Rostock T, Frohlich M, Sultan A, Servatius H, Hoffmann BA, Luker J, Berner I, 5148 Schaffer B, Wegscheider K, Lezius S, Willems S, Steven D. Five-year follow-up after catheter ablation 5149 of persistent atrial fibrillation using the stepwise approach and prognostic factors for success. Circ 5150 Arrhythm Electrophysiol 2015;8:308-317. 5151 Scherr D, Khairy P, Miyazaki S, Aurillac-Lavignolle V, Pascale P, Wilton SB, Ramoul K, 719. 5152 Komatsu Y, Roten L, Jadidi A, Linton N, Pedersen M, Daly M, O'Neill M, Knecht S, Weerasooriya R,

5153 Rostock T, Manninger M, Cochet H, Shah AJ, Yeim S, Denis A, Derval N, Hocini M, Sacher F, 5154 Haissaguerre M, Jais P. Five-year outcome of catheter ablation of persistent atrial fibrillation using 5155 termination of atrial fibrillation as a procedural endpoint. Circ Arrhythm Electrophysiol 2015;8:18-24. 5156 Al Halabi S, Qintar M, Hussein A, Alraies MC, Jones DG, Wong T, MacDonald MR, Petrie 720. 5157 MC, Cantillon D, Tarakji KG, Kanj M, Bhargava M, Varma N, Baranowski B, Wilkoff BL, Wazni O, 5158 Callahan T, Saliba W, Chung MK. Catheter Ablation for Atrial Fibrillation in Heart Failure Patients: A 5159 Meta-Analysis of Randomized Controlled Trials. JACC Clin Electrophysiol 2015;1:200-209. 5160 Hakalahti A, Biancari F, Nielsen JC, Raatikainen MJ. Radiofrequency ablation vs. 721. 5161 antiarrhythmic drug therapy as first line treatment of symptomatic atrial fibrillation: systematic review 5162 and meta-analysis. Europace 2015;17:370-378. 5163 Morillo CA, Verma A, Connolly SJ, Kuck KH, Nair GM, Champagne J, Sterns LD, Beresh H, 722. 5164 Healey JS, Natale A, RAAFT-2 Investigators. Radiofrequency ablation vs antiarrhythmic drugs as first-5165 line treatment of paroxysmal atrial fibrillation (RAAFT-2): a randomized trial. JAMA 2014:311:692-700. 5166 Wazni OM, Marrouche NF, Martin DO, Verma A, Bhargava M, Saliba W, Bash D, Schweikert 723. 5167 R, Brachmann J, Gunther J, Gutleben K, Pisano E, Potenza D, Fanelli R, Raviele A, Themistoclakis 5168 S. Rossillo A, Bonso A, Natale A. Radiofrequency ablation vs antiarrhythmic drugs as first-line 5169 treatment of symptomatic atrial fibrillation: a randomized trial. JAMA 2005;293:2634-2640. 5170 724. Oral H, Pappone C, Chugh A, Good E, Bogun F, Pelosi F, Jr., Bates ER, Lehmann MH, 5171 Vicedomini G, Augello G, Agricola E, Sala S, Santinelli V, Morady F. Circumferential pulmonary-vein 5172 ablation for chronic atrial fibrillation. N Engl J Med 2006;354:934-941. 5173 725. Stabile G, Bertaglia E, Senatore G, De Simone A, Zoppo F, Donnici G, Turco P, Pascotto P, 5174 Fazzari M, Vitale DF. Catheter ablation treatment in patients with drug-refractory atrial fibrillation: a 5175 prospective, multi-centre, randomized, controlled study (Catheter Ablation For The Cure Of Atrial 5176 Fibrillation Study). Eur Heart J 2006;27:216-221. 5177 726. Forleo GB, Mantica M, De Luca L, Leo R, Santini L, Panigada S, De Sanctis V, Pappalardo A, 5178 Laurenzi F, Avella A, Casella M, Dello Russo A, Romeo F, Pelargonio G, Tondo C. Catheter ablation 5179 of atrial fibrillation in patients with diabetes mellitus type 2: results from a randomized study 5180 comparing pulmonary vein isolation versus antiarrhythmic drug therapy. J Cardiovasc Electrophysiol 5181 2009;20:22-28. 5182 Cappato R, Calkins H, Chen SA, Davies W, Iesaka Y, Kalman J, Kim YH, Klein G, Natale A, 727. 5183 Packer D, Skanes A, Ambrogi F, Biganzoli E. Updated worldwide survey on the methods, efficacy, 5184 and safety of catheter ablation for human atrial fibrillation. Circ Arrhythm Electrophysiol 2010;3:32-38. 5185 728. Ganesan AN, Shipp NJ, Brooks AG, Kuklik P, Lau DH, Lim HS, Sullivan T, Roberts-Thomson 5186 KC, Sanders P. Long-term outcomes of catheter ablation of atrial fibrillation: a systematic review and 5187 meta-analysis. J Am Heart Assoc 2013:2:e004549. 5188 McLellan AJ, Ling LH, Azzopardi S, Lee GA, Lee G, Kumar S, Wong MC, Walters TE, Lee 729. 5189 JM, Looi KL, Halloran K, Stiles MK, Lever NA, Fynn SP, Heck PM, Sanders P, Morton JB, Kalman 5190 JM, Kistler PM. A minimal or maximal ablation strategy to achieve pulmonary vein isolation for 5191 paroxysmal atrial fibrillation: a prospective multi-centre randomized controlled trial (the Minimax 5192 study). Eur Heart J 2015;36:1812-1821. 5193 Verma A, Sanders P, Macle L, Deisenhofer I, Morillo CA, Chen J, Jiang CY, Ernst S, 730. 5194 Mantovan R. Substrate and Trigger Ablation for Reduction of Atrial Fibrillation Trial-Part II (STAR AF 5195 II): design and rationale. Am Heart J 2012;164:1-6 e6. 5196 731. Nery PB, Belliveau D, Nair GM, Bernick J, Redpath CJ, Szczotka A, Sadek MM, Green MS, 5197 Wells G, Birnie DH. Relationship Between Pulmonary Vein Reconnection and 5198 Atrial Fibrillation Recurrence. JACC Clin Electrophysiol 2016: [Epub ahead of print]. 5199 732. Luik A, Radzewitz A, Kieser M, Walter M, Bramlage P, Hormann P, Schmidt K, Horn N, 5200 Brinkmeier-Theofanopoulou M, Kunzmann K, Riexinger T, Schymik G, Merkel M, Schmitt C. 5201 Cryoballoon Versus Open Irrigated Radiofrequency Ablation in Patients With Paroxysmal Atrial 5202 Fibrillation: The Prospective, Randomized, Controlled, Noninferiority FreezeAF Study. Circulation 5203 2015;132:1311-1319. 5204 Schmidt M, Dorwarth U, Andresen D, Brachmann J, Kuck KH, Kuniss M, Lewalter T, Spitzer 733. 5205 S, Willems S, Senges J, Junger C, Hoffmann E. Cryoballoon versus RF ablation in paroxysmal atrial 5206 fibrillation: results from the German Ablation Registry. J Cardiovasc Electrophysiol 2014;25:1-7. 5207 Kuck KH, Brugada J, Furnkranz A, Metzner A, Ouyang F, Chun KR, Elvan A, Arentz T, 734. 5208 Bestehorn K, Pocock SJ, Albenque JP, Tondo C, FIRE AND ICE Investigators. Cryoballoon or 5209 Radiofrequency Ablation for Paroxysmal Atrial Fibrillation. N Engl J Med 2016: [Epub ahead of print]. 5210 Verma A, Jiang CY, Betts TR, Chen J, Deisenhofer I, Mantovan R, Macle L, Morillo CA, 735.

5211 Haverkamp W, Weerasooriya R, Albenque JP, Nardi S, Menardi E, Novak P, Sanders P, STAR AF II

5212	Investigators. Approaches to catheter ablation for persistent atrial fibrillation. N Engl J Med
5212	2015; 372 :1812-1822.
5213	736. Dong JZ, Sang CH, Yu RH, Long DY, Tang RB, Jiang CX, Ning M, Liu N, Liu XP, Du X, Tse
5214	HF, Ma CS. Prospective randomized comparison between a fixed '2C3L' approach vs. stepwise
5215	approach for catheter ablation of persistent atrial fibrillation. <i>Europace</i> 2015; 17 :1798-1806.
5210	
5218	Sporton S, Jones M, Joseph JP, Bashir Y, Betts TR, Thomas G, Staniforth A, Lee G, Kistler P,
5219	Rajappan K, Chow A, Schilling RJ. Maintenance of sinus rhythm with an ablation strategy in patients
5220	with atrial fibrillation is associated with a lower risk of stroke and death. <i>Heart</i> 2012; 98 :48-53.
5221	738. Providencia R, Lambiase PD, Srinivasan N, Ganesh Babu G, Bronis K, Ahsan S, Khan FZ,
5222	Chow AW, Rowland E, Lowe M, Segal OR. Is There Still a Role for Complex Fractionated Atrial
5223	Electrogram Ablation in Addition to Pulmonary Vein Isolation in Patients With Paroxysmal and
5224	Persistent Atrial Fibrillation? Meta-Analysis of 1415 Patients. Circ Arrhythm Electrophysiol
5225	2015; 8 :1017-1029.
5226	739. Mohanty S, Gianni C, Mohanty P, Halbfass P, Metz T, Trivedi C, Deneke T, Tomassoni G, Bai
5227	R, Al-Ahmad A, Bailey S, Burkhardt JD, Gallinghouse GJ, Horton R, Hranitzky PM, Sanchez JE, Di
5228	Biase L, Natale A. Impact of Rotor Ablation in Non-Paroxysmal AF Patients: Results from a
5229	Randomized Trial (OASIS). J Am Coll Cardiol 2016.
5230	740. Rolf S, Kircher S, Arya A, Eitel C, Sommer P, Richter S, Gaspar T, Bollmann A, Altmann D,
5231	Piedra C, Hindricks G, Piorkowski C. Tailored atrial substrate modification based on low-voltage areas
5232	in catheter ablation of atrial fibrillation. Circ Arrhythm Electrophysiol 2014;7:825-833.
5233	741. Shah AJ, Pascale P, Miyazaki S, Liu X, Roten L, Derval N, Jadidi AS, Scherr D, Wilton SB,
5234	Pedersen M, Knecht S, Sacher F, Jais P, Haissaguerre M, Hocini M. Prevalence and types of pitfall in
5235	the assessment of mitral isthmus linear conduction block. <i>Circ Arrhythm Electrophysiol</i> 2012; 5 :957-
5236	967.
5237	742. Macle L, Khairy P, Weerasooriya R, Novak P, Verma A, Willems S, Arentz T, Deisenhofer I,
5238	Veenhuyzen G, Scavee C, Jais P, Puererfellner H, Levesque S, Andrade JG, Rivard L, Guerra PG,
5239	Dubuc M, Thibault B, Talajic M, Roy D, Nattel S, ADVICE trial investigators. Adenosine-guided
5240	pulmonary vein isolation for the treatment of paroxysmal atrial fibrillation: an international, multicentre,
5241	randomised superiority trial. <i>Lancet</i> 2015; 386 :672-679.
5242 5243	743. Kobori A, Shizuta S, Inoue K, Kaitani K, Morimoto T, Nakazawa Y, Ozawa T, Kurotobi T,
5245 5244	Morishima I, Miura F, Watanabe T, Masuda M, Naito M, Fujimoto H, Nishida T, Furukawa Y,
5244	Shirayama T, Tanaka M, Okajima K, Yao T, Egami Y, Satomi K, Noda T, Miyamoto K, Haruna T, Kawaji T, Yoshizawa T, Toyota T, Yahata M, Nakai K, Sugiyama H, Higashi Y, Ito M, Horie M, Kusano
5245	KF, Shimizu W, Kamakura S, Kimura T, UNDER-ATP Trial Investigators. Adenosine triphosphate-
5240	guided pulmonary vein isolation for atrial fibrillation: the UNmasking Dormant Electrical Reconduction
5248	by Adenosine TriPhosphate (UNDER-ATP) trial. <i>Eur Heart J</i> 2015; 36 :3276-3287.
5249	744. Berntsen RF, Haland TF, Skardal R, Holm T. Focal impulse and rotor modulation as a stand-
5250	alone procedure for treatment of paroxysmal atrial fibrillation. A within-patient controlled study with
5250	implanted cardiac monitoring. <i>Heart Rhythm</i> 2016.
5252	745. Lee G, Sparks PB, Morton JB, Kistler PM, Vohra JK, Medi C, Rosso R, Teh A, Halloran K,
5253	Kalman JM. Low risk of major complications associated with pulmonary vein antral isolation for atrial
5254	fibrillation: results of 500 consecutive ablation procedures in patients with low prevalence of structural
5255	heart disease from a single center. <i>J Cardiovasc Electrophysiol</i> 2011; 22 :163-168.
5256	746. Wynn GJ, Das M, Bonnett LJ, Panikker S, Wong T, Gupta D. Efficacy of catheter ablation for
5257	persistent atrial fibrillation: a systematic review and meta-analysis of evidence from randomized and
5258	nonrandomized controlled trials. Circ Arrhythm Electrophysiol 2014;7:841-852.
5259	747. Seaburg L, Hess EP, Coylewright M, Ting HH, McLeod CJ, Montori VM. Shared decision
5260	making in atrial fibrillation: where we are and where we should be going. <i>Circulation</i> 2014; 129 :704-
5261	710.
5262	748. Dagres N, Hindricks G, Kottkamp H, Sommer P, Gaspar T, Bode K, Arya A, Husser D,
5263	Rallidis LS, Kremastinos DT, Piorkowski C. Complications of atrial fibrillation ablation in a high-volume
5264	center in 1,000 procedures: still cause for concern? <i>J Cardiovasc Electrophysiol</i> 2009; 20 :1014-1019.
5265	749. Deneke T, Jais P, Scaglione M, Schmitt R, L DIB, Christopoulos G, Schade A, Mugge A,
5266	Bansmann M, Nentwich K, Muller P, Krug J, Roos M, Halbfass P, Natale A, Gaita F, Haines D. Silent
5267	cerebral events/lesions related to atrial fibrillation ablation: a clinical review. J Cardiovasc
5268	Electrophysiol 2015; 26 :455-463.
5269	750. Gupta A, Perera T, Ganesan A, Sullivan T, Lau DH, Roberts-Thomson KC, Brooks AG,
5270	Sanders P. Complications of catheter ablation of atrial fibrillation: a systematic review. Circ Arrhythm

5271 *Electrophysiol* 2013;**6**:1082-1088.

5272 751. Cappato R, Calkins H, Chen SA, Davies W, Iesaka Y, Kalman J, Kim YH, Klein G, Natale A, 5273 Packer D, Ricci C, Skanes A, Ranucci M. Delayed cardiac tamponade after radiofrequency catheter 5274 ablation of atrial fibrillation: a worldwide report. J Am Coll Cardiol 2011;58:2696-2697. 5275 Haeusler KG, Kirchhof P, Endres M. Left atrial catheter ablation and ischemic stroke. Stroke 752. 5276 2012;43:265-270. 5277 753. Kosiuk J, Kornej J, Bollmann A, Piorkowski C, Myrda K, Arya A, Sommer P, Richter S, Rolf S, 5278 Husser D, Gaspar T, Lip GY, Hindricks G. Early cerebral thromboembolic complications after 5279 radiofrequency catheter ablation of atrial fibrillation: incidence, characteristics, and risk factors. Heart 5280 Rhythm 2014;11:1934-1940. 5281 754. Gaita F, Leclercq JF, Schumacher B, Scaglione M, Toso E, Halimi F, Schade A, Froehner S, 5282 Ziegler V, Sergi D, Cesarani F, Blandino A. Incidence of silent cerebral thromboembolic lesions after 5283 atrial fibrillation ablation may change according to technology used: comparison of irrigated 5284 radiofrequency, multipolar nonirrigated catheter and cryoballoon. J Cardiovasc Electrophysiol 5285 2011;22:961-968. 5286 Hsu LF, Jais P, Hocini M, Sanders P, Scavee C, Sacher F, Takahashi Y, Rotter M, Pasquie 755. 5287 JL, Clementy J, Haissaguerre M. Incidence and prevention of cardiac tamponade complicating 5288 ablation for atrial fibrillation. Pacing Clin Electrophysiol 2005;28 Suppl 1:S106-109. 5289 756. Michowitz Y, Rahkovich M, Oral H, Zado ES, Tilz R, John S, Denis A, Di Biase L, Winkle RA, 5290 Mikhaylov EN, Ruskin JN, Yao Y, Josephson ME, Tanner H, Miller JM, Champagne J, Della Bella P, Kumagai K, Defaye P, Luria D, Lebedev DS, Natale A, Jais P, Hindricks G, Kuck KH, Marchlinski FE, 5291 5292 Morady F, Belhassen B. Effects of sex on the incidence of cardiac tamponade after catheter ablation 5293 of atrial fibrillation: results from a worldwide survey in 34 943 atrial fibrillation ablation procedures. Circ 5294 Arrhythm Electrophysiol 2014;7:274-280. 5295 757. Nair KK, Shurrab M, Skanes A, Danon A, Birnie D, Morillo C, Chauhan V, Mangat I, Ayala-5296 Paredes F, Champagne J, Nault I, Tang A, Verma A, Lashevsky I, Singh SM, Crystal E. The 5297 prevalence and risk factors for atrioesophageal fistula after percutaneous radiofrequency catheter 5298 ablation for atrial fibrillation: the Canadian experience. J Interv Card Electrophysiol 2014;39:139-144. 5299 758. Shah RU, Freeman JV, Shilane D, Wang PJ, Go AS, Hlatky MA. Procedural complications, 5300 rehospitalizations, and repeat procedures after catheter ablation for atrial fibrillation. J Am Coll Cardiol 5301 2012;59:143-149. 5302 759. Straube F, Dorwarth U, Schmidt M, Wankerl M, Ebersberger U, Hoffmann E. Comparison of 5303 the first and second cryoballoon: high-volume single-center safety and efficacy analysis. Circ 5304 Arrhythm Electrophysiol 2014;7:293-299. 5305 760. Di Biase L, Burkhardt JD, Santangeli P, Mohanty P, Sanchez JE, Horton R, Gallinghouse GJ, 5306 Themistoclakis S, Rossillo A, Lakkireddy D, Reddy M, Hao S, Hongo R, Beheiry S, Zagrodzky J, 5307 Rong B, Mohanty S, Elayi CS, Forleo G, Pelargonio G, Narducci ML, Dello Russo A, Casella M, 5308 Fassini G, Tondo C, Schweikert RA, Natale A. Periprocedural Stroke and Bleeding Complications in 5309 Patients Undergoing Catheter Ablation of Atrial Fibrillation With Different Anticoagulation 5310 Management: Results From the Role of Coumadin in Preventing Thromboembolism in Atrial 5311 Fibrillation (AF) Patients Undergoing Catheter Ablation (COMPARE) Randomized Trial. Circulation 5312 2014;129:2638-2644. 5313 Di Biase L, Lakkireddy D, Trivedi C, Deneke T, Martinek M, Mohanty S, Mohanty P, Prakash 761. 5314 S, Bai R, Reddy M, Gianni C, Horton R, Bailey S, Sigmund E, Derndorfer M, Schade A, Mueller P, 5315 Szoelloes A, Sanchez J, Al-Ahmad A, Hranitzky P, Gallinghouse GJ, Hongo RH, Beheiry S, 5316 Purerfellner H, Burkhardt JD, Natale A. Feasibility and safety of uninterrupted periprocedural 5317 apixaban administration in patients undergoing radiofrequency catheter ablation for atrial fibrillation: 5318 Results from a multicenter study. Heart Rhythm 2015;12:1162-1168. 5319 762. Hohnloser SH, Camm AJ. Safety and efficacy of dabigatran etexilate during catheter ablation 5320 of atrial fibrillation: a meta-analysis of the literature. Europace 2013;15:1407-1411. 5321 Lakkireddy D, Reddy YM, Di Biase L, Vallakati A, Mansour MC, Santangeli P, Gangireddy S, 763. 5322 Swarup V, Chalhoub F, Atkins D, Bommana S, Verma A, Sanchez JE, Burkhardt JD, Barrett CD, 5323 Baheiry S, Ruskin J, Reddy V, Natale A. Feasibility and safety of uninterrupted rivaroxaban for 5324 periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: 5325 results from a multicenter prospective registry. J Am Coll Cardiol 2014;63:982-988. 5326 764. Providencia R, Marijon E, Albenque JP, Combes S, Combes N, Jourda F, Hireche H, Morais 5327 J, Boveda S. Rivaroxaban and dabigatran in patients undergoing catheter ablation of atrial fibrillation. 5328 Europace 2014;16:1137-1144. 5329 Stepanyan G, Badhwar N, Lee RJ, Marcus GM, Lee BK, Tseng ZH, Vedantham V, Olgin J, 765. 5330 Scheinman M, Gerstenfeld EP. Safety of new oral anticoagulants for patients undergoing atrial

5331 fibrillation ablation. *J Interv Card Electrophysiol* 2014;**40**:33-38.

5332 766. Aryal MR, Ukaigwe A, Pandit A, Karmacharya P, Pradhan R, Mainali NR, Pathak R, Jalota L, 5333 Bhandari Y, Donato A. Meta-analysis of efficacy and safety of rivaroxaban compared with warfarin or 5334 dabigatran in patients undergoing catheter ablation for atrial fibrillation. Am J Cardiol 2014;114:577-5335 582. 5336 767. Kaess BM, Ammar S, Reents T, Dillier R, Lennerz C, Semmler V, Grebmer C, Bourier F, 5337 Buiatti A, Kolb C, Deisenhofer I, Hessling G. Comparison of safety of left atrial catheter ablation 5338 procedures for atrial arrhythmias under continuous anticoagulation with apixaban versus 5339 phenprocoumon. Am J Cardiol 2015;115:47-51. 5340 768. Cappato R, Marchlinski FE, Hohnloser SH, Naccarelli GV, Xiang J, Wilber DJ, Ma CS, Hess 5341 S, Wells DS, Juang G, Vijgen J, Hugl BJ, Balasubramaniam R, De Chillou C, Davies DW, Fields LE, 5342 Natale A, VENTURE-AF Investigators. Uninterrupted rivaroxaban vs. uninterrupted vitamin K 5343 antagonists for catheter ablation in non-valvular atrial fibrillation. Eur Heart J 2015;36:1805-1811. 5344 769. Wu S, Yang YM, Zhu J, Wan HB, Wang J, Zhang H, Shao XH. Meta-Analysis of Efficacy and 5345 Safety of New Oral Anticoagulants Compared With Uninterrupted Vitamin K Antagonists in Patients 5346 Undergoing Catheter Ablation for Atrial Fibrillation. Am J Cardiol 2016;117:926-934. 5347 770. Santarpia G, De Rosa S, Polimeni A, Giampa S, Micieli M, Curcio A, Indolfi C. Efficacy and 5348 Safety of Non-Vitamin K Antagonist Oral Anticoagulants versus Vitamin K Antagonist Oral 5349 Anticoagulants in Patients Undergoing Radiofrequency Catheter Ablation of Atrial Fibrillation: A Meta-5350 Analysis. PLoS One 2015;10:e0126512. 5351 771. Karasoy D, Gislason GH, Hansen J, Johannessen A, Kober L, Hvidtfeldt M, Ozcan C, Torp-5352 Pedersen C, Hansen ML. Oral anticoagulation therapy after radiofrequency ablation of atrial fibrillation 5353 and the risk of thromboembolism and serious bleeding: long-term follow-up in nationwide cohort of 5354 Denmark. Eur Heart J 2015;36:307-314a. 5355 772. Themistoclakis S, Corrado A, Marchlinski FE, Jais P, Zado E, Rossillo A, Di Biase L, Schweikert RA, Saliba WI, Horton R, Mohanty P, Patel D, Burkhardt DJ, Wazni OM, Bonso A, Callans 5356 5357 DJ, Haissaguerre M, Raviele A, Natale A. The risk of thromboembolism and need for oral 5358 anticoagulation after successful atrial fibrillation ablation. J Am Coll Cardiol 2010;55:735-743. 5359 Bunch TJ, May HT, Bair TL, Weiss JP, Crandall BG, Osborn JS, Mallender C, Anderson JL, 773. 5360 Muhlestein BJ, Lappe DL, Day JD. Atrial fibrillation ablation patients have long-term stroke rates 5361 similar to patients without atrial fibrillation regardless of CHADS2 score. Heart Rhythm 2013;10:1272-5362 1277. 5363 774. Nedios S, Kornej J, Koutalas E, Bertagnolli L, Kosiuk J, Rolf S, Arya A, Sommer P, Husser D, 5364 Hindricks G, Bollmann A. Left atrial appendage morphology and thromboembolic risk after catheter 5365 ablation for atrial fibrillation. Heart Rhythm 2014;11:2239-2246. 5366 Reynolds MR, Gunnarsson CL, Hunter TD, Ladapo JA, March JL, Zhang M, Hao SC. Health 775. 5367 outcomes with catheter ablation or antiarrhythmic drug therapy in atrial fibrillation: results of a 5368 propensity-matched analysis. Circ Cardiovasc Qual Outcomes 2012;5:171-181. 5369 Gallo C, Battaglia A, Anselmino M, Bianchi F, Grossi S, Nangeroni G, Toso E, Gaido L, 776. 5370 Scaglione M, Ferraris F, Gaita F. Long-term events following atrial fibrillation rate control or 5371 transcatheter ablation: a multicenter observational study. J Cardiovasc Med (Hagerstown) 5372 2016;**17**:187-193. 5373 Di Biase L, Mohanty P, Mohanty S, Santangeli P, Trivedi C, Lakkireddy D, Reddy M, Jais P, 777. 5374 Themistoclakis S, Dello Russo A, Casella M, Pelargonio G, Narducci ML, Schweikert R, Neuzil P, 5375 Sanchez J, Horton R, Beheiry S, Hongo R, Hao S, Rossillo A, Forleo G, Tondo C, Burkhardt JD, 5376 Haissaguerre M, Natale A. Ablation vs. Amiodarone for Treatment of Persistent Atrial Fibrillation in 5377 Patients With Congestive Heart Failure and an Implanted Device: Results From the AATAC 5378 Multicenter Randomized Trial. Circulation 2016. 5379 778. Hunter RJ, Berriman TJ, Diab I, Kamdar R, Richmond L, Baker V, Goromonzi F, Sawhney V, 5380 Duncan E, Page SP, Ullah W, Unsworth B, Mayet J, Dhinoja M, Earley MJ, Sporton S, Schilling RJ. A 5381 randomized controlled trial of catheter ablation versus medical treatment of atrial fibrillation in heart 5382 failure (the CAMTAF trial). Circ Arrhythm Electrophysiol 2014;7:31-38. 5383 MacDonald MR, Connelly DT, Hawkins NM, Steedman T, Payne J, Shaw M, Denvir M, 779. 5384 Bhagra S, Small S, Martin W, McMurray JJ, Petrie MC. Radiofrequency ablation for persistent atrial 5385 fibrillation in patients with advanced heart failure and severe left ventricular systolic dysfunction: a 5386 randomised controlled trial. Heart 2011;97:740-747. 5387 Dagres N, Varounis C, Gaspar T, Piorkowski C, Eitel C, Iliodromitis EK, Lekakis JP, Flevari P, 780. 5388 Simeonidou E, Rallidis LS, Tsougos E, Hindricks G, Sommer P, Anastasiou-Nana M. Catheter 5389 ablation for atrial fibrillation in patients with left ventricular systolic dysfunction. A systematic review

5390 and meta-analysis. *J Card Fail* 2011;**17**:964-970.

5391 781. Piorkowski C, Kottkamp H, Tanner H, Kobza R, Nielsen JC, Arya A, Hindricks G. Value of 5392 different follow-up strategies to assess the efficacy of circumferential pulmonary vein ablation for the 5393 curative treatment of atrial fibrillation. J Cardiovasc Electrophysiol 2005;16:1286-1292. 5394 Verma A, Champagne J, Sapp J, Essebag V, Novak P, Skanes A, Morillo CA, Khaykin Y, 782. 5395 Birnie D. Discerning the incidence of symptomatic and asymptomatic episodes of atrial fibrillation 5396 before and after catheter ablation (DISCERN AF): a prospective, multicenter study. JAMA Intern Med 5397 2013;**173**:149-156. 5398 Cox JL, Boineau JP, Schuessler RB, Ferguson TB, Jr., Cain ME, Lindsay BD, Corr PB, Kater 783. 5399 KM, Lappas DG. Successful surgical treatment of atrial fibrillation. Review and clinical update. JAMA 5400 1991;**266**:1976-1980. 5401 Cox JL, Schuessler RB, D'Agostino HJ, Jr., Stone CM, Chang BC, Cain ME, Corr PB, 784. 5402 Boineau JP. The surgical treatment of atrial fibrillation. III. Development of a definitive surgical 5403 procedure. J Thorac Cardiovasc Surg 1991;101:569-583. 5404 Stulak JM. Suri RM. Burkhart HM. Dalv RC. Dearani JA. Greason KL. Jovce LD. Park SJ. 785. 5405 Schaff HV. Surgical ablation for atrial fibrillation for two decades: are the results of new techniques 5406 equivalent to the Cox maze III procedure? J Thorac Cardiovasc Surg 2014;147:1478-1486. Basu S, Nagendran M, Maruthappu M. How effective is bipolar radiofrequency ablation for 5407 786. 5408 atrial fibrillation during concomitant cardiac surgery? Interact Cardiovasc Thorac Surg 2012;15:741-5409 748. 5410 Lin Z, Shan ZG, Liao CX, Chen LW. The effect of microwave and bipolar radio-frequency 787. 5411 ablation in the surgical treatment of permanent atrial fibrillation during valve surgery. Thorac 5412 Cardiovasc Surg 2011;59:460-464. 5413 McCarthy PM, Kruse J, Shalli S, Ilkhanoff L, Goldberger JJ, Kadish AH, Arora R, Lee R. 788. 5414 Where does atrial fibrillation surgery fail? Implications for increasing effectiveness of ablation. J Thorac Cardiovasc Surg 2010;139:860-867. 5415 5416 789. Abreu Filho CA, Lisboa LA, Dallan LA, Spina GS, Grinberg M, Scanavacca M, Sosa EA, 5417 Ramires JA, Oliveira SA. Effectiveness of the maze procedure using cooled-tip radiofrequency 5418 ablation in patients with permanent atrial fibrillation and rheumatic mitral valve disease. Circulation 5419 2005;112:120-25. 5420 790. Blomstrom-Lundqvist C, Johansson B, Berglin E, Nilsson L, Jensen SM, Thelin S, Holmgren 5421 A, Edvardsson N, Kallner G, Blomstrom P. A randomized double-blind study of epicardial left atrial 5422 cryoablation for permanent atrial fibrillation in patients undergoing mitral valve surgery: the SWEDish 5423 Multicentre Atrial Fibrillation study (SWEDMAF). Eur Heart J 2007;28:2902-2908. 5424 791. Chevalier P, Leizorovicz A, Maureira P, Carteaux JP, Corbineau H, Caus T, DeBreyne B, 5425 Mabot P, Dechillou C, Deharo JC, Barry S, Touboul P, Villemot JP, Obadia JF. Left atrial 5426 radiofrequency ablation during mitral valve surgery: a prospective randomized multicentre study 5427 (SAFIR). Arch Cardiovasc Dis 2009;102:769-775. 5428 Deneke T, Khargi K, Grewe PH, Laczkovics A, von Dryander S, Lawo T, Muller KM, Lemke B. 792. 5429 Efficacy of an additional MAZE procedure using cooled-tip radiofrequency ablation in patients with 5430 chronic atrial fibrillation and mitral valve disease. A randomized, prospective trial. Eur Heart J 5431 2002;**23**:558-566. 5432 Doukas G, Samani NJ, Alexiou C, Oc M, Chin DT, Stafford PG, Ng LL, Spyt TJ. Left atrial 793. 5433 radiofrequency ablation during mitral valve surgery for continuous atrial fibrillation: a randomized 5434 controlled trial. JAMA 2005;294:2323-2329. 5435 Schuetz A, Schulze CJ, Sarvanakis KK, Mair H, Plazer H, Kilger E, Reichart B, Wildhirt SM. 794. 5436 Surgical treatment of permanent atrial fibrillation using microwave energy ablation: a prospective 5437 randomized clinical trial. Eur J Cardiothorac Surg 2003;24:475-480; discussion 480. 5438 795. Liu X, Tan HW, Wang XH, Shi HF, Li YZ, Li F, Zhou L, Gu JN. Efficacy of catheter ablation 5439 and surgical CryoMaze procedure in patients with long-lasting persistent atrial fibrillation and 5440 rheumatic heart disease: a randomized trial. Eur Heart J 2010;31:2633-2641. 5441 796. Cheng DC, Ad N, Martin J, Berglin EE, Chang BC, Doukas G, Gammie JS, Nitta T, Wolf RK, 5442 Puskas JD. Surgical ablation for atrial fibrillation in cardiac surgery: a meta-analysis and systematic 5443 review. Innovations (Phila) 2010;5:84-96. 5444 797. Barnett SD, Ad N. Surgical ablation as treatment for the elimination of atrial fibrillation: a 5445 meta-analysis. J Thorac Cardiovasc Surg 2006;131:1029-1035. 5446 Ad N, Henry L, Massimiano P, Pritchard G, Holmes SD. The state of surgical ablation for 798. 5447 atrial fibrillation in patients with mitral valve disease. Curr Opin Cardiol 2013;28:170-180. 5448 799. Gammie JS, Haddad M, Milford-Beland S, Welke KF, Ferguson TB, Jr., O'Brien SM, Griffith 5449 BP, Peterson ED. Atrial fibrillation correction surgery: lessons from the Society of Thoracic Surgeons 5450 National Cardiac Database. Ann Thorac Surg 2008;85:909-914.

5451 800. Chen MC, Chang JP, Chang HW. Preoperative atrial size predicts the success of 5452 radiofrequency maze procedure for permanent atrial fibrillation in patients undergoing concomitant 5453 valvular surgery. Chest 2004;125:2129-2134. 5454 Sunderland N, Maruthappu M, Nagendran M. What size of left atrium significantly impairs the 801. 5455 success of maze surgery for atrial fibrillation? Interact Cardiovasc Thorac Surg 2011;13:332-338. 5456 802. Chaiyaroj S, Ngarmukos T, Lertsithichai P. Predictors of sinus rhythm after radiofrequency 5457 maze and mitral valve surgery. Asian Cardiovasc Thorac Ann 2008;16:292-297. 5458 803. Gillinov AM, Bhavani S, Blackstone EH, Rajeswaran J, Svensson LG, Navia JL, Pettersson 5459 BG, Sabik JF, 3rd, Smedira NG, Mihaljevic T, McCarthy PM, Shewchik J, Natale A. Surgery for 5460 permanent atrial fibrillation: impact of patient factors and lesion set. Ann Thorac Surg 2006;82:502-5461 513: discussion 513-504. 5462 Beukema WP, Sie HT, Misier AR, Delnoy PP, Wellens HJ, Elvan A. Predictive factors of 804. 5463 sustained sinus rhythm and recurrent atrial fibrillation after a radiofrequency modified Maze 5464 procedure. Eur J Cardiothorac Surg 2008;34:771-775. 5465 Gillinov AM, Bakaeen F, McCarthy PM, Blackstone EH, Rajeswaran J, Pettersson G, Sabik 805. 5466 JF, 3rd, Najam F, Hill KM, Svensson LG, Cosgrove DM, Marrouche N, Natale A. Surgery for 5467 paroxysmal atrial fibrillation in the setting of mitral valve disease: a role for pulmonary vein isolation? 5468 Ann Thorac Surg 2006;81:19-26; discussion 27-18. 5469 Onorati F, Mariscalco G, Rubino AS, Serraino F, Santini F, Musazzi A, Klersy C, Sala A, 806. 5470 Renzulli A. Impact of lesion sets on mid-term results of surgical ablation procedure for atrial fibrillation. 5471 J Am Coll Cardiol 2011;57:931-940. 5472 Saint LL, Bailey MS, Prasad S, Guthrie TJ, Bell J, Moon MR, Lawton JS, Munfakh NA, 807. 5473 Schuessler RB, Damiano RJ, Jr., Maniar HS. Cox-Maze IV results for patients with lone atrial 5474 fibrillation versus concomitant mitral disease. Ann Thorac Surg 2012;93:789-794; discussion 794-785. 5475 808. Lawrance CP, Henn MC, Miller JR, Sinn LA, Schuessler RB, Maniar HS, Damiano RJ, Jr. A 5476 minimally invasive Cox maze IV procedure is as effective as sternotomy while decreasing major 5477 morbidity and hospital stay. J Thorac Cardiovasc Surg 2014;148:955-961; discussion 962-952. 5478 Edgerton JR, Brinkman WT, Weaver T, Prince SL, Culica D, Herbert MA, Mack MJ. 809. 5479 Pulmonary vein isolation and autonomic denervation for the management of paroxysmal atrial 5480 fibrillation by a minimally invasive surgical approach. J Thorac Cardiovasc Surg 2010;140:823-828. 5481 810. McClelland JH, Duke D, Reddy R. Preliminary results of a limited thoracotomy: new approach 5482 to treat atrial fibrillation. J Cardiovasc Electrophysiol 2007;18:1289-1295. 5483 811. Castella M, Pereda D, Mestres CA, Gomez F, Quintana E, Mulet J. Thoracoscopic pulmonary 5484 vein isolation in patients with atrial fibrillation and failed percutaneous ablation. J Thorac Cardiovasc 5485 Surg 2010;140:633-638. 5486 Krul SP, Driessen AH, van Boven WJ, Linnenbank AC, Geuzebroek GS, Jackman WM, Wilde 812. 5487 AA, de Bakker JM, de Groot JR. Thoracoscopic video-assisted pulmonary vein antrum isolation, ganglionated plexus ablation, and periprocedural confirmation of ablation lesions: first results of a 5488 5489 hybrid surgical-electrophysiological approach for atrial fibrillation. Circ Arrhythm Electrophysiol 5490 2011;**4**:262-270. 5491 La Meir M, Gelsomino S, Lorusso R, Luca F, Pison L, Parise O, Wellens F, Gensini GF, 813. 5492 Maessen J. The hybrid approach for the surgical treatment of lone atrial fibrillation: one-year results 5493 employing a monopolar radiofrequency source. J Cardiothorac Surg 2012;7:71. 5494 814. Wang S, Liu L, Zou C. Comparative study of video-assisted thoracoscopic surgery ablation 5495 and radiofrequency catheter ablation on treating paroxysmal atrial fibrillation: a randomized, controlled 5496 short-term trial. Chin Med J (Engl) 2014;127:2567-2570. 5497 815. Phan K, Phan S, Thiagalingam A, Medi C, Yan TD. Thoracoscopic surgical ablation versus 5498 catheter ablation for atrial fibrillation. Eur J Cardiothorac Surg 2016;49:1044-1051. 5499 816. Hu QM, Li Y, Xu CL, Han J, Zhang HB, Han W, Meng X. Analysis of risk factors for 5500 recurrence after video-assisted pulmonary vein isolation of lone atrial fibrillation-results of 5 years of 5501 follow-up. J Thorac Cardiovasc Surg 2014;148:2174-2180. 5502 Edgerton JR, Edgerton ZJ, Weaver T, Reed K, Prince S, Herbert MA, Mack MJ. Minimally 817. 5503 invasive pulmonary vein isolation and partial autonomic denervation for surgical treatment of atrial 5504 fibrillation. Ann Thorac Surg 2008;86:35-38; discussion 39. 5505 Wang J, Li Y, Shi J, Han J, Xu C, Ma C, Meng X. Minimally invasive surgical versus catheter 818. 5506 ablation for the long-lasting persistent atrial fibrillation. PLoS One 2011;6:e22122. 5507 819. Wang JG, Xin M, Han J, Li Y, Luo TG, Wang J, Meng F, Meng X. Ablation in selective 5508 patients with long-standing persistent atrial fibrillation: medium-term results of the Dallas lesion set. 5509 Eur J Cardiothorac Surg 2014;46:213-220.

5510 820. Sirak JH, Schwartzman D. Interim results of the 5-box thoracoscopic maze procedure. Ann 5511 Thorac Surg 2012;94:1880-1884. 5512 Kasirajan V, Spradlin EA, Mormando TE, Medina AE, Ovadia P, Schwartzman DS, Gaines 821. 5513 TE, Mumtaz MA, Downing SW, Ellenbogen KA. Minimally invasive surgery using bipolar 5514 radiofrequency energy is effective treatment for refractory atrial fibrillation. Ann Thorac Surg 5515 2012;93:1456-1461. 5516 Weimar T, Vosseler M, Czesla M, Boscheinen M, Hemmer WB, Doll KN. Approaching a 822. 5517 paradigm shift: endoscopic ablation of lone atrial fibrillation on the beating heart. Ann Thorac Surg 5518 2012;94:1886-1892. 5519 La Meir M, Gelsomino S, Luca F, Pison L, Parise O, Colella A, Gensini GF, Crijns H, Wellens 823. 5520 F, Maessen JG. Minimally invasive surgical treatment of lone atrial fibrillation: early results of hybrid 5521 versus standard minimally invasive approach employing radiofrequency sources. Int J Cardiol 5522 2013;167:1469-1475. 5523 Gelsomino S. Van Breugel HN. Pison L. Parise O. Criins HJ. Wellens F. Maessen JG. La Meir 824. 5524 M. Hybrid thoracoscopic and transvenous catheter ablation of atrial fibrillation. Eur J Cardiothorac 5525 Surg 2014;45:401-407. 5526 825. Pison L, La Meir M, van Opstal J, Blaauw Y, Maessen J, Crijns HJ. Hybrid thoracoscopic 5527 surgical and transvenous catheter ablation of atrial fibrillation. J Am Coll Cardiol 2012;60:54-61. 5528 826. De Maat GE, Van Gelder IC, Rienstra M, Quast AF, Tan ES, Wiesfeld AC, Pozzoli A, Mariani 5529 MA. Surgical vs. transcatheter pulmonary vein isolation as first invasive treatment in patients with 5530 atrial fibrillation: a matched group comparison. Europace 2014;16:33-39. 5531 Vadmann H, Nielsen PB, Hjortshoj SP, Riahi S, Rasmussen LH, Lip GY, Larsen TB. Atrial 827. 5532 flutter and thromboembolic risk: a systematic review. Heart 2015;101:1446-1455. 5533 828. Stulak JM, Dearani JA, Daly RC, Zehr KJ, Sundt TM, 3rd, Schaff HV. Left ventricular 5534 dysfunction in atrial fibrillation: restoration of sinus rhythm by the Cox-maze procedure significantly 5535 improves systolic function and functional status. Ann Thorac Surg 2006;82:494-501. 5536 829. Chen YW, Bai R, Lin T, Salim M, Sang CH, Long DY, Yu RH, Tang RB, Guo XY, Yan XL, Nie 5537 JG, Du X, Dong JZ, Ma CS. Pacing or ablation: which is better for paroxysmal atrial fibrillation-related 5538 tachycardia-bradycardia syndrome? Pacing Clin Electrophysiol 2014;37:403-411. 5539 830. Khaykin Y, Marrouche NF, Martin DO, Saliba W, Schweikert R, Wexman M, Strunk B, Beheiry 5540 S, Saad E, Bhargava M, Burkhardt JD, Joseph G, Tchou P, Natale A. Pulmonary vein isolation for 5541 atrial fibrillation in patients with symptomatic sinus bradycardia or pauses. J Cardiovasc Electrophysiol 5542 2004;15:784-789. 5543 831. Ad N, Henry L, Hunt S. Current role for surgery in treatment of lone atrial fibrillation. Semin 5544 Thorac Cardiovasc Surg 2012;24:42-50. 5545 832. Weimar T, Schena S, Bailey MS, Maniar HS, Schuessler RB, Cox JL, Damiano RJ, Jr. The 5546 cox-maze procedure for lone atrial fibrillation: a single-center experience over 2 decades. Circ 5547 Arrhythm Electrophysiol 2012;5:8-14. 5548 Ad N, Henry L, Hunt S, Holmes SD. Do we increase the operative risk by adding the Cox 833. 5549 Maze III procedure to a ortic valve replacement and coronary artery bypass surgery? J Thorac 5550 Cardiovasc Surg 2012;143:936-944. 5551 Prakash A, Saksena S, Krol RB, Filipecki A, Philip G. Catheter ablation of inducible atrial 834. 5552 flutter, in combination with atrial pacing and antiarrhythmic drugs ("hybrid therapy") improves rhythm 5553 control in patients with refractory atrial fibrillation. J Interv Card Electrophysiol 2002;6:165-172. 5554 Tai CT, Chiang CE, Lee SH, Chen YJ, Yu WC, Feng AN, Ding YA, Chang MS, Chen SA. 835. 5555 Persistent atrial flutter in patients treated for atrial fibrillation with amiodarone and propafenone: 5556 electrophysiologic characteristics, radiofrequency catheter ablation, and risk prediction [see 5557 comments]. J Cardiovasc Electrophysiol 1999;10:1180-1187. 5558 836. Stabile G, De Simone A, Turco P, La Rocca V, Nocerino P, Astarita C, Maresca F, De Matteis 5559 C, Di Napoli T, Stabile E, Vitale DF. Response to flecainide infusion predicts long-term success of 5560 hybrid pharmacologic and ablation therapy in patients with atrial fibrillation. J Am Coll Cardiol 5561 2001;37:1639-1644. 5562 837. Anastasio N, Frankel DS, Devell MW, Zado E, Gerstenfeld EP, Dixit S, Cooper J, Lin D, 5563 Marchlinski FE, Callans DJ. Nearly uniform failure of atrial flutter ablation and continuation of 5564 antiarrhythmic agents (hybrid therapy) for the long-term control of atrial fibrillation. J Interv Card 5565 Electrophysiol 2012;35:57-61. 5566 838. Garcia Seara J, Raposeiras Roubin S, Gude Sampedro F, Balboa Barreiro V, Martinez Sande 5567 JL, Rodriguez Manero M, Gonzalez Juanatey JR. Failure of hybrid therapy for the prevention of long-

5568 term recurrence of atrial fibrillation. Int J Cardiol 2014;176:74-79.

5569 839. Saksena S, Prakash A, Ziegler P, Hummel JD, Friedman P, Plumb VJ, Wyse DG, Johnson E, 5570 Fitts S, Mehra R. Improved suppression of recurrent atrial fibrillation with dual-site right atrial pacing 5571 and antiarrhythmic drug therapy. J Am Coll Cardiol 2002;40:1140-1150; discussion 1151-1142. 5572 Wharton JM, Sorrentino RA, Campbell P, Gonzalez-Zuelgaray J, Keating E, Curtis A, Grill C, 840. 5573 Hafley G, Lee K. Effect of pacing modality on atrial tachyarrhythmia recurrence in the tachycardia-5574 bradycardia syndrome: preliminary results of the Pacemaker Atrial Tachycardia Trial. Circulation 5575 1998;98 (suppl l):I-494 (abstract). 5576 Marinigh R, Lip GY, Fiotti N, Giansante C, Lane DA. Age as a risk factor for stroke in atrial 841. 5577 fibrillation patients: implications for thromboprophylaxis. J Am Coll Cardiol 2010;56:827-837. 5578 842. Gage BF, Boechler M, Doggette AL, Fortune G, Flaker GC, Rich MW, Radford MJ. Adverse 5579 outcomes and predictors of underuse of antithrombotic therapy in medicare beneficiaries with chronic 5580 atrial fibrillation. Stroke 2000;31:822-827. 5581 843. Andreotti F, Rocca B, Husted S, Ajjan RA, Ten Berg J, Cattaneo M, Collet JP, De Caterina R, 5582 Fox KA, Halvorsen S, Huber K, Hylek EM, Lip GY, Montalescot G, Morais J, Patrono C, Verheuot FW, 5583 Wallentin L, Weiss TW, Storey RF, ESC Thrombosis Working Group. Antithrombotic therapy in the 5584 elderly: expert position paper of the European Society of Cardiology Working Group on Thrombosis. 5585 Eur Heart J 2015;36:3238-3249. 5586 Priori SG, Blomstrom-Lundqvist C, Mazzanti A, Blom N, Borggrefe M, Camm J, Elliott PM, 844. 5587 Fitzsimons D, Hatala R, Hindricks G, Kirchhof P, Kjeldsen K, Kuck KH, Hernandez-Madrid A, Nikolaou 5588 N, Norekval TM, Spaulding C, Van Veldhuisen DJ. 2015 ESC Guidelines for the management of 5589 patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for 5590 the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac 5591 Death of the European Society of Cardiology (ESC). Endorsed by: Association for European 5592 Paediatric and Congenital Cardiology (AEPC). Eur Heart J 2015;36:2793-2867. 5593 845. Elliott PM, Anastasakis A, Borger MA, Borggrefe M, Cecchi F, Charron P, Hagege AA, Lafont 5594 A, Limongelli G, Mahrholdt H, McKenna WJ, Mogensen J, Nihoyannopoulos P, Nistri S, Pieper PG, 5595 Pieske B, Rapezzi C, Rutten FH, Tillmanns C, Watkins H. 2014 ESC Guidelines on diagnosis and 5596 management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of 5597 Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J 5598 2014;35:2733-2779. 5599 846. Johnson JN, Tester DJ, Perry J, Salisbury BA, Reed CR, Ackerman MJ. Prevalence of early-5600 onset atrial fibrillation in congenital long QT syndrome. Heart Rhythm 2008;5:704-709. 5601 847. Kirchhof P, Eckardt L, Franz MR, Monnig G, Loh P, Wedekind H, Schulze-Bahr E, Breithardt 5602 G, Haverkamp W. Prolonged atrial action potential durations and polymorphic atrial tachyarrhythmias 5603 in patients with long QT syndrome. J Cardiovasc Electrophysiol 2003;14:1027-1033. 5604 Zellerhoff S, Pistulli R, Monnig G, Hinterseer M, Beckmann BM, Kobe J, Steinbeck G, Kaab 848. 5605 S, Haverkamp W, Fabritz L, Gradaus R, Breithardt G, Schulze-Bahr E, Bocker D, Kirchhof P. Atrial 5606 Arrhythmias in long-QT syndrome under daily life conditions: a nested case control study. J 5607 Cardiovasc Electrophysiol 2009;20:401-407. 5608 Moss AJ, Zareba W, Benhorin J, Locati EH, Hall WJ, Robinson JL, Schwartz PJ, Towbin JA, 849. 5609 Vincent GM, Lehmann MH. ECG T-wave patterns in genetically distinct forms of the hereditary long 5610 QT syndrome. Circulation 1995;92:2929-2934. 5611 850. Schwartz PJ, Priori SG, Spazzolini C, Moss AJ, Vincent GM, Napolitano C, Denjoy I, 5612 Guicheney P, Breithardt G, Keating MT, Towbin JA, Beggs AH, Brink P, Wilde AA, Toivonen L, 5613 Zareba W, Robinson JL, Timothy KW, Corfield V, Wattanasirichaigoon D, Corbett C, Haverkamp W, 5614 Schulze-Bahr E, Lehmann MH, Schwartz K, Coumel P, Bloise R. Genotype-phenotype correlation in 5615 the long-QT syndrome: gene-specific triggers for life-threatening arrhythmias. Circulation 5616 2001;103:89-95. 5617 851. Eckardt L, Kirchhof P, Loh P, Schulze-Bahr E, Johna R, Wichter T, Breithardt G, Haverkamp 5618 W, Borggrefe M. Brugada syndrome and supraventricular tachyarrhythmias: a novel association? J 5619 Cardiovasc Electrophysiol 2001;12:680-685. 5620 Kaufman ES. Mechanisms and clinical management of inherited channelopathies: long QT 852. 5621 syndrome, Brugada syndrome, catecholaminergic polymorphic ventricular tachycardia, and short QT 5622 syndrome. Heart Rhythm 2009;6:S51-55. 5623 853. Antzelevitch C, Pollevick GD, Cordeiro JM, Casis O, Sanguinetti MC, Aizawa Y, Guerchicoff 5624 A, Pfeiffer R, Oliva A, Wollnik B, Gelber P, Bonaros EP, Jr., Burashnikov E, Wu Y, Sargent JD, 5625 Schickel S, Oberheiden R, Bhatia A, Hsu LF, Haissaguerre M, Schimpf R, Borggrefe M, Wolpert C. 5626 Loss-of-function mutations in the cardiac calcium channel underlie a new clinical entity characterized 5627 by ST-segment elevation, short QT intervals, and sudden cardiac death. Circulation 2007;115:442-5628 449.

5629 854. London B, Michalec M, Mehdi H, Zhu X, Kerchner L, Sanyal S, Viswanathan PC, Pfahnl AE, 5630 Shang LL, Madhusudanan M, Baty CJ, Lagana S, Aleong R, Gutmann R, Ackerman MJ, McNamara 5631 DM, Weiss R, Dudley SC, Jr. Mutation in glycerol-3-phosphate dehydrogenase 1 like gene (GPD1-L) 5632 decreases cardiac Na+ current and causes inherited arrhythmias. Circulation 2007;116:2260-2268. 5633 Watanabe H, Koopmann TT, Le Scouarnec S, Yang T, Ingram CR, Schott JJ, Demolombe S, 855. 5634 Probst V, Anselme F, Escande D, Wiesfeld AC, Pfeufer A, Kaab S, Wichmann HE, Hasdemir C, 5635 Aizawa Y, Wilde AA, Roden DM, Bezzina CR. Sodium channel beta1 subunit mutations associated 5636 with Brugada syndrome and cardiac conduction disease in humans. J Clin Invest 2008;118:2260-5637 2268. 5638 856. Brugada R, Hong K, Dumaine R, Cordeiro J, Gaita F, Borggrefe M, Menendez TM, Brugada 5639 J, Pollevick GD, Wolpert C, Burashnikov E, Matsuo K, Wu YS, Guerchicoff A, Bianchi F, Giustetto C, 5640 Schimpf R, Brugada P, Antzelevitch C. Sudden death associated with short-QT syndrome linked to 5641 mutations in HERG. Circulation 2004;109:30-35. 5642 Gaita F. Giustetto C. Bianchi F. Wolpert C. Schimpf R. Riccardi R. Grossi S. Richiardi E. 857. 5643 Borggrefe M. Short QT Syndrome: a familial cause of sudden death. Circulation 2003;108:965-970. 5644 858. Giustetto C, Di Monte F, Wolpert C, Borggrefe M, Schimpf R, Sbragia P, Leone G, Maury P, 5645 Anttonen O, Haissaguerre M, Gaita F. Short QT syndrome: clinical findings and diagnostic-therapeutic 5646 implications. Eur Heart J 2006;27:2440-2447. 5647 Bhuiyan ZA, van den Berg MP, van Tintelen JP, Bink-Boelkens MT, Wiesfeld AC, Alders M, 859. 5648 Postma AV, van Langen I, Mannens MM, Wilde AA. Expanding spectrum of human RYR2-related 5649 disease: new electrocardiographic, structural, and genetic features. Circulation 2007;116:1569-1576. 5650 860. Napolitano C, Priori SG. Diagnosis and treatment of catecholaminergic polymorphic 5651 ventricular tachycardia. Heart Rhythm 2007;4:675-678. 5652 861. Mohamed U, Napolitano C, Priori SG. Molecular and electrophysiological bases of 5653 catecholaminergic polymorphic ventricular tachycardia. J Cardiovasc Electrophysiol 2007;18:791-797. 5654 862. Lee CH, Liu PY, Lin LJ, Chen JH, Tsai LM. Clinical characteristics and outcomes of 5655 hypertrophic cardiomyopathy in Taiwan--a tertiary center experience. Clin Cardiol 2007;30:177-182. 5656 863. Losi MA, Betocchi S, Aversa M, Lombardi R, Miranda M, D'Alessandro G, Cacace A, 5657 Tocchetti CG, Barbati G, Chiariello M. Determinants of atrial fibrillation development in patients with 5658 hypertrophic cardiomyopathy. Am J Cardiol 2004;94:895-900. 5659 864. Maron BJ, Olivotto I, Bellone P, Conte MR, Cecchi F, Flygenring BP, Casey SA, Gohman TE, 5660 Bongioanni S, Spirito P. Clinical profile of stroke in 900 patients with hypertrophic cardiomyopathy. J 5661 Am Coll Cardiol 2002;39:301-307. 5662 865. Gollob MH, Seger JJ, Gollob TN, Tapscott T, Gonzales O, Bachinski L, Roberts R. Novel 5663 PRKAG2 mutation responsible for the genetic syndrome of ventricular preexcitation and conduction 5664 system disease with childhood onset and absence of cardiac hypertrophy. Circulation 2001;104:3030-5665 3033. 5666 Postma AV, van de Meerakker JB, Mathijssen IB, Barnett P, Christoffels VM, Ilgun A, Lam J, 866. 5667 Wilde AA, Lekanne Deprez RH, Moorman AF. A gain-of-function TBX5 mutation is associated with 5668 atypical Holt-Oram syndrome and paroxysmal atrial fibrillation. Circ Res 2008;102:1433-1442. Marcus FI, Edson S, Towbin JA. Genetics of arrhythmogenic right ventricular cardiomyopathy: 5669 867. 5670 a practical guide for physicians. J Am Coll Cardiol 2013;61:1945-1948. 5671 868. Chu AF, Zado E, Marchlinski FE. Atrial arrhythmias in patients with arrhythmogenic right 5672 ventricular cardiomyopathy/dysplasia and ventricular tachycardia. Am J Cardiol 2010;106:720-722. 5673 Blomstrom-Lundqvist C, Scheinman MM, Aliot EM, Alpert JS, Calkins H, Camm AJ, Campbell 869. 5674 WB, Haines DE, Kuck KH, Lerman BB, Miller DD, Shaeffer CW, Stevenson WG, Tomaselli GF, Antman EM, Smith SC, Jr., Alpert JS, Faxon DP, Fuster V, Gibbons RJ, Gregoratos G, Hiratzka LF, 5675 5676 Hunt SA, Jacobs AK, Russell RO, Jr., Priori SG, Blanc JJ, Budaj A, Burgos EF, Cowie M, Deckers 5677 JW, Garcia MA, Klein WW, Lekakis J, Lindahl B, Mazzotta G, Morais JC, Oto A, Smiseth O, Trappe 5678 HJ, European Society of Cardiology Committee, NASPE-Heart Rhythm Society. ACC/AHA/ESC 5679 guidelines for the management of patients with supraventricular arrhythmias--executive summary. a 5680 report of the American college of cardiology/American heart association task force on practice 5681 guidelines and the European society of cardiology committee for practice guidelines (writing 5682 committee to develop guidelines for the management of patients with supraventricular arrhythmias) 5683 developed in collaboration with NASPE-Heart Rhythm Society. J Am Coll Cardiol 2003;42:1493-1531. 5684 Tischenko A, Fox DJ, Yee R, Krahn AD, Skanes AC, Gula LJ, Klein GJ. When should we 870. 5685 recommend catheter ablation for patients with the Wolff-Parkinson-White syndrome? Curr Opin 5686 Cardiol 2008;23:32-37. 5687 Kibos A, Deharo JC, Adoubi A, Assouan X, Djianeb P. [Clinical and electrophysiological study 871.

5688 of asymptomatic Wolff-Parkinson-White syndrome]. Ann Cardiol Angeiol (Paris) 2007;**56**:237-240.

5689 872. Pappone C, Santinelli V, Manguso F, Augello G, Santinelli O, Vicedomini G, Gulletta S, 5690 Mazzone P, Tortoriello V, Pappone A, Dicandia C, Rosanio S. A randomized study of prophylactic 5691 catheter ablation in asymptomatic patients with the Wolff-Parkinson-White syndrome. N Engl J Med 5692 2003;349:1803-1811. 5693 Boahene KA, Klein GJ, Yee R, Sharma AD, Fujimura O. Termination of acute atrial fibrillation 873. 5694 in the Wolff-Parkinson-White syndrome by procainamide and propafenone: importance of atrial 5695 fibrillatory cycle length. J Am Coll Cardiol 1990;16:1408-1414. 5696 874. O'Nunain S, Garratt CJ, Linker NJ, Gill J, Ward DE, Camm AJ. A comparison of intravenous 5697 propafenone and flecainide in the treatment of tachycardias associated with the Wolff-Parkinson-5698 White syndrome. Pacing Clin Electrophysiol 1991;14:2028-2034. 5699 Manolis AS, Estes NA, 3rd. Supraventricular tachycardia. Mechanisms and therapy. Arch 875. 5700 Intern Med 1987;147:1706-1716. 5701 876. Simonian SM, Lotfipour S, Wall C, Langdorf MI. Challenging the superiority of amiodarone for 5702 rate control in Wolff-Parkinson-White and atrial fibrillation. Intern Emerg Med 2010;5:421-426. 5703 Guttmann OP, Rahman MS, O'Mahony C, Anastasakis A, Elliott PM. Atrial fibrillation and 877. 5704 thromboembolism in patients with hypertrophic cardiomyopathy: systematic review. Heart 5705 2014;100:465-472. 5706 878. Olivotto I, Cecchi F, Casey SA, Dolara A, Traverse JH, Maron BJ. Impact of atrial fibrillation 5707 on the clinical course of hypertrophic cardiomyopathy. Circulation 2001;104:2517-2524. 5708 Cecchi F, Olivotto I, Montereggi A, Squillatini G, Dolara A, Maron BJ. Prognostic value of non-879. 5709 sustained ventricular tachycardia and the potential role of amiodarone treatment in hypertrophic 5710 cardiomyopathy: assessment in an unselected non-referral based patient population. Heart 5711 1998;79:331-336. 5712 880. Bunch TJ, Munger TM, Friedman PA, Asirvatham SJ, Brady PA, Cha YM, Rea RF, Shen WK, Powell BD, Ommen SR, Monahan KH, Haroldson JM, Packer DL. Substrate and procedural 5713 5714 predictors of outcomes after catheter ablation for atrial fibrillation in patients with hypertrophic 5715 cardiomyopathy. J Cardiovasc Electrophysiol 2008;19:1009-1014. 5716 Di Donna P, Olivotto I, Delcre SD, Caponi D, Scaglione M, Nault I, Montefusco A, Girolami F, 881. 5717 Cecchi F, Haissaguerre M, Gaita F. Efficacy of catheter ablation for atrial fibrillation in hypertrophic 5718 cardiomyopathy: impact of age, atrial remodelling, and disease progression. Europace 2010;12:347-5719 355. 5720 882. Gaita F, Di Donna P, Olivotto I, Scaglione M, Ferrero I, Montefusco A, Caponi D, Conte MR, 5721 Nistri S, Cecchi F. Usefulness and safety of transcatheter ablation of atrial fibrillation in patients with 5722 hypertrophic cardiomyopathy. Am J Cardiol 2007;99:1575-1581. 5723 Kilicaslan F, Verma A, Saad E, Themistoclakis S, Bonso A, Raviele A, Bozbas H, Andrews 883. 5724 MW, Beheiry S, Hao S, Cummings JE, Marrouche NF, Lakkireddy D, Wazni O, Yamaji H, Saenz LC, 5725 Saliba W, Schweikert RA, Natale A. Efficacy of catheter ablation of atrial fibrillation in patients with 5726 hypertrophic obstructive cardiomyopathy. Heart Rhythm 2006;3:275-280. 5727 884. McCready JW, Smedley T, Lambiase PD, Ahsan SY, Segal OR, Rowland E, Lowe MD, Chow 5728 AW. Predictors of recurrence following radiofrequency ablation for persistent atrial fibrillation. 5729 Europace 2011;13:355-361. 5730 Ritchie MD, Rowan S, Kucera G, Stubblefield T, Blair M, Carter S, Roden DM, Darbar D. 885. 5731 Chromosome 4q25 variants are genetic modifiers of rare ion channel mutations associated with 5732 familial atrial fibrillation. J Am Coll Cardiol 2012;60:1173-1181. 5733 Mann SA, Otway R, Guo G, Soka M, Karlsdotter L, Trivedi G, Ohanian M, Zodgekar P, Smith 886. 5734 RA, Wouters MA, Subbiah R, Walker B, Kuchar D, Sanders P, Griffiths L, Vandenberg JI, Fatkin D. 5735 Epistatic effects of potassium channel variation on cardiac repolarization and atrial fibrillation risk. J 5736 Am Coll Cardiol 2012;59:1017-1025. 5737 887. Giustetto C, Cerrato N, Gribaudo E, Scrocco C, Castagno D, Richiardi E, Giachino D, Bianchi 5738 F, Barbonaglia L, Ferraro A. Atrial fibrillation in a large population with Brugada electrocardiographic 5739 pattern: prevalence, management, and correlation with prognosis. Heart Rhythm 2014;11:259-265. 5740 Darbar D, Kannankeril PJ, Donahue BS, Kucera G, Stubblefield T, Haines JL, George AL, Jr., 888. 5741 Roden DM. Cardiac sodium channel (SCN5A) variants associated with atrial fibrillation. Circulation 5742 2008:117:1927-1935. 5743 Olson TM, Michels VV, Ballew JD, Reyna SP, Karst ML, Herron KJ, Horton SC, Rodeheffer 889. 5744 RJ, Anderson JL. Sodium channel mutations and susceptibility to heart failure and atrial fibrillation. 5745 JAMA 2005;293:447-454. 5746 Ellinor PT, Moore RK, Patton KK, Ruskin JN, Pollak MR, Macrae CA. Mutations in the long 890. 5747 QT gene, KCNQ1, are an uncommon cause of atrial fibrillation. *Heart* 2004;**90**:1487-1488.

Priori SG, Wilde AA, Horie M, Cho Y, Behr ER, Berul C, Blom N, Brugada J, Chiang CE, 5748 891. 5749 Huikuri H, Kannankeril P, Krahn A, Leenhardt A, Moss A, Schwartz PJ, Shimizu W, Tomaselli G, 5750 Tracy C, Ackerman M, Belhassen B, Estes NA, 3rd, Fatkin D, Kalman J, Kaufman E, Kirchhof P. 5751 Schulze-Bahr E, Wolpert C, Vohra J, Refaat M, Etheridge SP, Campbell RM, Martin ET, Quek SC. 5752 Executive summary: HRS/EHRA/APHRS expert consensus statement on the diagnosis and 5753 management of patients with inherited primary arrhythmia syndromes. Europace 2013;15:1389-1406. 5754 Antz M, Weiss C, Volkmer M, Hebe J, Ernst S, Ouyang F, Kuck KH. Risk of sudden death 892. 5755 after successful accessory atrioventricular pathway ablation in resuscitated patients with Wolff-5756 Parkinson-White syndrome. J Cardiovasc Electrophysiol 2002;13:231-236. 5757 893. Timmermans C, Smeets JL, Rodriguez LM, Vrouchos G, van den Dool A, Wellens HJ. 5758 Aborted sudden death in the Wolff-Parkinson-White syndrome. Am J Cardiol 1995;76:492-494. 5759 894. Bromberg BI, Lindsay BD, Cain ME, Cox JL. Impact of clinical history and electrophysiologic 5760 characterization of accessory pathways on management strategies to reduce sudden death among 5761 children with Wolff-Parkinson-White syndrome. J Am Coll Cardiol 1996;27:690-695. 5762 Al-Khatib SM, Arshad A, Balk EM, Das SR, Hsu JC, Joglar JA, Page RL. Risk stratification for 895. 5763 arrhythmic events in patients with asymptomatic pre-excitation: A systematic review for the 2015 5764 ACC/AHA/HRS guideline for the management of adult patients with supraventricular tachycardia: A 5765 Report of the American College of Cardiology/American Heart Association Task Force on Clinical 5766 Practice Guidelines and the Heart Rhythm Society. Heart Rhythm 2016;13:e222-237. 5767 Maron BJ, Ommen SR, Semsarian C, Spirito P, Olivotto I, Maron MS. Hypertrophic 896. 5768 cardiomyopathy: present and future, with translation into contemporary cardiovascular medicine. J Am 5769 Coll Cardiol 2014;64:83-99. 5770 897. Robinson K, Frenneaux MP, Stockins B, Karatasakis G, Poloniecki JD, McKenna WJ. Atrial 5771 fibrillation in hypertrophic cardiomyopathy: a longitudinal study. J Am Coll Cardiol 1990;15:1279-1285. 5772 898. Mozaffarian D, Furberg CD, Psaty BM, Siscovick D. Physical activity and incidence of atrial 5773 fibrillation in older adults: the cardiovascular health study. Circulation 2008;118:800-807. 5774 899. Elosua R, Arquer A, Mont L, Sambola A, Molina L, Garcia-Moran E, Brugada J, Marrugat J. 5775 Sport practice and the risk of lone atrial fibrillation: a case-control study. Int J Cardiol 2006;108:332-5776 337. 5777 900. Mont L, Sambola A, Brugada J, Vacca M, Marrugat J, Elosua R, Pare C, Azqueta M, Sanz G. 5778 Long-lasting sport practice and lone atrial fibrillation. Eur Heart J 2002:23:477-482. 5779 901. Abdulla J, Nielsen JR. Is the risk of atrial fibrillation higher in athletes than in the general 5780 population? A systematic review and meta-analysis. Europace 2009;11:1156-1159. 5781 902. Thelle DS, Selmer R, Gjesdal K, Sakshaug S, Jugessur A, Graff-Iversen S, Tverdal A, Nystad 5782 W. Resting heart rate and physical activity as risk factors for lone atrial fibrillation: a prospective study 5783 of 309,540 men and women. Heart 2013;99:1755-1760. 5784 903. Wilhelm M, Roten L, Tanner H, Wilhelm I, Schmid JP, Saner H. Atrial remodeling, autonomic 5785 tone, and lifetime training hours in nonelite athletes. Am J Cardiol 2011;108:580-585. 5786 Guasch E, Benito B, Qi X, Cifelli C, Naud P, Shi Y, Mighiu A, Tardif JC, Tadevosyan A, Chen 904. 5787 Y, Gillis MA, Iwasaki YK, Dobrev D, Mont L, Heximer S, Nattel S. Atrial fibrillation promotion by 5788 endurance exercise: demonstration and mechanistic exploration in an animal model. J Am Coll 5789 Cardiol 2013;62:68-77. 5790 Andersen K, Farahmand B, Ahlbom A, Held C, Ljunghall S, Michaelsson K, Sundstrom J. 905. 5791 Risk of arrhythmias in 52 755 long-distance cross-country skiers: a cohort study. Eur Heart J 5792 2013;34:3624-3631. 5793 Karjalainen J, Kujala UM, Kaprio J, Sarna S, Viitasalo M. Lone atrial fibrillation in vigorously 906. 5794 exercising middle aged men: case-control study. BMJ 1998;316:1784-1785. 5795 907. Biffi A, Maron BJ, Culasso F, Verdile L, Fernando F, Di Giacinto B, Di Paolo FM, Spataro A, 5796 Delise P, Pelliccia A. Patterns of ventricular tachyarrhythmias associated with training, deconditioning 5797 and retraining in elite athletes without cardiovascular abnormalities. Am J Cardiol 2011;107:697-703. 5798 908. Calvo N, Mont L, Tamborero D, Berruezo A, Viola G, Guasch E, Nadal M, Andreu D, Vidal B, 5799 Sitges M, Brugada J. Efficacy of circumferential pulmonary vein ablation of atrial fibrillation in 5800 endurance athletes. Europace 2010;12:30-36. 5801 909. Koopman P, Nuvens D, Garweg C, La Gerche A, De Buck S, Van Casteren L, Alzand B, 5802 Willems R, Heidbuchel H. Efficacy of radiofrequency catheter ablation in athletes with atrial fibrillation. 5803 Europace 2011;13:1386-1393. 5804 910. Heidbuchel H, Panhuyzen-Goedkoop N, Corrado D, Hoffmann E, Biffi A, Delise P, 5805 Blomstrom-Lundqvist C, Vanhees L, Ivarhoff P, Dorwarth U, Pelliccia A. Recommendations for 5806 participation in leisure-time physical activity and competitive sports in patients with arrhythmias and

5807 potentially arrhythmogenic conditions Part I: Supraventricular arrhythmias and pacemakers. Eur J 5808 Cardiovasc Prev Rehabil 2006;13:475-484. 5809 Silversides CK, Harris L, Haberer K, Sermer M, Colman JM, Siu SC. Recurrence rates of 911. 5810 arrhythmias during pregnancy in women with previous tachyarrhythmia and impact on fetal and 5811 neonatal outcomes. Am J Cardiol 2006;97:1206-1212. 5812 912. Salam AM, Ertekin E, van Hagen IM, Al Suwaidi J, Ruys TPE, Johnson MR, Gumbiene L, 5813 Frogoudaki AA, Sorour KA, Iserin L, Ladouceur M, van Oppen ACC, Hall R, Roos-Hesselink JW. 5814 Atrial Fibrillation or Flutter During Pregnancy in Patients With Structural Heart Disease: Data From the 5815 ROPAC (Registry on Pregnancy and Cardiac Disease). JACC Clin Electrophysiol 2015;1:284-292. 5816 Baumgartner H, Bonhoeffer P, De Groot NM, de Haan F, Deanfield JE, Galie N, Gatzoulis 913. 5817 MA, Gohlke-Baerwolf C, Kaemmerer H, Kilner P, Meijboom F, Mulder BJ, Oechslin E, Oliver JM, 5818 Serraf A, Szatmari A, Thaulow E, Vouhe PR, Walma E. ESC Guidelines for the management of 5819 grown-up congenital heart disease (new version 2010). Eur Heart J 2010;31:2915-2957. 5820 914. Page RL. Treatment of arrhythmias during pregnancy. Am Heart J 1995;130:871-876. 5821 915. Magee LA, Duley L. Oral beta-blockers for mild to moderate hypertension during pregnancy. 5822 Cochrane Database Syst Rev 2003;3:CD002863. 5823 916. Mitani GM, Steinberg I, Lien EJ, Harrison EC, Elkayam U. The pharmacokinetics of 5824 antiarrhythmic agents in pregnancy and lactation. Clin Pharmacokinet 1987;12:253-291. 5825 917. Gowda RM, Khan IA, Mehta NJ, Vasavada BC, Sacchi TJ. Cardiac arrhythmias in pregnancy: 5826 clinical and therapeutic considerations. Int J Cardiol 2003;88:129-133. 5827 918. Joint Formulary Committee. British National Formulary (online). 5828 http://www.medicinescomplete.com. Date last accessed 02/12/2014 2014 5829 919. Bartalena L, Bogazzi F, Braverman LE, Martino E. Effects of amiodarone administration 5830 during pregnancy on neonatal thyroid function and subsequent neurodevelopment. J Endocrinol 5831 Invest 2001;24:116-130. 5832 920. Jaeggi ET, Carvalho JS, De Groot E, Api O, Clur SA, Rammeloo L, McCrindle BW, Rvan G, 5833 Manlhiot C, Blom NA. Comparison of transplacental treatment of fetal supraventricular 5834 tachyarrhythmias with digoxin, flecainide, and sotalol: results of a nonrandomized multicenter study. 5835 Circulation 2011;124:1747-1754. 5836 Tromp CHN, Nanne ACM, Pernet PJM, Tukkie R, Bolte AC. Electrical cardioversion during 921. 5837 pregnancy: safe or not? Neth Heart J 2011;19:134-136. 5838 Ghosh N, Luk A, Derzko C, Dorian P, Chow CM. The acute treatment of maternal 922. 5839 supraventricular tachycardias during pregnancy: a review of the literature. J Obstet Gynaecol Can 5840 2011;33:17-23. 5841 Bates SM, Greer IA, Middeldorp S, Veenstra DL, Prabulos AM, Vandvik PO, American 923. 5842 College of Chest Physicians. VTE, thrombophilia, antithrombotic therapy, and pregnancy: 5843 Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians 5844 Evidence-Based Clinical Practice Guidelines. Chest 2012;141:e691S-736S. 5845 Ahlsson AJ, Bodin L, Lundblad OH, Englund AG. Postoperative atrial fibrillation is not 924. 5846 correlated to C-reactive protein. Ann Thorac Surg 2007;83:1332-1337. 5847 925. Arsenault KA, Yusuf AM, Crystal E, Healey JS, Morillo CA, Nair GM, Whitlock RP. 5848 Interventions for preventing post-operative atrial fibrillation in patients undergoing heart surgery. 5849 Cochrane Database Syst Rev 2013;1:Cd003611. 5850 Mathew JP, Fontes ML, Tudor IC, Ramsay J, Duke P, Mazer CD, Barash PG, Hsu PH, 926. 5851 Mangano DT. A multicenter risk index for atrial fibrillation after cardiac surgery. JAMA 2004;291:1720-5852 1729. 5853 927. Steinberg BA, Zhao Y, He X, Hernandez AF, Fullerton DA, Thomas KL, Mills R, Klaskala W. 5854 Peterson ED, Piccini JP. Management of postoperative atrial fibrillation and subsequent outcomes in 5855 contemporary patients undergoing cardiac surgery: insights from the Society of Thoracic Surgeons 5856 CAPS-Care Atrial Fibrillation Registry. Clin Cardiol 2014;37:7-13. 5857 928. Khan MF, Wendel CS, Movahed MR. Prevention of post-coronary artery bypass grafting 5858 (CABG) atrial fibrillation: efficacy of prophylactic beta-blockers in the modern era: a meta-analysis of 5859 latest randomized controlled trials. Ann Noninvasive Electrocardiol 2013;18:58-68. 5860 929. Burgess DC, Kilborn MJ, Keech AC. Interventions for prevention of post-operative atrial 5861 fibrillation and its complications after cardiac surgery: a meta-analysis. Eur Heart J 2006;27:2846-5862 2857. 5863 930. Chatterjee S, Sardar P, Mukherjee D, Lichstein E, Aikat S. Timing and route of amiodarone 5864 for prevention of postoperative atrial fibrillation after cardiac surgery: a network regression meta-5865 analysis. Pacing Clin Electrophysiol 2013;36:1017-1023.

5866 931. Zhu J, Wang C, Gao D, Zhang C, Zhang Y, Lu Y, Gao Y. Meta-analysis of amiodarone versus 5867 beta-blocker as a prophylactic therapy against atrial fibrillation following cardiac surgery. Intern Med J 5868 2012;42:1078-1087. 5869 Fauchier L, Clementy N, Babuty D. Statin therapy and atrial fibrillation: systematic review and 932. 5870 updated meta-analysis of published randomized controlled trials. Curr Opin Cardiol 2013;28:7-18. 5871 933. Zheng H, Xue S, Hu ZL, Shan JG, Yang WG. The use of statins to prevent postoperative 5872 atrial fibrillation after coronary artery bypass grafting: a meta-analysis of 12 studies. J Cardiovasc 5873 Pharmacol 2014;64:285-292. 5874 934. Casadei B, OTHERS. Statin Therapy In Cardiac Surgery (STICS) Trial. N Engl J Med 5875 2016;TO BE ADDED. 5876 Cook RC, Yamashita MH, Kearns M, Ramanathan K, Gin K, Humphries KH. Prophylactic 935. 5877 magnesium does not prevent atrial fibrillation after cardiac surgery: a meta-analysis. Ann Thorac Surg 5878 2013;95:533-541. 5879 De Oliveira GS. Jr., Knautz JS. Sherwani S. McCarthy RJ. Systemic magnesium to reduce 936. 5880 postoperative arrhythmias after coronary artery bypass graft surgery: a meta-analysis of randomized 5881 controlled trials. J Cardiothorac Vasc Anesth 2012;26:643-650. 5882 937. Costanzo S, di Niro V, Di Castelnuovo A, Gianfagna F, Donati MB, de Gaetano G, lacoviello 5883 L. Prevention of postoperative atrial fibrillation in open heart surgery patients by preoperative 5884 supplementation of n-3 polyunsaturated fatty acids: an updated meta-analysis. J Thorac Cardiovasc 5885 Surg 2013;**146**:906-911. 5886 Farquharson AL, Metcalf RG, Sanders P, Stuklis R, Edwards JR, Gibson RA, Cleland LG, 938. 5887 Sullivan TR, James MJ, Young GD. Effect of dietary fish oil on atrial fibrillation after cardiac surgery. 5888 Am J Cardiol 2011;108:851-856. 5889 Heidarsdottir R, Arnar DO, Skuladottir GV, Torfason B, Edvardsson V, Gottskalksson G, 939. 5890 Palsson R, Indridason OS. Does treatment with n-3 polyunsaturated fatty acids prevent atrial 5891 fibrillation after open heart surgery? Europace 2010;12:356-363. 5892 940. Mariani J, Doval HC, Nul D, Varini S, Grancelli H, Ferrante D, Tognoni G, Macchia A. N-3 5893 polyunsaturated fatty acids to prevent atrial fibrillation: updated systematic review and meta-analysis 5894 of randomized controlled trials. J Am Heart Assoc 2013;2:e005033. 5895 941. Rodrigo R, Korantzopoulos P, Cereceda M, Asenjo R, Zamorano J, Villalabeitia E, Baeza C, 5896 Aguayo R, Castillo R, Carrasco R, Gormaz JG. A randomized controlled trial to prevent post-operative 5897 atrial fibrillation by antioxidant reinforcement. J Am Coll Cardiol 2013;62:1457-1465. 5898 942. Saravanan P, Bridgewater B, West AL, O'Neill SC, Calder PC, Davidson NC. Omega-3 fatty 5899 acid supplementation does not reduce risk of atrial fibrillation after coronary artery bypass surgery: a 5900 randomized, double-blind, placebo-controlled clinical trial. Circ Arrhythm Electrophysiol 2010;3:46-53. 5901 Wu JH, Marchioli R, Silletta MG, Macchia A, Song X, Siscovick DS, Harris WS, Masson S, 943. 5902 Latini R, Albert C, Brown NJ, Lamarra M, Favaloro RR, Mozaffarian D. Plasma phospholipid omega-3 5903 fatty acids and incidence of postoperative atrial fibrillation in the OPERA trial. J Am Heart Assoc 5904 2013;2:e000397. 5905 Xin W, Wei W, Lin Z, Zhang X, Yang H, Zhang T, Li B, Mi S. Fish oil and atrial fibrillation after 944. 5906 cardiac surgery: a meta-analysis of randomized controlled trials. PLoS One 2013;8:e72913. 5907 Zhang B, Zhen Y, Tao A, Bao Z, Zhang G. Polyunsaturated fatty acids for the prevention of 945. 5908 atrial fibrillation after cardiac surgery: an updated meta-analysis of randomized controlled trials. J 5909 Cardiol 2014;63:53-59. 5910 Imazio M, Brucato A, Ferrazzi P, Pullara A, Adler Y, Barosi A, Caforio AL, Cemin R, Chirillo F, 946. 5911 Comoglio C, Cugola D, Cumetti D, Dyrda O, Ferrua S, Finkelstein Y, Flocco R, Gandino A, Hoit B, Innocente F, Maestroni S, Musumeci F, Oh J, Pergolini A, Polizzi V, Ristic A, Simon C, Spodick DH, 5912 5913 Tarzia V, Trimboli S, Valenti A, Belli R, Gaita F, COPPS-2 Investigators. Colchicine for prevention of 5914 postpericardiotomy syndrome and postoperative atrial fibrillation: the COPPS-2 randomized clinical 5915 trial. JAMA 2014;312:1016-1023. 5916 947. Cappabianca G, Rotunno C, de Luca Tupputi Schinosa L, Ranieri VM, Paparella D. Protective 5917 effects of steroids in cardiac surgery: a meta-analysis of randomized double-blind trials. J 5918 Cardiothorac Vasc Anesth 2011;25:156-165. 5919 948. Viviano A, Kanagasabay R, Zakkar M. Is perioperative corticosteroid administration 5920 associated with a reduced incidence of postoperative atrial fibrillation in adult cardiac surgery? 5921 Interact Cardiovasc Thorac Surg 2014;18:225-229. 5922 949. Kaleda VI, McCormack DJ, Shipolini AR. Does posterior pericardiotomy reduce the incidence 5923 of atrial fibrillation after coronary artery bypass grafting surgery? Interact Cardiovasc Thorac Surg 5924 2012;14:384-389.

5925 950. Dunning J, Treasure T, Versteegh M, Nashef SA. Guidelines on the prevention and 5926 management of de novo atrial fibrillation after cardiac and thoracic surgery. Eur J Cardiothorac Surg 5927 2006;30:852-872. 5928 LaPar DJ, Speir AM, Crosby IK, Fonner E, Jr., Brown M, Rich JB, Quader M, Kern JA, Kron 951. 5929 IL, Ailawadi G, Investigators for the Virginia Cardiac Surgery Quality Initiative. Postoperative atrial 5930 fibrillation significantly increases mortality, hospital readmission, and hospital costs. Ann Thorac Surg 5931 2014;98:527-533; discussion 533. 5932 952. Saxena A, Dinh DT, Smith JA, Shardey GC, Reid CM, Newcomb AE. Usefulness of 5933 postoperative atrial fibrillation as an independent predictor for worse early and late outcomes after 5934 isolated coronary artery bypass grafting (multicenter Australian study of 19,497 patients). Am J 5935 Cardiol 2012;109:219-225. 5936 Gialdini G, Nearing K, Bhave PD, Bonuccelli U, Iadecola C, Healey JS, Kamel H. 953. 5937 Perioperative atrial fibrillation and the long-term risk of ischemic stroke. JAMA 2014;312:616-622. 5938 954. Ahlsson A, Bodin L, Fengsrud E, Englund A. Patients with postoperative atrial fibrillation have 5939 a doubled cardiovascular mortality. Scand Cardiovasc J 2009;43:330-336. 5940 955. Ahlsson A, Fengsrud E, Bodin L, Englund A. Postoperative atrial fibrillation in patients 5941 undergoing aortocoronary bypass surgery carries an eightfold risk of future atrial fibrillation and a 5942 doubled cardiovascular mortality. Eur J Cardiothorac Surg 2010;37:1353-1359. 5943 Mariscalco G, Klersy C, Zanobini M, Banach M, Ferrarese S, Borsani P, Cantore C, Biglioli P, 956. 5944 Sala A. Atrial fibrillation after isolated coronary surgery affects late survival. Circulation 5945 2008;118:1612-1618. 5946 Villareal RP, Hariharan R, Liu BC, Kar B, Lee VV, Elayda M, Lopez JA, Rasekh A, Wilson JM, 957. 5947 Massumi A. Postoperative atrial fibrillation and mortality after coronary artery bypass surgery. J Am 5948 Coll Cardiol 2004;43:742-748. 5949 958. Phan K, Ha HS, Phan S, Medi C, Thomas SP, Yan TD. New-onset atrial fibrillation following 5950 coronary bypass surgery predicts long-term mortality: a systematic review and meta-analysis. Eur J 5951 Cardiothorac Surg 2015;48:817-824. 5952 959. El-Chami MF, Kilgo P, Thourani V, Lattouf OM, Delurgio DB, Guyton RA, Leon AR, Puskas 5953 JD. New-onset atrial fibrillation predicts long-term mortality after coronary artery bypass graft. J Am 5954 Coll Cardiol 2010;55:1370-1376. 5955 960. Anderson E, Dyke C, Levy JH. Anticoagulation strategies for the management of 5956 postoperative atrial fibrillation. Clin Lab Med 2014;34:537-561. 5957 961. Heldal M, Atar D. Pharmacological conversion of recent-onset atrial fibrillation: a systematic 5958 review. Scand Cardiovasc J Suppl 2013;47:2-10. 5959 Gillinov AM, Bagiella E, Moskowitz AJ, Raiten JM, Groh MA, Bowdish ME, Ailawadi G, 962. 5960 Kirkwood KA, Perrault LP, Parides MK, Smith li RL, Kern JA, Dussault G, Hackmann AE, Jeffries NO, 5961 Miller MA, Taddei-Peters WC, Rose EA, Weisel RD, Williams DL, Mangusan RF, Argenziano M, 5962 Moquete EG, O'Sullivan KL, Pellerin M, Shah KJ, Gammie JS, Mayer ML, Voisine P, Gelijns AC, 5963 O'Gara PT, Mack MJ, CTSN. Rate Control versus Rhythm Control for Atrial Fibrillation after Cardiac 5964 Surgery. N Engl J Med 2016: [Epub ahead of print]. Triedman JK. Arrhythmias in adults with congenital heart disease. Heart 2002;87:383-389. 5965 963. 5966 964. Ammash NM, Phillips SD, Hodge DO, Connolly HM, Grogan MA, Friedman PA, Warnes CA, 5967 Asirvatham SJ. Outcome of direct current cardioversion for atrial arrhythmias in adults with congenital 5968 heart disease. Int J Cardiol 2012;154:270-274. 5969 Greason KL, Dearani JA, Theodoro DA, Porter CB, Warnes CA, Danielson GK. Surgical 965. 5970 management of atrial tachyarrhythmias associated with congenital cardiac anomalies: Mayo Clinic 5971 experience. Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu 2003;6:59-71. 5972 966. Payne L, Zeigler VL, Gillette PC. Acute cardiac arrhythmias following surgery for congenital 5973 heart disease: mechanisms, diagnostic tools, and management. Crit Care Nurs Clin North Am 5974 2011;23:255-272. 5975 967. Koyak Z, Harris L, de Groot JR, Silversides CK, Oechslin EN, Bouma BJ, Budts W, 5976 Zwinderman AH, Van Gelder IC, Mulder BJ. Sudden cardiac death in adult congenital heart disease. 5977 Circulation 2012;126:1944-1954. 5978 968. Jensen AS, Idorn L, Norager B, Veilstrup N, Sondergaard L. Anticoagulation in adults with 5979 congenital heart disease: The who, the when and the how? Heart 2014. 5980 Fujita S, Takahashi K, Takeuchi D, Manaka T, Shoda M, Hagiwara N, Kurosawa H, Nakanishi 969. 5981 T. Management of late atrial tachyarrhythmia long after Fontan operation. J Cardiol 2009;53:410-416. 5982 Feltes TF, Friedman RA. Transesophageal echocardiographic detection of atrial thrombi in 970. 5983 patients with nonfibrillation atrial tachyarrhythmias and congenital heart disease. J Am Coll Cardiol 5984 1994;**24**:1365-1370.

5985 971. Nagao K, Tsuchihashi K, Tanaka S, limura O. [Studies on atrial arrhythmias in atrial septal 5986 defect. The influences of aging on atrial fibrillation]. Nihon Ronen Igakkai Zasshi 1995;32:27-32. 5987 Giamberti A, Chessa M, Abella R, Butera G, Negura D, Foresti S, Carminati M, Cappato R, 972. 5988 Frigiola A. Surgical treatment of arrhythmias in adults with congenital heart defects. Int J Cardiol 5989 2008;129:37-41. 5990 Roos-Hesselink JW, Meijboom FJ, Spitaels SE, van Domburg R, van Rijen EH, Utens EM, 973. 5991 Bogers AJ, Simoons ML. Excellent survival and low incidence of arrhythmias, stroke and heart failure 5992 long-term after surgical ASD closure at young age. A prospective follow-up study of 21-33 years. Eur 5993 Heart J 2003;24:190-197. 5994 Yamada T, McElderry HT, Muto M, Murakami Y, Kay GN. Pulmonary vein isolation in patients 974. 5995 with paroxysmal atrial fibrillation after direct suture closure of congenital atrial septal defect. Circ J 5996 2007:71:1989-1992. 5997 975. Van De Bruaene A, Delcroix M, Pasquet A, De Backer J, Paelinck B, Morissens M, Budts W. 5998 The importance of pulmonary artery pressures on late atrial arrhythmia in transcatheter and surgically 5999 closed ASD type secundum. Int J Cardiol 2011;152:192-195. 6000 976. de Salle P, Goenen M, Lecron J, Jaumin P, Tremouroux J. [Rhythm disorders occurring after 6001 surgical closure of the interatrial communication]. Acta Cardiol 1975;30:239-249. 6002 977. Scaglione M, Caponi D, Ebrille E, Di Donna P, Di Clemente F, Battaglia A, Raimondo C, 6003 Appendino M, Gaita F. Very long-term results of electroanatomic-guided radiofrequency ablation of 6004 atrial arrhythmias in patients with surgically corrected atrial septal defect. Europace 2014;16:1800-6005 1807. 6006 978. Kanter RJ, Garson A, Jr. Atrial arrhythmias during chronic follow-up of surgery for complex 6007 congenital heart disease. Pacing Clin Electrophysiol 1997;20:502-511. 6008 979. Porter CJ, Garson A. Incidence and management of dysrhythmias after Fontan procedure. 6009 Herz 1993;18:318-327. 6010 980. Gelatt M, Hamilton RM, McCrindle BW, Gow RM, Williams WG, Trusler GA, Freedom RM. 6011 Risk factors for atrial tachyarrhythmias after the Fontan operation. J Am Coll Cardiol 1994;24:1735-1741. 6012 6013 981. Peters NS, Somerville J. Arrhythmias after the Fontan procedure. Br Heart J 1992;68:199-6014 204. 6015 982. Kwak JG, Kim WH, Lee JR, Kim YJ. Surgical therapy of arrhythmias in single-ventricle 6016 patients undergoing Fontan or Fontan conversion. J Card Surg 2009;24:738-741. 6017 983. Backer CL, Tsao S, Deal BJ, Mavroudis C. Maze procedure in single ventricle patients. Semin 6018 Thorac Cardiovasc Surg Pediatr Card Surg Annu 2008:44-48. 6019 Deal BJ, Mavroudis C, Backer CL. The role of concomitant arrhythmia surgery in patients 984. 6020 undergoing repair of congenital heart disease. Pacing Clin Electrophysiol 2008;31 Suppl 1:S13-16. 6021 985. Gandhi SK. Atrial arrhythmia surgery in congenital heart disease. J Interv Card Electrophysiol 6022 2007;20:119-125. 6023 Correa R, Sherwin ED, Kovach J, Mah DY, Alexander ME, Cecchin F, Walsh EP, Triedman 986. 6024 JK, Abrams DJ. Mechanism and ablation of arrhythmia following total cavopulmonary connection. Circ 6025 Arrhythm Electrophysiol 2015;8:318-325. 6026 Khairy P, Aboulhosn J, Gurvitz MZ, Opotowsky AR, Mongeon FP, Kay J, Valente AM, Earing 987. 6027 MG, Lui G, Gersony DR, Cook S, Ting JG, Nickolaus MJ, Webb G, Landzberg MJ, Broberg CS, 6028 Alliance for Adult Research in Congenital Cardiology. Arrhythmia burden in adults with surgically 6029 repaired tetralogy of Fallot: a multi-institutional study. Circulation 2010;122:868-875. 6030 Kobayashi J, Yamamoto F, Nakano K, Sasako Y, Kitamura S, Kosakai Y. Maze procedure for 988. 6031 atrial fibrillation associated with atrial septal defect. Circulation 1998;98:11399-402. 6032 989. Shim H, Yang JH, Park PW, Jeong DS, Jun TG. Efficacy of the maze procedure for atrial 6033 fibrillation associated with atrial septal defect. Korean J Thorac Cardiovasc Surg 2013;46:98-103. 6034 990. Gutierrez SD, Earing MG, Singh AK, Tweddell JS, Bartz PJ. Atrial tachyarrhythmias and the 6035 Cox-maze procedure in congenital heart disease. Congenit Heart Dis 2013;8:434-439. 6036 Sherwin ED, Triedman JK, Walsh EP. Update on interventional electrophysiology in 991. 6037 congenital heart disease: evolving solutions for complex hearts. Circ Arrhythm Electrophysiol 6038 2013;**6**:1032-1040. 6039 992. Wellens HJ. Contemporary management of atrial flutter. *Circulation* 2002;**106**:649-652. 6040 Bertaglia E, Zoppo F, Bonso A, Proclemer A, Verlato R, Coro L, Mantovan R, D'Este D, Zerbo 993. 6041 F, Pascotto P. Long term follow up of radiofrequency catheter ablation of atrial flutter: clinical course 6042 and predictors of atrial fibrillation occurrence. Heart 2004;90:59-63.

6043 994. Seara JG, Roubin SR, Gude Sampedro F, Barreiro VB, Sande JM, Manero MR, Grandio PC, 6044 Alvarez B, Juanatey JG. Risk of atrial fibrillation, stroke, and death after radiofrequency catheter 6045 ablation of typical atrial flutter. Clin Res Cardiol 2014;103:543-552. 6046 Brembilla-Perrot B, Girerd N, Sellal JM, Olivier A, Manenti V, Villemin T, Beurrier D, de 995. 6047 Chillou C, Louis P, Selton O, de la Chaise AT. Risk of atrial fibrillation after atrial flutter ablation: 6048 impact of AF history, gender, and antiarrhythmic drug medication. J Cardiovasc Electrophysiol 6049 2014;25:813-820. 6050 996. Bronis K, Metaxa S, Koulouris S, Manolis AS. Vernakalant: review of a novel atrial selective 6051 antiarrhythmic agent and its place in current treatment of atrial fibrillation. Hosp Chronicles 6052 2012;7:171-181. 6053 997. Nair M, George LK, Koshy SK. Safety and efficacy of ibutilide in cardioversion of atrial flutter 6054 and fibrillation. J Am Board Fam Med 2011;24:86-92. 6055 998. Reisinger J, Gstrein C, Winter T, Zeindlhofer E, Hollinger K, Mori M, Schiller A, Winter A, 6056 Geiger H, Siostrzonek P. Optimization of initial energy for cardioversion of atrial tachyarrhythmias with 6057 biphasic shocks. Am J Emerg Med 2010;28:159-165. 6058 999. Pinski SL, Sgarbossa EB, Ching E, Trohman RG. A comparison of 50-J versus 100-J shocks 6059 for direct-current cardioversion of atrial flutter. Am Heart J 1999;137:439-442. 6060 1000. Manolis AS, Dragazis I, Kapelakis I, Papadimitriou P, Sakellaris N. Transesophageal 6061 overdrive pacing: A simple and versatile tool. Hosp Chronicles 2013;8:143-145. 6062 Poulidakis E, Manolis AS. Transvenous temporary cardiac pacing. Rhythmos 2014;9:20-27. 1001. Spector P, Reynolds MR, Calkins H, Sondhi M, Xu Y, Martin A, Williams CJ, Sledge I. Meta-6063 1002. 6064 analysis of ablation of atrial flutter and supraventricular tachycardia. Am J Cardiol 2009;104:671-677. 6065 1003. Schmieder S, Ndrepepa G, Dong J, Zrenner B, Schreieck J, Schneider MA, Karch MR, 6066 Schmitt C. Acute and long-term results of radiofrequency ablation of common atrial flutter and the 6067 influence of the right atrial isthmus ablation on the occurrence of atrial fibrillation. Eur Heart J 6068 2003;24:956-962. 6069 1004. Bandini A, Golia P, Caroli E, Biancoli S, Galvani M. Atrial fibrillation after typical atrial flutter 6070 ablation: a long-term follow-up. J Cardiovasc Med (Hagerstown) 2011;12:110-115. 6071 Dewland TA, Glidden DV, Marcus GM. Healthcare utilization and clinical outcomes after 1005. 6072 catheter ablation of atrial flutter. PLoS One 2014;9:e100509. 6073 1006. Esato M, Hindricks G, Sommer P, Arya A, Gaspar T, Bode K, Bollmann A, Wetzel U, Hilbert 6074 S, Kircher S, Eitel C, Piorkowski C. Color-coded three-dimensional entrainment mapping for analysis 6075 and treatment of atrial macroreentrant tachycardia. Heart Rhythm 2009;6:349-358. 6076 Huo Y, Schoenbauer R, Richter S, Rolf S, Sommer P, Arva A, Rastan A, Doll N, Mohr FW, 1007 6077 Hindricks G, Piorkowski C, Gaspar T. Atrial Arrhythmias Following Surgical AF Ablation: 6078 Electrophysiological Findings, Ablation Strategies, and Clinical Outcome. J Cardiovasc Electrophysiol 6079 2014;25:725-738. 6080 1008. Institute of Medicine Committee on Quality of Health Care in America. Crossing the Quality 6081 Chasm: A New Health System for the 21st Century. Washington (DC): National Academies Press 6082 (US); 2001. 6083 Bodenheimer T, Wagner EH, Grumbach K. Improving primary care for patients with chronic 1009. 6084 illness. JAMA 2002;288:1775-1779. 6085 1010. Hibbard JH, Greene J. What the evidence shows about patient activation: better health 6086 outcomes and care experiences; fewer data on costs. Health Aff (Millwood) 2013;32:207-214. 6087 McCabe PJ. Self-management of atrial fibrillation: a new frontier for nursing research. Prog 1011. 6088 Cardiovasc Nurs 2008;23:37-40. 6089 1012. Lip GY, Kamath S, Jafri M, Mohammed A, Bareford D. Ethnic differences in patient 6090 perceptions of atrial fibrillation and anticoagulation therapy: the West Birmingham Atrial Fibrillation 6091 Project. Stroke 2002;33:238-242. 6092 1013. Clarkesmith DE, Pattison HM, Lane DA. Educational and behavioural interventions for 6093 anticoagulant therapy in patients with atrial fibrillation. Cochrane Database Syst Rev 6094 2013;6:Cd008600. 6095 1014. Clarkesmith DE, Pattison HM, Lip GY, Lane DA. Educational intervention improves 6096 anticoagulation control in atrial fibrillation patients: the TREAT randomised trial. PLoS One 6097 2013;8:e74037. 6098 1015. Smith DE, Xuereb CB, Pattison HM, Lip GY, Lane DA. TRial of an Educational intervention on 6099 patients' knowledge of Atrial fibrillation and anticoagulant therapy, INR control, and outcome of 6100 Treatment with warfarin (TREAT). BMC Cardiovasc Disord 2010;10:21. Smith MB, Christensen N, Wang S, Strohecker J, Day JD, Weiss JP, Crandall BG, Osborn 6101 1016. 6102 JS, Anderson JL, Horne BD, Muhlestein JB, Lappe DL, Moss H, Oliver J, Viau K, Bunch TJ. Warfarin

- 6103 knowledge in patients with atrial fibrillation: implications for safety, efficacy, and education strategies. 6104 Cardiology 2010;**116**:61-69. 6105 1017. Aliot E, Breithardt G, Brugada J, Camm J, Lip GY, Vardas PE, Wagner M, Atrial Fibrillation 6106 AWareness and Risk Education group [comprising the Atrial Fibrillation Association (AFA), the European Heart Rhythm Association (EHRA), Stroke Alliance for Europe (SAFE), and the World Heart 6107 6108 Federation (WHF)]. An international survey of physician and patient understanding, perception, and 6109 attitudes to atrial fibrillation and its contribution to cardiovascular disease morbidity and mortality. 6110 Europace 2010;**12**:626-633. 6111 1018. Hendriks JM, Crijns HJ, Tieleman RG, Vrijhoef HJ. The atrial fibrillation knowledge scale: 6112 development, validation and results. Int J Cardiol 2013;168:1422-1428. 6113 McCabe PJ. What patients want and need to know about atrial fibrillation. J Multidiscip 1019. 6114 Healthc 2011;**4**:413-419. 6115 1020. Lorig KR, Holman H. Self-management education: history, definition, outcomes, and 6116 mechanisms. Ann Behav Med 2003;26:1-7. 6117 Stiggelbout AM, Van der Weijden T, De Wit MP, Frosch D, Legare F, Montori VM, Trevena L, 1021. 6118 Elwyn G. Shared decision making: really putting patients at the centre of healthcare. BMJ 6119 2012;344:e256. 6120 1022. Stacey D, Legare F, Col NF, Bennett CL, Barry MJ, Eden KB, Holmes-Rovner M, Llewellyn-6121 Thomas H, Lyddiatt A, Thomson R, Trevena L, Wu JH. Decision aids for people facing health 6122 treatment or screening decisions. Cochrane Database Syst Rev 2014;1:CD001431. 6123 Elwyn G, Frosch D, Thomson R, Joseph-Williams N, Lloyd A, Kinnersley P, Cording E, 1023. 6124 Tomson D, Dodd C, Rollnick S, Edwards A, Barry M. Shared decision making: a model for clinical 6125 practice. J Gen Intern Med 2012;27:1361-1367. 6126 Van Wagoner DR, Piccini JP, Albert CM, Anderson ME, Benjamin EJ, Brundel B, Califf RM, 1024. 6127 Calkins H, Chen PS, Chiamvimonvat N, Darbar D, Eckhardt LL, Ellinor PT, Exner DV, Fogel RI, Gillis 6128 AM, Healey J, Hohnloser SH, Kamel H, Lathrop DA, Lip GY, Mehra R, Narayan SM, Olgin J, Packer 6129 D, Peters NS, Roden DM, Ross HM, Sheldon R, Wehrens XH. Progress toward the prevention and 6130 treatment of atrial fibrillation: A summary of the Heart Rhythm Society Research Forum on the 6131 Treatment and Prevention of Atrial Fibrillation, Washington, DC, December 9-10, 2013. Heart Rhythm 6132 2015;12:e5-e29. 6133 1025. van Nieuwenhuizen KM, van der Worp HB, Algra A, Kappelle LJ, Rinkel GJ, van Gelder IC, 6134 Schutgens RE, Klijn CJ, APACHE-AF Investigators. Apixaban versus Antiplatelet drugs or no 6135 antithrombotic drugs after anticoagulation-associated intraCerebral HaEmorrhage in patients with 6136 Atrial Fibrillation (APACHE-AF): study protocol for a randomised controlled trial. Trials 2015;16:393. 6137 Gronberg T, Nuotio I, Nikkinen M, Ylitalo A, Vasankari T, Hartikainen JE. Airaksinen KE. 1026. 6138 Arrhythmic complications after electrical cardioversion of acute atrial fibrillation: the FinCV study. 6139 Europace 2013;15:1432-1435. 6140 1027. Tse HF, Lau CP. Does sinus rhythm beget sinus rhythm? Effects of prompt cardioversion on 6141 the frequency and persistence of recurrent atrial fibrillation. Card Electrophysiol Rev 2003;7:359-365. 6142 Van Gelder IC, Hemels ME. The progressive nature of atrial fibrillation: a rationale for early 1028. 6143 restoration and maintenance of sinus rhythm. Europace 2006;8:943-949. 6144 Liu ZJ, Fu WG, Guo ZY, Shen LG, Shi ZY, Li JH. Updated systematic review and meta-1029. 6145 analysis of randomized clinical trials comparing carotid artery stenting and carotid endarterectomy in 6146 the treatment of carotid stenosis. Ann Vasc Surg 2012;26:576-590. 6147 Taylor DW, Barnett HJM, Haynes RB, Ferguson GG, Sackett DL, Thorpe KE, Simard D, 1030. 6148 Silver FL, Hachinski V, Clagett GP, barnes R, Spence JD, ASA and Carotid Endarterectomy (ACE) 6149 trial collaborators. Low-dose and high-dose acetylsalicylic acid for patients undergoing carotid 6150 endarterectomy: a randomised controlled trial. Lancet 1999;353:2179-2184. 6151 1031. Watanabe M, Chaudhry SA, Adil MM, Alqadri SL, Majidi S, Semaan E, Qureshi AI. The effect 6152 of atrial fibrillation on outcomes in patients undergoing carotid endarterectomy or stent placement in 6153 general practice. J Vasc Surg 2015;61:927-932. 6154 Breithardt G, Baumgartner H, Berkowitz SD, Hellkamp AS, Piccini JP, Stevens SR, 1032. 6155 Lokhnygina Y, Patel MR, Halperin JL, Singer DE, Hankey GJ, Hacke W, Becker RC, Nessel CC, 6156 Mahaffey KW, Fox KA, Califf RM, ROCHET AF Steering Committee & Investigators. Clinical 6157 characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial 6158 fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trial. 6159 Eur Heart J 2014;35:3377-3385.
 - 6160 1033. Philippart R, Brunet-Bernard A, Clementy N, Bourguignon T, Mirza A, Babuty D, Angoulvant 6161 D, Lip GY, Fauchier L. Prognostic value of CHA2DS2-VASc score in patients with 'non-valvular atrial

- 6162 fibrillation' and valvular heart disease: the Loire Valley Atrial Fibrillation Project. Eur Heart J
- 6163 2015;**36**:1822-1830.
- 6164 1034. Breithardt G, Baumgartner H. Valvular heart disease among non-valvular atrial fibrillation: a 6165 misnomer, in search of a new term. *Eur Heart J* 2015;**36**:1794-1797.
- 6166 1035. Wolf RK, Schneeberger EW, Osterday R, Miller D, Merrill W, Flege JB, Jr., Gillinov AM.
- 6167 Video-assisted bilateral pulmonary vein isolation and left atrial appendage exclusion for atrial
- 6168 fibrillation. J Thorac Cardiovasc Surg 2005;**130**:797-802.
- 6169 1036. Yilmaz A, Van Putte BP, Van Boven WJ. Completely thoracoscopic bilateral pulmonary vein

6170 isolation and left atrial appendage exclusion for atrial fibrillation. *J Thorac Cardiovasc Surg* 6171 2008;**136**:521-522.

- 6172 1037. Salzberg SP, Plass A, Emmert MY, Desbiolles L, Alkadhi H, Grunenfelder J, Genoni M. Left
- 6173 atrial appendage clip occlusion: early clinical results. *J Thorac Cardiovasc Surg* 2010;**139**:1269-1274.
- 6174 1038. Papworth Hospital NHS Foundation Trust. A randomised controlled trial to investigate the
- 6175 clinical and cost effectiveness of adding an ablation device-based maze procedure as a routine
- 6176 adjunct to elective cardiac surgery for patients with pre-existing atrial fibrillation.
- 6177 <u>http://www.isrctn.com/ISRCTN82731440</u>. Date last accessed 5 May 2016 ISRCTN82731440
- 6178 1039. Efficacy and safety of ablation for patients with non-paroxysmal atrial fibrillation. doi:
- 6179 10.1002/14651858.CD012088.pub2
- 6180 1040. Concomitant atrial fibrillation surgery for people undergoing cardiac surgery. doi:
- 6181 10.1002/14651858.CD011814.pub2
- 6182 1041. Hemingway CPRD data (when published)
- 6183 1042. MANTRA-PAF 5 yr outcomes (when published)